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Protein tyrosine kinases (PTKs, or TKs) have emerged as one of the most intensively 
pursued targets in the development of anti-cancer therapeutics, due to their critical roles in 
the phosphotyrosine (pTyr)-mediated signaling network that regulates many cancer-related 
cellular activities. The TKs, tyrosine phosphorylation phosphatases (PTPs) and pTyr 
recognition SH2 proteins are intensively tyrosine phosphorylated, which play a pivotal role 
in determining the signaling outcome of this network. More than 50% of all human proteins 
are tyrosine phosphorylated and many of these TK substrates have been proven functional 
in TK regulated cellular activities. Therefore, proteomics studies of tyrosine 
phosphorylation are of great value for expanding our understanding of this network and its 
role in tumorigenesis.  
Taking advantage an engineered SH2 domain with superb pTyr binding affinity, an SH2-
affinity purification mass spectrometry (SH2-AP-MS) assay was developed and optimized 
for global TK status profiling by determining the abundance of functionally significant TK 
pTyr peptides including the activation loops. Multiple known TK biomarkers were 
identified by this assay from a minute amount of protein extracts from cultured cells or 
clinical leukemia or solid tumor samples. In the quantitative AP-MS study of cancer cells 
treated by targeted therapeutics, differential TK responses were monitored. The receptor c-
Kit was found to be dramatically upregulated with long-term trastuzumab treatment which 
contributed to acquired trastuzumab resistance in the SK-BR-3 breast cancer cells. These 
results revealed the potential applications of SH2-AP-MS in the discovery of novel TK 
biomarkers and examination of TK positive cancers in the clinical setting. In addition, a 
SH2 superbinder modified yeast two hybrid (Y2H) system was developed that is 
potentially capable of identifying TK substrate in a high-precision and high-throughput 
manner. This system consisted of an SH2-superbinder-fused bait that greatly promoted the 
reporter gene readout, a TK substrate prey or cDNA library preys, and a co-expressed TK 
under the control of a conditional promoter that allowed for reverse screen to eliminate 
false positives. In a medium-scale cDNA library screening for Src kinase substrates, 94 
positive colonies were isolated representing 48 unique in-frame proteins or protein 
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Chapter 1  
1 General Introduction 
Proteins are fundamental biomolecules in the cell that participate in all cellular activities. 
One well known function of proteins in the cell is as enzymes, which catalyze biochemical 
reactions, including the processes of assembly and degradation of proteins. The human 
genome harbours approximately 20,000 genes, and the proteins encoded by more than 
18,000 genes have been identified in at least one human tissue (Wilhelm et al., 2014). 
Typically in a human cell, around 10,000 to 13,000 genes together express a few billion 
protein molecules, with the most abundant proteins each consisting of several million 
copies (Milo, 2013). In a HeLa cell of 400 picogram in dry weight, the protein content is 
approximately 300 picograms (Finka and Goloubinoff, 2013; Volpe and Eremenko-Volpe, 
1970). 
The complexity of the proteome, the complement of all proteins, modified or not, in an 
organism is thought to be increase with the number of genes. For example, viruses may 
contain only a few genes, yeast and E. coli , in contrast, have about 5,000 genes (Bassett et 
al., 1996; Blattner et al., 1997), while mice and humans have over 20,000 genes (Lander et 
al., 2001; Mouse Genome Sequencing et al., 2002). Some species have exceptionally large 
genomes. For example, Arabidopsis (Arabidopsis thaliana) has approximately the same 
number of genes as humans (Arabidopsis Genome, 2000), and rice (Oryza Sativa) has a 
genome twice the size of the human genome with over 40,000 genes (Goff et al., 2002). 
However, plant genomes are usually less heterogeneous, which is likely evolved along with 
polyploidy (Van de Peer et al., 2017). Rice and wheat are naturally polyploid, Arabidopsis 
is diploid but have many polyploid cell types, such as the pavement cells which could be 
up to 128-ploid (Lee et al., 2013). Besides the number of genes, post-translational 
modifications (PTMs) on proteins make large contributions to the complexity of the human 
proteome, which generate variants of protein molecules that may behave differentially in 
vivo (Hunter, 2007; Jungblut et al., 2008). Phosphorylation is one of the most common and 
studied reversible protein PTM. Protein kinases catalyze this process by transferring a γ-
phosphate group to the substrate protein, principally on serine, threonine or tyrosine 
residues, while phosphatases are responsible for removing the phosphate group from these 
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amino acid residues (Johnson and Lewis, 2001). Humans have evolved a highly 
complicated protein PTM system, with about one thousand genes being directly involved 
in protein phosphorylation, for example (Sharma et al., 2014). In contrast, yeast and plants 
which have a much less sophisticated protein PTM system, lack kinases for tyrosine 
phosphorylation (Lim and Pawson, 2010).  
Pioneering studies on protein phosphorylation were carried out in the 1950s, with 
serine/threonine phosphorylation first described in 1954 (Burnett and Kennedy, 1954; 
Fischer and Krebs, 1955; Krebs and Fischer, 1956). Likely due to the much lower 
occurrence and stability of tyrosine phosphorylation in vivo (Manning et al., 2002; Ushiro 
and Cohen, 1980), the phosphorylation of tyrosine was reported almost 25 years later, even 
though in vitro synthesis of phosphotyrosine in 1933 already revealed the theoretical 
possibility of tyrosine phosphorylation (Eckhart et al., 1979; Levene and Schormuller, 
1933; Sefton et al., 1980). The first isolated kinase, protein kinase A (PKA) was reported 
in 1968 (Walsh et al., 1968) and the first isolated tyrosine kinase, Src, was reported in 1979 
(Oppermann et al., 1979). The human genome encodes about 400 serine/threonine kinases 
(STKs) but only 90 protein tyrosine kinases (PTKs, or TKs) (Manning et al., 2002), 
suggesting that serine/threonine phosphorylation is dominant. Indeed,  STKs are 
responsible for about 95% of all amino acid phosphorylation (Ushiro and Cohen, 1980). It 
was initially estimated that one-third of human proteins are substrates of protein kinases 
(Cohen, 2000), however, with the advancement  of modified-peptide enrichment and mass 
spectrometry (MS) technologies, the numbers of reported protein phosphorylation and 
other modification sites are increasing at an exponential rate (Sharma et al., 2014). Even 
the less abundant tyrosine phosphorylation has been identified in approximately 10, 000 
sites from half of all human proteins, according to the ProteomeScout database (Matlock 
et al., 2015). Our preliminary phosphotyrosine proteomics study, employing a new 
tyrosine-phosphorylated peptide enrichment strategy which will be introduced in this 
thesis, reported over 3, 000 novel tyrosine phosphorylation sites identified from nine lab-
cultured cancer cell lines (Bian et al., 2016). 
Phosphorylation plays an important role in the regulation of protein functions. It has been 
implicated in mediating many signal transduction pathways and cellular activities (Adams, 
2001; Johnson and Lewis, 2001). Since the phosphate group is charged and hydrophilic in 
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the physiological environment, phosphorylation and de-phosphorylation could result in 
protein conformational changes, thereby altering the protein function directly. However, 
tyrosine phosphorylation is somehow distinct from serine or threonine phosphorylation. In 
many cases, phosphorylation of tyrosine alters protein-protein interactions instead of 
directly altering protein conformation. On a serine or threonine residue, the phosphate 
group is attached to the β-OH group on the amino acid side chain. However, on a tyrosine 
residue, the phosphate group is linked to the O4 position of the phenolic ring, which is 
located much further away from the amino acid backbone. From a biophysical perspective, 
the phosphate on a tyrosine residue will result in less impact to the charge status and hydro-
dynamics of nearby amino acids. This distinct structure likely provides a more recognizable 
site for specific binding, thereby allowing the evolution of highly specific tyrosine 
phosphorylation regulating modules including TKs, pTyr binding domains/proteins and 
tyrosine phosphorylation phosphatases (PTPs) (Hunter, 2014). In addition, at the cellular 
level, unlike the serine or threonine phosphatases, PTPs typically maintain a highly active 
status, therefore resulting in a very short half-life for tyrosine phosphorylation (minutes or 
even seconds in many cases) (Kleiman et al., 2011; Tonks, 2006). This dynamic nature 
greatly facilitates a pTyr modulating role in signal transduction, which relies on fast 
changes of component status (Hunter, 2014). Indeed, with 90 TKs, 107 PTPs and 120 pTyr-
recognition Src Homolog 2 (SH2)-containing proteins (Liu et al., 2012; Liu et al., 2006; 
Liu et al., 2011), humans have evolved a complex regulatory network that precisely tunes 
the dynamics of tyrosine phosphorylation on over 10,000 sites throughout the proteome. 
This, in turn, mediates a number of key cellular activities in vivo, including the aberrant 
stimulation of the MAPK pathway (cell proliferation) and PI3K-Akt pathway (cell 
survival) in tumorigenesis and cancer malignance  (Lim and Pawson, 2010). 
TKs are generally classified into two families according to their distinct sub-cellular 
localizations. The membrane-localized receptor tyrosine kinase (RTK) family has 58 
members distributed into 20 subfamilies (ALK; AXL; DDR; EPH; ErbB; FGFR; INSR; 
MET; MUSK; PDGFR; PTK7; RET; ROR; ROS; RYK; TIE; TRK; VEGFR; AATYK), 
and the cytosol-localized protein tyrosine kinase (CTK) family has 32 members distributed 
into 10 subfamilies (ABL; ACK; CSK; FAK; FES; FRK; JAK; SRC; TEC; SYK) 
(Robinson et al., 2000). Despite the relatively small gene family size, it must be noted that 
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aberrant activation of TKs, especially RTKs, have been reported as a pivotal driver of 
tumorigenesis and cancer malignancy in a multitude of cancer types  and at least twenty 
TKs have been verified as oncogenes or proto-oncogenes (Gharwan and Groninger, 2016; 
Hunter, 2009; Wu et al., 2015), including the first described oncogene Src that was reported 
in 1979 (Oppermann et al., 1979; Sefton et al., 1980; Stehelin et al., 1977). Presently, more 
than half of the approved targeted therapeutics (precision medicines) in cancer treatment 
are either small molecule TK inhibitors or RTK inhibition antibodies (Bhullar et al., 2018; 
Gharwan and Groninger, 2016; Twomey et al., 2017; Wu et al., 2015; Zhang et al., 2009). 
As a result, tyrosine phosphorylation and its mediated signal transduction are among the 





 TK inhibition drugs in cancer therapy 
The discovery that the viral protein v-Src with TK activity transformed human cells 
immediately suggested that TKs and tyrosine phosphorylation might be a significant 
mechanism of transformation (Hunter and Sefton, 1980; Sefton et al., 1980). Later, an 
investigation into human oncogenes quickly revealed a fusion of the BCR protein and ABL 
tyrosine kinase (BCR-ABL) was essential and sufficient for the malignant transformation 
of CML (chronic myelogenous leukemia), and was responsible for the phenotypic 
abnormalities of CML that identified as Philadelphia chromosome positive (Ph+) (Daley 
and Baltimore, 1988; Daley et al., 1990). Philadelphia chromosome is the hallmark of CML 
and found in over 90% of CML patients (Nowell, 1962), which arises from a 
t(9;22)(q34;q11) reciprocal translocation in chromosomes (Rowley, 1973). The molecular 
consequence of this translocation is the replacement of the first ABL exon by a fragment 
from the BCR gene, resulting in the fusion protein BCR-ABL that has deregulated kinase 
activity (Ben-Neriah et al., 1986).  These findings lead to further investigation focusing on 
BCR-ABL fusion and finally the approval of the first targeted anti-cancer therapeutic 
imatinib (Gleevec®, Novartis) (Buchdunger et al., 1996; Druker and Lydon, 2000). Unlike 
most other small molecule TK inhibitors (TKIs) that are ATP (nucleoside triphosphate) 
mimics, imatinib binds close to the ABL ATP binding site and locks it in a self-inhibited 
conformation, thereby, inhibiting the kinase activity semi-competitively. Imatinib is highly 
effective in clinical application, and generally well tolerated in most patients with Ph+ 
CML. The overall survival rate remains high after 5 years of follow-up, and historical 
comparison to other treatments also indicates greatly improved survival outcome (Moen et 
al., 2007). In the long term, a recent study reports a striking 83.3% overall survival rate at 
10 years of CML patients receiving imatinib treatment (Hochhaus et al., 2017). 
Following the milestone approval of imatinib, kinases, especially TKs, quickly emerged as 
the most intensively pursued targets in both cancer biology research and anti-cancer 
therapeutic development. To date, many TKs have been proven as oncogenes or proto-
oncogenes in research labs, and over twenty TKs are already validated as biomarkers in 
many different cancer types (Kannaiyan and Mahadevan, 2018; Levitzki, 2013; Wu et al., 
2015). Tens of TK inhibition molecules have been clinically approved, making up more 
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than half of all approved targeted therapeutics in cancer therapy (Bhullar et al., 2018; 
Gharwan and Groninger, 2016; Twomey et al., 2017; Wu et al., 2015; Zhang et al., 2009).. 
Following the great success of imatinib, several other small molecule inhibitors have been 
clinically approved that target ABL and its fusion variants, including bosutinib (Bosulif®, 
Pfizer), dasatinib (Sprycel®, Bristol-Myers Squibb), nilotinib (Tasigna®, Novartis) and 
ponatinib (Iclusig®, Takeda), which are significantly more potent or overcome imatinib 
resistance (Quintas-Cardama et al., 2007; Rossari et al., 2018). Additionally, the 
application of imatinib has also been expanded to the treatment of Ph+ acute lymphocytic 
leukemia (ALL), gastrointestinal stromal tumors (GIST), systemic mastocytosis, and 
myelodysplastic syndrome (Rossari et al., 2018).  
Like that of BCR-ABL, fusion TKs with deregulated kinase activity is a common 
oncogenic mechanism (Medves and Demoulin, 2012). The RTK anaplastic lymphoma 
kinase (ALK), also known as CD246 (cluster of differentiation 246), was also first 
described in a chromosomal translocation as a fusion TK (NPM-ALK) in anaplastic large-
cell non-Hodgkin’s lymphoma (ALCL), though it was not initially described as an 
oncogene (Morris et al., 1994; Shiota et al., 1994). In 2008, ALK was identified as a 
biomarker in neuroblastoma, a most intractable pediatric cancer (Chen et al., 2008; 
Janoueix-Lerosey et al., 2008). It should be noted that the ALK inhibitor crizotinib 
(Xalkori®, Pfizer) was clinically approved two years after these reports, which set a record 
time from biomarker discovery to clinical approval in the development of targeted 
therapeutics. Although not fully elucidated, ALK appears to be localized in a frequent 
translocation region of the chromosome, and it has been reported that ALK forms over 30 
oncogenic fusions with at least 22 fusion partners in different cancer types (Hallberg and 
Palmer, 2013). In addition to these fusion TKs, amplification of TK genes, overexpression 
of TKs, truncation of TK proteins, constitutively active TK mutants and abnormalities of 
TK regulators are also very common in many different cancer types which drives 
tumorigenesis and cancer malignancy via similar pathways (Du and Lovly, 2018). For 
instance, in breast cancer, approximately 15%~30% of patients have tumors that exhibit 
overexpression, amplification, or both of the RTK ErbB2 (HER2, human epidermal growth 
factor receptor 2) (Cameron et al., 2017; Seidman et al., 2008; Vogel et al., 2002). This 
subtype is termed as HER2 positive breast cancer, and the use of the humanized ErbB2 
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inhibition antibody trastuzumab (Herceptin®, GenenTech),  is now the standard of care for 
these patients (Cameron et al., 2017; Seidman et al., 2008; Vogel et al., 2002).  
Two major types of TK inhibition molecules have been developed as therapeutics for TK 
positive cancers: humanized monoclonal antibodies against the RTK extra-cellular region 
and small molecule inhibitors (Kannaiyan and Mahadevan, 2018; Wu et al., 2015). The 
antibodies bind to the RTK extracellular region in the extracellular matrix, which either 
blocks the binding of ligands (growth factors) or disturbs the ligand-stimulated 
dimerization of the extracellular region, both of which are required for full RTK activation 
and the subsequent stimulation of cell proliferation and survival signals. The small 
molecule inhibitors simply penetrate cell membrane and bind to the TK kinase domain to 




 TKI resistance and TK signaling network complexity 
Cellular signal transduction could rely on the spatiotemporal dynamics of macromolecules, 
for example reversible modifications on receptors (Bergeron et al., 2016). Among all these 
PTMs, tyrosine phosphorylation, as well as pTyr-mediated signal transduction, have been 
extensively studied due to their significance in numerous cellular activities, including 
differentiation, proliferation, motility and apoptosis, that are closely related to 
tumorigenesis and cancer malignancy (Hunter, 2009; Lim and Pawson, 2010; Seet et al., 
2006). As introduced earlier, the human genome encodes 90 TKs, 107 PTPs and 120 SH2-
containing proteins, which serve as the writer, eraser and reader modules respectively in 
the pTyr toolkit (Lim and Pawson, 2010). Even with this relatively simple toolkit, the pTyr-
mediated signaling network is a highly-complicated and multilayer-regulatory network, 
which also contains many functionally redundant and promiscuous components (Yarden 
and Sliwkowski, 2001). Despite the tens of thousands of related research papers that have 
been published, there is still a lack of comprehensive understanding of this network and its 
consequences in normal cellular activities and tumorigenesis. For instance, the constitutive 
stimulation by nerve growth factor (NGF) triggers rat PC12 pheochromocytoma cell 
differentiation, but transient stimulation only promotes cell proliferation. Under both 
conditions, the NGF growth factor specifically binds to tropomyosin receptor kinase A 
(TrkA) and sequentially stimulate the MAPK signaling pathway, which is required for both 
the cell differentiation and proliferation (Klesse et al., 1999).  
The complexity of the pTyr-mediated signaling network seems essential for fine-tuning the 
phosphorylation on over 10,000 sites using just a few hundred TKs, PTPs and SH2 proteins. 
However, the frequent functional redundancy, cross talking and signal feedback also means 
that the network may have difficulty recovering once disturbed, as is seen in cancer cells. 
In the clinic, this may also increase the difficulty for treating TK positive cancer, especially 
when the TK biomarker is not the dominant driver of tumorigenesis and malignance. In the 
application of TK inhibition drugs, both intrinsic and acquired drug resistance are widely 
observed across different cancer types (Levitzki, 2013; Lovly and Shaw, 2014). ErbB2 
(HER2) is a biomarker diagnosed in up to 30% of breast cancer patients (Cameron et al., 
2017; Seidman et al., 2008; Vogel et al., 2002), and it was validated that ErbB2 alone was 
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sufficient for tumor formation and maintenance in HER2 breast cancer (Drebin et al., 
1985). However, only about 30% of HER2 positive patients are sensitive to the targeted 
therapeutic trastuzumab, and the duration of drug response only ranges from 5 to 9 months 
in many cases (Seidman et al., 2008). Resistance and short-term effects are also found in 
the application of many other anti-cancer targeted therapeutics (Levitzki, 2013; Lovly and 
Shaw, 2014). To date, different theories have been made to explain the resistance of 
targeted therapeutics, although most of these studies are non-systematic and based on 
laboratory models. However, it is obvious that many theories are related to the plasticity of 
the pTyr-mediated signaling network in both intrinsic and drug-induced resistances. Even 
if the on-target TK biomarkers are inhibited, the network might self-adjust to maintain the 
activation of oncogenic signals. The deregulation of non-target TKs was observed in many 
cases, which could bypass the inhibition of on-target TK to stimulate cell proliferation and 
survival (Du and Lovly, 2018; Levitzki, 2013; Lovly and Shaw, 2014). Due to the 
difficulties in collecting and analyzing patient-derived samples, there is still a lack of large-
scale studies that could comprehensively decipher the drug resistance mechanism, even for 
a given targeted therapeutic in a specific cancer type. A recent review summarized some 
clinic-based studies on drug resistance in non-small-cell lung cancer (NSCLC) that is 
positive for EGFR or ALK (Lin and Shaw, 2016). It is estimated that up to 70% of drug 
resistance cases, in both EGFR and ALK-positive NSCLC, are likely related to the 
retention of TK activity, either by introducing additional mutations in on-target TKs that 
abolishes drug binding and increases kinase activity, or deregulation of non-target TKs that 
compensates for the loss of on-target TK activity by drug inhibition.   
1.2.1 Multi-functional components  
The mix and match of functionalities in these “writer, eraser and reader” proteins contribute 
to the regulation of the pTyr-mediated signaling network. The “writer-reader” type TKs, 
“eraser-reader” type PTPs are very common in this network because many TKs and PTPs 
also contain SH2 domains. These proteins are also direct TK substrates and highly tyrosine 
phosphorylated in vivo (Hornbeck et al., 2015; Matlock et al., 2015). Over 1000 pTyr sites 
have been identified in only 90 TKs, which are produced by either intramolecular 
phosphorylation or intermolecular phosphorylation. The regulation of Src kinase is a good 
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example exhibiting complicated but fine-tuned regulation caused by the mix and match 
nature of “writer, eraser and reader” functionalities, as well as some other factors. As 
introduced above, Src is the first described proto-oncogene, and aberrant activation of Src 
can drive the transformation of normal cells into cancerous cells (Oppermann et al., 1979; 
Sefton et al., 1980; Stehelin et al., 1977). From the N- to C-terminus, the Src protein 
contains a 14-carbon myristoyl group attached to an SH4 domain, a Unique domain, an 
SH3 domain, an SH2 domain, an SH2-kinase linker, a tyrosine kinase domain, and a 
carboxy-terminus regulatory tail (Roskoski, 2004). The Src kinase is highly tyrosine-
phosphorylated in vivo and contains at least 11 pTyr sites (Y93, Y134, Y139, Y187, Y216, 
Y232, Y338, Y419, Y439, Y522, Y530) (Hornbeck et al., 2015), of which phosphorylation 
on Y419 and Y530 (Y416 and Y527 in chicken Src) are most abundant and play a pivotal 
role in the regulation of Src activity (Roskoski, 2004; Roskoski, 2005). At the protein level, 
the full activation of Src kinase requires phosphorylation of Y419 and de-phosphorylation 
of Y530. Y419 is in the highly-conserved activation loop within the kinase domain, whose 
autophosphorylation displaces the activation loop away from the substrate binding pocket 
to set the kinase domain in an open status. Y530 is more critical in the regulation of Src 
activation. Once phosphorylated, it binds to the intramolecular SH2 domain and this 
conformation completely blocks substrate access to the kinase domain regardless of the 
Y419 phosphorylation status. A similar regulatory mechanism is also observed in other Src 
family members which share a highly conserved structure and sequence (Thomas and 
Brugge, 1997). Y530 in Src is phosphorylated by Csk (c-terminal Src kinase) and Csk-
homologous kinase, and de-phosphorylated primarily by PTP1B (protein tyrosine 
phosphatase 1B) (Bjorge et al., 2000). It is intriguing that PTP1B specifically localizes to 
the cytosolic face of the endoplasmic reticulum (ER) system while Src is a cytosolic kinase 
mainly associating to the cell membrane (Frangioni et al., 1992; Resh, 1994), which 
indicates that the PTP1B mediated Src dephosphorylation is spatiotemporally regulated at 
the subcellular level. A microscopy-based cell biology study exhibited the co-localization 
of Src and PTP1B scattered throughout the ER system (Monteleone et al., 2012), 
demonstrating that subcellular distribution might involve in the regulation of Src activity 
as well. In addition to the intramolecular pTyr site, the Src SH2 domain also directly binds 
to pTyr sites in other proteins in vivo, such as the phosphorylated Y397 in the focal 
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adhesion kinase (FAK), or  protein tyrosine kinase 2 (PTK2) (Xing et al., 1994). The 
consequence of this binding is further phosphorylation at multiple sites in FAK and the 
formation of Src-FAK complex, which in turn phosphorylates a number of cytoskeleton-
associated proteins to regulate cell motility (Mitra and Schlaepfer, 2006). 
Besides the writer-readers or eraser-readers, it is common that other SH2-containing 
enzymes are also directly involved in the regulation of the pTyr-mediated signaling 
network. The SH2-containing E3 ligase Cbl family, including Cbl, Cbl-b and Cbl-c in 
mammals, have emerged as dominant negative regulators of many RTKs by ubiquitinating 
active RTKs for internalization, which either results in RTK removal from the cell 
membrane or degradation via the lysosome (Liyasova et al., 2015; Mohapatra et al., 2013; 
Sorkin and Von Zastrow, 2002). It has also been reported that Cbl family proteins may play 
a positive role in pTyr-mediated signal transduction by acting as adaptor proteins to recruit 
other signaling molecules to active RTKs (Scott et al., 2005; Waterman et al., 2002).  
Previous work in our lab also reveals an orthogonal regulatory mechanism to this network. 
We found that the pTyr-binding adaptor protein Numb might also generally function in the 
internalization of RTKs by recruiting endocytosis-related proteins (Wei et al., 2018). In 
this process, two Numb isoforms tend to behave in opposing ways in directing ALK to 
distinct post-endocytic trafficking destinations (Wei et al., 2019). The Numb isoforms bind 
to the same ALK intracellular region but recruit different endocytic proteins. One Numb 
isoform mainly directs ALK from the early endosome to late endosome which ultimately 
degrade in the lysosome. In contrast, a second Numb isoform could promote ALK 
recycling from the early endosome to the cell membrane therefore only temporarily 
regulating the on-membrane ALK abundance.   
1.2.2 Functional redundancy 
The pTyr-mediated signaling network exhibits a clear multi-layered structure (Yarden and 
Sliwkowski, 2001). From the extracellular matrix to the cytoplasm, this network consists 
of growth factors that initiate signal transduction, RTKs that transfer signaling through the 
cell membrane, SH2 domain-containing proteins and cytosol TKs that amplify signaling, 
and downstream effectors that alter cellular activities accordingly. Functional redundancy, 
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cross-talk and promiscuity seem highly frequent in this network, likely due to structural 
and functional conservation among components within the same layer. 
Our understanding of this network is largely based on studies of the ErbB RTK subfamily 
(Fig.1.2). ErbBs serve as an entry portal to transduce a signal from the extracellular matrix 
into the cytoplasm (Holbro and Hynes, 2004). Intriguingly, the downstream signaling 
outcome is somehow flexible even when the signal transduction is via the same ErbB 
members (Yarden and Sliwkowski, 2001). There are at least three major regulatory layers 
together deciding the signaling outcome: 1) Growth factors. The human genome encodes 
four ErbB family members, EGFR (ErbB1), ErbB2 (HER2), ErbB3 and ErbB4. The ErbB 
proteins, like most other RTKs, share an identical molecular architecture, made up of an 
ectodomain (extracellular domain, ECD), a short and single transmembrane region, an 
intracellular tyrosine kinase domain and a flexible C-terminal tail with multiple pTyr sites. 
There are 11 different ligands in total, and all generated from extracellular cleavage of 
other transmembrane proteins that can bind to and activate at least one ErbB member. 
These include EGF (epidermal growth factor) (Cohen, 1962, 1964), TGF-α  (transforming 
growth factor alpha) (Derynck et al., 1984; Marquardt et al., 1984), HB-EGF (Heparin-
binding EGF-like growth factor) (Higashiyama et al., 1991), amphiregulin (Shoyab et al., 
1989), betacellulin (Sasada et al., 1993; Shing et al., 1993), epigen (Strachan et al., 2001), 
epiregulin (Jones et al., 1999; Toyoda et al., 1995), NRG1 (neuregulin-1) (Peles et al., 
1992), NRG2 (neuregulin-2) (Chang et al., 1997), NRG3 (neuregulin-3) (Zhang et al., 
1997) and NRG4 (neuregulin-4) (Harari et al., 1999). All ErbB members exhibit ligand 
preference, and none of these members can bind to all ligands (Fuller et al., 2008; Linggi 
and Carpenter, 2006); 2) Homo- and hetero-dimerization occur among ErbB members. 
Dimerization takes place between any two ErbB protein molecules upon the ligand binding. 
Among all ErbB molecules, the homo-dimerization of ErbB2 and its subsequent activation 
seems least dependent on the ligand, which has the capacity to dimerize in the absence of 
ligand binding and overexpression of ErbB2 alone is able to promote ErbB2 homo-
dimerization and transform cells (Lemmon, 2009); 3). Four ErbB members generate at least 
61 pTyr sites, which bind to tens of SH2 domain-containing proteins in vitro and in vivo, 
and a variety of SH2 domain-containing proteins may compete for binding to the same 
pTyr sites in vivo (Jones et al., 2006). Some SH2 containing proteins, such as Shc adaptor 
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protein, could be phosphorylated upon binding to the active ErbB or other RTKs, which in 
turn recruits more SH2 domain-containing proteins to amplify signaling further or 
introduce additional regulators (Good et al., 2011). Upon EGF stimulation, the Shc scaffold 
protein could undergo multiple waves of phosphorylation that couple with distinct 
signaling modules thereby resulting in differential signaling outcomes (Zheng et al., 2013). 
Therefore, all these components together yield a highly versatile phosphorylation status 
among the four ErbB members and adaptor proteins, which in turn trigger a multitude of 




       
 
Figure 1.1 Schematic of ErbB RTK activation 
The RTK ErbB proteins consist of an ectodomain, a single transmembrane region, an intracellular 
tyrosine kinase domain and a flexible C-terminus tail with multiple pTyr sites. Upon the binding 
of extracellular growth factors, two ErbB protein molecules dimerize to come together and activate 
the intracellular kinase domains. The active kinase domains phosphorylate multiple intracellular 
tyrosine residues which in turn recruit downstream effectors such as Src kinase and Shc scaffold 




 Discovery of the SH2 Superbinder 
The SH2 (Src Homology 2) domain is a structurally conserved noncatalytic protein domain 
that specifically binds to phosphorylated tyrosine residues, first described in the Src family 
kinases (Sadowski et al., 1986). SH2 is the largest family of pTyr-binding modules, and 
the human genome encodes ~120 SH2 domains in ~110 proteins (Liu et al., 2006). 
Regarding the structure, all SH2 domains are comprised of about 100 amino acids and 
share an identical structure with a central seven-stranded beta sheet flanked by two alpha 
helices (Kuriyan and Cowburn, 1997; Waksman et al., 1992; Waksman et al., 2004). 
Generally, SH2 domains only bind to phosphorylated tyrosine residues (Songyang et al., 
1993; Songyang et al., 1994), with a few exceptions (Kaneko et al., 2012b; Liu et al., 2006; 
Pawson, 2004). The pTyr-SH2 binding typically has a moderate affinity, with equilibrium 
dissociation constants (Kd) ranging from 0.1 µM to 10 µM in many cases  (Jones et al., 
2006; Ladbury and Arold, 2011; Ladbury et al., 1995). This relatively weak binding allows 
rapid association and disassociation between SH2 modules and phosphotyrosine so that the 
signal from an active tyrosine kinase is promptly transmitted to the downstream proteins 
and the pTyr-mediated signaling network can adapt to stimuli effectively.  The structure of 
SH2 domains in complex with phosphotyrosine-containing peptides reveals two major 
binding pockets on the surface responsible for binding: 1) a conserved pTyr-binding pocket 
provides basal binding affinity and specificity; 2) a secondary binding pocket with 
preference for the amino acids C-terminal of the pTyr residue in the ligand, which enhances 
the SH2-pTyr binding specificity. It has been previously reported that the pTyr residue 
only contributes around half of the binding free energy (ΔG°) of a pTyr ligand to an SH2 
domain (Waksman et al., 2004). The typical pTyr-binding pocket is comprised of around 
a dozen residues, which makes it practical to screen for high-affinity mutants in directed 
evolution via phage display. Previously, Dr. Kaneko in our lab, together with our 
collaborators, created a library of mutant Fyn SH2 domains, in which the 15 pTyr-binding 
pocket residues (R1-K2-A3-R4-S5-E6-T7-T8-A9-S10-L11-S12-K13-H14-K15) were 
randomized to generate over 1010 unique mutants. The SH2 mutant library was expressed 
on the M13 bacteriophage which was then enriched for binding to pTyr peptides derived 
from in vivo tyrosine phosphorylation proteins. The bacteriophage clones with high binding 
affinity were sequenced to reveal the mutated residues contributing to enhanced SH2 
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binding affinity. It was revealed that not all residues in the pocket are equally evolvable. 
Some residues are resistant to substitution, such as R4, a residue that is conserved in all 
natural human SH2 domains and crucial for pTyr binding (Bradshaw et al., 1999). At 
physiological pH, the positively charged arginine could directly bind to the negatively 
charged phosphate from tyrosine residue. Three hydrophilic residues (T8/S10/K15) are 
highly evolvable and had the highest substitution frequencies. Substitution of the three 
hydrophilic residues by hydrophobic residues  were identified in most high affinity 
bacteriophage clones. A triple mutant, T8V/S10A/K15L, was named “superbinder” 
because it exhibited greatly enhanced binding affinity for pTyr peptides both in vitro and 
in vivo. For some native pTyr peptides that bind to the wild-type Fyn SH2 domain in the 
micromolar (µM) Kd scale, their binding affinities to the superbinder are comparable to 
typical antibody-antigen binding affinity, with Kd in the low nanomolar (nM) range 
(Kaneko et al., 2012b). Because the pTyr-binding pocket is highly conserved across the 
SH2 domains, the same mutations introduced into other SH2 domains, such as those from 
Src and Grb2, also created superbinders (Huang et al., 2017; Kaneko et al., 2012a). More 
importantly, the T8V/S10A/K15L mutant is readily expressed in E.Coli, and this 





 Potential applications of the SH2 superbinder 
Taking advantage of this enhanced pTyr-binding SH2 domain, we are set out to develop a 
series of SH2-based assays that could be applied in fields with emerging significance but 
face a lack of specialized research tools due to the complex and promiscuous nature of the 
pTyr-mediated signaling network.  
Primarily, a SH2-based pTyr peptide affinity purification mass-spectrometry (SH2-AP-
MS) assay was developed for comprehensively profiling TK active status in vivo by 
determining the abundance of TK phosphorylated peptides, since phosphorylation is 
essential for the activation and regulation of many TKs. Conventionally, a similar strategy 
using anti-pTyr antibodies has been employed in phosphotyrosine proteomics studies. In 
the SH2-AP-MS strategy, the antibody was replaced by an engineered SH2 superbinder. 
Compared to antibodies, the superbinder is easily manufactured in bulk with minimal cost 
and stays stable for months at 4 °C, which make it applicable in large-scale and long-term 
studies. In addition, the SH2-AP-MS has several advantages compared to conventional TK 
activity assays and bears the potential to be further optimized for the examination of TK 
biomarkers in clinical samples. For this thesis study, the workflow of SH2 affinity 
purification was optimized to improve the efficiency of pTyr peptide enrichment. 
Moreover, the superbinder was further engineered by mutating two non-functional cysteine 
residues within the SH2 domain while an additional cysteine residue was introduced to the 
C-terminus (by Courtney Voss), which allows the covalent immobilization to iodoacetate 
group-coated resin without disturbing pTyr binding. In addition, the affinity purification 
buffer was modified to eliminate non-specific electrostatic binding of peptides rich in 
aspartic acid and/or glutamic acid (assisted by Dr. Tomonori Kaneko). With the optimized 
assay, known TK biomarkers were successfully detected from a minute amount of protein 
samples purified from either lab cultured cancer cells or clinical samples, including solid 
tumor FFPE slides prepared for standard IHC (immunohistochemistry) examination in the 
clinic. This assay also exhibited great expandability and could be used for the profiling of 
PTPs, immune-receptor tyrosine-based regulatory motifs and a variety of different TK 
substrates. In principle, once integrated with the well-developed phosphor-serine/threonine 
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enrichment strategy, the SH2-AP-MS strategy could be adapted for global profiling of the 
protein phosphotome.  
A SH2 superbinder modified yeast two hybrid (Y2H) system was also designed to identify 
TK substrates. Due to the complex and promiscuous nature of the pTyr-mediated signaling 
network, conventional assays, such as the in vitro kinase assay and mass spectrometry-
based in vivo assay, are not necessarily reliable in identifying direct TK substrates.  Despite 
the fact that the number of reported pTyr sites has exploded in recent years, profiling of 
TK-substrate pairings is severely lagging. The modified Y2H is based on a strategy 
reported in previous Y2H studies (Clark and Peterson, 2002; Grossmann et al., 2015), in 
which a TK, a GAL4 DNA binding domain-fused SH2 (bait) and a substrate-fused GAL4 
transcription activation domain (prey) were co-expressed in the yeast. Once the substrate 
is phosphorylated, it can bind to the SH2 to indirectly connect the GAL4 DNA binding 
domain and transcription activation domain, thereby forming a fully functional GAL4 
transcription factor to trigger reporter gene expression. By replacing the natural SH2 with 
the superbinder mutant and introducing reverse screening, the sensitivity and accuracy of 
this modified Y2H system was greatly improved. This modified Y2H is capable of 
profiling TK-substrate pairing in a high-throughput and high-precision manner. In a 
middle-scale screen against a human cDNA library of 170,000 mated cells, 9 known Src 
kinase substrates were recapitulated from a total of 48 positive candidates.  
Overall, this thesis work has revealed a variety of applications of the SH2 superbinder in 
proteomics and molecular biology. The SH2-AP-MS also bears great potential to be further 






Adams, J.A. (2001). Kinetic and catalytic mechanisms of protein kinases. Chem Rev 101, 
2271-2290. 
Arabidopsis Genome, I. (2000). Analysis of the genome sequence of the flowering plant 
Arabidopsis thaliana. Nature 408, 796-815. 
Bassett, D.E., Jr., Basrai, M.A., Connelly, C., Hyland, K.M., Kitagawa, K., Mayer, M.L., 
Morrow, D.M., Page, A.M., Resto, V.A., Skibbens, R.V., et al. (1996). Exploiting the 
complete yeast genome sequence. Current opinion in genetics & development 6, 763-766. 
Ben-Neriah, Y., Daley, G.Q., Mes-Masson, A.M., Witte, O.N., and Baltimore, D. (1986). 
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl 
hybrid gene. Science 233, 212-214. 
Bergeron, J.J., Di Guglielmo, G.M., Dahan, S., Dominguez, M., and Posner, B.I. (2016). 
Spatial and Temporal Regulation of Receptor Tyrosine Kinase Activation and Intracellular 
Signal Transduction. Annu Rev Biochem 85, 573-597. 
Bhullar, K.S., Lagaron, N.O., McGowan, E.M., Parmar, I., Jha, A., Hubbard, B.P., and 
Rupasinghe, H.P.V. (2018). Kinase-targeted cancer therapies: progress, challenges and 
future directions. Mol Cancer 17, 48. 
Bian, Y., Li, L., Dong, M., Liu, X., Kaneko, T., Cheng, K., Liu, H., Voss, C., Cao, X., 
Wang, Y., et al. (2016). Ultra-deep tyrosine phosphoproteomics enabled by a 
phosphotyrosine superbinder. Nat Chem Biol 12, 959-966. 
Bjorge, J.D., Pang, A., and Fujita, D.J. (2000). Identification of protein-tyrosine 
phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating 
and activating c-Src in several human breast cancer cell lines. J Biol Chem 275, 41439-
41446. 
Blattner, F.R., Plunkett, G., 3rd, Bloch, C.A., Perna, N.T., Burland, V., Riley, M., Collado-
Vides, J., Glasner, J.D., Rode, C.K., Mayhew, G.F., et al. (1997). The complete genome 
sequence of Escherichia coli K-12. Science 277, 1453-1462. 
Bradshaw, J.M., Mitaxov, V., and Waksman, G. (1999). Investigation of phosphotyrosine 
recognition by the SH2 domain of the Src kinase. J Mol Biol 293, 971-985. 
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Muller, M., Druker, B.J., and 
Lydon, N.B. (1996). Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 
2-phenylaminopyrimidine derivative. Cancer Res 56, 100-104. 
Burnett, G., and Kennedy, E.P. (1954). The enzymatic phosphorylation of proteins. J Biol 
Chem 211, 969-980. 
Cameron, D., Piccart-Gebhart, M.J., Gelber, R.D., Procter, M., Goldhirsch, A., de 
Azambuja, E., Castro, G., Jr., Untch, M., Smith, I., Gianni, L., et al. (2017). 11 years' 
follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast 
cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389, 1195-1205. 
20 
 
Chang, H., Riese, D.J., 2nd, Gilbert, W., Stern, D.F., and McMahan, U.J. (1997). Ligands 
for ErbB-family receptors encoded by a neuregulin-like gene. Nature 387, 509-512. 
Chen, Y., Takita, J., Choi, Y.L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., 
Kikuchi, A., Igarashi, T., et al. (2008). Oncogenic mutations of ALK kinase in 
neuroblastoma. Nature 455, 971-974. 
Clark, D.D., and Peterson, B.R. (2002). Rapid detection of protein tyrosine kinase activity 
in recombinant yeast expressing a universal substrate. J Proteome Res 1, 207-209. 
Cohen, P. (2000). The regulation of protein function by multisite phosphorylation--a 25 
year update. Trends Biochem Sci 25, 596-601. 
Cohen, S. (1962). Isolation of a mouse submaxillary gland protein accelerating incisor 
eruption and eyelid opening in the new-born animal. J Biol Chem 237, 1555-1562. 
Cohen, S. (1964). Isolation and Biological Effects of an Epidermal Growth-Stimulating 
Protein. Natl Cancer Inst Monogr 13, 13-37. 
Daley, G.Q., and Baltimore, D. (1988). Transformation of an interleukin 3-dependent 
hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. 
Proc Natl Acad Sci U S A 85, 9312-9316. 
Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronic myelogenous 
leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 
824-830. 
Derynck, R., Roberts, A.B., Winkler, M.E., Chen, E.Y., and Goeddel, D.V. (1984). Human 
transforming growth factor-alpha: precursor structure and expression in E. coli. Cell 38, 
287-297. 
Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A., and Greene, M.I. (1985). Down-
modulation of an oncogene protein product and reversion of the transformed phenotype by 
monoclonal antibodies. Cell 41, 697-706. 
Druker, B.J., and Lydon, N.B. (2000). Lessons learned from the development of an abl 
tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105, 3-7. 
Du, Z., and Lovly, C.M. (2018). Mechanisms of receptor tyrosine kinase activation in 
cancer. Mol Cancer 17, 58. 
Eckhart, W., Hutchinson, M.A., and Hunter, T. (1979). An activity phosphorylating 
tyrosine in polyoma T antigen immunoprecipitates. Cell 18, 925-933. 
Finka, A., and Goloubinoff, P. (2013). Proteomic data from human cell cultures refine 
mechanisms of chaperone-mediated protein homeostasis. Cell Stress Chaperones 18, 591-
605. 
Fischer, E.H., and Krebs, E.G. (1955). Conversion of phosphorylase b to phosphorylase a 
in muscle extracts. J Biol Chem 216, 121-132. 
21 
 
Frangioni, J.V., Beahm, P.H., Shifrin, V., Jost, C.A., and Neel, B.G. (1992). The 
nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic reticulum 
via its 35 amino acid C-terminal sequence. Cell 68, 545-560. 
Fuller, S.J., Sivarajah, K., and Sugden, P.H. (2008). ErbB receptors, their ligands, and the 
consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol 44, 
831-854. 
Gharwan, H., and Groninger, H. (2016). Kinase inhibitors and monoclonal antibodies in 
oncology: clinical implications. Nat Rev Clin Oncol 13, 209-227. 
Goff, S.A., Ricke, D., Lan, T.H., Presting, G., Wang, R., Dunn, M., Glazebrook, J., 
Sessions, A., Oeller, P., Varma, H., et al. (2002). A draft sequence of the rice genome 
(Oryza sativa L. ssp. japonica). Science 296, 92-100. 
Good, M.C., Zalatan, J.G., and Lim, W.A. (2011). Scaffold proteins: hubs for controlling 
the flow of cellular information. Science 332, 680-686. 
Grossmann, A., Benlasfer, N., Birth, P., Hegele, A., Wachsmuth, F., Apelt, L., and Stelzl, 
U. (2015). Phospho-tyrosine dependent protein-protein interaction network. Molecular 
systems biology 11, 794. 
Hallberg, B., and Palmer, R.H. (2013). Mechanistic insight into ALK receptor tyrosine 
kinase in human cancer biology. Nat Rev Cancer 13, 685-700. 
Harari, D., Tzahar, E., Romano, J., Shelly, M., Pierce, J.H., Andrews, G.C., and Yarden, 
Y. (1999). Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor 
tyrosine kinase. Oncogene 18, 2681-2689. 
Higashiyama, S., Abraham, J.A., Miller, J., Fiddes, J.C., and Klagsbrun, M. (1991). A 
heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. 
Science 251, 936-939. 
Hochhaus, A., Larson, R.A., Guilhot, F., Radich, J.P., Branford, S., Hughes, T.P., 
Baccarani, M., Deininger, M.W., Cervantes, F., Fujihara, S., et al. (2017). Long-Term 
Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 376, 917-
927. 
Holbro, T., and Hynes, N.E. (2004). ErbB receptors: directing key signaling networks 
throughout life. Annu Rev Pharmacol Toxicol 44, 195-217. 
Hornbeck, P.V., Zhang, B., Murray, B., Kornhauser, J.M., Latham, V., and Skrzypek, E. 
(2015). PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 
43, D512-520. 
Huang, H., Kaneko, T., Sidhu, S.S., and Li, S.S. (2017). Creation of Phosphotyrosine 
Superbinders by Directed Evolution of an SH2 Domain. Methods Mol Biol 1555, 225-254. 
Hunter, T. (2007). The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol 
Cell 28, 730-738. 
22 
 
Hunter, T. (2009). Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell 
Biol 21, 140-146. 
Hunter, T. (2014). The genesis of tyrosine phosphorylation. Cold Spring Harb Perspect 
Biol 6, a020644. 
Hunter, T., and Sefton, B.M. (1980). Transforming gene product of Rous sarcoma virus 
phosphorylates tyrosine. Proc Natl Acad Sci U S A 77, 1311-1315. 
Janoueix-Lerosey, I., Lequin, D., Brugieres, L., Ribeiro, A., de Pontual, L., Combaret, V., 
Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008). Somatic and 
germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 
967-970. 
Johnson, L.N., and Lewis, R.J. (2001). Structural basis for control by phosphorylation. 
Chem Rev 101, 2209-2242. 
Jones, J.T., Akita, R.W., and Sliwkowski, M.X. (1999). Binding specificities and affinities 
of egf domains for ErbB receptors. FEBS Lett 447, 227-231. 
Jones, R.B., Gordus, A., Krall, J.A., and MacBeath, G. (2006). A quantitative protein 
interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174. 
Jungblut, P.R., Holzhutter, H.G., Apweiler, R., and Schluter, H. (2008). The speciation of 
the proteome. Chem Cent J 2, 16. 
Kaneko, T., Huang, H., Cao, X., Li, X., Li, C., Voss, C., Sidhu, S.S., and Li, S.S. (2012a). 
Superbinder SH2 domains act as antagonists of cell signaling. Sci Signal 5, ra68. 
Kaneko, T., Joshi, R., Feller, S.M., and Li, S.S. (2012b). Phosphotyrosine recognition 
domains: the typical, the atypical and the versatile. Cell Commun Signal 10, 32. 
Kannaiyan, R., and Mahadevan, D. (2018). A comprehensive review of protein kinase 
inhibitors for cancer therapy. Expert Rev Anticancer Ther 18, 1249-1270. 
Kleiman, L.B., Maiwald, T., Conzelmann, H., Lauffenburger, D.A., and Sorger, P.K. 
(2011). Rapid phospho-turnover by receptor tyrosine kinases impacts downstream 
signaling and drug binding. Mol Cell 43, 723-737. 
Klesse, L.J., Meyers, K.A., Marshall, C.J., and Parada, L.F. (1999). Nerve growth factor 
induces survival and differentiation through two distinct signaling cascades in PC12 cells. 
Oncogene 18, 2055-2068. 
Krebs, E.G., and Fischer, E.H. (1956). The phosphorylase b to a converting enzyme of 
rabbit skeletal muscle. Biochim Biophys Acta 20, 150-157. 
Kuriyan, J., and Cowburn, D. (1997). Modular peptide recognition domains in eukaryotic 
signaling. Annu Rev Biophys Biomol Struct 26, 259-288. 
Ladbury, J.E., and Arold, S.T. (2011). Energetics of Src homology domain interactions in 
receptor tyrosine kinase-mediated signaling. Methods Enzymol 488, 147-183. 
23 
 
Ladbury, J.E., Lemmon, M.A., Zhou, M., Green, J., Botfield, M.C., and Schlessinger, J. 
(1995). Measurement of the binding of tyrosyl phosphopeptides to SH2 domains: a 
reappraisal. Proc Natl Acad Sci U S A 92, 3199-3203. 
Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, K., 
Dewar, K., Doyle, M., FitzHugh, W., et al. (2001). Initial sequencing and analysis of the 
human genome. Nature 409, 860-921. 
Lee, E., Liu, X., Eglit, Y., and Sack, F. (2013). FOUR LIPS and MYB88 conditionally 
restrict the G1/S transition during stomatal formation. J Exp Bot 64, 5207-5219. 
Lemmon, M.A. (2009). Ligand-induced ErbB receptor dimerization. Exp Cell Res 315, 
638-648. 
Levene, P.A., and Schormuller, A. (1933). The synthesis of tyrosinephosphoric acid. 
Journal of Biological Chemistry 100, 583-587. 
Levitzki, A. (2013). Tyrosine kinase inhibitors: views of selectivity, sensitivity, and 
clinical performance. Annu Rev Pharmacol Toxicol 53, 161-185. 
Lim, W.A., and Pawson, T. (2010). Phosphotyrosine signaling: evolving a new cellular 
communication system. Cell 142, 661-667. 
Lin, J.J., and Shaw, A.T. (2016). Resisting Resistance: Targeted Therapies in Lung Cancer. 
Trends Cancer 2, 350-364. 
Linggi, B., and Carpenter, G. (2006). ErbB receptors: new insights on mechanisms and 
biology. Trends Cell Biol 16, 649-656. 
Liu, B.A., Engelmann, B.W., and Nash, P.D. (2012). The language of SH2 domain 
interactions defines phosphotyrosine-mediated signal transduction. FEBS Lett 586, 2597-
2605. 
Liu, B.A., Jablonowski, K., Raina, M., Arcé, M., Pawson, T., and Nash, P.D. (2006). The 
Human and Mouse Complement of SH2 Domain Proteins—Establishing the Boundaries 
of Phosphotyrosine Signaling. In Molecular Cell, pp. 851-868. 
Liu, B.A., Shah, E., Jablonowski, K., Stergachis, A., Engelmann, B., and Nash, P.D. 
(2011). The SH2 domain-containing proteins in 21 species establish the provenance and 
scope of phosphotyrosine signaling in eukaryotes. Sci Signal 4, ra83. 
Liyasova, M.S., Ma, K., and Lipkowitz, S. (2015). Molecular pathways: cbl proteins in 
tumorigenesis and antitumor immunity-opportunities for cancer treatment. Clin Cancer Res 
21, 1789-1794. 
Lovly, C.M., and Shaw, A.T. (2014). Molecular pathways: resistance to kinase inhibitors 
and implications for therapeutic strategies. Clin Cancer Res 20, 2249-2256. 
Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002). The 
protein kinase complement of the human genome. Science 298, 1912-1934. 
24 
 
Marquardt, H., Hunkapiller, M.W., Hood, L.E., and Todaro, G.J. (1984). Rat transforming 
growth factor type 1: structure and relation to epidermal growth factor. Science 223, 1079-
1082. 
Matlock, M.K., Holehouse, A.S., and Naegle, K.M. (2015). ProteomeScout: a repository 
and analysis resource for post-translational modifications and proteins. Nucleic Acids Res 
43, D521-530. 
Medves, S., and Demoulin, J.B. (2012). Tyrosine kinase gene fusions in cancer: translating 
mechanisms into targeted therapies. J Cell Mol Med 16, 237-248. 
Milo, R. (2013). What is the total number of protein molecules per cell volume? A call to 
rethink some published values. Bioessays 35, 1050-1055. 
Mitra, S.K., and Schlaepfer, D.D. (2006). Integrin-regulated FAK-Src signaling in normal 
and cancer cells. Curr Opin Cell Biol 18, 516-523. 
Moen, M.D., McKeage, K., Plosker, G.L., and Siddiqui, M.A. (2007). Imatinib: a review 
of its use in chronic myeloid leukaemia. Drugs 67, 299-320. 
Mohapatra, B., Ahmad, G., Nadeau, S., Zutshi, N., An, W., Scheffe, S., Dong, L., Feng, 
D., Goetz, B., Arya, P., et al. (2013). Protein tyrosine kinase regulation by ubiquitination: 
critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta 1833, 122-139. 
Monteleone, M.C., Gonzalez Wusener, A.E., Burdisso, J.E., Conde, C., Caceres, A., and 
Arregui, C.O. (2012). ER-bound protein tyrosine phosphatase PTP1B interacts with Src at 
the plasma membrane/substrate interface. PLoS One 7, e38948. 
Morris, S.W., Kirstein, M.N., Valentine, M.B., Dittmer, K.G., Shapiro, D.N., Saltman, 
D.L., and Look, A.T. (1994). Fusion of a kinase gene, ALK, to a nucleolar protein gene, 
NPM, in non-Hodgkin's lymphoma. Science 263, 1281-1284. 
Mouse Genome Sequencing, C., Waterston, R.H., Lindblad-Toh, K., Birney, E., Rogers, 
J., Abril, J.F., Agarwal, P., Agarwala, R., Ainscough, R., Alexandersson, M., et al. (2002). 
Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520-562. 
Nowell, P.C. (1962). The minute chromosome (Phl) in chronic granulocytic leukemia. Blut 
8, 65-66. 
Oppermann, H., Levinson, A.D., Varmus, H.E., Levintow, L., and Bishop, J.M. (1979). 
Uninfected vertebrate cells contain a protein that is closely related to the product of the 
avian sarcoma virus transforming gene (src). Proc Natl Acad Sci U S A 76, 1804-1808. 
Pawson, T. (2004). Specificity in signal transduction: from phosphotyrosine-SH2 domain 
interactions to complex cellular systems. Cell 116, 191-203. 
Peles, E., Bacus, S.S., Koski, R.A., Lu, H.S., Wen, D., Ogden, S.G., Levy, R.B., and 
Yarden, Y. (1992). Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein 
that induces differentiation of mammary tumor cells. Cell 69, 205-216. 
Quintas-Cardama, A., Kantarjian, H., and Cortes, J. (2007). Flying under the radar: the new 
wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6, 834-848. 
25 
 
Resh, M.D. (1994). Myristylation and palmitylation of Src family members: the fats of the 
matter. Cell 76, 411-413. 
Robinson, D.R., Wu, Y.M., and Lin, S.F. (2000). The protein tyrosine kinase family of the 
human genome. Oncogene 19, 5548-5557. 
Roskoski, R. (2004). Src protein-tyrosine kinase structure and regulation. In Biochemical 
and Biophysical Research Communications, pp. 1155-1164. 
Roskoski, R., Jr. (2005). Src kinase regulation by phosphorylation and dephosphorylation. 
Biochem Biophys Res Commun 331, 1-14. 
Rossari, F., Minutolo, F., and Orciuolo, E. (2018). Past, present, and future of Bcr-Abl 
inhibitors: from chemical development to clinical efficacy. J Hematol Oncol 11, 84. 
Rowley, J.D. (1973). Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 
243, 290-293. 
Sadowski, I., Stone, J.C., and Pawson, T. (1986). A noncatalytic domain conserved among 
cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming 
activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol 6, 4396-4408. 
Sasada, R., Ono, Y., Taniyama, Y., Shing, Y., Folkman, J., and Igarashi, K. (1993). 
Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF 
family. Biochem Biophys Res Commun 190, 1173-1179. 
Scott, R.P., Eketjall, S., Aineskog, H., and Ibanez, C.F. (2005). Distinct turnover of 
alternatively spliced isoforms of the RET kinase receptor mediated by differential 
recruitment of the Cbl ubiquitin ligase. J Biol Chem 280, 13442-13449. 
Seet, B.T., Dikic, I., Zhou, M.M., and Pawson, T. (2006). Reading protein modifications 
with interaction domains. Nat Rev Mol Cell Biol 7, 473-483. 
Sefton, B.M., Hunter, T., Beemon, K., and Eckhart, W. (1980). Evidence that the 
phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus. 
Cell 20, 807-816. 
Seidman, A.D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P.K., Gipson, G., 
Burstein, H., Lake, D., Shapiro, C.L., et al. (2008). Randomized phase III trial of weekly 
compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for 
all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 
nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin 
Oncol 26, 1642-1649. 
Sharma, K., D'Souza, R.C., Tyanova, S., Schaab, C., Wisniewski, J.R., Cox, J., and Mann, 
M. (2014). Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr 
and Ser/Thr-based signaling. Cell Rep 8, 1583-1594. 
Shing, Y., Christofori, G., Hanahan, D., Ono, Y., Sasada, R., Igarashi, K., and Folkman, J. 
(1993). Betacellulin: a mitogen from pancreatic beta cell tumors. Science 259, 1604-1607. 
26 
 
Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T., and Mori, S. (1994). 
Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human 
Ki-1 lymphoma cell line, AMS3. Oncogene 9, 1567-1574. 
Shoyab, M., Plowman, G.D., McDonald, V.L., Bradley, J.G., and Todaro, G.J. (1989). 
Structure and function of human amphiregulin: a member of the epidermal growth factor 
family. Science 243, 1074-1076. 
Songyang, Z., Shoelson, S.E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W.G., King, F., 
Roberts, T., Ratnofsky, S., Lechleider, R.J., et al. (1993). SH2 domains recognize specific 
phosphopeptide sequences. Cell 72, 767-778. 
Songyang, Z., Shoelson, S.E., McGlade, J., Olivier, P., Pawson, T., Bustelo, X.R., 
Barbacid, M., Sabe, H., Hanafusa, H., Yi, T., et al. (1994). Specific motifs recognized by 
the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol Cell Biol 
14, 2777-2785. 
Sorkin, A., and Von Zastrow, M. (2002). Signal transduction and endocytosis: close 
encounters of many kinds. Nat Rev Mol Cell Biol 3, 600-614. 
Stehelin, D., Fujita, D.J., Padgett, T., Varmus, H.E., and Bishop, J.M. (1977). Detection 
and enumeration of transformation-defective strains of avian sarcoma virus with molecular 
hybridization. Virology 76, 675-684. 
Strachan, L., Murison, J.G., Prestidge, R.L., Sleeman, M.A., Watson, J.D., and Kumble, 
K.D. (2001). Cloning and biological activity of epigen, a novel member of the epidermal 
growth factor superfamily. J Biol Chem 276, 18265-18271. 
Thomas, S.M., and Brugge, J.S. (1997). Cellular functions regulated by Src family kinases. 
Annu Rev Cell Dev Biol 13, 513-609. 
Tonks, N.K. (2006). Protein tyrosine phosphatases: from genes, to function, to disease. Nat 
Rev Mol Cell Biol 7, 833-846. 
Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., Isobe, T., Okuyama, T., and 
Hanada, K. (1995). Epiregulin. A novel epidermal growth factor with mitogenic activity 
for rat primary hepatocytes. J Biol Chem 270, 7495-7500. 
Twomey, J.D., Brahme, N.N., and Zhang, B. (2017). Drug-biomarker co-development in 
oncology - 20 years and counting. Drug Resist Updat 30, 48-62. 
Ushiro, H., and Cohen, S. (1980). Identification of phosphotyrosine as a product of 
epidermal growth factor-activated protein kinase in A-431 cell membranes. J Biol Chem 
255, 8363-8365. 
Van de Peer, Y., Mizrachi, E., and Marchal, K. (2017). The evolutionary significance of 
polyploidy. Nat Rev Genet 18, 411-424. 
Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., 
Slamon, D.J., Murphy, M., Novotny, W.F., Burchmore, M., et al. (2002). Efficacy and 
safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing 
metastatic breast cancer. J Clin Oncol 20, 719-726. 
27 
 
Volpe, P., and Eremenko-Volpe, T. (1970). Quantitative studies on cell proteins in 
suspension cultures. Eur J Biochem 12, 195-200. 
Waksman, G., Kominos, D., Robertson, S.C., Pant, N., Baltimore, D., Birge, R.B., 
Cowburn, D., Hanafusa, H., Mayer, B.J., Overduin, M., et al. (1992). Crystal structure of 
the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-
phosphorylated peptides. Nature 358, 646-653. 
Waksman, G., Kumaran, S., and Lubman, O. (2004). SH2 domains: role, structure and 
implications for molecular medicine. Expert Rev Mol Med 6, 1-18. 
Walsh, D.A., Perkins, J.P., and Krebs, E.G. (1968). An adenosine 3',5'-monophosphate-
dependant protein kinase from rabbit skeletal muscle. J Biol Chem 243, 3763-3765. 
Waterman, H., Katz, M., Rubin, C., Shtiegman, K., Lavi, S., Elson, A., Jovin, T., and 
Yarden, Y. (2002). A mutant EGF-receptor defective in ubiquitylation and endocytosis 
unveils a role for Grb2 in negative signaling. EMBO J 21, 303-313. 
Wei, R., Kaneko, T., Liu, X., Liu, H., Li, L., Voss, C., Liu, E., He, N., and Li, S.S. (2018). 
Interactome Mapping Uncovers a General Role for Numb in Protein Kinase Regulation. 
Mol Cell Proteomics 17, 2216-2228. 
Wei, R., Liu, X., Voss, C., Qin, W., Dagnino, L., Li, L., Vigny, M., and Li, S.S. (2019). 
NUMB regulates the endocytosis and activity of the anaplastic lymphoma kinase in an 
isoform-specific manner. J Mol Cell Biol. 
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A.M., Lieberenz, M., Savitski, M.M., 
Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., et al. (2014). Mass-spectrometry-based 
draft of the human proteome. Nature 509, 582-587. 
Wu, P., Nielsen, T.E., and Clausen, M.H. (2015). FDA-approved small-molecule kinase 
inhibitors. Trends Pharmacol Sci 36, 422-439. 
Xing, Z., Chen, H.C., Nowlen, J.K., Taylor, S.J., Shalloway, D., and Guan, J.L. (1994). 
Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. 
Mol Biol Cell 5, 413-421. 
Yarden, Y., and Sliwkowski, M.X. (2001). Untangling the ErbB signalling network. Nat 
Rev Mol Cell Biol 2, 127-137. 
Zhang, D., Sliwkowski, M.X., Mark, M., Frantz, G., Akita, R., Sun, Y., Hillan, K., 
Crowley, C., Brush, J., and Godowski, P.J. (1997). Neuregulin-3 (NRG3): a novel neural 
tissue-enriched protein that binds and activates ErbB4. Proc Natl Acad Sci U S A 94, 9562-
9567. 
Zhang, J., Yang, P.L., and Gray, N.S. (2009). Targeting cancer with small molecule kinase 
inhibitors. Nat Rev Cancer 9, 28-39. 
Zheng, Y., Zhang, C., Croucher, D.R., Soliman, M.A., St-Denis, N., Pasculescu, A., 
Taylor, L., Tate, S.A., Hardy, W.R., Colwill, K., et al. (2013). Temporal regulation of EGF 




2 SH2 superbinder-AP-MS for Examining TK Activation in 
Cancer Samples 
 Abstract 
The human genome harbors 90 TK genes. Over 20 of these have been characterized as 
biomarkers across a wide variety of cancers and more than half of all approved anti-cancer 
targeted therapeutics are TK inhibition molecules. Many TKs are functionally redundant 
and stimulate the same oncogenic signaling pathways, therefore the retention of (on-target 
or non-target) TK activity becomes one of the major influences on the efficacy of TK 
inhibition therapy. The examination of TK biomarkers mainly relies on the gold standard 
IHC and FISH assays, which are low-multiplexing and incapable of profiling TK activity 
systematically due to the limitations of visual perception. Next generation sequencing has 
recently been approved for screening genomic alterations in cancer, but gene 
amplification/mutation are not direct indicators of TK activity. Here we have developed a 
superbinder SH2 enabled AP-MS assay for evaluating TK activity by targeting functional 
pTyr sites on 87 TKs. This assay combines a highly efficient pTyr affinity purification 
afforded by the superbinder SH2 and MS analysis. In the examination of clinical samples, 
the activation loop peptides of known TK biomarkers were identified from both leukemia 
whole blood and solid tumors tissues, even from a minute amount of protein recovered 
from a few FFPE (formalin-fixed, paraffin-embedded) slides. In cell models of drug 
resistance, TK reprogramming was monitored in the SK-BR-3 breast cancer cells treated 
with trastuzumab, and the deregulation of c-Kit receptor tyrosine kinase was shown to be 
responsible for acquired trastuzumab resistance. The SH2-AP-MS approach bears great 
potential for discovering TK biomarkers and deciphering resistance mechanism to targeted 
therapeutics. This assay has potential to be applied either independently or as a 







Along with the great success of anti-cancer targeted therapeutics, the biomarker-based 
classification of cancer subtypes has become crucial for guiding the design of therapy in 
the clinic, particularly for the treatment of advanced stage cancer (Mabert et al., 2014). The 
identification of selected TKs, as well as other types of biomarkers, have become routine 
examinations for many cancer types in clinical laboratory (Pavlou et al., 2013). As 
introduced earlier, ErbB2 (HER2) is a TK biomarker in breast cancer. The analysis of 
ErbB2, estrogen receptor (ER) and progesterone receptor (PR) are already widely accepted 
for classifying breast cancer (Gradishar et al., 2018). Conventionally, examination of 
protein or gene biomarkers all employ the same strategies and techniques: immune-
histochemistry (IHC) assays for evaluating protein abundance and in situ hybridization 
assays (ISH) for detecting gene fusion or amplification. These robust assays are relatively 
sensitive and accurate and have been used in both research and clinic laboratories for 
decades. Until now there are still massive efforts underway to develop these gold standard 
examination tools to match the continuous discovery of new biomarkers in different 
diseases including cancer. However, with the emergence of the personal/precision 
medicine concept, these conventional tools are being challenged by more comprehensive 
and quantitative omics techniques (Collins et al., 2017; Jung, 2016; Tanase et al., 2016).  
2.2.1 Limitations of conventional TK examination assays 
Several limitations can impede the application of conventional assays in comprehensive 
evaluation of TK activity in cancer. 
1) Low multiplexing capability. Conventional biomarker diagnostic assays rely on the 
specific interaction between biomarkers and probes and generally follow the same strategy: 
staining the biopsy tissue section with probes and then visualizing the probe/biomarker by 
microscopy. Theoretically the probes, either specific antibodies or complementary nucleic 
acid fragments, are highly selective, therefore it is possible to apply multiple probes to 
detect their corresponding biomarkers simultaneously. However, multiplexing is greatly 
limited by the visual perception adopted in all these assays. In a high-end fluorescence 
microscope, combinations of different excitation sources and emission filters may visualize 
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four to five spectrally distinct fluorochromes simultaneously. It is possible to precisely 
excite more fluorochromes with different laser sources, but the wide emission spectra 
(typically 40~50 nm with broad tails) can result in severe spectral overlapping in the narrow 
blue-to-red spectral window, which means the emission from a given fluorochrome 
contributes to the signal of multiple emission channels. Currently quadruplex IHC seems 
to be the highest level of multiplexing IHC that can be potentially applied in FFPE 
examination in the clinic (Dixon et al., 2015). Some of our preliminary data already reveals 
that cancer cells may co-express multiple TKs in relatively high levels, for which only a 
cocktail of corresponding TK inhibitors can effectively inhibit cell proliferation (Bian et 
al., 2016). Clearly, quadruplex IHC is incapable of revealing  the complexity of TK 
activation in some cancers. Over 20 TKs have been identified as biomarkers in various 
cancer types and it is likely that more TKs and TK associated proteins will be added to the 
list of potential therapeutic targets in the future (Kannaiyan and Mahadevan, 2018; 
Levitzki, 2013; Wu et al., 2015). Using a different strategy of microscopic detection may 
improve the technique. For instance, characterizing photostability or Raman scattering can 
distinguish spectra-overlapping fluorochromes and greatly increase the multiplexing level 
(Orth et al., 2018; Wei et al., 2017). However, none of these microscopy technologies have 
been applied in biopsy examination in the clinic to date, and technically speaking, multi-
probe staining is not a practical assay. 
2) Compromised data reproducibility. It is believed that different labs or pathologists may 
have slightly different criteria to determine TK status, especially when the TK abundance 
or amplification are not strongly positive or negative (Handorf et al., 2013). The classic 
IHC assay and fluorescent in situ hybridization (FISH) assay both have a complicated 
sample preparation process consisting of tens of steps including tissue fixation, 
dehydration, paraffin embedding, sectioning and re-hydration, all before incubation with 
antibody or nucleic acid probes. Days of bench work will be required for obtaining the raw 
data. Even though highly stringent protocols have been established for these assays, the 
batch-to-batch variation is still hardly eliminated or minimized to a certain level 
consistently. The inherent heterogeneity in the distribution of TK positive cells within the 
tumor may pose another problem. It was previously estimated that more than 10% of 
HER2-positive breast cancer diagnosis yield inaccurate results, falsely reporting HER2 
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status (Paik et al., 2002; Perez et al., 2006; Sauter et al., 2009; Sui et al., 2009; Wolff et al., 
2007). Taking advantage of rapidly-developing artificial intelligence (AI, or deep learning) 
technology, some attempts have been made to automate image analysis to increase the 
accuracy of microscopy-based analysis and help reduce human error (Khosravi et al., 
2017). However, image analysis AI platforms are still frequently unreliable, often unable 
to distinguish dogs from cats, for example. 
3) Less quantitative reporting. In HER2 biopsy examination by IHC or FISH, the status of 
HER2 is classified as 0 degree (HER2 negative), +1 degree (HER2 positive, marginal), +2 
degree and highest +3 degree (HER2 positive). A noticeable problem of HER2 examination 
is its accuracy or the value in guiding therapy design. Based on clinical trials and 
subsequent statistical studies, the degree of HER2 activation determined by IHC/FISH did 
not correlate well with response to treatment with HER2 inhibition antibody trastuzumab 
(Denkert et al., 2013; Vassilakopoulou et al., 2014; Xu et al., 2016). In fact, approximately 
70% of breast patients diagnosed as HER2 positive do not respond to trastuzumab 
treatment at all (Perez et al., 2010; Seidman et al., 2008). Using the same assays, the MCF7 
cell line is defined as HER2 0 degree or +1 degree because HER2 expression is detectable 
but relatively less-abundant in MCF7. In contrast, the SK-BR-3 or BT-474 cell lines are 
HER2 +3 degree as they are known cell lines expressing high levels of HER2. 
Quantitatively, SK-BR-3 or BT-474 cells express 100~150-fold higher HER2 protein 
compared to MCF7 cells (Bian et al., 2016; Holliday and Speirs, 2011; Subik et al., 2010). 
It could be anticipated a quantitative and comprehensive report would provide more 
invaluable guidance for physicians to design the strategy of treatment and decide the dose 
of therapeutics precisely. As will be presented in this thesis, ErbB2 (HER2) is the dominant 
RTK in SK-BR-3 and BT-474, while multiple RTKs are co-deregulated in MCF7 including 
ErbB2, DDR1(Epithelial discoidin domain-containing receptor) and IGF-1R/INSR 
(Insulin receptors). None of these RTKs are extremely active in MCF7 cells, but their 
expression profiles are all relatively abundant among nine cancer cell lines examined (Bian 
et al., 2016). It is intriguing that only a combination of inhibitors against 
ErbB2/DDR1/INGF-1R/INSR exhibited great inhibitory effect on MCF7 cell viability, 
which was additive and dose-dependent, but individual inhibitors at an identical 
concentration had little to no effect on MCF7 cell viability. 
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2.2.2 Mass spectrometry  
Mass spectrometry (MS) is an analytical technique that is powerful and widely applied in 
bio-omics studies (Aebersold and Goodlett, 2001; Vestal, 2011). The basic principle of 
mass spectrometry is to generate ions from the analyte by applicable ionization methods, 
to separate the ions by their distinct mass-to-charge (m/z) ratio using mass analyzers, and 
to determine the abundance of ions qualitatively or quantitatively using ion detectors 
(Gross, 2004). Regarding the proteomics study, which is largely depending on the analysis 
of peptides enzymatically digested from proteins, liquid chromatography-electrospray 
ionization-tandem mass spectrometry (LC-ESI-MS/MS) systems are preferred. These MS 
systems convert peptides into ions by electrospray ionization, and combine the physical 
separation capability of LC (or high-performance liquid chromatography, HPLC) with the 
mass analysis capability of MS. In tandem MS systems with multiple mass analyzers, the 
mass-selected ions (MS1) are subjected to a second (MS2) or even more rounds of mass 
spectrometric analysis (MSn), which exhibits great advantages for the analysis of specific 
organic compounds in a complex matrix, such as peptides digested from whole cell lysate 
(McLafferty, 1981). A collision module is typically equipped in tandem MS systems 
between MS1 and MS2, which allows the collision between ionized analytes and neutral 
gas atoms (helium, nitrogen or argon). During collision, some energy is converted into 
internal energy resulting in bond breakages within the analytes. This process is known as 
collision-induced dissociation (CID) or collision-activated dissociation (CAD) (Jennings, 
2000). In a classic tandem MS workflow, the analytes are first ionized, and the target ions 
are filtered from the matrix in the first mass analyzer. The selected analytes are then 
fragmented in the collision module, and from the daughter ions the secondary mass 
analyzer isolates target ions again which are finally quantified in the ion detector 
(McLafferty, 1981). Theoretically for peptide or protein analyses, the amino acid sequence 
and modification could be clearly elucidated by analyzing the data combined from MS1 
and MS2. In the form of LC-MS/MS, this workflow becomes even more specific when the 
peptides are pre-separated by chromatography. 
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2.2.2.1 Mass spectrometry systems used in this study 
Two tandem LC-MS systems, the SCIEX triple-quadrupole MS system and the Thermo 
QExactive quadrupole-orbitrap hybrid MS system, were used in my studies.  
The quadrupole is a classic type of mass analyzer (Dawson, 1986; Gross, 2004; Miller and 
Denton, 1986). A quadrupole analyzer consists of four cylindrical (z-direction) rod 
electrodes, or even hyperbolically shaped rods (Thermo), that are arranged in a square 
configuration (xy-plane). The pairs of opposite rods are each connected to radio-frequency 
(RF) and direct-current (DC) power supplies at the same potential. Once an ion enters the 
quadrupole via the z-direction, the ion will oscillate in the xy-directions due to the periodic 
attraction/repulsion forces generated from the RF and DC electrical fields. As the space is 
limited among the quadrupole in xy-directions, some ions may hit the rods and become 
neutralized due to over-the-range oscillation amplitudes in xy-directions, while other ions 
may pass through, thereby selected by the quadrupole MS analyzer. By defining the RF 
and DC voltage and frequency, a narrow m/z window could be opened for the pass-through 
of ions with specific m/z values. The triple-quadrupole MS is a tandem mass spectrometer 
consisting of two quadrupole MS analyzers (MS1/MS2), and a non-mass-selected (RF 
only) quadrupole (collision cell) between MS1 and MS2 for analyte fragmentation. This 
design was first developed in late 1970s (Yost and Enke, 1978), is currently the most 
reliable and robust MS system used in a multitude of research and industrial fields, and is 
arguably the best choice of equipment for quantitative targeted proteomics.  
A major drawback of the triple-quadrupole is the low resolving power (mass resolution). 
Mass resolution is the degree of separation of analytes with slightly different m/z values 
and defined as the smallest difference in m/z (Δm/z) that can be distinguished for a given 
m/z value: resolution = (m/z) / (Δm/z). Typically, the quadrupole resolution is only a few 
thousands which restricts its applications to tasks that do not require high resolution. Mass 
accuracy is another parameter closely related to the mass resolution, which can be 
calculated as the absolute mass difference (experimental v.s. theoretical) divided by 
theoretical mass and given in parts per million (ppm). Similarly, a quadrupole does not 
have excellent mass accuracy, even though mechanical optimization is being continuously 
developed (Yang et al., 2002). Due to the lower resolution and accuracy, quantitative 
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proteomics typically require more procedures and additional testing using synthesized 
peptides in the triple-quadrupole system (Gross, 2004). Multiple rounds of ion selection 
and parameter optimization for individual synthetic peptides need to be carried out and a 
standard MS2 spectral library is usually built in this process.  In the analysis of bio-
materials that are highly complicated and may contain a lot of interfering ions (analytes 
with similar LC elution timing and close m/z values in MS1/MS2), the MS2 spectrum of a 
targeted peptide can be searched in the standard spectral library, thereby allowing the 
selection of genuine daughter ions derived from the target peptides. 
The orbitrap is an ion-trap type of mass analyzer employing ion trapping in an electrostatic-
only field, which is generated between an outer barrel-like electrode and a coaxial inner 
spindle-like electrode (Makarov, 2000). In the presence of an RT field (as that in a 
quadrupole), ions orbit around the coaxial inner electrode that perform harmonic oscillation 
with frequencies determined by the corresponding m/z values. The image charge induced 
by the ion motion passing near the conductor (image current) is then recorded and 
converted to a mass spectrum by Fourier transform (Hu et al., 2005; Makarov, 2000). A 
great advantage of orbitrap mass analyzer is high mass resolution and mass accuracy. The 
proto-type orbitrap built in 1990s already reached a resolution of 140,000.  Our Thermo 
QExactive system has a resolution ranging from 17,500 to 140,000. Even with a resolution 
of 17,500, mass accuracy is typically within 5 ppm for most peptides, which is comparable 
to decent triple quadrupole systems or even better. In addition, unlike the quadrupole mass 
analyzer that only selects one ion in one scanning round, the orbitrap analyzer can handle 
and detect tens of ions simultaneously, making it more practical in discovery proteomics 
studies.  
2.2.2.2 Protein digestion  
Even though intact proteins or protein complexes are analyzable in some specialized MS 
systems, enzymatically digested peptides are still the most common analytes in MS-based 
proteomics studies, therefore protein digestion using a dedicated protease represents a key 
procedure in the classic proteomics experiment. The serine protease trypsin is 
predominantly utilized to cleave proteins, mainly due to its sequence-specificity, high 
activity, and cost-efficiency.  Trypsin was discovered over a century ago and is widely 
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found in the digestive system of vertebrates where it hydrolyzes food proteins (Rawlings 
and Barrett, 1994). Trypsin cleaves peptide chains specifically at the carboxy-terminal of 
the amino acids Arginine (R) and Lysine (K), except when followed by Proline (P). Wild 
type trypsin undergoes autolysis, which generates pseudotrypsin with broadened cleavage 
specificity. To eliminate the possible mis-cleavages produced by pseudotrypsin, trypsin is 
usually modified in lysine residues by reductive methylation (Keil-Dlouha et al., 1971; 
Rice et al., 1977), yielding an autolysis-resistant trypsin variant that is more suitable for 
proteomics studies.  
The length of tryptic digested peptides typically ranges between 8 and 30 amino acids, 
which are efficiently separated by LC using reversed-phase chromatography (hydrophobic 
chromatography) with an octadecyl-carbon chain (C18) bonded silica as the stationary 
phase, and a mixture of water (polar) and organic solvent (acetonitrile, ACN, non-polar) as 
the mobile phase. C18 is hydrophobic and has a strong affinity for hydrophobic peptides 
in the polar mobile phase, which can be eluted from C18 by decreasing the polarity of the 
solution in the mobile phase. In a mobile phase gradient with decreasing polarity, peptides 
with increasing hydrophobicity will be eluted sequentially. Following LC separation, 
tryptic digested peptides are also optimal for ionization in ESI. Arginine and lysine are two 
of the three positive amino acids. During ionization in the acidic mobile phase, the amine 
group at the amino-terminus and arginine or lysine at the carboxyl-terminus typically make 
the peptide +2 charged. If another positive amino acid histidine is included in the sequence, 
or there is a R/K miscleavage, the peptide ion could be +3 charged. Both +2 and +3 
charging, and even +4 charging of most tryptic digested peptides all fall within the 
appropriate m/z range for MS detection.  
2.2.2.3 Peptide fragmentation 
Peptide fragmentation and subsequent MS2 analysis is crucial for identifying the peptide 
sequence and PTMs on specific amino acids. During fragmentation, the flying peptides 
collide with neutral gas atoms and break into charged fragments (daughter ions). Several 
daughter ion types may be generated due to the different break sites within the peptides, 
which is determined by many factors including peptide sequence, charge status, collision 
energy etc. As shown in Fig.2.1, if a precursor peptide breaks once in the peptide backbone, 
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six different types of daughter ions may be produced, which are also termed “sequence 
ions” as they carry an intact amino-terminus or carboxyl-terminus containing fragments of 
the precursor peptide (Roepstorff and Fohlman, 1984). The fragments with the intact 
amino-terminus are named as a, b and c ions, whereas their complementary fragments with 
intact carboxyl-terminus are referred to as x, y and z ions. The distribution of positive 
(basic) amino acids (R/K/H) and charge status are key factors governing the fragmentation 
behavior of protonated peptides. Among all ions, b and y type ions are the most common 
ion types. y ions are most important sequence ions for tryptic peptides and y1 and y2 ions 
are almost universally present in MS2, while b2 and b3 ions are also present in most MS2 
peptide spectrums.   
Breakage in the side chain or multiple breakages in the backbone produce additional types 
of daughter ions. Compared to the sequence ions with intact amino- or carboxyl-termini, 
these ions are usually less important for proteomics studies. However, in some specific MS 
applications, detection of non-sequence ions is of great value as well. For instance, a 
combination of a type and y type cleavages produces immonium ions that carry 
composition information for amino acids. In the detection of pTyr peptides, the existence 
of immonium ion at m/z 216.0426 is solid evidence of tyrosine phosphorylation. Because 
the non-sequencing ions are usually located in the low m/z range and less abundant than 






Figure 2.1 Nomenclature for peptide fragmentation 
Simplified nomenclature for peptide cleavage within backbone and fragmented ions in collision 




2.2.2.4 Mass spectrometry methods 
In MS-based proteomics studies, there are two fundamental strategies: targeted 
quantification and discovery-based identification. With a targeted quantification, the goal 
is to monitor a selection of peptides/proteins of interest with high sensitivity, 
reproducibility and quantitative accuracy. On the other hand, with discovery-based 
identification, the goal is to identify as many peptides/proteins as possible, and in this case, 
the abundance of analytes is qualitative only or relatively quantitative (Doerr, 2012, 2014). 
The targeted strategy of mass spectrometry usually combines tandem MS analyzers with 
LC to detect a specific analyte at a specific time (LC retention time). There are several MS 
methods usually applied in the qualification and quantification of peptides: multiple 
(selected) reaction monitoring (MRM/SRM), parallel reaction monitoring (PRM) and 
selected ion monitoring (SIM).  
MRM is a widely accepted method in quantitative targeted proteomics, performed on the 
classic triple quadrupole MS system introduced above. The precursor is first isolated in 
MS1 to enter the collision cell for fragmentation, then a specific daughter ion is isolated 
again in MS2 to enter the detector. In MRM, the m/z values of both precursor and daughter 
ions need to be defined and the daughter ions are scanned sequentially. Once the MS2 
spectral library and calibration curve are built using standard/synthesized peptides, MRM 
can quantify the peptide abundance absolutely and accurately.  
Both PRM and SIM are newer methods developed along with the application of orbitrap 
MS analyzer. Because the orbitrap analyzer can analyze all detectable daughter ions in a 
wide m/z range simultaneously, only the m/z values of precursors are defined in PRM and 
SIM methods. In our QExactive quadrupole-orbitrap MS system, PRM uses the front-end 
quadrupole (MS1) analyzer to isolate the precursor, then fragments it in the collision cell 
and finally detects all daughter ions in the orbitrap (MS2) analyzer. SIM collects the data 
for daughter ions in the same way as PRM, but also measures the precursor abundance 
directly without fragmentation in another scanning. Therefore, PRM identifies and 
quantifies peptides using daughter ion data, while SIM identifies peptides using daughter 
ion data but quantifies peptides using precursor ion data. Because the fragmentation 
efficiency is limited, SIM has significant higher sensitivity than PRM. On the other hand, 
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PRM has an advantage over SIM with improved signal-to-noise ratio rather than absolute 
signal, especially in the analysis of highly complicated samples (Gallien et al., 2012). 
Taking advantage of the high resolving power of orbitrap, both PRM and SIM provide high 
selectivity and high sensitivity for confident peptide confirmation, and therefore are 
extremely suitable for identifying a large number of peptides in complicated samples. With 
proper parameter optimization, even hundreds of peptides could be quantified in a single 
test (Kuhlmann et al., 2018). Due to the inherent nature of the orbitrap analyzer, PRM and 
SIM are less quantitative compared to MRM, and require internal standards for proper 
quantification. 
2.2.3 Affinity purification of modified peptides 
Even though protein phosphorylation is a very abundant PTM within the proteome and 
two-thirds of all human proteins are phosphorylated on multiple sites (Sharma et al., 2014), 
phosphorylated peptides only make up a small portion of all peptides digested from the cell 
lysate. Theoretically, the MS should be able to directly isolate and detect phosphorylated 
peptides from the matrix. However, this is highly impractical, even with the highest-end 
MS systems, because of the overwhelming signals from much more abundant non-
phosphorylated peptides. The signal for most phosphorylated peptides could be easily 
masked by non-phosphorylated peptides with close m/z values. Therefore, affinity 
purification (AP) of phosphorylated peptides, as well as any other modified peptides, is an 
essential step in sample preparation for MS-based PTM studies (Fila and Honys, 2012). 
Most enrichment strategies are based on affinity chromatography or immunoprecipitation 
to isolate modified peptides with enhanced affinities to the matrix or PTM-specific 
antibodies. Titanium dioxide (TiO2) and immobilized metal ion affinity chromatography 
(IMAC) are able to capture phosphorylated peptides effectively (de Graaf et al., 2014; 
Sharma et al., 2014; Zhou et al., 2013), but they are only used for enriching pSer and pThr 
peptides. The much less abundant pTyr peptides are usually enriched using anti-pTyr 
antibodies (Rikova et al., 2007; Tinti et al., 2012; Zhang et al., 2005). 
We developed an engineered SH2 superbinder as an ideal reagent for affinity purification 
of pTyr peptides and subsequent MS analysis (Bian et al., 2016). From the study of nine 
lab-cultured cancer cell lines, the SH2-AP-MS approach led to the identification of around 
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10,000 unique pTyr sites, of which over 3,000 sites are novel. Compared to the most 
commonly used 4G10 anti-pTyr antibody, the superbinder has a comparable pTyr 
enriching ability at the same molar amount. The superbinder and 4G10 exhibit differential 
specificity since each method can identify a large portion of unique pTyr peptides.  
However, when 20-fold molar excess amount of the SH2 superbinder was applied, it was 
able to capture almost all pTyr peptides captured as 4G10, plus numerous others. 
Therefore, the SH2 superbinder bears great potential to be used as an alternative to anti-
pTyr antibodies in AP-MS. More importantly, the superbinder is easily expressed and 
purified from bacteria at minimal cost and has excellent stability. 
2.2.4 SH2-AP-MS  
As introduced earlier, TKs are a major type of biomarkers and therapeutic targets in cancer. 
More than half of the FDA approved anti-cancer targeted drugs are TK inhibition 
molecules. In addition, immune checkpoint inhibition therapeutics, such as the humanized 
anti-PD1/PDL1 antibodies, are also designed to interfere with TK activation in immune 
cells (Wilkinson and Leishman, 2018). A common consequence of these therapies is the 
change of tyrosine phosphorylation status in either TK or TK substrates, especially on the 
sites determining kinase activity and signal transduction. This raises the possibility to 
evaluate TK activity and drug response by tracking the PTM dynamics on functional pTyr 
sites. Indeed, some conventional IHC based TK examination assays take advantage of the 
specific anti-pTyr antibodies that only recognize site-specific phosphorylated TK variants, 
which represent active forms of the corresponding TKs (Mandell, 2008). To meet the 
emerging requirement for precision medicine, we have developed an SH2-AP-MS assay 
for simultaneous detection of 79 (PRM) or 157 (MRM) functional pTyr peptides that cover 
up to 87 TKs, including all known TK biomarkers and additional (proto)oncogenic TKs. 
High multiplexity is a major advantage of this approach, compared to the gold standard 
IHC/FISH assays. Since MS is sensitive analytic equipment and the SH2 superbinder 
affinity purification is highly efficient, this assay only requires tens of micrograms of 
proteins, or even less, which can be easily extracted from cultured cells, fast frozen (FF) 




A variety of different patient-derived samples from both solid tumors and leukemia were 
analyzed by this assay, including breast cancer, lung cancer, bile duct cancer, acute 
myelogenous leukemia and chronic lymphocytic leukemia. Several known TK biomarkers 
in these cancer types, such as ALK, BTK and FGFR, were detected with solid MS/MS 
data. This assay was also applied to assess transient TK kinome reprogram in cultured SK-
BR-3 HER2 breast cancer cells treated with the HER2 inhibitor lapatinib. Lapatinib 
inhibition caused acute EGFR/ErbB2/Src activity loss. ErBB2 activity was recovered 
between 24 to 48 hours but both EGFR and Src retained low-level activity.  In addition, 
the mechanism of acquired drug was investigated, which is common in the clinic and one 
of the main reasons for compromised efficiency of targeted therapies. Due to difficulty in 
obtaining patient-derived samples before and after targeted therapy, a trastuzumab resistant 
model was established in SK-BR-3 cells, which were continuously exposed to a low dose 
of trastuzumab for over six months in the lab.  The SH2-AP-MS analysis revealed a 
dramatic increase in the phosphorylation of c-Kit at the activation loop tyrosine residue in 
the resistant clone, consistent with the findings from transcriptome sequencing.  The c-Kit 
inhibitor imatinib alone had little effect on cell viability, however, it re-sensitized the 
resistant cells to trastuzumab treatment, indicating the activation of c-Kit compensated for 
the loss of HER2 activity and contributed to trastuzumab resistance in SK-BR-3 cells. 
Overall, these data have revealed the potential value of the SH2-AP-MS assay in both 




 Materials and Methods 
2.3.1 Cell culture 
All breast cancer cell lines used in this study were grown in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 10% FBS, 100 µg/ml penicillin, 100 
µg/ml streptomycin and 2 mg/ml L-Glutamine. Cells were incubated at 37 °C in a 
humidified atmosphere containing 5% carbon dioxide. 
2.3.2 SH2 superbinder purification and immobilization 
The SH2 superbinder engineered from human Src tyrosine kinase was integrated into the 
pETM-30 vector for GST (glutathione S-transferase) fusion, or the pETM-11 for His (poly-
histidine) fusion (by Courtney Voss). The plasmids were transformed into the BL21 strain 
of Escherichia coli. Positive colonies were isolated by antibiotic resistance and grown in 
liquid Lysogeny Broth (LB) medium (10 g/L tryptone, 5 g/L yeast extract and 10 g/L 
sodium chloride) to reach OD600 0.6~0.8. The cells were then induced by 0.5 mM IPTG 
(isopropyl β-D-1-thiogalactopyranoside) for 16~18 hours at 18 °C with slow rotation. Cells 
were harvested by centrifugation and either processed immediately or stored as a dry pellet 
at -80 °C.  
For GST purification, cells collected from 100 ml culture were resuspended in 10 ml PBS 
(phosphate-buffered saline) buffer containing 2% (v/v) protease inhibitor cocktail (Sigma), 
2% (v/v) Triton X-100, 1 mg/ml lysozyme and 20 units/ml benzonase. The suspension was 
sonicated for 50 seconds (5 seconds * 10 times) and then incubated for 30 minutes on ice. 
Next, the lysate was centrifuged at 15,000 g for 30 minutes at 4 °C and the cleared 
supernatant was flowed through a column with 0.5 ml pre-equilibrated glutathione agarose 
(GST) beads (GenScript). The beads were then washed by 10 ml PBS buffer and the 
purified GST-tagged protein was eluted by PBS buffer containing 10 mM Glutathione.  
The procedures for His-tagged superbinder purification and subsequent immobilization 
were optimized by Dr. Kaneko. The expression of His-tagged superbinder was induced in 
BL21 cells following the same procedures described above. Cells collected from 400 ml 
culture were suspended in 10 ml lysis buffer (50 mM sodium phosphate, 150 mM NaCl, 
20 mM imidazole, 2% (v/v) protease inhibitor cocktail (Sigma), 0.5% (v/v) Triton-X100, 
43 
 
1 mg/ml lysozyme, 20 units/ml benzonase and 0.5 mM TCEP (tris(2-chloroethyl) 
phosphine), pH 8.0). The suspension was sonicated for 50 seconds (5 seconds × 10) and 
then lysed for 30 minutes on ice. Next, the lysate was centrifuged at 15,000 g for 30 minutes 
at 4 °C and the cleared supernatant was passed through the column with 0.8 ml pre-
equilibrated nickel-NTA beads (GenScript). The beads were then washed by 20 ml high-
salt washing buffer (50 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, pH 8.0). 
The purified His-tagged protein was eluted by 4 ml elution buffer (50 mM sodium 
phosphate, 150 mM NaCl, 250 mM imidazole, pH 8.0) and the elution was mixed with 4 
ml coupling buffer (50 mM sodium phosphate, 150 mM NaCl, 20 mM imidazole, 5 mM 
EDTA, pH 8.0). The final elution was filtered, and the protein concentration was adjusted 
to 1 mg/ml by adding coupling buffer. 
For immobilization, 15 mg (in 15ml buffer) superbinder was incubated with 5 ml SulfoLink 
beads (Thermo) for 30 minutes at room temperature, with head-to-toe rotation mixing. The 
beads were collected by centrifugation and then washed in the column with 20 ml coupling 
buffer (flow-through). To neutralize un-reacted iodoacetyl groups, the beads were 
incubated with 15 ml blocking buffer (50 mM cysteine in coupling buffer, filtered) for 45 
minutes at room temperature, with occasional re-suspending. Next, the beads were washed 
in the column with 20 ml washing buffer (50 mM Tris-HCl, 1 M NaCl, pH 8.0, flow-
through) and finally re-suspended in storage buffer (50 mM Tris-HCl, 50 mM NaCl, 0.2% 
sodium azide, pH 7.6). Stocked at 4°C, the SulfoLink-superbinder beads maintain over 
90% activity after two months. 
2.3.3 Free peptide and on-membrane peptide synthesis 
Both free and membrane-bound peptides were synthesized on an automatic Intavis peptide 
synthesizer, using the solid phase peptide synthesis method (Kent, 1988). All regular and 
modified (phosphorylated) amino acids were protected by Fmoc (9-fluorenylmethyl-
oxycarbonyl) or Boc (tert-butyloxycarbonyl) groups to prevent unwanted reactions among 
peptide side chains and the amine group. For free peptides that were synthesized as MS 
standards, Wang-resin conjugated with either arginine (Wang-R) or lysine (Wang-K) were 
used as the solid support phase, since tryptic digestion used in this study only generated 
R/K ending peptides. In the first synthesis cycle (coupling), the protection group 
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(Fmoc/Boc) in R or K was removed with 20% piperidine in DMF (N, N-
Dimethylformamide) which released the free amine group for subsequent coupling. The 
next protected amino acid was attached to this amine group via its carboxyl group, forming 
an amide bond. All un-occupied amine groups were then blocked (acetylated) with acetic 
anhydride to avoid any further incorrect amine bonds in following cycles. Next, 
deprotection was carried out again to generate the free amine group ready for the coupling 
of next amino acid. At the end of the synthesis, the crude peptides were cleaved from the 
solid support resin using a mixture containing 95% TFA (trifluoroacetic acid), 3% TIPS 
(tri-isopropylsilane) and 2% water, which would also remove all other protecting groups 
on amino acid side chains. On-membrane peptides (peptide-array) were synthesized 
following similar procedures, however the solid support phase was replaced with a home-
made amine-derivative cellulose membrane (filter paper) (Frank, 1992).  
To make the amine-derivative cellulose membrane, qualitative filter papers (Whatman) 
were first treated with 100 ml methanol containing 1.2% (v/v) perchloric acid for 15 
minutes, washed with 100 ml 100% ethanol three times and air dried. The filter papers 
were incubated in a mixture with 72 ml dioxane, 8ml epibromohydrine and 800 µl of 60% 
perchloric acid for 3 hours, washed with 100 ml 100% ethanol three times then air dried 
again. Next, the filter papers were incubated in 100 ml 50% 1, 3 diaminopropane (v/v) in 
DMF for at least 16 hours with slow rotation. The filter papers were then washed 
sequentially in 100 ml DMF, 100ml ethanol, 100 ml water and 100ml ethanol, 20 minutes 
per wash and three times in each solution.  The membranes were air-dried following the 
last wash in ethanol. Finally, the filter papers were incubated in 100 ml 0.5 M MeNa 
(sodium methoxide) in methanol for 15 minutes, washed in water three times then air-dried. 
The amine-derivative filter papers were stored at -20 °C and stable for months.  
2.3.4 Far Western blot of peptide array membrane 
Peptide array membranes were pre-blocked with 5% skim milk (m/v) in TBST buffer (0.1 
M Tris-HCl, 150 mM NaCl, and 0.1% Tween 20, pH 7.4) for 1 hour at room temperature, 
with slow shaking. The 4G10 Platinum anti-pTyr antibody (a mixture of 4G10 and pY20 
mouse mAbs, Millipore) was directly added into the blocking solution at 1:1000 ratio to 
blot the membrane for 1 hour at room temperature, with slow shaking. Then the membranes 
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were washed with TBST buffer three times, 5 minutes per wash. Next, the membranes were 
probed with secondary antibody anti-mouse-HRP (1:1000) in 5% (m/v) skim milk in TBST 
buffer for 1 hour at room temperature followed by the same washing procedures. Finally, 
the peptide array was visualized using ECL solution in a Bio-Rad imaging system.  After 
the 4G10 Platinum blotting, the peptide array membranes were washed and incubated for 
30 minutes at room temperature in stripping buffer (1.5% glycine, 0.1% SDS, 1% tween 
20, pH 2.2) (Kaufmann et al., 1987; Kaufmann and Kellner, 1998). The membranes were 
then blotted with GST-tagged SH2 superbinder and anti-GST-HRP sequentially following 
the same procedures described above.  
2.3.5 Protein tryptic digestion and pTyr peptide enrichment 
The total protein was harvested from different materials, including cultured cells, 
peripheral blood mononuclear cells (PBMCs) isolated from whole blood, fast-frozen and 
FFPE slides of tumor tissues. The cells were first washed with ice-cold PBS buffer once 
and directly lysed in 8M urea containing 50 mM Tris-HCl (pH7.6) and complete 
mammalian cell protease inhibitor cocktail (Sigma). Cell debris was removed by 
centrifugation, then the supernatant was transferred into a fresh tube and mixed with 5-fold 
volume of cold precipitation mixture (50% acetone, 50% ethanol and 0.1% acetic acid). 
The fast-frozen tissues were manually ground with liquid nitrogen then processed in a 
similar manner as described above. The FFPE slides were first de-waxed by washing in 
xylene and ethanol sequentially. The tissue specimens were detached from the glass slides 
then resuspended in 6M GuHCl containing 25 mM DTT and 50mM Tris-HCl (pH7.6). The 
protein was recovered (de-crosslinked) by heating at 100 °C (boiling water bath) for 30 
minutes then 80 °C for 2 hours. Debris and undissolved protein were removed by 
centrifugation, then the supernatant was transferred into a fresh tube and mixed with 5-fold 
volume of cold precipitation mixture. 
After at least two hours of precipitation in -20 °C, the protein precipitate was collected by 
centrifugation and washed with 75% ethanol, then dissolved in 100 μl 8 M urea or 6 M 
GuHCl with sonication in water bath. The protein concentration was determined by the 
Bradford protein assay (BioRad) with a liner range 200 μg/ml ~ 1400 μg/ml. The protein 
was reduced using 5 mM 1,4-dithiothreitol (DTT) for one hour and alkylated in 14 mM 
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iodoacetamide (IAA) in darkness for an additional hour. Unreacted IAA was neutralized 
by adding 5 mM DTT in excess. Tryptic digestion was carried out at 37 °C overnight with 
an enzyme-to-protein ratio of 1:20 ~1:40 (w/w) according to the manufacture’s protocol 
(Promega, V5111). 
The resulting peptide mixture was desalted using a Strata-X polymeric SPE column 
(Phenomenex), and then re-suspended in 900 μl modified IAP buffer (50 mM Tris-HCl, 50 
mM NaCl, pH 7.6). For affinity purification, 300 μg of on-bead superbinder (100 μl) was 
used for the enrichment of each sample. The peptide matrix was incubated with the beads 
for two hours at 4 °C with head-to-toe rotation. Then the beads were washed two times 
with 1 ml high-salt modified IAP buffer (50 mM Tris-HCl, 200 mM NaCl, pH7.6), and 
two times with 1ml 50 mM ammonium bicarbonate. In each washing, the mixture was 
rotated for 1 minute at room temperature. For elution, the beads were incubated with 200 
μl 1% TFA for 10 minutes, with occasional re-suspending. The enriched peptide was dried 
using a speed vacuum, then re-dissolved in 0.1% formic acid (FA) at an appropriate volume 
for direct MS injection. 
2.3.6 Mass spectrometric analysis 
The MS experiments were performed on the Thermo QExactive quadrupole-orbitrap 
hybrid MS system equipped with a Thermo nanoLC 1000, or the SCIEX Qtrap 6500+ 
triple-quadrupole MS system equipped with a Waters NanoAcquity UPLC. Both LC 
systems were configured in a two-column (trapping column and analytic column) setting.  
In the Thermo system, a C18 trapping column (length 3 cm, diameter 75 µm, particle size 
3 µm, pore size 100 Å) and a C18 analytic column (length 50 cm, diameter 75 µm, particle 
size 2 µm, pore size 100 Å, spray tip built in) were used. In the SCIEX system, a C18 
trapping column (length 2 cm, diameter 180 µm, particle size 3 µm, pore size 100 Å) and 
a C18 analytic column (length 20 cm, diameter 75 µm, particle size 1.7 µm, pore size 130 
Å) were used. The flow rate was set at 300 nl/min and a 1~2 hours gradient (3% to 35% 
acetonitrile in 0.1% FA) was used for separating the peptide matrix in both systems.  
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2.3.7 Cell proliferation assay 
Cell viability was evaluated using WST-8 cell counting kit (Cayman). The WST-8 
monosodium salt, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium, is bio-reducible and produces a water-soluable orange formazan dye in the 
presence of cellular dehydrogenases. The amount of formazan dye produced is linearly 
proportional to the number of cells or the overall cell viability. Cells were cultured in 90 
µl culture medium in 96-well tissue culture plates (Sarstedt). 10 µl of WST-8 working 
solution was directly added to the culture medium and the plate was then incubated for 30 
minutes to 1 hour in the incubation chamber. The absorbance at 460 nm was determined 
using a plate reader (PerkinElmer).  
2.3.8 mRNA isolation and RNA-seq 
Cells were cultured in 6-well tissue culture plates (Sarstedt) and total mRNA was isolated 
by TRIzol following the manufacturer’s protocol (Invitrogen). Briefly, cells were washed 
once with warm PBS buffer, then 0.5 ml TRIzol was added to the culture dish to directly 
lyse the cells. The lysate was pipetted up and down several times and incubated for 5 
minutes for complete lysis. Then, the cells were transferred to a microcentrifuge tube and 
0.1 ml of chloroform was added and mixed well by vortex.  The mixture was centrifuged 
at 15,000 g for 15 minutes at 4 °C and the colorless upper aqueous phase was transferred 
into a fresh microcentrifuge tube. 0.25 ml isopropanol was added into the aqueous phase 
for precipitating the RNA. cDNA was synthesized by reverse-transcription and then 
analyzed by next generation sequencing (NGS) performed on the Illumina Miseq system 






2.4.1 Abundance of TK phosphorylated peptides indicate TK activity 
We previously established a strategy for systematic identification of pTyr sites by AP-MS 
using the Src SH2 superbinder (GST-tagged) as the affinity reagent (Bian et al., 2016). In 
the study of nine cultured cancer cell lines, ~ 10,000 pTyr peptides were identified, of 
which over 3,000 sites were novel. As expected, a large portion of these pTyr peptides 
belong to TKs, SH2-containing proteins and PTPs, which are subject to intensive 
regulation of tyrosine phosphorylation (Hornbeck et al., 2015; Matlock et al., 2015). From 
the same dataset, tens of phosphorylated kinase activation loop peptides were also 
identified whose relative abundance closely correlated to the activation status of the 
corresponding TKs among these cancer cell lines. For example, a high abundance of ErbB2 
(HER2) phosphorylated activation loop was detected in BT-474 and SK-BR-3 cells, which 
are classified as HER2 + 3 breast cancer cells by IHC/FISH. 
Even though in vivo TK activity can be determined by multiple regulatory mechanisms 
(Huse and Kuriyan, 2002; Pawson and Scott, 2005), the phosphorylation of tyrosine 
residues within the kinase activation loop is essential for TK activation in many cases (Feng 
et al., 1997; Nolen et al., 2004; Rikova et al., 2007; Schindler et al., 2000; Zhang et al., 
2000). The activation loop is a short, flexible region within the kinase domain, located 
close to the catalytic loop in the three-dimensional structure (Knighton et al., 1991; Kornev 
and Taylor, 2010). In many non-constitutively active TKs, activation loop phosphorylation 
will counteract the positive charge of the arginine in the catalytic core which then opens 
for substrate access (Johnson and Lewis, 2001; Kornev and Taylor, 2010; Meng and Roux, 
2014; Tokunaga et al., 2014). Similarly, in many serine/threonine kinases, a conserved 
threonine residue is typically found in the activation loop, and phosphorylation of this 
residue is required for kinase activation as well.  The human genome encodes 90 TKs, 
which share a highly conserved activation loop region containing one or two conserved 
tyrosine residues, as aligned in Suppl.2.1. A small portion of serine/threonine kinases have 
non-classic activation loops, such as the MAPK subfamily that contain a T-D/E-Y motif 
and require dual phosphorylation in both threonine and tyrosine residues for kinase 
activation (Cargnello and Roux, 2011). A few phosphorylated MAPK activation loops have 
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been successfully detected by AP-MS previously (Hornbeck et al., 2015), including 
MAPK1 (Erk2) and MAPK3 (Erk1) which are master regulators of cell proliferation 
(Boulton et al., 1991; Jones and Kazlauskas, 2001; Raman et al., 2007; Rubinfeld and 
Seger, 2005; Squires et al., 2002).  
Most TK activation loops are compatible with trypsin digestion, producing peptides 
suitable in length for LC-MS analysis. Therefore, a hypothesis is formed based on the 
understanding of these sequentially and functionally conserved kinase activation loops, 
that protein kinase status might be comprehensively evaluated using AP-MS by 
determining the abundance of the phosphorylated activation loop peptides. Theoretically, 
this is feasible since phosphor-peptide enrichment and MS analysis have been well 
developed. Immobilized Metal Affinity Chromatography (IMAC) is the most widely used 
method to purify  pSer/pThr peptides according to their affinity to specific metal ions (de 
Graaf et al., 2014; Sharma et al., 2014; Zhou et al., 2013), and the SH2 superbinder has 
been demonstrated as an excellent reagent for pTyr peptide enrichment as well (Bian et al., 
2016). By combining both reagents, it is possible to enrich pTyr and pSer/pThr peptides 
sequentially from the same sample and profile the activation of all protein kinases in a 
single experiment.  
In a previous study of nine cancer cell lines, 35 TK activation loops were identified in at 
least one cell line. Label free quantification was used to generate a heatmap of activation 
loop phosphorylation (Tab.2.1). As expected, different cell lines exhibited differential 
activation loop phosphorylation patterns, suggesting that tyrosine kinase activation could 
be cell type specific. Based on the corresponding activation loop phosphorylation, more 
cytosolic TKs were activated in Jurkat T cells, but not in non-hematopoietic cells. 
Conversely, numerous RTK activation loops were detected in all but the Jurkat T cells. 
This suggests that RTKs may be the major type of oncogenic drivers in cancer cells of 






Table 2.1 Activation loop phosphorylation profiles determined by SH2-AP-MS 
 
A heatmap outlining phosphorylation status of TK activation loops in nine cancer cell lines determined by 
SH2-AP-MS. Raw data was obtained from a full scanning (full MS/data-dependent MS2) performed on a 
Thermo QExactive. The spectral peak area of MS1 was used for the quantification of peptide abundance and 
Z-scores of Log2 intensity values were represented. Blank spaces indicate instances for which the 
corresponding phosphorylated activation loops were not detected. This figure was published and modified 




To validate whether the MS data faithfully recapitulated TK phosphorylation status in vivo, 
Western blotting was used to evaluate the phosphorylation status of the activation loops of 
ErbB2 (pTyr_877) and IGF-1R/INSR (pTyr_1161_1165_1166).  Using pTyr site-specific 
antibodies, four breast cancer cell lines MCF7, BT-474, SK-BR-3 and MDA-MB-231 
exhibited distinct ErbB2 and IGF-1R activation loop phosphorylation patterns by western 
blot. These four cell lines also represent the major breast cancer subtypes (Holliday and 
Speirs, 2011; Subik et al., 2010): MCF7 is “Luminal A” subtype (ER+, PR+/-, HER2-, or 
HER2 +1); BT-474 is “Luminal B” subtype (ER+, PE+/-, HER2+); SK-BR-3 is “HER2-
enriched” subtype (ER-, PR-, HER2+); and MDA-MB-231 is “Triple-negative” subtype 
(ER-, PR-, HER2-). ErbB2 was highly expressed and phosphorylated in the activation loop 
in both BT-474 and SK-BR-3 cells, and IGF-1R was highly expressed and phosphorylated 
in the activation loop in MCF7 cells (Fig.2.2 A-B). A moderate level of IGF-1R protein 
expression and activation loop phosphorylation was also observed in BT-474 and MDA-
MB-231 cells. These results agree in principle with the activation-loop phosphorylation 
status profiled by MS (Tab.2.1). To determine whether activation loop phosphorylation 
predicts kinase activity, activation (phosphorylation)-dependent recruitment of adaptor 
proteins to ErbB2 and IGF-1R was also examined (Dey et al., 1996; Xie et al., 1995). It is 
apparent that more Grb2 was recruited by ErbB2 in BT-474 and SK-BR-3 cells and more 
IRS-1 was recruited by IGF-1R in MCF7 cells (Fig.2.2 A-B). 
Because TKs are major drivers of tumorigenesis, selective inhibition of deregulated TK is 
an effective strategy in cancer therapy. The efficacy of cell proliferation inhibition was 
tested by applying three TK inhibitors, lapatinib (EGFR/ErBB2), GSK1838705 (IGF-
1R/INSR) and DDR1-IN-1(DDR1) in the four cell lines. In the single inhibition test, the 
HER2 positive BT-474 and SK-BR-3 cells were only sensitive to lapatinib, as expected. 
MCF7 cells were sensitive to GSK1838705 but not lapatinib or DDR1-IN-1, while MDA-
MB-231 cells exhibited no response to any of these inhibitors (Fig.2.2 C-E). This indicates 
that IGF-1R plays a more important role than EGFR/ErbB2 or DDR1 in promoting MCF7 
cell proliferation, even though they were all found in a moderate activation status in MCF7 
by SH2-AP-MS. However, a combination of lapatinib and DDR1-IN-1 exhibited an 
obvious inhibition effect on MCF7 proliferation, which also further sensitized MCF7 cells 
to the treatment of GSK1838705 (Fig.2.2 F-G). Such an effect was not observed in BT-
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474, SK-BR-3 or MDA-MB-231 cells. These data suggest that EGFR/ErbB2 are the 
dominant drivers of cell proliferation in BT-474 and SK-BR-3 cells. BT-474 and SK-BR-
3 have moderate activation of DDR1 and IGF-1R, but neither significantly contributes to 
cell proliferation. In MCF7 cells, IGF-1R cooperates with EGFR/ErBB2 and DDR1 to 
promote cell proliferation together. Here, the quantitative kinase activity profiling by SH-
AP-MS presents accurate and valuable information regarding global TK activation and 
may be used to guide cancer treatment by specifically targeting multiple co-activated TKs 






Figure 2.2 SH2-AP-MS detects active TKs that drive cell proliferation 
 (A-B) ErbB2 and IGF-1R, which showed distinct activation loop phosphorylation patterns in the four breast 
cancer cell lines (Tab.2.1) were analyzed for protein expression, activation loop phosphorylation (using 
specific antibodies as indicated) and activation-dependent recruitment of SH2 proteins. High ErbB2 
expression, activation loop Y877 phosphorylation and Grb2 recruitment were observed in the BT-474 and 
SK-BR-3 cells. High IGF-1R expression, activation loop Y1161/1165/1166 phosphorylation and IRS-1 
recruitment were observed in MCF7 and BT-474 cells; (C-E) Distinct responses of the breast cancer cell lines 
MCF7, BT-474, SK-BR-3 and MDA-MB-231 to pharmacological inhibition of ErbB2 (by lapatinib), IGF-
1R (by GSK1838705) or DDR1 (by DDR1-IN-1), n=3; (F) Combined treatment of MCF-7 cells with 
lapatinib and DDR1-IN-1 significantly inhibit the cell proliferation. p < 0.01, n = 3; (G) Triple inhibition of 
IGF-1R, ErbB2 and DDR1 significantly inhibits proliferation of MCF7 cells compared to double or single 
inhibition treatment, p < 0.01, n = 4. These results were published and modified from (Bian et al., 2016) 
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To investigate the possibility of applying the SH2-AP-MS assay in examining TKs in 
clinically collected tumor tissues, which are processed using different procedures and 
typically supplied in a small amount, the entire SH2-AP-MS workflow was thoroughly 
optimized for maximizing the pTyr peptide recycling and MS discovery rates (assisted by 
Dr. Tomonori Kaneko). Subsequently, the TK activation status was re-evaluated in MCF7, 
BT-474, SK-BR-3 and MDA-MB-231 cells. 
Because protein tyrosine phosphatases (PTPs) are constitutively active in living cells, 
tyrosine phosphorylation usually has a short half-life in vivo, in many cases just a few 
minutes or even seconds if it is not protected through binding to an SH2 domain for 
example (Hunter, 2014; Kleiman et al., 2011). For most TK studies in cancer biology, 
including the work presented above (Tab.2.1, Fig.2.2), cell pre-treatment by sodium 
orthovanadate (pervanadate) is a key procedure which globally inhibits PTPs to preserve 
tyrosine phosphorylation (Huyer et al., 1997). In MS-based proteomics studies, this 
treatment was crucial for the detection of less-abundant or highly dynamic tyrosine 
phosphorylation sites. Even though pervanadate is a highly specific PTP inhibitor, the 
treatment is known to interfere with the pTyr-mediated signaling network. It was reported 
that pervanadate activated insulin receptors without the presence of insulin in cultured cells 
(Fantus et al., 1989). From a structural perspective, pervanadate should not act like a ligand 
to bind or stimulate insulin receptors. In a cell-free system, pervanadate did not alter the 
phosphorylation status of insulin receptors or interfere with the stimulating effect of insulin 
at all. In fact, pervanadate indirectly promoted the auto-phosphorylation level of insulin 
receptors by inhibiting PTPs, and the accumulated auto-phosphorylation in turn self-
activated the receptor (Shisheva and Shechter, 1993). Considering many RTKs undergo a 
similar process of activation, and cross-activation and feed-back loops are common in this 
signaling network, pervanadate may not simply preserve tyrosine phosphorylation but also 
alter the phosphorylation differentially on specific sites.  Therefore, sample collection 
procedures were simplified by directly lysing the cells without pervanadate treatment. In 
order to match the low protein amount collected from patient derived tissues, the cultured 
cell lysate protein amount was reduced from 5 mg to 300 μg. In addition, instead of using 
GST-tagged superbinder (on beads) as the affinity reagent, the superbinder was further 
engineered by mutating all endogenous cysteine residues and covalently linking the His-
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tagged superbinder to SulfoLink Coupling Resin (Thermo) via a single cysteine residue 
added to the C terminal tail.  This covalent-conjugated superbinder out-performed previous 
versions, as shown in other studies led by Dr. Tomonori Kaneko. Enrichment and MS 
analysis of the four breast cancer cell lines, MCF7, BT-474, SK-BR3 and MDA-MB-231 
were performed using the covalent-conjugated superbinder beads. Not surprisingly, the 
total number of identified pTyr peptides dropped by 90% and only 200~300 pTyr peptides 
were identified in each cell line. However, 69 pTyr peptides representing 38 TKs were still 
detected from 300 μg lysate, including 64% (16 out of 25) of the activation loops that were 
detected from 5 mg lysate before. Among the four cell lines, BT-474 and SK-BR-3 cells 
have the highest abundance of EGFR and ErbB2 peptides, MCF7 cells have the highest 
abundance of IGF-1R and INSR peptides, and MDA-MB-231 cells have the highest 
abundance of AXL and EPHA2 peptides (Tab.2.2). These results in general agree with the 




Table 2.2 TK pTyr peptide profiles in four breast cancer cell lines 
 
A heatmap to exhibit differential phosphorylation status of TK pTyr sites in four cultured breast cancer cell 
lines determined by SH2-AP-MS. Raw data was obtained from a full scanning (full MS/data-dependent MS2) 
performed on a Thermo QExactive. The spectral peak area of MS1 was used for the quantification of peptide 
abundance and Log2 intensity values were represented. Blank spaces indicate instances for which the 
corresponding phosphorylated peptides were not detected. All detected pTyr sites within TK activation loops 
were denoted by an asterisk. 
  
TK Position MCF7 BT474 SKBR3 231 TK Position MCF7 BT474 SKBR3 231
AXL (UFO) 702* 21.6 FRK 387* 19.6 17.2
AXL (UFO) 703* 20.8 FRK 497 19.9 19.8 21.1
CSF1R 923 14.7 FYN;YES1 213;222 18.6 19 19.7 19.7
DDR1 792 17.4 18.1 FYN;YES1 214;223 18.8 18.1
DDR1 796* 16.6 17 20.1 FYN;YES1;FGR 185;194;180 18.8 21.1 19.5 20.8
DDR1 797* 15.6 17.3 20.1 FYN;YES1;LCK;SRC 420;426;394;419* 19 23.2 21.3 23.2
DDR2 740* 20 IGF1R;INSRR 1161;1185 20.9 18.2 19.1
DDR2 741* 20 IGF1R;INSRR 1165;1189 19.6 18
EGFR 1110 21.8 22.7 21.1 INSRR 1145 16.2
EGFR 1172 25.9 26.4 22 INSRR 1146 16.2
EGFR 1197 17.1 17.1 JAK1 1034 20.2 18.2 20.6
EPHA1 781* 18.9 21.9 20.2 JAK2 221 15.5
EPHA2 588 21.8 22.8 21.3 26.2 LYN 194 17.5 19.6
EPHA2 594 22.8 22.8 23 28 LYN;HCK 397;411* 16.1
EPHA2 772* 19.2 21.1 21.6 25.6 MET 1234 20
EPHA2 960 15.4 17.2 16.2 19.1 PTK2 (FAK1) 397 18.2 18.8
EPHA4 602 23.1 21.9 16.9 PTK2 (FAK1) 570 16
EPHA7 597 19.8 19.4 PTK2 (FAK1) 576* 16.4 18.2 16.9 21.4
EPHA6;EPHA7 830;791* 20.9 19.3 PTK2 (FAK1) 577* 17.8 18.3 17.7 21.2
EPHB1;EPHB2 600;602 19.4 19.8 19.1 PTK2 (FAK1) 861 20.8 21.8
EPHB3 600 19.7 14.7 PTK2 (FAK1) 925 17.8
EPHB3 792* 21.8 PTK2B (FAK2) 579
EPHB3;EPHB4 608;590 19.7 22.9 17.3 14.9 PTK2B (FAK2) 580
EPHB3;EPHB4 614;596 22.7 25.6 20.9 19.1 PTK2B (FAK2) 819 16
EPHB4 774* 19 PTK2B (FAK2) 849 18.5 19.2
ERBB2 877* 17 27.3 25.8 20.8 PTK6 114 19.1
ERBB2 1139 20.8 19.7 PTK6 447 17.3 23.2 19.2 17.9
ERBB2 1248 18.6 30 29.3 22.2 RET 900 14.7
ERBB3 868* 16.8 RET 1096 17.6
ERBB3 1328 18.3 24.8 23.1 SYK (KSYK) 323 19.2 17.7
ERBB4 1150 19.1 SYK (KSYK) 352 20.1
ERBB4 1162 17.3 TNK2 (ACK1) 284* 19.2
ERBB4 1208 17 TNK2 (ACK1) 518 21
FER 402 18.1 20.8 18.1 20.8 TNK2 (ACK1) 859 19.1
FER 714* 17.9 18.3 TYK2 292 16.3
FGFR4 754 16.1 * activation loop
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The SH2-AP-MS results were further compared to transcriptome sequencing (NGS) data 
for the four breast cancer cell lines, which was archived in the Expression Atlas Database 
(Petryszak et al., 2016). Data for all TKs in these cell lines were extracted and ranked by 
TPM values (transcripts per kilobase million). The 10 most abundant (mRNA) TKs and 
MS detected pTyr sites in these TKs were summarized in Tab.2.3. Overall, 31 out of 40 
TKs were detected in the four cells by SH2-AP-MS, including the activation loops for the 
most abundant TK in individual cell lines (DDR1 in MCF-7; ErbB2 in BT-474; SK-BR-3; 
AXL in MDA-MB-231). Consistent with the TK inhibition test (Fig.2.2 C-G), DDR1 
(TPM 168) and IGF-1R (TPM 98) ranked 1st and 3rd in MCF7, while ErbB2 ranks 1st in 
both BT-474 (TPM 1365) and SK-BR-3 (TPM 1811). AXL (TPM 828) ranks 1st and MET 
(TPM 120) ranks 3rd in MDA-MB-231. Even though the inhibition of AXL or MET was 
not further investigated in MDA-MB-231 cells in this study, it has been previously reported 
that their inhibitors suppressed the growth and metastasis of xenografted MDA-MB-231 
cells (Holland et al., 2010; Mayer and Krop, 2010; Shen et al., 2018).  
Indeed, a few oncogenic TKs, that are relatively abundant in mRNA and functionally 
significant in vivo, were not detected by SH2-AP-MS in both 5 mg and 300 μg samples. In 
BT-474, 9 out the 10 most abundant TKs were detected in 300 μg lysate, except for ABL, 
which ranked 2nd. In the data obtained from 5 mg lysate, only a few non-loop pTyr sites 
were detected in BT-474. However, the ABL activation loop was detected in a few other 
cell lines (Tab.2.1). Obviously, ABL protein is expressed and functional in BT-474 cells, 
since specific inhibition of ABL sensitized BT-474 to fulvestrant (breast cancer hormonal 
therapeutic), reduced cell viability and prevented cell cycle progression by promoting 
fulvestrant-induced estrogen receptor degradation (Zhao et al., 2011; Zhao et al., 2010). 
Several reasons might cause this poor ABL activation loop detection in BT-474 cells, 
including non-optimal LC-MS parameters for this peptide, interference by other peptides 
in BT-474, or relatively low abundance of ABL phosphorylation in vivo. Among all four 
cell lines, a broad existence of EPH family members was observed. Over 20% of detected 
TK pTyr sites are from EFHA1/2/4/6/7 and EPHB1/2/3/4 (Tab.2.2), but few studies have 




Table 2.3 A comparison of TK profiles in SH2-AP-MS and RNA-seq 
 
The SH2-AP-MS detected TK pTyr sites were summarized with the 10 most abundant (mRNA) 
TKs in four breast cancer cell lines MCF7, BT-474, SK-BR3 and MDA-MB-231 (Expression Atlas 
DB). All pTyr sites within activation loops were denoted by an asterisk. Overall, pTyr sites were 
detected in 31 of 40 TKs. For the most abundant TKs in each cell line, DDR1 in MCF7, ErbB2 in 




In conclusion, the SH2-AP-MS assay generally enriched and detected TKs effectively in 
both the activation loops and other tyrosine phosphorylated sites. Most highly abundant 
TKs, particularly the validated TK biomarkers, were detectable from a small amount of 
cell lysate without pervanadate treatment. The MS-determined TK pTyr peptide intensities 
correlated well with TK mRNA abundance or TK biological function in the four breast 
cancer cell lines. If a more sensitive targeted MS approach could be established, and 
introducing internal standards in MS detection, the global TK activation status could be 
quantitively profiled in a single experiment using even less total lysate protein, which could 




2.4.2 Selection of TK phosphorylated peptides for targeted proteomics  
TKs are intensively tyrosine phosphorylated proteins and usually contain multiple pTyr 
sites. Among the 90 TKs, there are over 1,000 pTyr sites that have been identified at least 
once before (Hornbeck et al., 2015; Matlock et al., 2015). It is anticipated that the site-
specific modifications on TKs would vary in different backgrounds or physiological 
conditions (Yarden and Sliwkowski, 2001), but some TK pTyr sites including the 
activation loops seem more abundant and functionally significant. The PhosphoSitePlus 
database summarizes the number of records in which the modification is determined by 
either discovery MS studies (HTP, high throughput) or other approaches (LTP, low 
throughput) (Hornbeck et al., 2015). In the case of Src kinase, pTyr_419 (activation loop) 
and pTyr_530 (c-tail), which are known as two key regulatory sites for Src activation 
(Roskoski, 2004; Roskoski, 2005), rank 1st and 2nd in both HTP and LTP. In our 
preliminary SH2-AP-MS data, both sites are also ranked at the top among all detected Src 
pTyr sites (Bian et al., 2016). As shown in Tab.2.2, pTyr_419 seems to be the only detected 
and most abundant Src pTyr site among the four breast cancer cell lines. In the same 
dataset, three pTyr sites (pTyr_877, pTyr_1129, pTyr_1248) were detected in ErbB2, 
which ranked 3rd, 5th and 1st in HTP and LTP among 13 ErbB2 pTyr sites. pTyr_877 is 
located in the activation loop, pTyr_1139 is involved in the stimulation of various ErbB2 
downstream events including cell adhesion, cell growth and cell motility (Dankort et al., 
2001; Northey et al., 2008), while pTyr_1248 mainly promotes protein stabilization, 
maintains kinase activity, and generally contributes to all known ErBB2 functions (Dankort 
et al., 2001; Dittmar et al., 2002; Dong et al., 2017; Heinrich et al., 2010; Northey et al., 
2008). Therefore, phosphorylation on both the activation loop and other functional pTyr 
sites might be used as indicators of TK activity and function. Inclusion of non-loop pTyr 
sites in the targeted MS detection panel is immediately beneficial to cover TKs that have 
an activation loop peptide unfavored by either the tryptic digestion or LC-MS detection. A 
comprehensive detection panel will also make the analysis more insightful and better 
characterize the global TK status. For example, four members of the Src kinase family 
share an identical tryptic-digested activation loop (Src_pTyr_419, YES_pTyr_426, 
FYN_pTyr_420 and LCK_pTyr_394), therefore inclusion of unique non-loop pTyr 
peptides will help distinguish the Src family members. 
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The binding between ~1000 human TK pTyr sites and the SH2 superbinder was evaluated 
by far-western assay to identify the superbinder-favored pTyr sites. Peptides for all known 
TK pTyr sites were synthesized on nitrocellulose membranes, each peptide containing a 
phosphor-tyrosine flanked by 7 amino acid residues on each side. Information on site-
specific modifications and peptide sequences were extracted from the ProteomeScout 
database (Matlock et al., 2015). An artificial peptide G7-pY-G7 was synthesized as a 
positive control for relative quantification of binding affinities. The performance of the 
SH2 superbinder and anti-pTyr antibody 4G10 platinum (mouse monoclonal cocktail 
IgG2b 4G10 and PY20) were compared for recognizing these ~1000 peptides. In the far 
Western assay, the membranes were first hybridized with 4G10 platinum and anti-mouse-
HRP antibody sequentially, then illuminated by enhanced chemiluminescence (ECL) 
solution. The same membranes were then stripped for re-probing with GST tagged SH2 
superbinder (20 times molar amount compared to 4G10 platinum) and anti-GST-HRP 
antibody. As shown in Suppl.2.2, both the 4G10 antibody and the GST-tagged SH2 
superbinder generally performed well in recognizing ~500 pTyr sites. The binding affinity 
(equilibrium dissociation constant, Kd) between an antibody and a target antigen is usually 
in the low nano-molar (nM) range, typically a few nanomolar (Pan et al., 2016). The 
superbinder has greatly enhanced pTyr-binding affinity compared to its wild type variant, 
but still retains binding specificity and only has low nano-molar binding affinity to some 
optimal binding peptides (Kaneko et al., 2012a; Kaneko et al., 2012b). Not surprisingly, 
the superbinder clearly favored several of these TK pTyr peptides (Suppl.2.2), while the 
4G10 platinum antibody exhibited much less variance in blotting intensities. Compared to 
the positive control peptide G7-pY-G7, which bound to the superbinder with 510 nM 
affinity in solution (Kaneko et al., 2012a), ~76% of TK pTyr peptides exhibited higher blot 
intensities (suppl.2.3). The ErbB2_877 activation loop peptide displayed weak binding to 
the superbinder, with about half of the blot intensity on the far Western blot compared to 
the positive control peptide G7-pY-G7, but it was detected in multiple different cell lines 
in previous SH2-AP-MS studies. Therefore, it is estimated that over 95% of TK pTyr 
peptides could be captured by a saturating amount of superbinder in the affinity 
purification, which exhibit stronger binding to the superbinder than the ErbB2_877 peptide 
on the blot (suppl.2.3).  
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Tab.2.4 lists 67 trypsin-digested activation loop peptides, which represent 79 TKs, and 
their relative binding affinities to the superbinder. A few activation loops, such as the 
ErbB3_866 and LMTK2_295, were not tested in the far Western assay because the two 
sites were not archived in the ProteomeScout database when the peptide array was 
prepared. ErbB3 is considered to be a “dead” kinase, which dimerizes with other ErbB 
members that are solely responsible for ErbB3 intramolecular phosphorylation and 
subsequent recruitment of SH2 proteins (Yarden and Sliwkowski, 2001). However, some 
recent studies reveal that ErbB3 is capable of weak autophosphorylation (Shi et al., 2010; 
Steinkamp et al., 2014). Indeed, phosphorylation on ErbB3_868 and ErbB3_1328 was 
detected in BT-474 cells (Tab.2.2), with the ErbB3_868 peptide being the predicted 
activation loop. In another tumor tissue analysis presented below, LMTK2_295 peptides 
were also detected with reliable MS/MS spectra (Fig.2.4 G-I). Therefore, the 67 activation 




Table 2.4 Tryptic-digested TK activation loops 
 
A summary of 67 tryptic-digested activation loops representing 79 TKs, and their relative blot intensities to 
the superbinder as determined by far Western assay. Most activation loops bind to the superbinder with 
greater affinity than the ErbB2_877 activation loop. The ErbB3_868 and LMTK2_295 activation loops were 
not tested by the far Western assay but were detected by SH2-AP-MS in different samples (Tab.2.2; Fig.2.4 
G-I).  
  
Protein and site Sequence Intensity Protein and site Sequence Intensity
ABL1/2_393/439 LMTGDTY[Pho]TAHAGAK 0.95 INSRR_1145_1146 DVYETDY[Pho]Y[Pho]R 1.26/0.84
ACK1_284 ALPQNDDHY[Pho]VMQEHR 1.83 ITK_512 FVLDDQY[Pho]TSSTGTK 1.97
BLK_389 IIDSEY[Pho]TAQEGAK 0.71 JAK1_1034_1035 EY[Pho]Y[Pho]TVK 2.59/2.20
BMX_566 YVLDDQY[Pho]VSSVGTK 2.16 JAK3_980_981 DY[Pho]Y[Pho]VVR 3.01/2.92
BTK_551 YVLDDEY[Pho]TSSVGSK 2.31 KIT_823 NDSNY[Pho]VVK 2.26
CSF1R_809 DIMNDSNY[Pho]IVK 1.44 KSYK_525_526 ADENY[Pho]Y[Pho]K 2.32/1.14
DDR1_796_797 NLYAGDY[Pho]Y[Pho]R 2.04/1.79 LMTK1_283 EDY[Pho]FVTADQLWVPLR 1.99
DDR2_740_741 NLYSGDY[Pho]Y[Pho]R 3.16/2.25 LMTK2_295 EDY[Pho]IETDDK NA
EPHA1_781 LLDDFDGTY[Pho]ETQGGK 2.08 LMTK3_296_297 EDY[Pho]Y[Pho]LTPER 2.54/1.75
EPHA2_772 VLEDDPEATY[Pho]TTSGGK 1.09 MERTK/TYRO3_753_754/685_686 IYSGDY[Pho]Y[Pho]R 2.05/1.22
EPHA3/4/5_779/779/883 VLEDDPEAAY[Pho]TTR 1.35 MET_1234_1235 EY[Pho]Y[Pho]SVHNK 2.59/2.56
EPHA6/7_830/791 VLEDDPEAAY[Pho]TTTGGK 1.89 MUSK_755_756 NIYSADY[Pho]Y[Pho]K 2.57/1.49
EPHA8_793 VLEDDPDAAY[Pho]TTTGGK 2 NTRK1_680_681 DIYSTDY[Pho]Y[Pho]R 2.49/2.22
EPHB1_778 YLQDDTSDPTY[Pho]TSSLGGK 1.13 NTRK2/3_706_707/709_710 DVYSTDY[Pho]Y[Pho]R 2.4/1.89
EPHB2_780 FLEDDTSDPTY[Pho]TSALGGK 1.81 PGFRA_849 DIMHDSNY[Pho]VSK 1.39
EPHB3_792 FLEDDPSDPTY[Pho]TSSLGGK 1.46 PGFRB_857 DSNY[Pho]ISK 1.61
EPHB4_774 FLEENSSDPTY[Pho]TSSLGGK 1.5 PTK6_342 EDVY[Pho]LSHDHNIPYK 1.23
ErbB1(EGFR)_869 EY[Pho]HAEGGK 0.56 PTK7_960_961 DVYNSEY[Pho]Y[Pho]HFR 1.69
ERBB2_877 LLDIDETEY[Pho]HADGGK 0.54 RET_905 DVYEEDSY[Pho]VK 1.38
ERBB3_866 QLLY[Pho]SEAK NA RON_1238_1239 EY[Pho]Y[Pho]SVQQHR 3/2.94
ERBB4_875 EY[Pho]NADGGK 0.56 ROR1_645_646 EIYSADY[Pho]Y[Pho]R 2.52/NA
FAK1_576_577 YMEDSTY[Pho]Y[Pho]K 0.95/0.76 ROR2_645_646 EVYAADY[Pho]Y[Pho]K NA/2.98
FAK2_579_580 YIEDEDY[Pho]Y[Pho]K 1.43/2.24 SRC/YES/FYN/LCK_419/426/420/394 LIEDNEY[Pho]TAR 0.74
FER_714 QEDGGVY[Pho]SSSGLK 1.5 SRMS_380 DDIY[Pho]SPSSSSK 1.77
FES_713 EEADGVY[Pho]AASGGLR 1.13 TEC_519 YVLDDQY[Pho]TSSSGAK 1.6
FGFR1_653_654 DIHHIDY[Pho]Y[Pho]K 1.56/1.25 TIE1_1007 GEEVY[Pho]VK 1.04
FGFR2_656_657 DINNIDY[Pho]Y[Pho]K 1.89/1.46 TIE2_992 GQEVY[Pho]VK 1.08
FGFR3_647_648 DVHNLDY[Pho]Y[Pho]K 1.37/1.04 TXK_420 YVLDDEY[Pho]VSSFGAK 2.28
FGFR4_642_643 GVHHIDY[Pho]Y[Pho]K 1.75/1.16 TYK2_1054_1055 AVPEGHEY[Pho]Y[Pho]R 2.74/2.04
FGR_412 DDEY[Pho]NPCQGSK 0.29 UFO_702_703 IYNGDY[Pho]Y[Pho]R 1.68/1.12
FLT3_842 DIMSDSNY[Pho]VVR 1.59 VGFR1_1053 NPDY[Pho]VR 0.97
FRK_387 VDNEDIY[Pho]ESR 2.72 VGFR2/3_1059/1068 DPDY[Pho]VR 1.11
HCK/LYN_411/397 VIEDNEY[Pho]TAR 0.98 ZAP70_492_493 ALGADDSY[Pho]Y[Pho]TAR 0.88/2.55
IGF1R/INSR_1165_1166/1189_1190 DIYETDY[Pho]Y[Pho]R 0.88/1.07 All blot intensities were normalized to the blot intensity of G7-pY-G7 peptide
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Both PRM and MRM methods were used for the targeted proteomics studies using cell 
culture models and tumor tissues samples. First, a loop-panel was generated for PRM that 
included 67 activation loops, as well as 6 functionally significant and relatively abundant 
non-loop TK pTyr peptides (Suppl.2.4). All candidate peptides were synthesized in vitro 
to represent the tryptic-digested forms. Peptides with cysteine residues were alkylated by 
iodoacetamide (IAA). In the PRM test carried out on a Thermo QExactive MS system, the 
loop-panel peptides were found to the meet the following criteria: presence of a clearly 
defined peak, reproducibility of retention time and peak area. The retention time, charge 
status and optimal collision energy (CE) were then determined individually. In addition to 
the loop-panel, a more comprehensive full-panel was generated by introducing 1~3 non-
loop pTyr peptides for each TK, if available. pTyr sites with high HTP/LTP numbers, good 
superbinder binding affinities and functions in promoting TK activity or pTyr-mediated 
signaling were preferred. Similarly, the corresponding peptides were synthesized in vitro 
and tested by MRM on a Qtrap6500+ MS system. Some peptides with relatively poor MS 
detection were excluded, including a few activation loops that performed significantly 
worse than non-loop pTyr peptides within the same TKs. For example, EGFR_1172 
peptide, which is ranked 2nd among all EGFR pTyr sites in HTP/LTP and characterized as 
a modification inducing EGFR enzymatic activity, replaced EGFR_867 activation loop as 
the primary target of EGFR. The final full-panel consists of 60 activation loops and 97 non-
loop pTyr peptides that cover 87 TKs (Suppl.2.5), except for EPHAA, LTK and MATK, 
for which no pTyr sites were identified before or suitable for trypsin digestion. A few non-
TK pTyr peptides were also synthesized as controls, including the activation loops of 
MAPK1 (Erk2) and MAPK3 (Erk1), and the GSK3α_279 (GSK3β_216) peptide 
(GEPNVSpYICSR) which is constitutively phosphorylated in many cell lines (Doble and 
Woodgett, 2003). 
Due to the large number of target peptides, the absence of matrix with diversified pTyr 
peptides and difficulty to collect patient-derived samples expressing 87 TKs (or at least 
those validated TK biomarkers), it appears not practical to carry out standard tests for MS-
based peptide quantification, such as making the calibration curves, detecting interfering 
ions or determining the limits of detection/quantification for individual peptides. The 
MRM linearities of Src_419 and GSK3α_279 (GSK3β_216) peptides, shown in Fig.2.3, 
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were at least 4 orders of magnitude. Although stable isotope labelling provides the most 
precise target quantification and is least subject to interferences, the cost of high purity 
standards for all these peptides would also be prohibitive. Additional criteria were applied 
post-analysis to ensure correct identifications of the signal attributes to each of the target 
peptides. For all PRM/MRM detected TKs (pTyr peptides) presented in this study, 4~10 
transitions attributed to the target peptide were verified co-eluted and displaying identical 






Figure 2.3 The linearities of Src_419 and GSK3α_279 in MRM 
The linearities of Src_419 and GSK3α_279 peptides, as calculated by relative peak areas 





2.4.3 Identification of TK biomarkers in tumor tissues 
The initial PRM investigation was carried out using a few fast-frozen surgical breast tumor 
tissues (Ontario Tumor Bank). From 50 µg of lysate, multiple TKs and GSK3 were 
detected with reliable extracted ion chromatogram (XIC) data (Fig.2.4). To evaluate the 
PRM reproducibility, two biologically replicate samples were prepared from the same 
frozen tissue and two technical PRM replicates were tested for each sample. The GSK3 
peptide was detected as the dominant peak in all replicates, however it likely was not the 
optimal internal control due to the large variance observed across different samples (Fig.2.4 
A-B, D-E, G). The variation of GSK3 peak area was approximately 20% between two 
technical replicates and up to 40% between two biological replicates (Fig.2.4 C), but 
several folds across different tissues (Fig.2.4 A, D, G). This reproducibility is not ideal and 
only acceptable for qualitative analysis, considering the possible intratumor heterogeneity 
and limited accuracy of PRM. Activated CDC42 (ACK1_284) was the only TK peptide 
detected in sample #1 (Fig.2.4 A-B), which was previously reported as a deregulated TK 
in some breast cancer cell lines that promoted cell proliferation, invasion and colony 
forming ability (Wu et al., 2017). In samples #2 and #3, a few oncogenic or protooncogenic 
TKs were detected, including ALK_1507 (non-loop) (Fig.2.4 D-F), LMTK2_296 (Fig.2.4 
G-I) and Src family TKs (SRC_419/YES_426/FYN_420/LCK_394) (Fig.2.4 G-H, J). 
ALK is natively expressed during the early stages of embryonic development and in neural 
cells in adults (Iwahara et al., 1997; Morris et al., 1994; Morris et al., 1997). Although not 
defined as a breast cancer biomarker, ectopic expression of ALK has been identified in 
both breast cancer cell lines and patient-derived tissues in various reports (Hanna et al., 
2015; Kim et al., 2015; Krishnamurthy et al., 2013; Siraj et al., 2015). Tissue #1 and #2 
were HER2 positive according to records obtained from the Ontario Tumor Bank (#1 IHC; 
#2 FISH), however, no phosphorylated ErbB2 peptide was detected in these tissues, while 
the control experiment using the SK-BR-3 cell line exhibited the highest peak of ErbB2 
activation loop among all detected peptides (Fig.2.4 K). Next, ErbB2 protein and 
phosphorylation levels in these tissue samples were evaluated by Western blot. As shown 
in Fig.2.4 L, SK-BR-3 exhibited high ErbB2 expression and phosphorylation, while only 
weak ErbB2 expression was observed in tissue sample #2 and no ErbB2 phosphorylation 





Figure 2.4 PRM analysis of fast frozen breast cancer tissues 
SH2-AP-MS (PRM) analysis of fast frozen surgically-resected breast cancer tissues.  (A-B) Two 
PRM biological replicates of 50 µg protein extracted from a HER2 positive (IHC) breast cancer 
tissue (#1). GSK3 and ACK were detected in both samples; (C) The data reproducibility of GSK3 
69 
 
and ACK peptides detected in two biological replicates as shown in A-B, n=2; (D-E) Two PRM 
biological replicates of 50 µg protein extracted from a HER2 positive (FISH) breast cancer tissue 
(#2). GSK3, EPHB3 and ALK were detected in both samples; F) XIC of ALK_1507 non-loop pTyr 
peptide detected in tissue #2; (G-H) The PRM result of 50 µg protein extracted from a HER2 
negative breast cancer tissue (#3). The dominant GSK3 peak was excluded from the spectra to 
better visualize low-abundant detected TKs; (I) XIC of LMTK2_295 activation loop detected in 
tissue #3; (J) XIC of Src TK family activation loop detected in tissue #3. The activation loop is 
conserved in Src, Yes, Fyn and Lck (phosphorylated on Y419/426/420/394); (K) The PRM result 
of 20 µg SKBR3 cell lysate (pervanadate treated). The ErbB2 activation loop and Src TK family 
activation loop were dominant in the spectra; (L) western blot of total protein lysate extracted from 
tissues and SK-BR-3 cells by anti-ErbB2 and anti-ErbB2_pY877 antibodies. 20 µg total lysate was 
loaded for gel electrophoresis. Only weak ErBB2 expression was detected in tissue #2 but no 
phospho-ErbB2 was detected in any tissues. The positive control SK-BR-3 cells exhibited strong 




Furthermore, PRM was performed on samples collected from other cancer types, including 
primary peripheral blood mononuclear cells (PBMCs) isolated from acute myeloid 
leukemia (AML) and chronic lymphocytic leukemia (CLL) whole blood, and FFPE 
(formalin-fixed paraffin-embedded) slides for lung cancer and biliary cancer tissues. The 
Src kinase family is known to be highly active in immune cells, while two Src family 
activation loops, the Src/Yes/Fyn/Lck activation loop and the Hck/Lyn activation loop, 
were detected in all PBMC samples (Fig.2.5 A-C). A few additional activation loops were 
detected from 90 μg AML sample with relatively high abundance (Fig.2.5 B). BTK is a 
biomarker in chronic lymphocytic leukemia (CLL) but recently validated as potential 
biomarker in AML as well (Prada-Arismendy et al., 2017; Rushworth et al., 2014). Fes is 
widely expressed in myeloid cell lineages and required for oncogenic FLT3 signaling in 
AML (Voisset et al., 2010; Weir et al., 2017). The FFPE slides of lung cancer and biliary 
cancer each had approximately 1 cm2 of 5-micron thickness tissue specimen. Similarly, 
known and new potential TK biomarkers were detected in both lung cancer and biliary 
cancer samples, each from 4 specimens on FFPE slides (Fig.2.5 D-E). ALK is a well-
defined biomarker in non-small cell lung cancer (NSCLC) and FGFR1 gene amplification 
has been identified in approximately 23% NSCLC and 6% small cell lung cancer (SCLC) 
cases (Fig.2.5 D)  (Peifer et al., 2012; Thai and Solomon, 2018; Weiss et al., 2010). In 
biliary cancer, deregulation of FGFR family members and insulin receptors were also 
reported previously (Fig.2.5 E) (Rizvi and Borad, 2016; Suzuki et al., 2015; Valle et al., 
2017). GSK3 was only detected in one PBMC sample but not in fixed lung cancer or biliary 





Figure 2.5 PRM analysis of PBMCs and formalin-fixed solid tumor specimens 
SH2-AP-MS (PRM) analysis of samples from leukemia, lung cancer and biliary cancer. (A) The 
activation loops of Src/Yes/Fyn/Lck and Fyn/Hck were detected from PBMC cells isolated from 
healthy whole blood. The protein amount is less than 20 µg; (B) The activation loops of BTK, 
Src/Yes/Fyn/Lck, Fyn/Hck and Fes were detected from PBMC cells isolated from AML whole 
blood. The protein amount is 90 µg; (C) The activation loops of Src and LMTK1 were detected 
from PBMC cells isolated from CLL whole blood. The protein amount is less than 20 µg; (E) The 
activation loops of FGFR1 and TXK, and non-loop pTyr peptide of ALK_1507 were detected from 
lung cancer FFPE slides. The protein amount is less than 20 µg; (F) The activation loops of ZAP70, 
FGFR1, FGFR3, IGF-1R/INSR and RET were detected from biliary cancer FFPE slides. The 




2.4.4 Tracking kinome dynamics in response to targeted therapeutic 
Even though a few known and potential TK biomarkers were identified by PRM in 
different clinically-collected tumor tissues, validation analyses using conventional 
approaches were generally not practical due to the limited sample size. To further evaluate 
the accuracy of the SH2-AP-MS assay, MRM was used to track TK kinome dynamics in 
cultured cells treated with a TK inhibitor. In cancer treatment, the complexity of oncogenic 
signaling pathways greatly limits the efficacy of component-by-component targeted 
therapies, therefore it is anticipated that a comprehensive analysis of how oncogenic 
signaling can be adapted to drugs could provide great opportunity to treat tumors with high 
specificity and efficacy (Logue and Morrison, 2012). For TKs, especially the oncogenic or 
proto-oncogenic TKs, a few assays have been developed to globally profile TK activation 
status for research only. R&D Systems® designed an on-membrane antibody array that 
could capture and quantify the relative activities of tens of TKs in a single test, and 
RayBiotech® developed a similar ELISA-based assay. AP-MS has also been tested for 
profiling the full human kinome including both STKs and TKs. The multiplexed kinase 
inhibitor (MIB) MS strategy uses low-specificity small molecule kinase inhibitors as 
affinity reagents to enrich active forms of kinases, which generally bind to ATP-mimicking 
kinase inhibitors. When compared to next generation sequencing, MIB-AP-MS could 
identify approximately 50-60% of the expressed kinome. Due to the compromised binding 
affinities of the kinase inhibitors, MIB-AP-MS typically requires milligram-scale lysate 
protein for the affinity purification, and kinases must be in a non-denatured, active 
conformation for binding the affinity reagents (Duncan et al., 2012; Stuhlmiller et al., 
2015).   
Using SH2-AP-MS, TK kinome profiling was performed on SK-BR-3 cells treated with 
lapatinib. SK-BR-3 expresses moderate levels of EGFR and high levels of ErbB2, and 
therefore is sensitive to the EGFR/ErbB2 dual-specificity inhibitor lapatinib (Fig.2.2 C). 
SK-BR-3 cells were treated with lapatinib for two days and total cell lysate was collected 
at 0, 2, 6, 12, 24, 48 hours. Samples of 50 μg lysate were analyzed individually by MRM 
using the full-panel. As shown in Fig.2.6 A-C, a few oncogenic TKs were detected at all 
time points, including the non-loop peptide EGFR_1172 (Fig.2.6 E), ErbB2_877 activation 
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loop (Fig.2.6 F) and Src activation loop (Fig.2.6 G), which are among the most abundant 
TK pTyr peptides in untreated SK-BR-3 (Tab.2.2). SK-BR-3 is known to express all three 
TKs and respond to their inhibitors, with an IC50 of 15 nM to lapatinib (highly sensitive) 
and 4.17 μM to dasatinib (Src inhibitor, moderately sensitive) (Stanley et al., 2017). 
Phosphorylation of EGFR_1172 and Src_419 was attenuated upon lapatinib treatment for 
48 hours (Fig.2.6 G, I). As introduced earlier, phosphorylation on both sites promotes 
kinase activity, therefore EGFR and Src should be inhibited by lapatinib after 48 hours 
treatment. In contrast, phosphorylation on ErbB2_877 was more dynamic, which decreased 
at 24 hours but increased between 24 hours and 48 hours, indicating a re-gaining of ErbB2 
kinase activity during the treatment (Fig.2.6 H). The same observations were reported in a 
previous study of lapatinib treated SK-BR-3 cells, which were validated by both MIB-AP-





Figure 2.6 Tracking kinome reprogramming in SK-BR-3 cells 
SH2-AP-MS (PRM) analysis of SK-BR-3 cells treated with lapatinib for 48 hours. (A-C) EGFR, 
ErbB2 and Src were detected in 50 μg cell lysate of SK-BR-3 cells treated with lapatinib for 0 hour, 
12 hours and 48 hours; (D) XIC of EGFR_1172 non-loop pTyr peptide; (E) XIC of ErbB2_877 
activation loop peptide; (F) XIC of Src activation loop peptide; (G-I) The relative quantification of 
peak areas of EGFR, ErbB2 and Src peptides in MRM at six time points of lapatinib treatment. For 
EGFR and Src peptides, phosphorylation was inhibited by lapatinib after 48 hours treatment. For 
the ErbB2 peptide, phosphorylation was only inhibited by lapatinib for 24 hours and recovered 




2.4.5 Deciphering the mechanism of acquired trastuzumab resistance 
In addition to short-term and temporary drug-induced TK kinome reprogramming, the TK 
kinome may be permanently altered during long-term drug treatment of TK positive 
cancers. In treating HER2 positive breast cancer, the humanized antibody trastuzumab 
shows considerable clinical efficacy and extends overall survival (Cameron et al., 2017; 
Seidman et al., 2008; Vogel et al., 2002). However,  in many cases, the  trastuzumab-
sensitive patients only responded to this therapy for five to nine months when acquired 
resistance became established. Even though the resistant mechanism could be complex, 
Trastuzmab resistance has been previously shown to be driven by the deregulation of non-
target TKs, including overactivation of EGFR, IGF-1R, Src kinases or overexpression of 
hepatocyte growth factor (Dua et al., 2010; Lu et al., 2001; Moulder et al., 2001; Nahta et 
al., 2005; Ritter et al., 2007; Shattuck et al., 2008; Zhang et al., 2011). 
Following an established strategy (Zhang et al., 2011), a trastuzumab resistant clone was 
built in the lab. SK-BR-3 cells were incubated with a low dose (4 µg/ml and 8 µg/ml) of 
trastuzumab for over six months for the selection of resistant cells (Zhang et al., 2011). 
Compared to the parental cells (SKBR3o), resistant cells (SKBR3r) exhibited little 
morphological change but were significantly less sensitive to trastuzumab (Fig.2.7 A-B). 
In the SH2-AP-MS (MRM) analysis, EGFR_1172, ErbB2 activation loop and Src 
activation loop were still the best detected peptides, although their relative abundance was 
slightly altered in the resistant cells (Fig.2.7 C-E). According to the MRM quantification, 
EGFR_1172 and ErbB2_877 phosphorylation exhibited little variance, while Src 
phosphorylation increased by about two-folds in the resistant cells (Fig.2.7 E). The 
MAPK1 (Erk2) activation loop was detected in both cell lines at a consistent level, 
indicating that the resistant cells retained a comparable active-status in cell proliferation. It 
is intriguing that the c-Kit activation loop (NDSNYVVK, c-Kit_823) was detected in the 
resistant cells (Fig.2.7 D). c-Kit, also known as mast/stem cell growth factor receptor 
(SCFR) or CD117, is a proto-oncogenic RTK first described as a cellular homolog of the 
feline sarcoma viral oncogene v-Kit (Yarden et al., 1987). Like many other oncogenic 
RTKs, deregulation of c-Kit results in the activation of cell proliferation and survival 
signaling pathways in various cancer types (Hirota et al., 2002; Lennartsson et al., 2005; 
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Lennartsson and Ronnstrand, 2012). In transcriptome sequencing, c-Kit was found to be 
the most up-regulated TK with an 80- fold increase in mRNA abundance in the resistant 
cells (Fig.2.7 F).  
In a previous study of acquired trastuzumab resistance, Src was concluded as a key 
modulator of the trastuzumab response, which was activated in both intrinsic and acquired 
resistant HER2 positive cells, including SK-BR-3 (Zhang et al., 2011). Here only a 
moderate increase of Src phosphorylation was observed. The efficacy of cell proliferation 
inhibition was further tested by applying three inhibitors, trastuzumab (HER2), imatinib 
(c-Kit) and SKI-1 (Src) (Fig.2.7 G). The parental cells were only sensitive to trastuzumab, 
while combining inhibition of c-Kit and Src brought no additional effect to trastuzumab. 
In contrast, the resistant cells became moderately sensitive to imatinib and the imatinib 
inhibition sensitized the resistant cells to trastuzumab treatment.  
Together these data indicate that ErbB2 is active and a dominant driver of cell proliferation 
in both parental and resistant SK-RB-3 cells. Both c-Kit expression and activation are 






Figure 2.7 c-Kit is responsible for trastuzumab resistance in SK-BR-3 cells 
Deregulated c-Kit contributes to the acquired trastuzumab resistance in SK-BR-3 cells, which was 
established by exposing cultured cells to a low dose of trastuzumab for six months. (A) The 
morphology of parental (SKBR3o) and resistant (SKBR3r) cells; (B) SKBR3r cells are less 
sensitive to trastuzumab treatment. Cell proliferation was determined by WST-8 assay, n=3, 
p<0.05; (C-D) SH2-AP-MS (MRM) analysis of 50 μg cell lysate of SKBR3o and SKBR3r cells. 
EGFR_1172, and activation loops of ErBB2, Src and MAPK1(Erk2) were detected in both cells; 
(E) Ratio of peptide abundance (SKBR3r/SKBR3o) determined by MS; (F) Ratio of TK expression 
levels (log2 value, SKBR3r/SKBR3o) determined by transcriptome sequencing (data by Dr. 
Lyugao Qin and Dr. Xiaoling Liu). c-Kit is the most upregulated TK with 80-fold increase in 
transcription; (G) Inhibition of c-Kit but not Src re-sensitized SKBR3r cells for trastuzumab 
treatment. Inhibitors and concentrations: trastuzumab (HER2), 8 μg/ml; imatinib (c-Kit), 2 μM; 





The SH2-AP-MS is an orthogonal method for comprehensive evaluation of TK activity, 
designed for the analysis of TK functional phosphorylation sites that are affinity-purified 
by the SH2 superbinder. As phosphorylation is essential for TK activation and pTyr-
mediated signal transduction in many cases, phosphorylation status on functional tyrosine 
residues could be a reliable indicator of TK activity. The binding between the superbinder 
SH2 and around 1000 TK pTyr sites was globally characterized, allowing the selection of 
superbinder-favored sites for target proteomic studies. In the optimized affinity purification 
workflow, pTyr peptides were effectively enriched by a saturating amount of the SH2 
superbinder. Comparable enrichment efficacy could be reached using anti-pTyr antibodies 
in theory, however the high cost of antibodies makes this impractical. The SH2-AP-MS 
has great sensitivity and sample compatibility, and therefore may be further optimized for 
the TK examination in patient tissues, and even FFPE specimens after IHC/FISH staining. 
In comparison with IHC/FISH/NGS, the SH2-AP-MS approach detects the active TK 
forms. Potentially, this assay will be able to eliminate some false positives of conventional 
methods because gene amplification or protein expression is not well correlated with kinase 
activity. Even though not as comprehensive as the NGS platform, the MS detection panel 
could be further expanded to increase the level of multiplexing. Phosphorylation sites on 
SH2-containing adaptors, scaffold proteins, and the components of PI3K pathways, or 
other TK activity inhibitory sites could be included to generate the TK signaling panel for 
MS detection. Since activation loop phosphorylation is typically occurring in 
serine/threonine kinase activation, it is also possible to integrate IMAC in the affinity 
purification for sequential isolation pTyr and pSer/pThr peptides, which would allow for 
systematic analysis of any selected protein kinases and substrate proteins in a single test.  
As an analytical technology with high levels of sensitivity and accuracy, MS has been 
widely used in many fields including clinical laboratories. A gas chromatography (GC)-
MS method was first approved for the screening of drugs of abuse in the 1980s (Health and 
Services, 1988). Since then many additional small molecules were added into the MS 
detection list in the clinic, including therapeutic drugs, metabolites indicating inborn errors 
of metabolism and  steroid hormones (Jannetto and Fitzgerald, 2016). Even though MS is 
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capable of detecting a wide range of analytes from small molecules to intact proteins, the 
MS analysis of biomarkers from a protein matrix is much more challenging for the clinical 
laboratory, mainly due to regulatory issues, difficulties in sample preparation and running 
complex analytic systems. With constant technological advancements, MS has begun to 
transform practices in the clinical laboratory. In 2013, the Biotyper (Bruker) MALDI 
(Matrix Assisted Laser Desorption/Ionization)-TOF MS system was approved for 
identifying gram negative bacterial species in the clinic (Clark et al., 2013). In the Biotyper 
test, intact proteins were directly ionized from the microbes by MALDI and analyzed in a 
TOF mass analyzer. The spectrums were then matched to a reference library of known 
clinical strains. This entire workflow only takes approximately 15 minutes, thereby greatly 
reducing the cost of reagents and labor compared to conventional culture techniques, and 
brings potential healthcare benefit for rapid pathogen identification (Croxatto et al., 2012; 
Demirev and Fenselau, 2008).  
Due to technical limits, the Biotyper is only capable of identifying the most abundant 
proteins in microbes, but its design is highly robust and reliable, therefore suitable for 
clinical practice. In contrast, our SH2-AP-MS detection of TK biomarkers is much more 
sensitive and precise but requires specific proficiency for sample preparation and MS 
method development. In addition, the compromised durability (uptime) is a common 
concern for all complex tandem MS systems. The filter aided sample preparation (FASP) 
strategy can be tested for improving the SH2 affinity purification (Manza et al., 2005), 
which may simplify the procedures and further increase the pTyr peptide recycle rate.  In 
the current workflow, multiple steps result in sample loss, including the protein 
precipitation from raw extraction, C18 desalting and several rounds of resuspending and 
buffer exchange. By using a filtered column, some of these steps can be merged and carried 
out in the filter column, and C18 desalting can potentially be omitted. C18 desalting is an 
important step in sample preparation as salts that ionize during electrospray suppress the 
signal from peptides, however desalting is a main cause of sample loss, due to incomplete 
and irreversible peptide binding. Ideally in the proposed FASP-SH2-AP workflow, protein 
(raw extract) is reduced, alkylated and digested all within the filter column. Next, the 
tryptic digested peptides are collected by centrifugation while trypsin is trapped by the 
filter. Then the enrichment is directly performed in the peptide flow-through without buffer 
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exchange, as the superbinder SH2 is stable and active under high salt conditions (e.g. 2M 
Urea). Last, the SH2 beads are washed and eluted following the established procedures and 
the elution is ready for direct LC injection. By using rapid-digest trypsin, the entire process 
can be finished within 8 hours. 
The abundance of pTyr peptides can be absolutely quantified by introducing isotope-
labelled peptide standards before the affinity purification. However, this is impractical due 
to the long list of target peptides and high cost of isotope-labelled peptide synthesis and 
purification. The GSK3α_279 was previously thought to be a constitutive phosphorylation 
site, but it exhibited wide variation among different samples and was even absent in some 
cases therefore it is not worthwhile to make a few isotope-labelled peptides as universal 
standards, either. Considering that TKs are usually among the most intensively tyrosine 
phosphorylated proteins, and the known TK biomarker loops are frequently the most 
abundant peaks in the corresponding cell lines (Tab.2.1, Tab.2.2), the qualitative or semi-
quantitative analysis is still invaluable for identifying TK biomarkers or abnormal TK 
activation. Future studies may be focused on translating the SH2 superbinder AP-MS 
approach to the cancer clinic to inform target therapy, starting with commonly occurring 
cancer types, such as breast cancer and non-small cell lung cancer. The isotope-labelled 
peptides for key pTyr sites, including ErbB2, ALK, Src and MAPKs, will be introduced 
for absolute MS quantification. The standard IHC/FISH tests can be carried out 
simultaneously, to allow comparison of the results obtained from the SH2-AP-MS 
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 Supplemental data 
Suppl. 2.1 Alignment of activation loop regions of human TKs 
 
# ID Name Sequence Alignment
1 P00519 ABL1 ---GD-TYT--------------AHAGA-KFPIKWTAPESLA-------YNKFSIKSDVW 423
2 P42684 ABL2 ---GD-TYT--------------AHAGA-KFPIKWTAPESLA-------YNTFSIKSDVW 469
3 Q07912 ACK1 --QNDDHYV--------------MQEHR-KVPFAWCAPESLK-------TRTFSHASDTW 314
4 Q9UM73 ALK --RAS-YYR--------------KGGCA-MLPVKWMPPEAFM-------EGIFTSKTDTW 1313
5 P51451 BLK ---DS-EYT--------------AQEGA-KFPIKWTAPEAIH-------FGVFTIKADVW 419
6 P51813 BMX ---DD-QYV--------------SSVGT-KFPVKWSAPEVFH-------YFKYSSKSDVW 596
7 Q06187 BTK ---DD-EYT--------------SSVGS-KFPVRWSPPEVLM-------YSKFSSKSDIW 581
8 P07333 CSF1R ---NDSNYI--------------VKGNA-RLPVKWMAPESIF-------DCVYTVQSDVW 839
9 P41240 CSK --------S--------------TQDTG-KLPVKWTAPEALR-------EKKFSTKSDVW 370
10 Q08345 DDR1 --AGD-YYR--------------VQGRA-VLPIRWMAWECIL-------MGKFTTASDVW 827
11 Q16832 DDR2 --SGD-YYR--------------IQGRA-VLPIRWMSWESIL-------LGKFTTASDVW 771
12 P00533 EGFR AEEK--EYH---------------AEGG-KVPIKWMALESIL-------HRIYTHQSDVW 898
13 P21709 EPHA1 DFDG--TYE---------------TQGG-KIPIRWTAPEAIA-------HRIFTTASDVW 810
14 P29317 EPHA2 DDPEA-TYT---------------TSGG-KIPIRWTAPEAIS-------YRKFTSASDVW 801
15 P29320 EPHA3 DDPEA-AYT---------------TRGG-KIPIRWTSPEAIA-------YRKFTSASDVW 808
16 P54764 EPHA4 DDPEA-AYT---------------TRGG-KIPIRWTAPEAIA-------YRKFTSASDVW 808
17 P54756 EPHA5 DDPEA-AYT---------------TRGG-KIPIRWTAPEAIA-------FRKFTSASDVW 862
18 Q9UF33 EPHA6 DDPEA-AYT---------------TTGG-KIPIRWTAPEAIA-------YRKFSSASDAW 860
19 Q15375 EPHA7 DDPEA-VYT---------------TTGG-KIPVRWTAPEAIQ-------YRKFTSASDVW 820
20 P29322 EPHA8 DDPDA-AYT---------------TTGG-KIPIRWTAPEAIA-------FRTFSSASDVW 822
21 P54762 EPHB1 DDTSDPTYT--------------SSLGG-KIPVRWTAPEAIA-------YRKFTSASDVW 808
22 P29323 EPHB2 DDTSDPTYT--------------SALGG-KIPIRWTAPEAIQ-------YRKFTSASDVW 810
23 P54753 EPHB3 DDPSDPTYT--------------SSLGG-KIPIRWTAPEAIA-------YRKFTSASDVW 822
24 P54760 EPHB4 ENSSDPTYT--------------SSLGG-KIPIRWTAPEAIA-------FRKFTSASDAW 804
25 O15197 EPHB6 ------------------------PQGP-SCLLRWAAPEVIA-------HGKHTTSSDVW 845
26 P04626 ERBB2 IDET--EYH---------------ADGG-KVPIKWMALESIL-------RRRFTHQSDVW 906
27 P21860 ERBB3 PDDK--QLL---------------YSEA-KTPIKWMALESIH-------FGKYTHQSDVW 895
28 Q15303 ERBB4 GDEK--EYN---------------ADGG-KMPIKWMALECIH-------YRKFTHQSDVW 904
29 Q05397 FAK1 --DST-YYK--------------A-SKG-KLPIKWMAPESIN-------FRRFTSASDVW 606
30 Q14289 FAK2 --DED-YYK--------------A-SVT-RLPIKWMSPESIN-------FRRFTTASDVW 609
31 P16591 FER ---GG-VYS--------------S-SGLKQIPIKWTAPEALN-------YGRYSSESDVW 744
32 P07332 FES ---DG-VYA--------------ASGGLRQVPVKWTAPEALN-------YGRYSSESDVW 744
33 P11362 FGFR1 --HID-YYK--------------KTTNG-RLPVKWMAPEALF-------DRIYTHQSDVW 684
34 P21802 FGFR2 --NID-YYK--------------KTTNG-RLPVKWMAPEALF-------DRVYTHQSDVW 687
35 P22607 FGFR3 --NLD-YYK--------------KTTNG-RLPVKWMAPEALF-------DRVYTHQSDVW 678
36 P22455 FGFR4 --HID-YYK--------------KTSNG-RLPVKWMAPEALF-------DRVYTHQSDVW 673
37 P09769 FGR ---DD-EYN--------------PCQGS-KFPIKWTAPEAAL-------FGRFTIKSDVW 442
38 P36888 FLT3 ---SDSNYV--------------VRGNA-RLPVKWMAPESLF-------EGIYTIKSDVW 872
39 P42685 FRK VDNED-IYE--------------SRHEI-KLPVKWTAPEAIR-------SNKFSIKSDVW 417
40 P06241 FYN ---DN-EYT--------------ARQGA-KFPIKWTAPEAAL-------YGRFTIKSDVW 450
41 P08631 HCK ---DN-EYT--------------AREGA-KFPIKWTAPEAIN-------FGSFTIKSDVW 441
42 P08069 IGF1R --ETD-YYR--------------KGGKG-LLPVRWMSPESLK-------DGVFTTYSDVW 1196
43 P06213 INSR --ETD-YYR--------------KGGKG-LLPVRWMAPESLK-------DGVFTTSSDMW 1220
44 P14616 INSRR --ETD-YYR--------------KGGKG-LLPVRWMAPESLK-------DGIFTTHSDVW 1176
45 Q08881 ITK ---DD-QYT--------------SSTGT-KFPVKWASPEVFS-------FSRYSSKSDVW 542
46 P23458 JAK1 --TDKEYYT--------------VKDDR-DSPVFWYAPECLM-------QSKFYIASDVW 1065
47 O60674 JAK2 --QDKEYYK--------------VKEPG-ESPIFWYAPESLT-------ESKFSVASDVW 1038





49 P10721 KIT ---NDSNYV--------------VKGNA-RLPVKWMAPESIF-------NCVYTFESDVW 853
50 P43405 KSYK A-DEN-YYK--------------AQTHG-KWPVKWYAPECIN-------YYKFSSKSDVW 556
51 P06239 LCK ---DN-EYT--------------AREGA-KFPIKWTAPEAIN-------YGTFTIKSDVW 424
52 Q6ZMQ8 LMTK1 --RED-YFV--------------TADQL-WVPLRWIAPELVDEVHSNLLVVDQTKSGNVW 321
53 Q8IWU2 LMTK2 --KED-YIE--------------TDDKK-VFPLRWTAPELVTSFQDRLLTADQTKYSNIW 333
54 Q96Q04 LMTK3 --KED-YYL--------------TPERL-WIPLRWAAPELLGELHGTFMVVDQSRESNIW 334
55 P29376 LTK --RAS-YYR--------------RGDRA-LLPVKWMPPEAFL-------EGIFTSKTDSW 707
56 P07948 LYN ---DN-EYT--------------AREGA-KFPIKWTAPEAIN-------FGCFTIKSDVW 427
57 P42679 MATK --------K--------------GLDSS-RLPVKWTAPEALK-------HGKFTSKSDVW 408
58 Q12866 MERTK --SGD-YYR---------------QGRIAKMPVKWIAIESLA-------DRVYTSKSDVW 784
59 P08581 MET --DKE-YYSV-------------HNKTGAKLPVKWMALESLQ-------TQKFTTKSDVW 1267
60 O15146 MUSK --SAD-YYK--------------ANEND-AIPIRWMPPESIF-------YNRYTTESDVW 786
61 P04629 NTRK1 --STD-YYR--------------VGGRT-MLPIRWMPPESIL-------YRKFTTESDVW 711
62 Q16620 NTRK2 --STD-YYR--------------VGGHT-MLPIRWMPPESIM-------YRKFTTESDVW 737
63 Q16288 NTRK3 --STD-YYRLFNPSGNDFCIWCEVGGHT-MLPIRWMPPESIM-------YRKFTTESDVW 754
64 P16234 PGFRA ---HDSNYV--------------SKGST-FLPVKWMAPESIF-------DNLYTTLSDVW 879
65 P09619 PGFRB ---RDSNYI--------------SKGST-FLPLKWMAPESIF-------NSLYTTLSDVW 887
66 Q13882 PTK6 ---ED-VYL--------------S-HDH-NIPYKWTAPEALS-------RGHYSTKSDVW 371
67 Q13308 PTK7 ---NSEYYH---------------FRQA-WVPLRWMSPEAIL-------EGDFSTKSDVW 990
68 P07949 RET --EED-SYV--------------KRSQG-RIPVKWMAIESLF-------DHIYTTQSDVW 935
69 Q04912 RON --DRE-YYSV-------------QQHRHARLPVKWMALESLQ-------TYRFTTKSDVW 1271
70 Q01973 ROR1 --SAD-YYR--------------VQSKS-LLPIRWMPPEAIM-------YGKFSSDSDIW 676
71 Q01974 ROR2 --AAD-YYK--------------LLGNS-LLPIRWMAPEAIM-------YGKFSIDSDIW 676
72 P08922 ROS1 --KND-YYR--------------KRGEG-LLPVRWMAPESLM-------DGIFTTQSDVW 2145
73 P34925 RYK --PMD-YHC---------------LGDNENRPVRWMALESLV-------NNEFSSASDVW 523
74 P12931 SRC ---DN-EYT--------------ARQGA-KFPIKWTAPEAAL-------YGRFTIKSDVW 449
75 Q9H3Y6 SRMS ---DD-IYS--------------PSSSS-KIPVKWTAPEAAN-------YRVFSQKSDVW 410
76 Q6J9G0 STYK1 T--RG-A-----------------ISSTQTIPLKWLAPERLL-------LRPASIRADVW 310
77 P42680 TEC ---DD-QYT--------------SSSGA-KFPVKWCPPEVFN-------YSRFSSKSDVW 549
78 P35590 TIE1 ------VYV--------------KKTMG-RLPVRWMAIESLN-------YSVYTTKSDVW 1037
79 Q02763 TIE2 ------VYV--------------KKTMG-RLPVRWMAIESLN-------YSVYTTNSDVW 1022
80 Q13470 TNK1 --GARGRYV--------------MGGPR-PIPYAWCAPESLR-------HGAFSSASDVW 307
81 P42681 TXK ---DD-EYV--------------SSFGA-KFPIKWSPPEVFL-------FNKYSSKSDVW 450
82 P29597 TYK2 --EGHEYYR--------------VREDG-DSPVFWYAPECLK-------EYKFYYASDVW 1085
83 Q06418 TYRO3 --SGD-YYR---------------QGCASKLPVKWLALESLA-------DNLYTVQSDVW 716
84 P30530 UFO --NGD-YYR---------------QGRIAKMPVKWIAIESLA-------DRVYTSKSDVW 733
85 P17948 VGFR1 ---KNPDYV--------------RKGDT-RLPLKWMAPESIF-------DKIYSTKSDVW 1083
86 P35968 VGFR2 ---KDPDYV--------------RKGDA-RLPLKWMAPETIF-------DRVYTIQSDVW 1089
87 P35916 VGFR3 ---KDPDYV--------------RKGSA-RLPLKWMAPESIF-------DKVYTTQSDVW 1098
88 P07947 YES ---DN-EYT--------------ARQGA-KFPIKWTAPEAAL-------YGRFTIKSDVW 456
89 P43403 ZAP70 A-DDS-YYT--------------ARSAG-KWPLKWYAPECIN-------FRKFSSRSDVW 523
       *
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Suppl. 2.3 TK pTyr sites and their relative blot intensities to the superbinder 
Protein Sequence Site Intensity Trypsin digestion 
ABL1 CTREPPFpYIITEFMTa Y312 2.79 Y 
ABL1 QGWVPSNpYITPVNSLa Y115 2.33 Y 
ABL1 IITEFMTpYGNLLDYLa Y320 2.2 Y 
ABL1 HKLGGGQpYGEVYEGVa Y253 2.01 Y 
ABL1 TAPESLApYNKFSIKSa Y413 1.85 Y 
ABL1 YEGVWKKpYSLTVAVKa Y264 1.81 Y 
ABL1 VSRNAAEpYLLSSGINa Y139 1.75 Y 
ABL1 SLEKHSWpYHGPVSRNa Y128 1.65 Y 
ABL1 TASDGKLpYVSSESRFa Y185 1.58 Y 
ABL1 GGQYGEVpYEGVWKKYa Y257 1.42 Y 
ABL1 KRNKPTVpYGVSPNYDa Y226 1.31 Y 
ABL1 EGCPEKVpYELMRACWa Y469 1.31 Y 
ABL1 LYTFCVSpYVDSIQQMa Y1070 1.13 Y 
ABL1 VYGVSPNpYDKWEMERa Y232 1.12 Y 
ABL1 LEAGKNLpYTFCVSYVa Y1064 1 Y 
ABL1 RLMTGDTpYTAHAGAKa Y393 0.95 Y 
ABL1 EKLRVLGpYNHNGEWCa Y93 0.89 Y 
ABL2 QGWVPSNpYITPVNSLa Y161 2.23 Y 
ABL2 TTADGKVpYVTAESRFa Y231 2.21 Y 
ABL2 TAPESLApYNTFSIKSa Y459 2.02 Y 
ABL2 VSRSAAEpYLLSSLINa Y185 1.94 Y 
ABL2 SSSSVVPpYLPRLPILa Y568 1.74 Y 
ABL2 YVGVWKKpYSLTVAVKa Y310 1.6 Y 
ABL2 HKLGGGQpYGEVYVGVa Y299 1.55 Y 
ABL2 SLEKHSWpYHGPVSRSa Y174 1.53 Y 
ABL2 GGQYGEVpYVGVWKKYa Y303 1.4 Y 
ABL2 KCNKPTVpYGVSPIHDa Y272 1.15 Y 
ABL2 NLVPPKCpYGGSFAQRa Y718 1.15 Y 
ABL2 EGCPPKVpYELMRACWa Y515 1.13 Y 
ABL2 EKLRVLGpYNQNGEWSa Y139 0.99 Y 
ABL2 RLMTGDTpYTAHAGAKa Y439 0.78 Y 
ACK1 KKVSSTHpYYLLPERPa Y859 3.45 Y 
ACK1 HRNLIRLpYGVVLTPPa Y193 3.42 Y 
ACK1 SFASDPKpYATPQVIQa Y827 2.73 Y 
ACK1 KVSSTHYpYLLPERPSa Y860 2.63 Y 
ACK1 LLPERPSpYLERYQRFa Y868 2.15 Y 
ACK1 LPQNDDHpYVMQEHRKa Y284 1.83 Y 
ACK1 GGVKKPTpYDPVSEDQa Y518 1.48 Y 
ALK QPREPLSpYSRLQRKSa Y46 1.66 Y 
ALK MELQSPEpYKLSKLRTa Y1078 1.05 Y 
ALK KNCPGPVpYRIMTQCWa Y1359 0.86 Y 
ALK MTDYNPNpYCFAGKTSa Y1096 0.63 Y 
ALK TSLWNPTpYGSWFTEKa Y1507 0.62 Y 
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ALK TSTIMTDpYNPNYCFAa Y1092 0.59 Y 
BLK VVTKEPIpYIVTEYMAa Y309 2.99 Y 
BLK CLDEGGYpYISPRITFa Y188 2.58 Y 
BLK RCLDEGGpYYISPRITa Y187 2.11 Y 
BLK LVTGREGpYVPSNFVAa Y107 1.98 Y 
BLK YTATERQpYELQPaaaa Y501 1.65 Y 
BLK LQALVQHpYSKKGDGLa Y205 1.02 Y 
BLK PIYIVTEpYMARGCLLa Y314 0.92 Y 
BLK QIAEGMApYIERMNSIa Y350 0.91 Y 
BLK ARIIDSEpYTAQEGAKa Y389 0.71 Y 
BMX RYVLDDQpYVSSVGTKa Y566 2.16 Y 
BMX NSSQVGMpYTVSLFSKa Y330 1.42 Y 
BMX LGKWKGQpYDVAVKMIa Y440 1.3 Y 
BMX LTKTNLSpYYEYDKMKa Y40 0.83 Y 
BMX SSTSLAQpYDSNSKKIa Y216 0.45 Y 
BMX KLYLAENpYCFDSIPKa Y365 0.42 Y 
BTK RYVLDDEpYTSSVGSKa Y551 2.31 Y 
BTK TVHKLSYpYEYDFERGa Y40 2.23 Y 
BTK LKKVVALpYDYMPMNAa Y223 1.98 Y 
BTK CSTPQSQpYYLAEKHLa Y344 1.84 Y 
BTK STPQSQYpYLAEKHLFa Y345 1.74 Y 
BTK PQGVIRHpYVVCSTPQa Y334 1.67 Y 
BTK DVCEAMEpYLESKQFLa Y511 1.32 Y 
BTK KVVALYDpYMPMNANDa Y225 0.96 Y 
BTK HEKLVQLpYGVCTKQRa Y461 0.8 Y 
BTK IAQGLRLpYRPHLASEa Y617 0.72 Y 
BTK GLISRLKpYPVSQQNKa Y375 0.51 Y 
CSF1R EDRRERDpYTNLPSSSa Y923 1.55 Y 
CSF1R DIMNDSNpYIVKGNARa Y809 1.44 Y 
CSF1R YKLVKDGpYQMAQPAFa Y873 1.37 Y 
CSF1R DPEGGVDpYKNIHLEKa Y699 1.21 Y 
CSK VEEKGGLpYIVTEYMAa Y263 1.86 Y 
CSK DGCPPAVpYEVMKNCWa Y416 1.55 Y 
CSK EGIIPANpYVQKREGVa Y64 1.41 Y 
CSK DVCEAMEpYLEGNNFVa Y304 1.35 Y 
CSK EQAERLLpYPPETGLFa Y97 0.89 Y 
CSK VAAQDEFpYRSGWALNa Y184 0.85 Y 
CSK AKGSLVDpYLRSRGRSa Y277 0.84 Y 
DDR1 RNLYAGDpYYRVQGRAa Y796 2.04 Y 
DDR1 PACPQGLpYELMLRCWa Y881 2.04 Y 
DDR1 NLYAGDYpYRVQGRAVa Y797 1.79 Y 
DDR1 FGMSRNLpYAGDYYRVa Y792 1.78 Y 
DDR1 YRLLLATpYARPPRGPa Y520 1.43 Y 
DDR1 RDQGRQVpYLSRPPACa Y869 1.43 Y 
DDR1 GPREPPPpYQEPRPRGa Y484 1.25 Y 
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DDR2 RNLYSGDpYYRIQGRAa Y740 3.16 Y 
DDR2 EQGSNSTpYDRIFPLRa Y471 2.9 Y 
DDR2 SDVRTVSpYTNLKFMAa Y684 2.84 Y 
DDR2 FGMSRNLpYSGDYYRIa Y736 2.3 Y 
DDR2 IFPLRPDpYQEPSRLIa Y481 2.26 Y 
DDR2 NLYSGDYpYRIQGRAVa Y741 2.25 Y 
DDR2 RDQGRQTpYLPQPAICa Y813 0.62 Y 
EGFR MARDPQRpYLVIQGDEa Y978 2.8 Y 
EGFR NMYYENSpYALAVLSNa Y117 2.21 Y 
EGFR IIRGNMYpYENSYALAa Y113 2.03 Y 
EGFR STAENAEpYLRVAPQSa Y1197 1.74 Y 
EGFR ISLDNPDpYQQDFFPKa Y1172 1.72 Y 
EGFR KEILDEApYVMASVDNa Y764 1.7 Y 
EGFR NCIQCAHpYIDGPHCVa Y585 1.38 Y 
EGFR SGAFGTVpYKGLWIPEa Y727 1.35 Y 
EGFR SPTDSNFpYRALMDEEa Y998 1.32 Y 
EGFR QIIRGNMpYYENSYALa Y112 1.25 Y 
EGFR PICTIDVpYMIMVKCWa Y944 1.23 Y 
EGFR GSVQNPVpYHNQPLNPa Y1110 0.99 Y 
EGFR QIAKGMNpYLEDRRLVa Y827 0.82 Y 
EGFR LGAEEKEpYHAEGGKVa Y869 0.56 Y 
EPHA1 LDDFDGTpYETQGGKIa Y781 2.08 Y 
EPHA2 EHFMAAGpYTAIEKVVa Y930 2.64 Y 
EPHA2 RQSPEDVpYFSKSEQLa Y575 2.24 Y 
EPHA2 GHQKRIApYSLLGLKDa Y960 2.17 Y 
EPHA2 QLKPLKTpYVDPHTYEa Y588 1.6 Y 
EPHA2 TYVDPHTpYEDPNQAVa Y594 1.34 Y 
EPHA2 EDDPEATpYTTSGGKIa Y772 1.09 Y 
EPHA2 ESIKMQQpYTEHFMAAa Y921 0.94 Y 
EPHA2 KYLANMNpYVHRDLAAa Y735 0.77 Y 
EPHA2 TAPEAISpYRKFTSASa Y791 0.71 Y 
EPHA2 PMMIITEpYMENGALDa Y694 0.64 Y 
EPHA2 LEGVISKpYKPMMIITa Y685 0.33 Y 
EPHA2 AGEFGEVpYKGMLKTSa Y628 0.32 Y 
EPHA3 CKETFNLpYYMESDDDa Y123 1.68 Y 
EPHA3 EDDPEAApYTTRGGKIa Y779 1.35 Y 
EPHA3 KYLSDMGpYVHRDLAAa Y742 1.27 Y 
EPHA3 TYVDPHTpYEDPTQAVa Y602 1.14 Y 
EPHA3 KLPGLRTpYVDPHTYEa Y596 1.04 Y 
EPHA3 GIASGMKpYLSDMGYVa Y736 0.97 Y 
EPHA3 KETFNLYpYMESDDDHa Y124 0.83 Y 
EPHA3 EIFTGVEpYSSCDTIAa Y937 0.72 Y 
EPHA3 IKTLKVGpYTEKQRRDa Y659 0.58 Y 
EPHA3 PVMIVTEpYMENGSLDa Y701 0.57 Y 
EPHA4 LNQGVRTpYVDPFTYEa Y596 1.73 Y 
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EPHA4 TYVDPFTpYEDPNQAVa Y602 1.57 Y 
EPHA4 EDDPEAApYTTRGGKIa Y779 1.44 Y 
EPHA4 TAPEAIApYRKFTSASa Y798 1.17 Y 
EPHA5 TYIDPHTpYEDPNQAVa Y656 2.01 Y 
EPHA5 KLPGVRTpYIDPHTYEa Y650 1.84 Y 
EPHA5 KCMCKAGpYEEKNGTCa Y295 1.28 Y 
EPHA5 EDDPEAApYTTRGGKIa Y833 1.13 Y 
EPHA5 SPLGSGApYRSVGEWLa Y967 0.82 Y 
EPHA5 KYLSDMGpYVHRDLAAa Y796 0.8 Y 
EPHA5 GISAGMKpYLSDMGYVa Y790 0.5 Y 
EPHA5 IKTLKVGpYTEKQRRDa Y713 0.35 Y 
EPHA6 EDDPEAApYTTTGGKIa Y831 1.89 Y 
EPHA6 TYIDPDTpYEDPSLAVa Y612 1.24 Y 
EPHA6 KYLSDMGpYVHRDLAAa Y794 1.07 Y 
EPHA6 TAPEAIApYRKFSSASa Y850 0.89 Y 
EPHA6 GIASGMKpYLSDMGYVa Y788 0.83 Y 
EPHA6 RFPGIKTpYIDPDTYEa Y606 0.71 Y 
EPHA7 EDDPEAVpYTTTGGKIa Y791 2.47 Y 
EPHA7 QEGDEELpYFHFKFPGa Y597 1.98 Y 
EPHA7 GIAAGMRpYLADMGYVa Y748 1.58 Y 
EPHA7 RYLADMGpYVHRDLAAa Y754 1.31 Y 
EPHA7 TAPEAIQpYRKFTSASa Y810 0.95 Y 
EPHA7 KFPGTKTpYIDPETYEa Y608 0.8 Y 
EPHA7 TYIDPETpYEDPNRAVa Y614 0.65 Y 
EPHA7 IKTLKVGpYTEKQRRDa Y671 0.53 Y 
EPHA8 FYAEPHTpYEEPGRAGa Y616 2.33 Y 
EPHA8 EDDPDAApYTTTGGKIa Y793 2 Y 
EPHA8 LAMIVTEpYMENGSLDa Y715 1.19 Y 
EPHB1 YSDKLQHpYSTGRGSPa Y582 1.3 Y 
EPHB1 DDTSDPTpYTSSLGGKa Y778 1.13 Y 
EPHB1 GSPGMKIpYIDPFTYEa Y594 0.96 Y 
EPHB1 TAPEAIApYRKFTSASa Y798 0.8 Y 
EPHB1 KYLAEMNpYVHRDLAAa Y740 0.78 Y 
EPHB1 AYSKEAVpYSDKLQHYa Y575 0.63 Y 
EPHB1 IYIDPFTpYEDPNEAVa Y600 0.56 Y 
EPHB1 SDFGLSRpYLQDDTSDa Y768 0.49 Y 
EPHB1 AGEFGEVpYKGRLKLPa Y634 0.45 Y 
EPHB2 YTDKLQHpYTSGHMTPa Y584 2.21 Y 
EPHB2 LDRTIPDpYTSFNTVDa Y912 2.14 Y 
EPHB2 DDTSDPTpYTSALGGKa Y780 1.81 Y 
EPHB2 GRYSGKMpYFQTMTEAa Y524 1.48 Y 
EPHB2 KYLADMNpYVHRDLAAa Y742 1.42 Y 
EPHB2 PVSRSGFpYLAFQDYGa Y175 1.42 Y 
EPHB2 MTPGMKIpYIDPFTYEa Y596 1.4 Y 
EPHB2 FERADSEpYTDKLQHYa Y577 1.11 Y 
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EPHB2 GIAAGMKpYLADMNYVa Y736 1.1 Y 
EPHB2 IYIDPFTpYEDPNEAVa Y602 1.07 Y 
EPHB2 YEKELSEpYNATAIKSa Y481 0.96 Y 
EPHB2 DDTSDPTpYTSALGGKa Y781 0.85 Y 
EPHB2 IKTLKSGpYTEKQRRDa Y659 0.69 Y 
EPHB2 TAPEAIQpYRKFTSASa Y800 0.53 Y 
EPHB2 FYLAFQDpYGGCMSLIa Y181 0.41 Y 
EPHB3 LDRTVPDpYTTFTTVGa Y924 3.78 Y 
EPHB3 DDPSDPTpYTSSLGGKa Y792 1.46 Y 
EPHB3 YTEKLQQpYIAPGMKVa Y600 1.22 Y 
EPHB3 IAPGMKVpYIDPFTYEa Y608 1.16 Y 
EPHB3 TAPEAIApYRKFTSASa Y812 1.05 Y 
EPHB3 KYLSEMNpYVHRDLAAa Y754 1.01 Y 
EPHB3 RHGSDSEpYTEKLQQYa Y593 0.96 Y 
EPHB3 VYIDPFTpYEDPNEAVa Y614 0.66 Y 
EPHB4 AKEIDVSpYVKIEEVIa Y614 3.97 Y 
EPHB4 LDQRQPHpYSAFGSVGa Y906 2.34 Y 
EPHB4 YSDKHGQpYLIGHGTKa Y581 1.86 Y 
EPHB4 ENSSDPTpYTSSLGGKa Y774 1.5 Y 
EPHB4 IGHGTKVpYIDPFTYEa Y590 1.43 Y 
EPHB4 GGREDLTpYALRCRECa Y357 1.14 Y 
EPHB4 SNGREAEpYSDKHGQYa Y574 0.99 Y 
EPHB4 TGGPAPQpYaaaaaaaa Y987 0.98 Y 
EPHB4 VYIDPFTpYEDPNEAVa Y596 0.95 Y 
EPHB6 AREVDPApYIKIEEVIa Y669 3.34 Y 
EPHB6 YTEQLQQpYSSPGLGVa Y635 2.76 Y 
EPHB6 SPGLGVKpYYIDPSTYa Y644 1.82 Y 
EPHB6 YYIDPSTpYEDPCQAIa Y651 1.79 Y 
EPHB6 PGLGVKYpYIDPSTYEa Y645 1.68 Y 
ERBB2 SPLDSTFpYRSLLEDDa Y1005 1.95 Y 
ERBB2 KEILDEApYVMAGVGSa Y772 1.74 Y 
ERBB2 PTAENPEpYLGLDVPVa Y1248 1.69 Y 
ERBB2 SGAFGTVpYKGIWIPDa Y735 1.29 Y 
ERBB2 LDIDETEpYHADGGKVa Y877 0.54 Y 
ERBB3 HQAPHVHpYARLKTLRa Y1307 2.69 Y 
ERBB3 SAFDNPDpYWHSRLFPa Y1328 1.69 Y 
ERBB3 RPRGDSApYHSQRHSLa Y1132 1.54 Y 
ERBB4 MARDPQRpYLVIQGDDa Y984 3.17 Y 
ERBB4 PPKAEDEpYVNEPLYLa Y1202 2.04 Y 
ERBB4 EYVNEPLpYLNTFANTa Y1208 1.92 Y 
ERBB4 KAFDNPDpYWNHSLPPa Y1242 1.89 Y 
ERBB4 STLQHPDpYLQEYSTKa Y1258 1.69 Y 
ERBB4 HPDYLQEpYSTKYFYKa Y1262 1.46 Y 
ERBB4 QALDNPEpYHNASNGPa Y1188 1.41 Y 
ERBB4 GHSPPPApYTPMSGNQa Y1056 1.4 Y 
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ERBB4 SGAFGTVpYKGIWVPEa Y733 1.15 Y 
ERBB4 GELDEEGpYMTPMRDKa Y1150 0.99 Y 
ERBB4 DQNKFLCpYADTIHWQa Y157 0.84 Y 
ERBB4 RDKPKQEpYLNPVEENa Y1162 0.8 Y 
ERBB4 EDSSTQRpYSADPTVFa Y1128 0.74 Y 
ERBB4 EQGVSVPpYRAPTSTIa Y1081 0.68 Y 
ERBB4 MSGNQFVpYRDGGFAAa Y1066 0.68 Y 
ERBB4 LEGDEKEpYNADGGKMa Y875 0.56 Y 
FAK1 DRSNDKVpYENVTGLVa Y925 3.86 Y 
FAK1 ALEKKSNpYEVLEKDVa Y194 3.09 Y 
FAK1 KPTLNFFpYQQVKSDYa Y148 2.65 Y 
FAK1 KMKLAQQpYVMTSLQQa Y1007 2.05 Y 
FAK1 YQQVKSDpYMLEIADQa Y155 1.69 Y 
FAK1 GDFGLSRpYMEDSTYYa Y570 1.35 Y 
FAK1 RYMEDSTpYYKASKGKa Y576 0.95 Y 
FAK1 YMEDSTYpYKASKGKLa Y577 0.76 Y 
FAK1 MTSLQQEpYKKQMLTAa Y1016 0.33 Y 
FAK2 CQLPPEGpYVVVVKNVa Y906 3.16 Y 
FAK2 EGFFGEVpYEGVYTNHa Y440 2.72 Y 
FAK2 RYIEDEDpYYKASVTRa Y579 2.24 Y 
FAK2 DRTDDLVpYLNVMELVa Y881 2.19 Y 
FAK2 GDFGLSRpYIEDEDYYa Y573 1.76 Y 
FAK2 TPEKEVGpYLEFTGPPa Y849 1.75 Y 
FAK2 QKQMVEDpYQWLRQEEa Y819 1.65 Y 
FAK2 YIEDEDYpYKASVTRLa Y580 1.43 Y 
FAK2 VCSLSDVpYQMEKDIAa Y683 1.27 Y 
FAK2 RRPGGPQpYGIAREDVa Y418 1.1 Y 
FAK2 KSLDPMVpYMNDKSPLa Y834 0.52 Y 
FAK2 PKPSRPKpYRPPPQTNa Y722 0.41 Y 
FER LKGIFDEpYSQITSLVa Y229 3.59 Y 
FER SHGKPGEpYVLSVYSDa Y492 3 Y 
FER KQQVKKSpYIGVHQQIa Y114 2.33 Y 
FER TAPEALNpYGRYSSESa Y734 1.82 Y 
FER RQEDGGVpYSSSGLKQa Y714 1.5 Y 
FER EPPPVVNpYEEDARSVa Y402 1.35 Y 
FER GEYVLSVpYSDGQRRHa Y497 1.34 Y 
FER EAKILKQpYDHPNIVKa Y615 0.94 Y 
FES RIQPEAEpYQGFLRQYa Y261 1.56 Y 
FES TAPEALNpYGRYSSESa Y734 1.35 Y 
FES REEADGVpYAASGGLRa Y713 1.14 Y 
FES EARILKQpYSHPNIVRa Y614 1.08 Y 
FES SAQAKRKpYQEASKDKa Y156 0.6 Y 
FGFR1 IGPDNLPpYVQILKTAa Y307 3.01 Y 
FGFR1 IGGYKVRpYATWSIIMa Y210 2.55 Y 
FGFR1 MLAGVSEpYELPEDPRa Y463 2.07 Y 
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FGFR1 KDLVSCApYQVARGMEa Y605 1.77 Y 
FGFR1 RDIHHIDpYYKKTTNGa Y653 1.56 Y 
FGFR1 RRPPGLEpYCYNPSHNa Y583 1.25 Y 
FGFR1 DIHHIDYpYKKTTNGRa Y654 1.25 Y 
FGFR1 NRMPVAPpYWTSPEKMa Y154 1.18 Y 
FGFR1 SKGNLREpYLQARRPPa Y572 1.06 Y 
FGFR1 PPGLEYCpYNPSHNPEa Y585 0.62 Y 
FGFR1 SNCTNELpYMMMRDCWa Y730 0.61 Y 
FGFR1 QVARGMEpYLASKKCIa Y613 0.53 Y 
FGFR1 VEFMCKVpYSDPQPHIa Y280 0.51 Y 
FGFR2 RRPPGMEpYSYDINRVa Y586 2.09 Y 
FGFR2 PPGMEYSpYDINRVPEa Y588 1.92 Y 
FGFR2 RDINNIDpYYKKTTNGa Y656 1.89 Y 
FGFR2 DINNIDYpYKKTTNGRa Y657 1.46 Y 
FGFR2 KDLVSCTpYQLARGMEa Y608 1.44 Y 
FGFR2 QLARGMEpYLASQKCIa Y616 0.98 Y 
FGFR2 ANCTNELpYMMMRDCWa Y733 0.55 Y 
FGFR3 KDLVSCApYQVARGMEa Y599 1.6 Y 
FGFR3 ANCTHDLpYMIMRECWa Y724 1.57 Y 
FGFR3 RDVHNLDpYYKKTTNGa Y647 1.37 Y 
FGFR3 DVHNLDYpYKKTTNGRa Y648 1.04 Y 
FGFR3 RRPPGLDpYSFDTCKPa Y577 0.73 Y 
FGFR3 QVARGMEpYLASQKCIa Y607 0.62 Y 
FGFR4 RGVHHIDpYYKKTSNGa Y642 1.75 Y 
FGFR4 LLAVSEEpYLDLRLTFa Y754 1.31 Y 
FGFR4 GVHHIDYpYKKTSNGRa Y643 1.16 Y 
FGR KLDMGGYpYITTRVQFa Y209 3.04 Y 
FGR RKLDMGGpYYITTRVQa Y208 2.75 Y 
FGR VTLFIALpYDYEARTEa Y86 2.01 Y 
FGR SETTKGApYSLSIRDWa Y180 1.87 Y 
FGR LEGDFRSpYGAADHYGa Y28 1.1 Y 
FGR SYGAADHpYGPDPTKAa Y34 0.63 Y 
FGR RLIKDDEpYNPCQGSKa Y412 0.29 Y 
FLT3 VSECPHTpYQNRRPFSa Y969 2.29 Y 
FLT3 QKGLDNGpYSISKFCNa Y401 2.25 Y 
FLT3 SIRNTLLpYTLRRPYFa Y166 2.18 Y 
FLT3 FYVDFREpYEYDLKWEa Y597 2.09 Y 
FLT3 HKHQPGEpYIFHAENDa Y416 1.96 Y 
FLT3 VDFREYEpYDLKWEFPa Y599 1.93 Y 
FLT3 KEHNFSFpYPTFQSHPa Y726 1.59 Y 
FLT3 DIMSDSNpYVVRGNARa Y842 1.59 Y 
FLT3 KVMNATApYGISKTGVa Y630 1.03 Y 
FRK CTLEDPIpYIITELMRa Y303 4.09 Y 
FRK QSQRHGHpYFVALFDYa Y46 2.77 Y 
FRK KVDNEDIpYESRHEIKa Y387 2.72 Y 
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FRK SSQQLQGpYIPSNYVAa Y99 2.52 Y 
FRK LNEFVSHpYTKTSDGLa Y193 2.27 Y 
FRK YFETDSSpYSDANNFIa Y497 2.15 Y 
FRK YFVALFDpYQARTAEDa Y53 1.97 Y 
FRK QGYIPSNpYVAEDRSLa Y104 1.94 Y 
FRK LVGEHNIpYKVADFGLa Y368 1.76 Y 
FRK PAPFDLSpYKTVDQWEa Y221 1.37 Y 
FRK RHGSLQEpYLQNDTGSa Y317 0.95 Y 
FRK DAEKQLLpYSENKTGSa Y132 0.9 Y 
FYN VVSEEPIpYIVTEYMNa Y339 3.5 Y 
FYN VTLFVALpYDYEARTEa Y91 2.61 Y 
FYN RKLDNGGpYYITTRAQa Y213 2.36 Y 
FYN KLDNGGYpYITTRAQFa Y214 1.96 Y 
FYN SETTKGApYSLSIRDWa Y185 1.87 Y 
FYN TAPEAALpYGRFTIKSa Y440 1.24 Y 
FYN RLIEDNEpYTARQGAKa Y417 0.81 Y 
FYN RLIEDNEpYTARQGAKa Y420 0.73 Y 
HCK VVTKEPIpYIITEFMAa Y330 3.77 Y 
HCK TLDNGGFpYISPRSTFa Y209 3.21 Y 
HCK SETTKGSpYSLSVRDYa Y180 2.39 Y 
HCK LATRKEGpYIPSNYVAa Y127 1.98 Y 
HCK RVIEDNEpYTAREGAKa Y411 0.98 Y 
IGF1R QGSFGMVpYEGVAKGVa Y1014 3.55 Y 
IGF1R GLKPWTQpYAVYVKAVa Y577 3.41 Y 
IGF1R GWKLFYNpYALVIFEMa Y115 3.19 Y 
IGF1R IRGWKLFpYNYALVIFa Y113 2.97 Y 
IGF1R GFREVSFpYYSEENKLa Y1280 2.64 Y 
IGF1R PWTQYAVpYVKAVTLTa Y580 2.47 Y 
IGF1R FGMTRDIpYETDYYRKa Y1161 2.08 Y 
IGF1R FREVSFYpYSEENKLPa Y1281 1.5 Y 
IGF1R DIYETDYpYRKGGKGLa Y1166 1.07 Y 
IGF1R NLKDIGLpYNLRNITRa Y131 1.04 Y 
IGF1R RDIYETDpYYRKGGKGa Y1165 0.88 Y 
IGF1R SFDERQPpYAHMNGGRa Y1346 0.52 Y 
INSR YLKIRRSpYALVSLSFa Y401 4.4 Y 
INSR SLGFKRSpYEEHIPYTa Y1355 2.78 Y 
INSR FGMTRDIpYETDYYRKa Y1185 2.58 Y 
INSR QGSFGMVpYEGNARDIa Y1038 2.03 Y 
INSR YLLLFRVpYGLESLKDa Y94 1.7 Y 
INSR GLRHFTGpYRIELQACa Y818 1.59 Y 
INSR RDIYETDpYYRKGGKGa Y1189 1.35 Y 
INSR DIYETDYpYRKGGKGLa Y1190 1.11 Y 
INSR SYEEHIPpYTHMNGGKa Y1361 0.83 Y 
INSRR QGSFGMVpYEGLARGLa Y994 2.61 Y 
INSRR RDVYETDpYYRKGGKGa Y1145 1.26 Y 
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INSRR GLRHFTEpYRIDIHACa Y783 1.08 Y 
INSRR DVYETDYpYRKGGKGLa Y1146 0.84 Y 
ITK DSRTAGTpYTVSVFTKa Y273 3.23 Y 
ITK SPNNLETpYEWYNKSIa Y237 3.11 Y 
ITK DRNGHEGpYVPSSYLVa Y220 2.97 Y 
ITK RLASTHVpYQIMNHCWa Y588 2.18 Y 
ITK VHDNYLLpYVFAPDREa Y90 2.07 Y 
ITK RFVLDDQpYTSSTGTKa Y512 1.97 Y 
ITK EGYVPSSpYLVEKSPNa Y225 1.68 Y 
ITK GLVTRLRpYPVCFGRQa Y336 1.42 Y 
ITK LTKASLApYFEDRHGKa Y40 0.53 Y 
ITK ALRRNEEpYCLLDSSEa Y198 0.49 Y 
ITK NNSLVPKpYHPNFWMDa Y120 0.48 Y 
ITK LATGCAQpYDPTKNASa Y146 0.39 Y 
JAK1 FVSLVDGpYFRLTADAa Y412 4.01 Y 
JAK1 AIETDKEpYYTVKDDRa Y1034 2.59 Y 
JAK1 PNCPDEVpYQLMRKCWa Y1125 2.33 Y 
JAK1 IETDKEYpYTVKDDRDa Y1035 2.2 Y 
JAK1 KDISYKRpYIPETLNKa Y220 1.94 Y 
JAK1 QICKGMDpYLGSRQYVa Y993 1.64 Y 
JAK1 AQEWQPVpYPMSQLSFa Y568 0.92 Y 
JAK1 YSGTLMDpYKDDEGTSa Y605 0.68 Y 
JAK2 DQTPLAIpYNSISYKTa Y201 3.65 Y 
JAK2 FVSLIDGpYYRLTADAa Y372 3.11 Y 
JAK2 IRAKIQDpYHILTRKRa Y221 2.77 Y 
JAK2 NLKLIMEpYLPYGSLRa Y931 2.55 Y 
JAK2 SPKDFNKpYFLTFAVEa Y435 2.55 Y 
JAK2 LIMEYLPpYGSLRDYLa Y934 2.41 Y 
JAK2 AIYNSISpYKTFLPKCa Y206 1.81 Y 
JAK2 GSVEMCRpYDPLQDNTa Y868 1.74 Y 
JAK2 VRREVGDpYGQLHETEa Y570 1.72 Y 
JAK2 VSLIDGYpYRLTADAHa Y373 1.72 Y 
JAK2 QICKGMEpYLGTKRYIa Y966 1.57 Y 
JAK2 AGNQTGLpYVLRCSPKa Y423 1.27 Y 
JAK2 DHIKLLQpYTSQICKGa Y956 1.14 Y 
JAK2 KFGSLDTpYLKKNKNCa Y637 0.96 Y 
JAK2 LTADAHHpYLCKEVAPa Y382 0.55 Y 
JAK3 LPLDKDYpYVVREPGQa Y981 3.01 Y 
JAK3 LLPLDKDpYYVVREPGa Y980 2.92 Y 
JAK3 DASRLLLpYSSQICKGa Y929 1.94 Y 
JAK3 SLRLVMEpYLPSGCLRa Y904 1.62 Y 
KIT SESTNHIpYSNLANCSa Y936 2.81 Y 
KIT DIKNDSNpYVVKGNARa Y823 2.26 Y 
KIT RSVRIGSpYIERDVTPa Y747 2.12 Y 
KIT DHAEAALpYKNLLHSKa Y703 1.92 Y 
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KIT KVVEATApYGLIKSDAa Y609 1.64 Y 
KIT EHAPAEMpYDIMKTCWa Y900 1.33 Y 
KIT VMILTYKpYLQKPMYEa Y547 0.95 Y 
KIT GTVECKApYNDVGKTSa Y494 0.5 Y 
KIT FTDKWEDpYPKSENESa Y362 0.45 Y 
KSYK ELRLRNYpYYDVVNaaa Y630 3.04 Y 
KSYK VLLVTQHpYAKISDFGa Y507 3 Y 
KSYK LRLRNYYpYDVVNaaaa Y631 2.73 Y 
KSYK STVSFNPpYEPELAPWa Y323 2.61 Y 
KSYK YAPECINpYYKFSSKSa Y546 2.52 Y 
KSYK MQQLDNPpYIVRMIGIa Y431 2.4 Y 
KSYK ALRADENpYYKAQTHGa Y525 2.33 Y 
KSYK LWQLVEHpYSYKADGLa Y244 2.25 Y 
KSYK ERELNGTpYAIAGGRTa Y74 1.92 Y 
KSYK VELRLRNpYYYDVVNaa Y629 1.83 Y 
KSYK IISRIKSpYSFPKPGHa Y296 1.53 Y 
KSYK LLRQSRNpYLGGFALSa Y47 1.5 Y 
KSYK ARDNNGSpYALCLLHEa Y203 1.28 Y 
KSYK GKWPVKWpYAPECINYa Y539 1.25 Y 
KSYK LMWEAFSpYGQKPYRGa Y568 1.23 Y 
KSYK LRADENYpYKAQTHGKa Y526 1.14 Y 
KSYK QVSMGMKpYLEESNFVa Y484 0.83 Y 
KSYK EIRPKEVpYLDRKLLTa Y364 0.75 Y 
LCK NLDNGGFpYISPRITFa Y192 2.44 Y 
LCK FGEVWMGpYYNGHTKVa Y263 1.81 Y 
LCK TAPEAINpYGTFTIKSa Y414 1.7 Y 
LCK GEVWMGYpYNGHTKVAa Y264 1.68 Y 
LCK DNCPEELpYQLMRLCWa Y470 1.67 Y 
LCK LHELVRHpYTNASDGLa Y209 1.66 Y 
LCK EDRPTFDpYLRSVLEDa Y489 1.45 Y 
LCK FTATEGQpYQPQPaaaa Y505 1.39 Y 
LCK RLIEDNEpYTAREGAKa Y394 0.68 Y 
LMTK1 HCKYREDpYFVTADQLa Y283 1.99 Y 
LMTK1 SRGLNFEpYKWEAGRGa Y479 0.52 Y 
LMTK2 SWPHSAPpYSRFSISPa Y1468 2.69 Y 
LMTK2 PSLQTSKpYFSPPPPAa Y1448 1.6 Y 
LMTK2 TAGSQGSpYRDSAYFSa Y1100 0.95 Y 
LMTK3 HSNYKEDpYYLTPERLa Y296 2.54 Y 
LMTK3 LGEIFSDpYTPAQVVVa Y156 2.06 Y 
LMTK3 SNYKEDYpYLTPERLWa Y297 1.75 Y 
LYN HDKLVRLpYAVVTREEa Y306 3.47 Y 
LYN SLDNGGYpYISPRITFa Y173 3.38 Y 
LYN VTREEPIpYIITEYMAa Y316 3.34 Y 
LYN SLDNGGYpYISPRITFa Y194 3.21 Y 
LYN RSLDNGGpYYISPRITa Y193 3.2 Y 
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LYN FGEVWMGpYYNNSTKVa Y265 2.78 Y 
LYN LLYEIVTpYGKIPYPGa Y439 2.68 Y 
LYN GEVWMGYpYNNSTKVAa Y266 2.11 Y 
LYN EGFIPSNpYVAKLNTLa Y117 1.63 Y 
LYN ENCPDELpYDIMKMCWa Y473 1.41 Y 
LYN RVIEDNEpYTAREGAKa Y397 1.09 Y 
LYN PIYIITEpYMAKGSLLa Y321 0.83 Y 
LYN RVIEDNEpYTAREGAKa Y376 0.79 Y 
LYN MTALSQGpYRMPRVENa Y460 0.74 Y 
MERTK KKIYSGDpYYRQGRIAa Y753 2.05 Y 
MERTK FGLSKKIpYSGDYYRQa Y749 1.78 Y 
MERTK DSELVVNpYIAKKSFCa Y549 1.39 Y 
MERTK KIYSGDYpYRQGRIAKa Y754 1.23 Y 
MET YREDPIVpYEIHPTKSa Y745 2.83 Y 
MET RDMYDKEpYYSVHNKTa Y1234 2.59 Y 
MET DMYDKEYpYSVHNKTGa Y1235 2.56 Y 
MET EYCPDPLpYEVMLKCWa Y1313 2.41 Y 
MET RGHFGCVpYHGTLLDNa Y1093 1.96 Y 
MET NTFDITVpYLLQGRRLa Y1295 1.28 Y 
MET VSNESVDpYRATFPEDa Y1003 0.98 Y 
MET SPLVVLPpYMKHGDLRa Y1159 0.79 Y 
MET RRLLQPEpYCPDPLYEa Y1307 0.66 Y 
MUSK RNIYSADpYYKANENDa Y755 2.57 Y 
MUSK RLHPNPMpYQRMPLLLa Y554 1.83 Y 
MUSK FGLSRNIpYSADYYKAa Y751 1.65 Y 
MUSK YPRNNIEpYVRDIGEGa Y577 1.63 Y 
MUSK NIYSADYpYKANENDAa Y756 1.49 Y 
NTRK1 TYGKQPWpYQLSNTEAa Y729 2.79 Y 
NTRK1 RDIYSTDpYYRVGGRTa Y674 2.67 Y 
NTRK1 RDIYSTDpYYRVGGRTa Y680 2.49 Y 
NTRK1 DIYSTDYpYRVGGRTMa Y675 2.38 Y 
NTRK1 DIYSTDYpYRVGGRTMa Y681 2.22 Y 
NTRK1 FGMSRDIpYSTDYYRVa Y676 1.93 Y 
NTRK1 RACPPEVpYAIMRGCWa Y757 1.64 Y 
NTRK1 RACPPEVpYAIMRGCWa Y751 1.57 Y 
NTRK1 RACPPEVpYAIMRGCWa Y721 1.33 Y 
NTRK1 PLLMVFEpYMRHGDLNa Y591 1.08 Y 
NTRK1 LAQAPPVpYLDVLGaaa Y791 0.93 Y 
NTRK1 MPPESILpYRKFTTESa Y701 0.76 Y 
NTRK2 RDVYSTDpYYRVGGHTa Y706 2.4 Y 
NTRK2 FGMSRDVpYSTDYYRVa Y702 1.89 Y 
NTRK2 DVYSTDYpYRVGGHTMa Y707 1.86 Y 
NTRK2 LAKASPVpYLDILGaaa Y817 1.33 Y 
NTRK2 KVFLAECpYNLCPEQDa Y558 0.59 Y 
NTRK3 RDVYSTDpYYRLFNPSa Y709 3.63 Y 
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NTRK3 AKNPHLRpYINLSSNRa Y131 2.8 Y 
NTRK3 DVYSTDYpYRLFNPSGa Y710 2.72 Y 
NTRK3 FGMSRDVpYSTDYYRLa Y705 2.24 Y 
NTRK3 YVEDVNVpYFSKGRHGa Y604 2.09 Y 
NTRK3 KPLNHGIpYVEDVNVYa Y597 1.7 Y 
NTRK3 RVCPKEVpYDVMLGCWa Y800 1.15 Y 
NTRK3 PVIENPQpYFRQGHNCa Y516 1.13 Y 
NTRK3 KVFLAECpYNLSPTKDa Y558 1.12 Y 
PDGFRA ADESTRSpYVILSFENa Y720 3.2 Y 
PDGFRA RVDSDNApYIGVTYKNa Y988 2.9 Y 
PDGFRA DHATSEVpYEIMVKCWa Y926 2.01 Y 
PDGFRA PEKRPSFpYHLSEIVEa Y944 1.49 Y 
PDGFRA DIMHDSNpYVSKGSTFa Y849 1.39 Y 
PDGFRA KQADTTQpYVPMLERKa Y742 1.2 Y 
PDGFRA SDIQRSLpYDRPASYKa Y762 1.16 Y 
PDGFRA KVVEGTApYGLSRSQPa Y613 1.05 Y 
PDGFRA NAYIGVTpYKNEEDKLa Y993 0.82 Y 
PDGFRA ERKEVSKpYSDIQRSLa Y754 0.79 Y 
PDGFRA ENLLPGQpYKKSYEKIa Y958 0.75 Y 
PDGFRA SFENNGDpYMDMKQADa Y731 0.38 Y 
PDGFRA LYDRPASpYKKKSMLDa Y768 0.34 Y 
PDGFRB CTKGGPIpYIITEYCRa Y678 2.75 Y 
PDGFRB AHASDEIpYEIMQKCWa Y934 2.16 Y 
PDGFRB IITEYCRpYGDLVDYLa Y686 2.15 Y 
PDGFRB DIMRDSNpYISKGSTFa Y857 1.61 Y 
PDGFRB GEGYKKKpYQQVDEEFa Y970 1.59 Y 
PDGFRB SKDESVDpYVPMLDMKa Y751 1.5 Y 
PDGFRB PIYIITEpYCRYGDLVa Y683 1.42 Y 
PDGFRB RYGDLVDpYLHRNKHTa Y692 1.39 Y 
PTK6 SEKPSADpYVLSVRDTa Y114 3.08 Y 
PTK6 RLSSFTSpYENPTaaaa Y447 1.64 Y 
PTK6 RLIKEDVpYLSHDHNIa Y342 1.23 Y 
PTK6 SHDHNIPpYKWTAPEAa Y351 0.58 Y 
PTK7 CREAEPHpYMVLEYVDa Y872 2.6 Y 
PTK7 KDVYNSEpYYHFRQAWa Y960 1.69 Y 
PTK7 PHYMVLEpYVDLGDLKa Y877 1.1 Y 
RET HLKGRAGpYTTVAVKMa Y752 3.08 Y 
RET RYPNDSVpYANWMLSPa Y1096 2.77 Y 
RET PLLLIVEpYAKYGSLRa Y806 2.21 Y 
RET FGLSRDVpYEEDSYVKa Y900 2.14 Y 
RET TWIENKLpYGRISHAFa Y1062 1.82 Y 
RET DVYEEDSpYVKRSQGRa Y905 1.38 Y 
RET TNTGFPRpYPNDSVYAa Y1090 1.19 Y 
RET AQAFPVSpYSSSGARRa Y687 1.15 Y 
RET SRKVGPGpYLGSGGSRa Y826 0.98 Y 
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RET DNCSEEMpYRLMLQCWa Y981 0.84 Y 
RET HPHVIKLpYGACSQDGa Y791 0.36 Y 
RON RDILDREpYYSVQQHRa Y1238 3 Y 
RON DILDREYpYSVQQHRHa Y1239 2.94 Y 
RON GVVYHGEpYIDQAQNRa Y1101 1.69 Y 
RON QVARSMEpYLAEQKFVa Y1198 1.15 Y 
ROR1 REIYSADpYYRVQSKSa Y645 2.52 Y 
ROR2 EVYAADYpYKLLGNSLa Y646 2.98 Y 
ROR2 ATRNVLVpYDKLNVKIa Y624 1.94 Y 
ROR2 MAPEAIMpYGKFSIDSa Y666 0.94 Y 
ROS1 KYIIQWKpYAQLLGSWa Y135 2.36 Y 
ROS1 KNREGLNpYMVLATECa Y2274 2.28 Y 
ROS1 QLLGSWTpYTKTVSRPa Y144 2.05 Y 
ROS1 DISKGCVpYLERMHFIa Y2069 1.56 Y 
ROS1 GKPEGLNpYACLTHSGa Y2334 1.27 Y 
ROS1 IQIAVKNpYYSDPLEHa Y1535 1.15 Y 
RYK RDLFPMDpYHCLGDNEa Y492 0.42 Y 
SRC KLDSGGFpYITSRTQFa Y216 3.19 Y 
SRC VVSEEPIpYIVTEYMSa Y338 2.87 Y 
SRC VTTFVALpYDYESRTEa Y93 2.56 Y 
SRC AYVERMNpYVHRDLRAa Y385 2.16 Y 
SRC TAPEAALpYGRFTIKSa Y439 1.2 Y 
SRC SETTKGApYCLSVSDFa Y187 1.02 Y 
SRC RLIEDNEpYTARQGAKa Y419 0.74 Y 
SRMS RLLKDDIpYSPSSSSKa Y380 1.77 Y 
STYK1 MTMDGLLpYDLTEKQVa Y221 1.61 Y 
TEC RLERGQEpYLILEKNDa Y206 3.53 Y 
TEC DKYGNEGpYIPSNYVTa Y228 2.89 Y 
TEC WWRARDKpYGNEGYIPa Y223 2.84 Y 
TEC PTTAGFSpYEKWEINPa Y360 2.24 Y 
TEC KSNNLDQpYEWYCRNMa Y245 2.12 Y 
TEC EGYIPSNpYVTGKKSNa Y233 2.05 Y 
TEC RYVLDDQpYTSSSGAKa Y519 1.6 Y 
TEC VHDANTLpYIFAPSPQa Y90 1.58 Y 
TEC GLVTRLRpYPVSVKGKa Y343 1.03 Y 
TEC KFWTDGSpYQCCRQTEa Y130 0.31 Y 
TIE2 TYVNTTLpYEKFTYAGa Y1108 3.25 Y 
TIE2 CEHRGYLpYLAIEYAPa Y899 3.22 Y 
TIE2 MLEERKTpYVNTTLYEa Y1102 2.91 Y 
TIE2 GACEHRGpYLYLAIEYa Y897 2.76 Y 
TIE2 TLYEKFTpYAGIDCSAa Y1113 2.1 Y 
TIE2 NILVGENpYVAKIADFa Y976 1.49 Y 
TIE2 KNATITQpYQLKGLEPa Y697 1.3 Y 
TIE2 LSRGQEVpYVKKTMGRa Y992 1.08 Y 
TIE2 NNPDPTIpYPVLDWNDa Y816 0.62 Y 
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TIE1 MAIESLNpYSVYTTKSa Y1027 3.5 Y 
TIE1 GACKNRGpYLYIAIEYa Y912 3.24 Y 
TIE1 RNCDDEVpYELMRQCWa Y1083 2.35 Y 
TIE1 ESLNYSVpYTTKSDVWa Y1030 1.8 Y 
TIE1 LSRGEEVpYVKKTMGRa Y1007 1.04 Y 
TNK1 DLSAASRpYVLARPaaa Y656 2.96 Y 
TNK1 DLSAASRpYVLARPaaa Y661 2.61 Y 
TNK1 LGGARGRpYVMGGPRPa Y277 1.94 Y 
TNK1 PLCSRALpYSLALRCWa Y353 1.43 Y 
TNK1 CWRILEHpYQWDLSAAa Y651 1.19 Y 
TNK1 QLAGAMApYLGARGLVa Y235 1.11 Y 
TNK1 GGPRPIPpYAWCAPESa Y287 0.34 Y 
TXK RYVLDDEpYVSSFGAKa Y420 2.28 Y 
TXK KIQVKALpYDFLPREPa Y91 2.12 Y 
TYK2 PSEKEHFpYQRQHRLPa Y827 2.98 Y 
TYK2 FVSLVDGpYFRLTADSa Y423 2.96 Y 
TYK2 AVPEGHEpYYRVREDGa Y1054 2.74 Y 
TYK2 QGTRTNVpYEGRLRVEa Y604 2.62 Y 
TYK2 VPEGHEYpYRVREDGDa Y1055 2.04 Y 
TYK2 QAEGEPCpYIRDSGVAa Y292 1.45 Y 
TYK2 DKCPCEVpYHLMKNCWa Y1145 1.21 Y 
TYK2 LTADSSHpYLCHEVAPa Y433 0.79 Y 
TYRO3 FGLSRKIpYSGDYYRQa Y681 1.52 Y 
TYRO3 RKIYSGDpYYRQGCASa Y685 1.41 Y 
TYRO3 KIYSGDYpYRQGCASKa Y686 1.2 Y 
UFO GVENSEIpYDYLRQGNa Y759 3.13 Y 
UFO EVHPAGRpYVLCPSTTa Y866 2.55 Y 
UFO DLHSFLLpYSRLGDQPa Y634 1.74 Y 
UFO KKIYNGDpYYRQGRIAa Y702 1.68 Y 
UFO ADCLDGLpYALMSRCWa Y779 1.6 Y 
UFO RRKKETRpYGEVFEPTa Y481 1.22 Y 
UFO RLGDQPVpYLPTQMLVa Y643 1.13 Y 
UFO KIYNGDYpYRQGRIAKa Y703 1.12 Y 
UFO FGLSKKIpYNGDYYRQa Y698 1.08 Y 
VEGFR1 ARYLTRGpYSLIIKDVa Y388 3.71 Y 
VEGFR1 GSSDDVRpYVNAFKFMa Y1213 3.52 Y 
VEGFR1 SSEIKTDpYLSIIMDPa Y794 2.53 Y 
VEGFR1 CCSPPPDpYNSVVLYSa Y1327 2.38 Y 
VEGFR1 GSVESSApYLTVQGTSa Y745 2.12 Y 
VEGFR1 VIVEYCKpYGNLSNYLa Y914 2.11 Y 
VEGFR1 DYNSVVLpYSTPPIaaa Y1333 1.93 Y 
VEGFR1 EGKRRFTpYDHAELERa Y1309 1.91 Y 
VEGFR1 PLMVIVEpYCKYGNLSa Y911 1.53 Y 
VEGFR1 KYGNLSNpYLKSKRDLa Y920 1.12 Y 
VEGFR1 DIYKNPDpYVRKGDTRa Y1053 0.97 Y 
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VEGFR1 EQCERLPpYDASKWEFa Y815 0.82 Y 
VEGFR2 GGELKTGpYLSIVMDPa Y801 2.46 Y 
VEGFR2 RFRQGKDpYVGAIPVDa Y951 2.14 Y 
VEGFR2 VCDPKFHpYDNTAGISa Y1214 2.07 Y 
VEGFR2 DIYKDPDpYVRKGDARa Y1059 1.11 Y 
VEGFR2 NTAGISQpYLQNSKRKa Y1223 0.85 Y 
VEGFR2 EEAPEDLpYKDFLTLEa Y996 0.73 Y 
VEGFR3 RHSLAARpYYNWVSFPa Y1230 2.49 Y 
VEGFR3 HSLAARYpYNWVSFPGa Y1231 2.48 Y 
VEGFR3 DIYKDPDpYVRKGSARa Y1068 1.36 Y 
VEGFR3 HLGRVLGpYGAFGKVVa Y853 1.33 Y 
VEGFR3 FPMTPTTpYKGSVDNQa Y1265 0.4 Y 
VEGFR3 NANVSAMpYKCVVSNKa Y532 0.35 Y 
YES1 HDKLVPLpYAVVSEEPa Y336 3.79 Y 
YES1 VVSEEPIpYIVTEFMSa Y345 3.55 Y 
YES1 RKLDNGGpYYITTRAQa Y222 3.46 Y 
YES1 KLDNGGYpYITTRAQFa Y223 2.67 Y 
YES1 SETTKGApYSLSIRDWa Y194 1.95 Y 
YES1 TAPEAALpYGRFTIKSa Y446 1.39 Y 
YES1 RLIEDNEpYTARQGAKa Y426 0.96 Y 
ZAP70 LIYGKTVpYHYLISQDa Y209 3.97 Y 
ZAP70 PRKEQGTpYALSLIYGa Y198 3.63 Y 
ZAP70 YGKTVYHpYLISQDKAa Y211 3.58 Y 
ZAP70 MHQLDNPpYIVRLIGVa Y397 3.34 Y 
ZAP70 EQRMRACpYYSLASKVa Y597 3.32 Y 
ZAP70 QRMRACYpYSLASKVEa Y598 2.95 Y 
ZAP70 CLRSLGGpYVLSLVHDa Y46 2.62 Y 
ZAP70 ALGADDSpYYTARSAGa Y492 2.55 Y 
ZAP70 AHERMPWpYHSSLTREa Y164 2.52 Y 
ZAP70 TYALSLIpYGKTVYHYa Y204 2.17 Y 
ZAP70 ERQLNGTpYAIAGGKAa Y69 2.12 Y 
ZAP70 EEAERKLpYSGAQTDGa Y178 1.78 Y 
ZAP70 PAELCEFpYSRDPDGLa Y87 1.57 Y 
ZAP70 DTLNSDGpYTPEPARIa Y292 1.43 Y 
ZAP70 PECPPELpYALMSDCWa Y569 1.22 Y 
ZAP70 LGADDSYpYTARSAGKa Y493 0.88 Y 
ZAP70 GKWPLKWpYAPECINFa Y506 0.62 Y 
ZAP70 TMWEALSpYGQKPYKKa Y535 0.54 Y 
ZAP70 SQDKAGKpYCIPEGTKa Y221 0.52 Y 
ZAP70 LKADGLIpYCLKEACPa Y248 0.28 Y 
ABL1 PNLFVALpYDFVASGDa Y70 1.92 N 
ABL1 KRNKPTVpYGVSPNYDa Y245 1.76 N 
ABL1 TASDGKLpYVSSESRFa Y204 1.76 N 
ABL1 HKLGGGQpYGEVYEGVa Y272 1.58 N 
ABL1 LRYEGRVpYHYRINTAa Y172 1.48 N 
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ABL1 YEGRVYHpYRINTASDa Y174 1.42 N 
ABL1 QRSISLRpYEGRVYHYa Y167 1.27 N 
ABL1 EGCPEKVpYELMRACWa Y488 1.15 N 
ABL1 YELLEKDpYRMERPEGa Y456 0.97 N 
ABL1 GLITTLHpYPAPKRNKa Y215 0.47 N 
ABL2 PNLFVALpYDFVASGDa Y80 3.21 N 
ABL2 ENQPHKKpYELTGNFSa Y683 2.41 N 
ABL2 LRYEGRVpYHYRINTTa Y218 2.32 N 
ABL2 PNLFVALpYDFVASGDa Y116 1.9 N 
ABL2 QLSISLRpYEGRVYHYa Y213 1.57 N 
ABL2 NLVPPKCpYGGSFAQRa Y682 1.29 N 
ABL2 HEALHRPpYGCDVEPQa Y59 0.79 N 
ABL2 PEALHRPpYGCDVEPQa Y80 0.5 N 
ABL2 GLVTTLHpYPAPKCNKa Y261 0.35 N 
ACK1 KVSSTHYpYLLPERPSa Y938 2.88 N 
ACK1 SFASDPKpYATPQVIQa Y905 2.28 N 
ACK1 RPSYLERpYQRFLREAa Y872 2.02 N 
ACK1 LPQNDDHpYVMQEHRKa Y347 1.29 N 
ACK1 FFTQKPTpYDPVSEDQa Y596 1.13 N 
ACK1 PLPPPPApYDDVAQDEa Y635 0.66 N 
ALK CGNVNYGpYQQQGLPLa Y1586 1.98 N 
ALK TAPGAGHpYEDTILKSa Y1604 1.84 N 
ALK HGAFGEVpYEGQVSGMa Y1131 1.77 N 
ALK FPCGNVNpYGYQQQGLa Y1584 1.58 N 
ALK NTALPIEpYGPLVEEEa Y1401 1.35 N 
ALK RDIYRASpYYRKGGCAa Y1282 0.92 N 
ALK FGMARDIpYRASYYRKa Y1278 0.64 N 
ALK DIYRASYpYRKGGCAMa Y1283 0.55 N 
BLK QSVLEDFpYTATERQYa Y494 1.4 N 
BTK DKNGQEGpYIPSNYVTa Y263 1.75 N 
BTK AEDSIEMpYEWYSKHMa Y279 1.59 N 
BTK TIPELINpYHQHNSAGa Y361 1.46 N 
CSF1R ESYEGNSpYTFIDPTQa Y561 3.62 N 
CSF1R RWKIIESpYEGNSYTFa Y556 2.38 N 
CSF1R IDPTQLPpYNEKWEFPa Y571 1.48 N 
CSF1R KYKQKPKpYQVRWKIIa Y546 1.3 N 
CSF1R SSQGVDTpYVEMRPVSa Y723 1.01 N 
CSF1R PLLQPNNpYQFCaaaaa Y969 0.97 N 
CSF1R NIHLEKKpYVRRDSGFa Y708 0.44 N 
DDR1 LLLSNPApYRLLLATYa Y513 1.33 N 
DDR1 AQGPTISpYPMLLHVAa Y740 0.87 N 
DDR1 PLCMITDpYMENGDLNa Y703 0.74 N 
DDR2 GPEGVPHpYAEADIVNa Y521 1.82 N 
EGFR MTFGSKPpYDGIPASEa Y915 1.83 N 
EGFR TAVGNPEpYLNTVQPTa Y1138 1.37 N 
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EGFR DVVDADEpYLIPQQGFa Y1016 1.34 N 
EGFR PFGCLLDpYVREHKDNa Y801 1.31 N 
EGFR TFLPVPEpYINQSVPKa Y1092 1.27 N 
EGFR ESILHRIpYTHQSDVWa Y891 0.91 N 
EGFR EDSFLQRpYSSDPTGAa Y1069 0.67 N 
EGFR APSRDPHpYQDPHSTAa Y1125 0.67 N 
EPHA1 ESIRMKRpYILHFHSAa Y930 2.96 N 
EPHA1 DKLWLKPpYVDLQAYEa Y599 1.95 N 
EPHA1 PYVDLQApYEDPAQGAa Y605 1.19 N 
EPHA2 NDMPIYMpYSVCNVMSa Y67 0.88 N 
EPHA3 ILLTVVIpYVLIGRFCa Y561 2.29 N 
EPHA3 LIGRFCGpYKSKHGADa Y570 0.61 N 
EPHA4 QAIKMDRpYKDNFTAAa Y928 0.85 N 
EPHA5 EAIKMGRpYTEIFMENa Y982 1.89 N 
EPHA6 PFQVTKLpYWLNEKWDa Y12 0.71 N 
EPHA6 DSIKMGQpYKNNFVAAa Y978 0.66 N 
EPHA7 QAIKMERpYKDNFTAAa Y940 0.66 N 
EPHA7 ALVSVKVpYYKKCWSIa Y201 0.52 N 
EPHA7 LVSVKVYpYKKCWSIIa Y202 0.52 N 
EPHA8 LAYGERPpYWNMTNRDa Y839 1.87 N 
EPHA8 LEYEIKYpYEKDKEMQa Y478 1.34 N 
EPHB1 SAIKMVQpYRDSFLTAa Y928 0.37 N 
EPHB2 EAIKMGQpYKESFANAa Y930 0.47 N 
EPHB2 EAIKMGQpYKESFANAa Y931 0.47 N 
EPHB2 LIAVRVFpYRKCPRIIa Y194 0.43 N 
EPHB4 RAIKMGRpYEESFAAAa Y924 2.36 N 
ERBB2 MTFGAKPpYDGIPAREa Y923 1.88 N 
ERBB2 TCSPQPEpYVNQPDVRa Y1139 1.36 N 
ERBB2 GAVENPEpYLTPQGGAa Y1196 1.35 N 
ERBB2 DLVDAEEpYLVPQQGFa Y1023 1.3 N 
ERBB2 SPAFDNLpYYWDQDPPa Y1221 1.26 N 
ERBB2 LPSETDGpYVAPLTCSa Y1127 1.22 N 
ERBB2 DPSPLQRpYSEDPTVPa Y1112 0.61 N 
ERBB2 PAFDNLYpYWDQDPPEa Y1222 0.4 N 
ERBB3 SSLEELGpYEYMDVGSa Y1222 3.09 N 
ERBB3 EEEDVNGpYVMPDTHLa Y1159 2.72 N 
ERBB3 GTTPDEDpYEYMNRQRa Y1260 2.51 N 
ERBB3 EEDEDEEpYEYMNRRRa Y1197 2.19 N 
ERBB3 CPASEQGpYEEMRAFQa Y1289 2.05 N 
ERBB3 PDDKQLLpYSEAKTPIa Y868 1.83 N 
ERBB3 TPDEDYEpYMNRQRDGa Y1262 1.43 N 
ERBB3 DEDEEYEpYMNRRRRHa Y1199 1.39 N 
ERBB3 NKRAMRRpYLERGESIa Y680 1.37 N 
ERBB3 GGGPGGDpYAAMGACPa Y1276 0.86 N 
ERBB3 LLSPSSGpYMPMNQGNa Y1054 0.71 N 
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ERBB4 DMMDAEEpYLVPQAFNa Y1022 3.07 N 
ERBB4 FNIPPPIpYTSRARIDa Y1035 2.08 N 
ERBB4 IVAENPEpYLSEFSLKa Y1284 1.34 N 
ERBB4 LQEYSTKpYFYKQNGRa Y1266 1.01 N 
ERBB4 NTLGKAEpYLKNNILSa Y1221 0.86 N 
ERBB4 EYSTKYFpYKQNGRIRa Y1268 0.8 N 
ERBB4 TVLPPPPpYRHRNTVVa Y1301 0.78 N 
FAK1 HMVQTNHpYQVSGYPGa Y742 3.09 N 
FAK1 SVSETDDpYAEIIDEEa Y397 2.63 N 
FAK1 PIGNQHIpYQPVGKPDa Y883 2.5 N 
FAK1 PIGNQHIpYQPVGKPDa Y861 2.44 N 
FAK1 SVSETDDpYAEIIDEEa Y419 2.32 N 
FAK1 PIGNQHIpYQPVGKPGa Y861 2.25 N 
FAK1 IIDEEDTpYTMPSTRDa Y429 1.63 N 
FAK1 IIDEEDTpYTMPSTRDa Y407 1.52 N 
FAK1 GDVHQGIpYMSPENPAa Y441 1.15 N 
FAK1 aaaMAAApYLDPNLNHa Y5 1.06 N 
FAK1 RYMEDSTpYYKASKGKa Y598 1.04 N 
FAK1 YMEDSTYpYKASKGKLa Y599 1.01 N 
FAK1 LSSPADSpYNEGVKLQa Y898 0.96 N 
FAK1 MADLIDGpYCRLVNGTa Y347 0.91 N 
FAK1 PKPSRPGpYPSPRSSEa Y720 0.75 N 
FAK1 TAMAGSIpYPGQASLLa Y761 0.59 N 
FAK2 CSIESDIpYAEIPDETa Y402 3.68 N 
FAK2 EQERNARpYRTPKILEa Y699 1.66 N 
FAK2 TLTSPMEpYPSPVNSLa Y756 0.67 N 
FER AQLHQNQpYYDITLPLa Y199 2.91 N 
FER QLHQNQYpYDITLPLLa Y200 2.64 N 
FER PLAEQDWpYHGAIPRIa Y461 1.9 N 
FES RPSFSTIpYQELQSIRa Y811 1.96 N 
FGFR1 LSMPLDQpYSPSFPDTa Y776 1.43 N 
FGFR1 EALFDRIpYTHQSDVWa Y677 1.27 N 
FGFR1 ALTSNQEpYLDLSMPLa Y766 1.17 N 
FGFR1 FTLGGSPpYPGVPVEEa Y701 0.52 N 
FGFR2 MLAGVSEpYELPEDPKa Y466 2.01 N 
FGFR2 LSQPLEQpYSPSYPDTa Y779 1.6 N 
FGFR2 TLTTNEEpYLDLSQPLa Y769 1.17 N 
FGFR2 FSPDPMPpYEPCLPQYa Y805 0.91 N 
FGFR2 YEPCLPQpYPHINGSVa Y812 0.74 N 
FGFR2 LEQYSPSpYPDTRSSCa Y783 0.5 N 
FGFR3 RDVHNLDpYYKKTTNGa Y535 1.72 N 
FGFR3 TVTSTDEpYLDLSAPFa Y760 1.34 N 
FGFR3 DVHNLDYpYKKTTNGRa Y536 1.33 N 
FGFR3 LSAPFEQpYSPGGQDTa Y770 1.3 N 
FGFR3 ANCTHDLpYMIMRECWa Y612 1.21 N 
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FGFR3 LSAPFEQpYSPGGQDTa Y658 0.96 N 
FGFR3 RRPPGLDpYSFDTCKPa Y465 0.57 N 
FGR HDKLVQLpYAVVSEEPa Y322 3.88 N 
FGR VVSEEPIpYIVTEFMCa Y331 3.35 N 
FGR PGCPASLpYEAMEQTWa Y488 1.21 N 
FGR LEQVEQGpYHMPCPPGa Y475 0.44 N 
FGR FTSAEPQpYQPGDQTaa Y523 0.4 N 
FLT3 KYKKQFRpYESQLQMVa Y572 3.58 N 
FLT3 TGSSDNEpYFYVDFREa Y589 3.37 N 
FLT3 ADAEEAMpYQNVDGRVa Y955 2.58 N 
FLT3 SSDNEYFpYVDFREYEa Y591 2.55 N 
FLT3 HSEDEIEpYENQKRLEa Y768 1.71 N 
FLT3 EDLLCFApYQVAKGMEa Y793 1.41 N 
FYN TDPTPQHpYPSFGVTSa Y39 1.89 N 
FYN SLNQSSGpYRYGTDPTa Y28 1.27 N 
FYN NQSSGYRpYGTDPTPQa Y30 1.07 N 
FYN FTATEPQpYQPGENLaa Y528 1.03 N 
FYN FTATEPQpYQPGENLaa Y531 1.01 N 
FYN LEQVERGpYRMPCPQDa Y483 0.32 N 
HCK IVVALYDpYEAIHHEDa Y89 4.89 N 
HCK QSVLDDFpYTATESQYa Y515 2.63 N 
HCK YTATESQpYQQQPaaaa Y522 1.94 N 
HCK ASPHCPVpYVPDPTSTa Y51 0.99 N 
IGF1R RLGNGVLpYASVNPEYa Y973 2.34 N 
IGF1R YASVNPEpYFSAADVYa Y980 1.83 N 
INSR YASSNPEpYLSASDVFa Y987 2.87 N 
INSR DGPLGPLpYASSNPEYa Y992 2.5 N 
INSR YASSNPEpYLSASDVFa Y999 1.74 N 
INSR EIADGMApYLNAKKFVa Y1149 1.12 N 
ITK ETVVIALpYDYQTNDPa Y180 2.04 N 
ITK PVTAGLRpYGKWVIDPa Y353 1.31 N 
ITK VVIALYDpYQTNDPQEa Y182 1.18 N 
JAK1 aaaaaMQpYLNIKEDCa Y3 2.19 N 
JAK1 ELPKDISpYKRYIPETa Y217 1.92 N 
JAK1 PSGSLKEpYLPKNKNKa Y967 0.57 N 
JAK2 NSLFTPDpYELLTENDa Y813 3.18 N 
JAK2 VLPQDKEpYYKVKEPGa Y1007 2.58 N 
JAK2 LINNCMDpYEPDFRPSa Y790 1.89 N 
JAK2 EYLGTKRpYIHRDLATa Y972 1.5 N 
JAK2 VLYRIRFpYFPRWYCSa Y119 1.47 N 
JAK2 LPQDKEYpYKVKEPGEa Y1008 1 N 
JAK2 PYGSLRDpYLQKHKERa Y940 0.83 N 
JAK3 NSLISSDpYELLSDPTa Y785 3.9 N 
JAK3 LVQPQSQpYQLSQMTFa Y506 2.77 N 
JAK3 QICKGMEpYLGSRRCVa Y939 0.93 N 
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JAK3 HGSFTKIpYRGCRHEVa Y536 0.48 N 
KIT EEINGNNpYVYIDPTQa Y568 2.85 N 
KIT DMKPGVSpYVVPTKADa Y730 2.72 N 
KIT INGNNYVpYIDPTQLPa Y570 2.17 N 
KIT KYLQKPMpYEVQWKVVa Y553 1.76 N 
KIT IIVMILTpYKYLQKPMa Y545 1.57 N 
KIT IDPTQLPpYDHKWEFPa Y578 0.78 N 
KIT CSDSTNEpYMDMKPGVa Y721 0.44 N 
KSYK LPMDTEVpYESPYADPa Y348 3.01 N 
KSYK KENLIREpYVKQTWNLa Y131 1.76 N 
KSYK SPADLCHpYHSQESDGa Y91 1.64 N 
KSYK TREEAEDpYLVQGGMSa Y28 1.37 N 
KSYK TEVYESPpYADPEEIRa Y352 0.73 N 
LCK HQRLVRLpYAVVTQEPa Y304 3.38 N 
LCK VVTQEPIpYIITEYMEa Y313 3 N 
LCK VRDPLVTpYEGSNPPAa Y51 1.39 N 
LCK DVCENCHpYPIVPLDGa Y25 1.11 N 
LCK QGEVVKHpYKIRNLDNa Y181 0.89 N 
LCK IQNLERGpYRMVRPDNa Y457 0.77 N 
LMTK2 HLDEGLSpYTSIFYPVa Y500 2.8 N 
LMTK2 SQGLSFEpYVWEAAKHa Y476 1.62 N 
LTK RDIYRASpYYRRGDRAa Y676 1.56 N 
LTK FGMARDIpYRASYYRRa Y672 1.46 N 
LTK DIYRASYpYRRGDRALa Y677 1.24 N 
LYN QSVLDDFpYTATEGQYa Y501 3.25 N 
LYN YTATEGQpYQQQPaaaa Y508 2.02 N 
LYN YTATEGQpYQQQPaaaa Y487 2.01 N 
LYN EERPTFDpYLQSVLDDa Y492 1.36 N 
LYN RNTERTIpYVRDPTSNa Y32 0.75 N 
MATK ACENKSWpYRVKHHTSa Y87 1.16 N 
MERTK RNQADVIpYVNTQLLEa Y872 3.3 N 
MERTK SKPHEGRpYILNGGSEa Y929 2.19 N 
MET YVHVNATpYVNVKCVAa Y1356 3.66 N 
MET STFIGEHpYVHVNATYa Y1349 2.9 N 
MET FGLARDMpYDKEYYSVa Y1230 2.67 N 
MET LDGILSKpYFDLIYVHa Y830 2.09 N 
MET LGSELVRpYDARVHTPa Y971 1.74 N 
MET NVKCVAPpYPSLLSSEa Y1365 1.05 N 
MET QVAKGMKpYLASKKFVa Y1194 0.78 N 
MET GSCRQVQpYPLTDMSPa Y1026 0.57 N 
MUSK MAHEEVIpYYVRDGNIa Y813 2.04 N 
NTRK1 FGMSRDIpYSTDYYRVa Y640 2.69 N 
NTRK1 QVAAGMVpYLAGLHFVa Y640 2.64 N 
NTRK1 RDIYSTDpYYRVGGRTa Y644 2.57 N 
NTRK1 DIYSTDYpYRVGGRTMa Y645 1.9 N 
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NTRK1 HIIENPQpYFSDACVHa Y490 1.33 N 
NTRK1 HIIENPQpYFSDACVHa Y496 1.31 N 
NTRK1 HIIENPQpYFSDACVHa Y460 1.08 N 
NTRK2 PVIENPQpYFGITNSQa Y516 2.89 N 
PDGFRA PGQYKKSpYEKIHLDFa Y962 3.54 N 
PDGFRA ISPDGHEpYIYVDPMQa Y572 3.35 N 
PDGFRA RLSADSGpYIIPLPDIa Y1018 3.34 N 
PDGFRA IWKQKPRpYEIRWRVIa Y555 3.12 N 
PDGFRA PDGHEYIpYVDPMQLPa Y574 2.03 N 
PDGFRA VDPMQLPpYDSRWEFPa Y582 0.96 N 
PDGFRB RPPSAELpYSNALPVGa Y716 2.96 N 
PDGFRB SSNYMAPpYDNYVPSAa Y775 2.78 N 
PDGFRB PNEGDNDpYIIPLPDPa Y1021 2.5 N 
PDGFRB VSSDGHEpYIYVDPMQa Y579 2.43 N 
PDGFRB LDTSSVLpYTAVQPNEa Y1009 2.12 N 
PDGFRB LWQKKPRpYEIRWKVIa Y562 2.04 N 
PDGFRB VDPMQLPpYDSTWELPa Y589 1.95 N 
PDGFRB YMAPYDNpYVPSAPERa Y778 1.91 N 
PDGFRB SDGHEYIpYVDPMQLPa Y581 1.65 N 
PDGFRB YNAIKRGpYRMAQPAHa Y921 1.29 N 
PDGFRB ADIESSNpYMAPYDNYa Y771 1.07 N 
PDGFRB DMKGDVKpYADIESSNa Y763 0.83 N 
PDGFRB TGESDGGpYMDMSKDEa Y740 0.45 N 
PTK6 GGAVAQGpYVPHNYLAa Y61 2.56 N 
PTK6 QAHLGPKpYVGLWDFKa Y13 1.7 N 
PTK6 DTQAVRHpYKIWRRAGa Y127 1.29 N 
PTK6 QGYVPHNpYLAERETVa Y66 1.26 N 
RET ESLFDHIpYTTQSDVWa Y928 1.61 N 
RET LIVEYAKpYGSLRGFLa Y809 1.6 N 
RET MMVKRRDpYLDLAASTa Y1015 1.05 N 
RET VTLGGNPpYPGIPPERa Y952 0.77 N 
RET QISQGMQpYLAEMKLVa Y864 0.68 N 
RET TPSDSLIpYDDGLSEEa Y1029 0.57 N 
RET TWIENKLpYGMSDPNWa Y1062 0.4 N 
RON YVQLPATpYMNLGPSTa Y1360 2.69 N 
RON SALLGDHpYVQLPATYa Y1353 2.42 N 
RON ATPLPILpYSGSDYRSa Y1012 1.84 N 
RON EYCPDSLpYQVMQQCWa Y1317 1.75 N 
RON ILYSGSDpYRSGLALPa Y1017 1.23 N 
ROR1 SNLSNPRpYPNYMFPSa Y786 3.27 N 
ROR1 SNPRYPNpYMFPSQGIa Y789 2.3 N 
ROR1 GYPIPPGpYAAFPAAHa Y828 2.15 N 
ROR1 AAFPAAHpYQPTGPPRa Y836 2.04 N 
ROR1 PPTASPGpYSDEYEEDa Y160 1.68 N 
ROR1 EDGFCQPpYRGIACARa Y173 0.95 N 
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ROR2 LYVPVNGpYQPVPAYGa Y824 2.55 N 
ROR2 SGSTSTGpYVTTAPSNa Y873 2.18 N 
ROR2 AWGNLSNpYNSSAQTSa Y755 1.01 N 
ROS1 CLLNEPQpYIILELMEa Y2023 3.77 N 
ROS1 VGLANACpYAIHTLPTa Y1923 2.71 N 
ROS1 YLYWTTLpYSVESTRLa Y807 2.69 N 
ROS1 SNLDVLNpYVQTGGRLa Y2173 2.54 N 
ROS1 DSVGGYLpYWTTLYSVa Y802 2.17 N 
ROS1 VVDSVGGpYLYWTTLYa Y800 1.8 N 
ROS1 RDIYKNDpYYRKRGEGa Y2114 1.33 N 
ROS1 DIYKNDYpYRKRGEGLa Y2115 1.14 N 
ROS1 FGLARDIpYKNDYYRKa Y2110 1.05 N 
ROS1 ACLTHSGpYGDGSDaaa Y2342 0.41 N 
ROS1 NFFLNSIpYKSRDEANa Y2227 0.36 N 
ROS1 CQEKQVApYCPSGKPEa Y2323 0.27 N 
SRC LQAFLEDpYFTSTEPQa Y522 2.26 N 
SRC FTSTEPQpYQPGENLaa Y530 1.55 N 
TEC EEIVVAMpYDFQAAEGa Y188 0.84 N 
TEC NNNIMIKpYHPKFWTDa Y120 0.45 N 
TIE2 GMTCAELpYEKLPQGYa Y1048 3.54 N 
TIE2 AIKRMKEpYASKDDHRa Y860 0.51 N 
TNK1 PKSKNWVpYKILGGFAa Y77 2.42 N 
TYK2 LTSQCLTpYEPTQRPSa Y851 1.8 N 
TYRO3 SASQDPLpYINIERAEa Y804 4.47 N 
TYRO3 GTPSDCRpYILTPGGLa Y849 3.23 N 
TYRO3 LPGRDQPpYSGAGDGSa Y828 1.8 N 
UFO QEPDEILpYVNMDEGGa Y821 1.38 N 
UFO ESLADRVpYTSKSDVWa Y726 0.76 N 
VEGFR1 VQQDGKDpYIPINAILa Y1169 2.7 N 
VEGFR1 ATEKSARpYLTRGYSLa Y383 1.96 N 
VEGFR1 ATSMFDDpYQGDSSTLa Y1242 1.16 N 
VEGFR1 FGLARDIpYKNPDYVRa Y1048 1.03 N 
VEGFR2 AQQDGKDpYIVLPISEa Y1175 3.42 N 
VEGFR2 GSNQTSGpYQSGYHSDa Y1305 2.4 N 
VEGFR2 FGLARDIpYKDPDYVRa Y1054 1.11 N 
VEGFR2 DDTDTTVpYSSEEAELa Y1319 0.89 N 
VEGFR2 TSGYQSGpYHSDDTDTa Y1309 0.71 N 
VEGFR3 ARGGQVFpYNSEYGELa Y1333 1.77 N 
VEGFR3 EQCEYLSpYDASQWEFa Y833 1.66 N 
VEGFR3 PLEEQCEpYLSYDASQa Y830 1.34 N 
VEGFR3 QVFYNSEpYGELSEPSa Y1337 1.2 N 
VEGFR3 FGLARDIpYKDPDYVRa Y1063 0.95 N 
VEGFR3 TFFTDNSpYaaaaaaaa Y1363 0.79 N 
YES1 VTIFVALpYDYEARTTa Y100 2.71 N 
YES1 IATGKNGpYIPSNYVAa Y141 2.05 N 
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YES1 NGYIPSNpYVAPADSIa Y146 1.95 N 
YES1 FTATEPQpYQPGENLaa Y537 1.44 N 
YES1 VSTSVSHpYGAEPTTVa Y32 1.13 N 
YES1 SIQAEEWpYFGKMGRKa Y159 0.69 N 
YES1 LEQVERGpYRMPCPQGa Y489 0.43 N 
YES1 NKSPAIKpYRPENTPEa Y16 0.32 N 
ZAP70 MPMDTSVpYESPYSDPa Y315 4.14 N 
ZAP70 AAHLPFFpYGSISRAEa Y12 2.04 N 
ZAP70 VLLVNRHpYAKISDFGa Y474 2 N 
ZAP70 RDAMVRDpYVRQTWKLa Y126 1.46 N 
ZAP70 TSVYESPpYSDPEELKa Y319 0.96 N 







Suppl. 2.4 Loop panel for PRM 
m/z charge Site Sequence 
506.22157 3 ABL1_2_393_439 LMTGDTY[Pho]TAHAGAK 
644.94013 3 ACK1_284 ALPQNDDHY[Pho]VMQEHR 
997.44022 2 ALK_1507(nonloop) PTSLWNPTY[Pho]GSWFTEK 
752.83199 2 BLK_389 IIDSEY[Pho]TAQEGAK 
827.37402 2 BMX_566 YVLDDQY[Pho]VSSVGTK 
821.84783 2 BTK_551 YVLDDEY[Pho]TSSVGSK 
464.53527 3 CSF1R_809 DIMNDSNY[Pho]IVK 
848.35785 2 CSK_184(nonloop) VMEGTVAAQDEFY[Pho]R 
647.73069 2 DDR1_796_797 NLYAGDY[Pho]Y[Pho]R 
655.72815 2 DDR2_740_741 NLYSGDY[Pho]Y[Pho]R 
869.86402 2 EPHA1_781 LLDDFDGTY[Pho]ETQGGK 
881.87458 2 EPHA2_772 VLEDDPEATY[Pho]TTSGGK 
780.33489 2 EPHA3_4_5_779_779_883 VLEDDPEAAY[Pho]TTR 
873.87712 2 EPHA6_7_830_791 VLEDDPEAAY[Pho]TTTGGK 
866.8693 2 EPHA8_793 VLEDDPDAAY[Pho]TTTGGK 
1014.4277 2 EPHB1_778 YLQDDTSDPTY[Pho]TSSLGGK 
998.9248 2 EPHB2_780 FLEDDTSDPTY[Pho]TSALGGK 
1004.9248 2 EPHB3_792 FLEDDPSDPTY[Pho]TSSLGGK 
1006.4303 2 EPHB4_774 FLEENSSDPTY[Pho]TSSLGGK 
1035.9294 2 EPHB6_651(nonloop) YYIDPSTY[Pho]EDPC[CAM]QAIR 
485.68694 2 ErbB1(EGFR)_869 EY[Pho]HAEGGK 
878.37729 2 ERBB2_877 LLDIDETEY[Pho]HADGGK 
585.92062 3 ERBB2_877 LLDIDETEY[Pho]HADGGK 
516.24409 2 ERBB3_866 QLLY[Pho]SEAK 
467.17112 2 ERBB4_875 EY[Pho]NADGGK 
680.21623 2 FAK1_576_577 YMEDSTY[Pho]Y[Pho]K 
699.23293 2 FAK2_579_580 YIEDEDY[Pho]Y[Pho]K 
703.7954 2 FER_714 QEDGGVY[Pho]SSSGLK 
737.81413 2 FES_713 EEADGVY[Pho]AASGGLR 
682.25962 2 FGFR1_653_654 DIHHIDY[Pho]Y[Pho]K 
455.1755 3 FGFR1_653_654 DIHHIDY[Pho]Y[Pho]K 
659.24363 2 FGFR2_656_657 DINNIDY[Pho]Y[Pho]K 
663.7438 2 FGFR3_647_648 DVHNLDY[Pho]Y[Pho]K 
646.24905 2 FGFR4_642_643 GVHHIDY[Pho]Y[Pho]K 
431.16846 3 FGFR4_642_643 GVHHIDY[Pho]Y[Pho]K 
464.83064 3 FGR_412 DDEY[Pho]NPC[CAM]QGSK 
689.78907 2 FLT3_842 DIMSDSNY[Pho]VVR 
660.2612 2 FRK_387 VDNEDIY[Pho]ESR 
645.27411 2 HCK_LYN_411_397 VIEDNEY[Pho]TAR 
466.49479 3 IGF1R_INSR_1165_1166_1189_1190 DIYETDY[Pho]Y[Pho]R 
692.23072 2 INSRR_1145_1146 DVYETDY[Pho]Y[Pho]R 
821.35583 2 ITK_512 FVLDDQY[Pho]TSSTGTK 




619.8001 2 JAK2_221(nonloop) IQDY[Pho]HILTR 
637.30295 3 JAK2_570(nonloop) EVGDY[Pho]GQLHETEVLLK 
487.67466 2 JAK3_980_981 DY[Pho]Y[Pho]VVR 
509.7157 2 KIT_823 NDSNY[Pho]VVK 
531.66449 2 KSYK_525_526 ADENY[Pho]Y[Pho]K 
966.45059 2 LMTK1_283 EDY[Pho]FVTADQLWVPLR 
644.63615 3 LMTK1_283 EDY[Pho]FVTADQLWVPLR 
604.22375 2 LMTK2_295 EDY[Pho]IETDDK 
673.24109 2 LMTK3_296_297 EDY[Pho]Y[Pho]LTPER 
598.70669 2 MERTK_TYRO3_753_754 685_686 IYSGDY[Pho]Y[Pho]R 
600.21214 2 MET_1234_1235 EY[Pho]Y[Pho]SVHNK 
648.7329 2 MUSK_755_756 NIYSADY[Pho]Y[Pho]K 
678.23327 2 NTRK1_680_681 DIYSTDY[Pho]Y[Pho]R 
671.22544 2 NTRK2_3_706_707_709_710 DVYSTDY[Pho]Y[Pho]R 
463.52325 3 PGFRA_849 DIMHDSNY[Pho]VSK 
453.68387 2 PGFRB_857 DSNY[Pho]ISK 
603.93297 3 PTK6_342 EDVY[Pho]LSHDHNIPYK 
826.79455 2 PTK7_960_961 DVYNSEY[Pho]Y[Pho]HFR 
551.53213 3 PTK7_960_961 DVYNSEY[Pho]Y[Pho]HFR 
663.7605 2 RET_905 DVYEEDSY[Pho]VK 
457.17064 3 RON_1238_1239 EY[Pho]Y[Pho]SVQQHR 
670.23581 2 ROR1_645_646 EIYSADY[Pho]Y[Pho]R 
641.22745 2 ROR2_645_646 EVYAADY[Pho]Y[Pho]K 
703.29525 3 ROS1_2274(nonloop) EGLNY[Pho]MVLATEC[CAM]GQGEEK 
652.28193 2 SRC_YES_FYN_LCK_419_426_420_394 LIEDNEY[Pho]TAR 
633.2503 2 SRMS_380 DDIY[Pho]SPSSSSK 
807.34018 2 TEC_519 YVLDDQY[Pho]TSSSGAK 
452.19661 2 TIE1_1007 GEEVY[Pho]VK 
451.7046 2 TIE2_992 GQEVY[Pho]VK 
836.86074 2 TXK_420 YVLDDEY[Pho]VSSFGAK 
460.83889 3 TYK2_1054_1055 AVPEGHEY[Pho]Y[Pho]R 
612.21214 2 UFO_702_703 IYNGDY[Pho]Y[Pho]R 
422.17347 2 VGFR1_1053 NPDY[Pho]VR 
422.66548 2 VGFR2_3_1059_1068 DPDY[Pho]VR 
731.76801 2 ZAP70_492_493 ALGADDSY[Pho]Y[Pho]TAR 
681.28141 2 GSK3_279_216 GEPNVSY[Pho]IC[CAM]SR 
652.77068 2 GSK3_279_216 GEPNVSY[Pho]ICSR 
777.99428 3 MAPK3 IADPEHDHTGFLT[Pho]EY[Pho]VATR 
768.65051 3 MAPK1 VADPDHDHTGFLT[Pho]EY[Pho]VATR 
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Suppl. 2.5 Full panel for MRM 
MS1 MS2 Fragments DP CE 
506.2216 346.1795 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3b3 68 25.1 
506.2216 619.2756 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3b6 68 25.1 
506.2216 346.2085 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3y4 68 25.1 
506.2216 483.2674 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3y5 68 25.1 
506.2216 554.3045 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3y6 68 25.1 
506.2216 655.3522 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3y7 68 25.1 
506.2216 898.3819 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3y8 68 25.1 
506.2216 999.4295 ABL1_2_393_439(loop).LMTGDTY[Pho]TAHAGAK.+3y9 68 25.1 
554.5905 441.2456 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3b4 71.5 27.8 
554.5905 540.314 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3b5 71.5 27.8 
554.5905 783.3437 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3b6 71.5 27.8 
554.5905 840.3651 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3b7 71.5 27.8 
554.5905 939.4336 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3b8 71.5 27.8 
554.5905 539.246 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3y4 71.5 27.8 
554.5905 636.2988 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3y5 71.5 27.8 
554.5905 723.3308 ABL1_226.NKPTVY[Pho]GVSPNYDK.+3y6 71.5 27.8 
861.3822 413.2143 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2b5 93.9 39.9 
861.3822 656.244 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2b6 93.9 39.9 
861.3822 941.3764 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2b9 93.9 39.9 
861.3822 489.282 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2y4 93.9 39.9 
861.3822 618.3246 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2y5 93.9 39.9 
861.3822 781.3879 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2y6 93.9 39.9 
861.3822 880.4563 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2y7 93.9 39.9 
861.3822 1066.52 ABL1_253.LGGGQY[Pho]GEVYEGVWK.+2y9 93.9 39.9 
1092.012 1183.457 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2b10 110.7 48.2 
1092.012 543.231 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2b5 110.7 48.2 
1092.012 642.2994 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2b6 110.7 48.2 
1092.012 940.4272 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2b9 110.7 48.2 
1092.012 389.2395 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2y3 110.7 48.2 
1092.012 590.3144 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2y5 110.7 48.2 
1092.012 786.4356 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2y7 110.7 48.2 
1092.012 887.4833 ABL2_161.NGQGWVPSNY[Pho]ITPVNSLEK.+2y8 110.7 48.2 
435.8557 411.1775 ABL2_174.HSWY[Pho]HGPVSR.+3b3 62.9 21.3 
435.8557 654.2072 ABL2_174.HSWY[Pho]HGPVSR.+3b4 62.9 21.3 
435.8557 361.2194 ABL2_174.HSWY[Pho]HGPVSR.+3y3 62.9 21.3 
435.8557 458.2722 ABL2_174.HSWY[Pho]HGPVSR.+3y4 62.9 21.3 
435.8557 515.2936 ABL2_174.HSWY[Pho]HGPVSR.+3y5 62.9 21.3 
435.8557 652.3525 ABL2_174.HSWY[Pho]HGPVSR.+3y6 62.9 21.3 
644.9401 754.3366 ACK1_284(loop).ALPQNDDHY[Pho]VMQEHR.+3b7 78.1 32.7 
644.9401 441.2205 ACK1_284(loop).ALPQNDDHY[Pho]VMQEHR.+3y3 78.1 32.7 
644.9401 569.279 ACK1_284(loop).ALPQNDDHY[Pho]VMQEHR.+3y4 78.1 32.7 
644.9401 700.3195 ACK1_284(loop).ALPQNDDHY[Pho]VMQEHR.+3y5 78.1 32.7 
644.9401 1042.418 ACK1_284(loop).ALPQNDDHY[Pho]VMQEHR.+3y7 78.1 32.7 
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644.9401 1179.477 ACK1_284(loop).ALPQNDDHY[Pho]VMQEHR.+3y8 78.1 32.7 
997.4402 399.2238 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2b4 103.8 44.8 
997.4402 585.3031 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2b5 103.8 44.8 
997.4402 699.3461 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2b6 103.8 44.8 
997.4402 524.2715 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2y4 103.8 44.8 
997.4402 710.3508 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2y5 103.8 44.8 
997.4402 854.4043 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2y7 103.8 44.8 
997.4402 1097.434 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2y8 103.8 44.8 
997.4402 1198.482 ALK_1507.PTSLWNPTY[Pho]GSWFTEK.+2y9 103.8 44.8 
752.832 429.2344 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2b4 86 36 
752.832 558.277 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2b5 86 36 
752.832 801.3066 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2b6 86 36 
752.832 1163.462 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2y10 86 36 
752.832 603.3097 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2y6 86 36 
752.832 704.3573 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2y7 86 36 
752.832 947.387 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2y8 86 36 
752.832 1076.43 BLK_389(loop).IIDSEY[Pho]TAQEGAK.+2y9 86 36 
688.2763 416.214 BMX_40.TNLSY[Pho]YEYDK.+2b4 81.3 33.6 
688.2763 822.307 BMX_40.TNLSY[Pho]YEYDK.+2b6 81.3 33.6 
688.2763 425.2031 BMX_40.TNLSY[Pho]YEYDK.+2y3 81.3 33.6 
688.2763 554.2457 BMX_40.TNLSY[Pho]YEYDK.+2y4 81.3 33.6 
688.2763 717.309 BMX_40.TNLSY[Pho]YEYDK.+2y5 81.3 33.6 
688.2763 960.3387 BMX_40.TNLSY[Pho]YEYDK.+2y6 81.3 33.6 
688.2763 1047.371 BMX_40.TNLSY[Pho]YEYDK.+2y7 81.3 33.6 
688.2763 1160.455 BMX_40.TNLSY[Pho]YEYDK.+2y8 81.3 33.6 
827.374 491.25 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2b4 91.4 38.6 
827.374 606.277 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2b5 91.4 38.6 
827.374 977.3652 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2b7 91.4 38.6 
827.374 1163.466 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2b9 91.4 38.6 
827.374 491.2824 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2y5 91.4 38.6 
827.374 578.3144 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2y6 91.4 38.6 
827.374 677.3828 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2y7 91.4 38.6 
827.374 920.4125 BMX_566(loop).YVLDDQY[Pho]VSSVGTK.+2y8 91.4 38.6 
821.8478 491.25 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2b4 91 38.4 
821.8478 735.3196 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2b6 91 38.4 
821.8478 978.3492 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2b7 91 38.4 
821.8478 1079.397 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2b8 91 38.4 
821.8478 477.2667 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2y5 91 38.4 
821.8478 564.2988 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2y6 91 38.4 
821.8478 665.3464 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2y7 91 38.4 
821.8478 908.3761 BTK_551(loop).YVLDDEY[Pho]TSSVGSK.+2y8 91 38.4 
696.2993 360.1588 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2b3 81.9 33.9 
696.2993 1146.417 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2b9 81.9 33.9 
696.2993 602.2949 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2y4 81.9 33.9 
696.2993 716.3379 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2y5 81.9 33.9 
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696.2993 803.3699 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2y6 81.9 33.9 
696.2993 918.3968 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2y7 81.9 33.9 
696.2993 1032.44 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2y8 81.9 33.9 
696.2993 1163.48 CSF1R_809(loop).DIMNDSNY[Pho]IVK.+2y9 81.9 33.9 
848.3578 360.1588 CSK_184.VMEGTVAAQDEFY[Pho]R.+2b3 93 39.4 
848.3578 518.2279 CSK_184.VMEGTVAAQDEFY[Pho]R.+2b5 93 39.4 
848.3578 617.2963 CSK_184.VMEGTVAAQDEFY[Pho]R.+2b6 93 39.4 
848.3578 565.217 CSK_184.VMEGTVAAQDEFY[Pho]R.+2y3 93 39.4 
848.3578 809.2866 CSK_184.VMEGTVAAQDEFY[Pho]R.+2y5 93 39.4 
848.3578 1008.382 CSK_184.VMEGTVAAQDEFY[Pho]R.+2y7 93 39.4 
848.3578 1178.488 CSK_184.VMEGTVAAQDEFY[Pho]R.+2y9 93 39.4 
647.7307 391.1976 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2b3 78.3 32.2 
647.7307 462.2347 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2b4 78.3 32.2 
647.7307 519.2562 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2b5 78.3 32.2 
647.7307 661.1783 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2y3 78.3 32.2 
647.7307 776.2052 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2y4 78.3 32.2 
647.7307 833.2267 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2y5 78.3 32.2 
647.7307 904.2638 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2y6 78.3 32.2 
647.7307 1067.327 DDR1_796_797(loop).NLYAGDY[Pho]Y[Pho]R.+2y7 78.3 32.2 
655.7282 391.1976 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2b3 78.9 32.5 
655.7282 478.2296 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2b4 78.9 32.5 
655.7282 535.2511 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2b5 78.9 32.5 
655.7282 661.1783 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2y3 78.9 32.5 
655.7282 776.2052 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2y4 78.9 32.5 
655.7282 833.2267 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2y5 78.9 32.5 
655.7282 920.2587 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2y6 78.9 32.5 
655.7282 1083.322 DDR2_740_741(loop).NLYSGDY[Pho]Y[Pho]R.+2y7 78.9 32.5 
645.7717 317.1456 EGFR_1197.GSTAENAEY[Pho]LR.+2b4 78.2 32.1 
645.7717 446.1882 EGFR_1197.GSTAENAEY[Pho]LR.+2b5 78.2 32.1 
645.7717 531.2327 EGFR_1197.GSTAENAEY[Pho]LR.+2y3 78.2 32.1 
645.7717 660.2753 EGFR_1197.GSTAENAEY[Pho]LR.+2y4 78.2 32.1 
645.7717 731.3124 EGFR_1197.GSTAENAEY[Pho]LR.+2y5 78.2 32.1 
645.7717 845.3553 EGFR_1197.GSTAENAEY[Pho]LR.+2y6 78.2 32.1 
645.7717 974.3979 EGFR_1197.GSTAENAEY[Pho]LR.+2y7 78.2 32.1 
645.7717 1045.435 EGFR_1197.GSTAENAEY[Pho]LR.+2y8 78.2 32.1 
822.8474 566.2755 EGFR_998.MHLPSPTDSNFY[Pho]R.+2b5 91.1 38.5 
822.8474 879.4029 EGFR_998.MHLPSPTDSNFY[Pho]R.+2b8 91.1 38.5 
822.8474 966.4349 EGFR_998.MHLPSPTDSNFY[Pho]R.+2b9 91.1 38.5 
822.8474 766.292 EGFR_998.MHLPSPTDSNFY[Pho]R.+2y5 91.1 38.5 
822.8474 881.3189 EGFR_998.MHLPSPTDSNFY[Pho]R.+2y6 91.1 38.5 
822.8474 982.3666 EGFR_998.MHLPSPTDSNFY[Pho]R.+2y7 91.1 38.5 
822.8474 1166.451 EGFR_998.MHLPSPTDSNFY[Pho]R.+2y9 91.1 38.5 
772.6705 410.1783 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3b4 87.4 39.6 
772.6705 523.2623 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3b5 87.4 39.6 
772.6705 838.4054 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3b8 87.4 39.6 
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772.6705 952.4483 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3b9 87.4 39.6 
772.6705 538.3024 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3y4 87.4 39.6 
772.6705 653.3293 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3y5 87.4 39.6 
772.6705 909.4465 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3y7 87.4 39.6 
772.6705 1152.476 EGFR_Y1172.GSHQISLDNPDY[Pho]QQDFFPK.+3y8 87.4 39.6 
869.864 457.2293 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2b4 94.5 40.2 
869.864 719.3246 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2b6 94.5 40.2 
869.864 1135.43 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2y10 94.5 40.2 
869.864 490.262 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2y5 94.5 40.2 
869.864 619.3046 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2y6 94.5 40.2 
869.864 862.3342 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2y7 94.5 40.2 
869.864 963.3819 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2y8 94.5 40.2 
869.864 1020.403 EPHA1_781(loop).LLDDFDGTY[Pho]ETQGGK.+2y9 94.5 40.2 
881.8746 457.2293 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2b4 95.4 40.6 
881.8746 572.2562 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2b5 95.4 40.6 
881.8746 869.3887 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2b8 95.4 40.6 
881.8746 1191.493 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2y11 95.4 40.6 
881.8746 550.2831 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2y6 95.4 40.6 
881.8746 793.3128 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2y7 95.4 40.6 
881.8746 894.3605 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2y8 95.4 40.6 
881.8746 965.3976 EPHA2_772(loop).VLEDDPEATY[Pho]TTSGGK.+2y9 95.4 40.6 
780.3349 572.2562 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2b5 88 36.9 
780.3349 1218.467 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2y10 88 36.9 
780.3349 377.2143 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2y3 88 36.9 
780.3349 620.244 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2y4 88 36.9 
780.3349 691.2811 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2y5 88 36.9 
780.3349 762.3182 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2y6 88 36.9 
780.3349 988.4136 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2y8 88 36.9 
780.3349 1103.44 EPHA3_4_5_779_779_883(loop).VLEDDPEAAY[Pho]TTR.+2y9 88 36.9 
873.8771 457.2293 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2b4 94.8 40.3 
873.8771 572.2562 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2b5 94.8 40.3 
873.8771 798.3516 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2b7 94.8 40.3 
873.8771 869.3887 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2b8 94.8 40.3 
873.8771 564.2988 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2y6 94.8 40.3 
873.8771 807.3284 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2y7 94.8 40.3 
873.8771 878.3655 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2y8 94.8 40.3 
873.8771 949.4027 EPHA6_7_830_791(loop).VLEDDPEAAY[Pho]TTTGGK.+2y9 94.8 40.3 
866.8693 342.2023 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2b3 94.3 40.1 
866.8693 457.2293 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2b4 94.3 40.1 
866.8693 572.2562 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2b5 94.3 40.1 
866.8693 1161.482 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2y11 94.3 40.1 
866.8693 564.2988 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2y6 94.3 40.1 
866.8693 807.3284 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2y7 94.3 40.1 
866.8693 878.3655 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2y8 94.3 40.1 
866.8693 949.4027 EPHA8_793(loop).VLEDDPDAAY[Pho]TTTGGK.+2y9 94.3 40.1 
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1014.428 635.2671 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2b5 105.1 45.4 
1014.428 938.3738 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2b8 105.1 45.4 
1014.428 1090.482 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2y10 105.1 45.4 
1014.428 1205.509 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2y11 105.1 45.4 
1014.428 461.2718 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2y5 105.1 45.4 
1014.428 548.3039 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2y6 105.1 45.4 
1014.428 649.3515 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2y7 105.1 45.4 
1014.428 892.3812 EPHB1_778(loop).YLQDDTSDPTY[Pho]TSSLGGK.+2y8 105.1 45.4 
998.9248 620.2562 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2b5 103.9 44.8 
998.9248 923.3629 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2b8 103.9 44.8 
998.9248 1074.487 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2y10 103.9 44.8 
998.9248 1189.514 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2y11 103.9 44.8 
998.9248 374.2398 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2y4 103.9 44.8 
998.9248 532.3089 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2y6 103.9 44.8 
998.9248 633.3566 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2y7 103.9 44.8 
998.9248 876.3863 EPHB2_780(loop).FLEDDTSDPTY[Pho]TSALGGK.+2y8 103.9 44.8 
1004.925 620.2562 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2b5 104.4 45 
1004.925 804.341 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2b7 104.4 45 
1004.925 919.368 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2b8 104.4 45 
1004.925 1090.482 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2y10 104.4 45 
1004.925 1205.509 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2y11 104.4 45 
1004.925 548.3039 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2y6 104.4 45 
1004.925 649.3515 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2y7 104.4 45 
1004.925 892.3812 EPHB3_792(loop).FLEDDPSDPTY[Pho]TSSLGGK.+2y8 104.4 45 
1006.43 1120.479 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2b10 104.5 45.1 
1006.43 922.3789 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2b8 104.5 45.1 
1006.43 1090.482 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2y10 104.5 45.1 
1006.43 1205.509 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2y11 104.5 45.1 
1006.43 461.2718 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2y5 104.5 45.1 
1006.43 548.3039 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2y6 104.5 45.1 
1006.43 649.3515 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2y7 104.5 45.1 
1006.43 892.3812 EPHB4_774(loop).FLEENSSDPTY[Pho]TSSLGGK.+2y8 104.5 45.1 
816.7209 1115.573 ERBB2_1005.FVVIQNEDLGPASPLDSTFY[Pho]R.+3b10 90.7 42 
816.7209 666.2647 ERBB2_1005.FVVIQNEDLGPASPLDSTFY[Pho]R.+3y4 90.7 42 
816.7209 753.2967 ERBB2_1005.FVVIQNEDLGPASPLDSTFY[Pho]R.+3y5 90.7 42 
816.7209 868.3237 ERBB2_1005.FVVIQNEDLGPASPLDSTFY[Pho]R.+3y6 90.7 42 
816.7209 981.4077 ERBB2_1005.FVVIQNEDLGPASPLDSTFY[Pho]R.+3y7 90.7 42 
816.7209 1078.461 ERBB2_1005.FVVIQNEDLGPASPLDSTFY[Pho]R.+3y8 90.7 42 
816.7209 1165.493 ERBB2_1005.FVVIQNEDLGPASPLDSTFY[Pho]R.+3y9 90.7 42 
639.8101 1066.461 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y10 77.8 31.9 
639.8101 489.2109 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y3 77.8 31.9 
639.8101 590.2586 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y4 77.8 31.9 
639.8101 647.28 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y5 77.8 31.9 
639.8101 794.3484 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y6 77.8 31.9 
639.8101 865.3855 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y7 77.8 31.9 
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639.8101 922.407 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y8 77.8 31.9 
639.8101 1009.439 ERBB2_735_ERBB4_733.VLGSGAFGTVY[Pho]K.+2y9 77.8 31.9 
878.3773 570.3134 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2b5 95.2 40.5 
878.3773 699.3559 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2b6 95.2 40.5 
878.3773 1186.441 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2y10 95.2 40.5 
878.3773 447.2198 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2y5 95.2 40.5 
878.3773 584.2787 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2y6 95.2 40.5 
878.3773 827.3084 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2y7 95.2 40.5 
878.3773 956.351 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2y8 95.2 40.5 
878.3773 1057.399 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+2y9 95.2 40.5 
585.9206 699.3559 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+3b6 73.8 29.5 
585.9206 376.1827 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+3y4 73.8 29.5 
585.9206 447.2198 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+3y5 73.8 29.5 
585.9206 584.2787 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+3y6 73.8 29.5 
585.9206 827.3084 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+3y7 73.8 29.5 
585.9206 956.351 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+3y8 73.8 29.5 
585.9206 1057.399 ERBB2_877(loop).LLDIDETEY[Pho]HADGGK.+3y9 73.8 29.5 
730.9637 922.4153 ERBB3_1328.SLEATDSAFDNPDY[Pho]WHSR.+3b9 84.4 37.4 
730.9637 585.2892 ERBB3_1328.SLEATDSAFDNPDY[Pho]WHSR.+3y4 84.4 37.4 
730.9637 828.3189 ERBB3_1328.SLEATDSAFDNPDY[Pho]WHSR.+3y5 84.4 37.4 
730.9637 943.3458 ERBB3_1328.SLEATDSAFDNPDY[Pho]WHSR.+3y6 84.4 37.4 
730.9637 1040.399 ERBB3_1328.SLEATDSAFDNPDY[Pho]WHSR.+3y7 84.4 37.4 
730.9637 1154.441 ERBB3_1328.SLEATDSAFDNPDY[Pho]WHSR.+3y8 84.4 37.4 
516.2441 598.2636 ERBB3_866(loop).QLLY[Pho]SEAK.+2b4 68.8 27.4 
516.2441 685.2957 ERBB3_866(loop).QLLY[Pho]SEAK.+2b5 68.8 27.4 
516.2441 814.3383 ERBB3_866(loop).QLLY[Pho]SEAK.+2b6 68.8 27.4 
516.2441 434.2245 ERBB3_866(loop).QLLY[Pho]SEAK.+2y4 68.8 27.4 
516.2441 677.2542 ERBB3_866(loop).QLLY[Pho]SEAK.+2y5 68.8 27.4 
516.2441 790.3383 ERBB3_866(loop).QLLY[Pho]SEAK.+2y6 68.8 27.4 
630.6154 567.2885 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3b5 77.1 31.9 
630.6154 779.3682 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3b7 77.1 31.9 
630.6154 1022.398 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3b8 77.1 31.9 
630.6154 498.2558 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3y4 77.1 31.9 
630.6154 627.2984 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3y5 77.1 31.9 
630.6154 755.357 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3y6 77.1 31.9 
630.6154 868.4411 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3y7 77.1 31.9 
630.6154 1111.471 ERBB4_1258.STLQHPDY[Pho]LQEYSTK.+3y8 77.1 31.9 
630.6154 430.2296 ERBB4_1262.STLQHPDYLQEY[Pho]STK.+3b4 77.1 31.9 
630.6154 567.2885 ERBB4_1262.STLQHPDYLQEY[Pho]STK.+3b5 77.1 31.9 
630.6154 664.3413 ERBB4_1262.STLQHPDYLQEY[Pho]STK.+3b6 77.1 31.9 
630.6154 779.3682 ERBB4_1262.STLQHPDYLQEY[Pho]STK.+3b7 77.1 31.9 
630.6154 335.1925 ERBB4_1262.STLQHPDYLQEY[Pho]STK.+3y3 77.1 31.9 
630.6154 1111.471 ERBB4_1262.STLQHPDYLQEY[Pho]STK.+3y8 77.1 31.9 
630.6154 1226.498 ERBB4_1262.STLQHPDYLQEY[Pho]STK.+3y9 77.1 31.9 
680.2162 539.1806 FAK1_576_577(loop).YMEDSTY[Pho]Y[Pho]K.+2b4 80.7 33.3 
126 
 
680.2162 626.2127 FAK1_576_577(loop).YMEDSTY[Pho]Y[Pho]K.+2b5 80.7 33.3 
680.2162 633.1721 FAK1_576_577(loop).YMEDSTY[Pho]Y[Pho]K.+2y3 80.7 33.3 
680.2162 734.2198 FAK1_576_577(loop).YMEDSTY[Pho]Y[Pho]K.+2y4 80.7 33.3 
680.2162 821.2518 FAK1_576_577(loop).YMEDSTY[Pho]Y[Pho]K.+2y5 80.7 33.3 
680.2162 936.2788 FAK1_576_577(loop).YMEDSTY[Pho]Y[Pho]K.+2y6 80.7 33.3 
680.2162 1065.321 FAK1_576_577(loop).YMEDSTY[Pho]Y[Pho]K.+2y7 80.7 33.3 
699.2329 650.2668 FAK2_579_580(loop).YIEDEDY[Pho]Y[Pho]K.+2b5 82.1 34 
699.2329 765.2937 FAK2_579_580(loop).YIEDEDY[Pho]Y[Pho]K.+2b6 82.1 34 
699.2329 633.1721 FAK2_579_580(loop).YIEDEDY[Pho]Y[Pho]K.+2y3 82.1 34 
699.2329 748.1991 FAK2_579_580(loop).YIEDEDY[Pho]Y[Pho]K.+2y4 82.1 34 
699.2329 992.2686 FAK2_579_580(loop).YIEDEDY[Pho]Y[Pho]K.+2y6 82.1 34 
699.2329 1121.311 FAK2_579_580(loop).YIEDEDY[Pho]Y[Pho]K.+2y7 82.1 34 
703.7954 1034.455 FER_714(loop).QEDGGVY[Pho]SSSGLK.+2y10 82.4 34.2 
703.7954 1149.482 FER_714(loop).QEDGGVY[Pho]SSSGLK.+2y11 82.4 34.2 
703.7954 491.2824 FER_714(loop).QEDGGVY[Pho]SSSGLK.+2y5 82.4 34.2 
703.7954 578.3144 FER_714(loop).QEDGGVY[Pho]SSSGLK.+2y6 82.4 34.2 
703.7954 821.3441 FER_714(loop).QEDGGVY[Pho]SSSGLK.+2y7 82.4 34.2 
703.7954 920.4125 FER_714(loop).QEDGGVY[Pho]SSSGLK.+2y8 82.4 34.2 
703.7954 977.434 FER_714(loop).QEDGGVY[Pho]SSSGLK.+2y9 82.4 34.2 
737.8141 601.2464 FES_713(loop).EEADGVY[Pho]AASGGLR.+2b6 84.9 35.4 
737.8141 1030.472 FES_713(loop).EEADGVY[Pho]AASGGLR.+2y10 84.9 35.4 
737.8141 1145.499 FES_713(loop).EEADGVY[Pho]AASGGLR.+2y11 84.9 35.4 
737.8141 560.3151 FES_713(loop).EEADGVY[Pho]AASGGLR.+2y6 84.9 35.4 
737.8141 631.3522 FES_713(loop).EEADGVY[Pho]AASGGLR.+2y7 84.9 35.4 
737.8141 874.3819 FES_713(loop).EEADGVY[Pho]AASGGLR.+2y8 84.9 35.4 
737.8141 973.4503 FES_713(loop).EEADGVY[Pho]AASGGLR.+2y9 84.9 35.4 
775.4049 383.1925 FGFR1_307.IGPDNLPY[Pho]VQILK.+2b4 87.6 36.8 
775.4049 497.2354 FGFR1_307.IGPDNLPY[Pho]VQILK.+2b5 87.6 36.8 
775.4049 610.3195 FGFR1_307.IGPDNLPY[Pho]VQILK.+2b6 87.6 36.8 
775.4049 843.4376 FGFR1_307.IGPDNLPY[Pho]VQILK.+2y6 87.6 36.8 
775.4049 940.4903 FGFR1_307.IGPDNLPY[Pho]VQILK.+2y7 87.6 36.8 
775.4049 1053.574 FGFR1_307.IGPDNLPY[Pho]VQILK.+2y8 87.6 36.8 
775.4049 1167.617 FGFR1_307.IGPDNLPY[Pho]VQILK.+2y9 87.6 36.8 
681.2996 415.2187 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2b4 80.8 33.4 
681.2996 646.2865 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2b6 80.8 33.4 
681.2996 345.2245 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2y3 80.8 33.4 
681.2996 473.2831 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2y4 80.8 33.4 
681.2996 716.3127 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2y5 80.8 33.4 
681.2996 787.3498 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2y6 80.8 33.4 
681.2996 947.3805 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2y7 80.8 33.4 
681.2996 1034.413 FGFR1_605_FGFR3_599.DLVSC[CAM]AY[Pho]QVAR.+2y8 80.8 33.4 
682.2596 503.2361 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2b4 80.9 33.4 
682.2596 616.3202 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2b5 80.9 33.4 
682.2596 731.3471 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2b6 80.9 33.4 
682.2596 974.3768 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2b7 80.9 33.4 
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682.2596 748.1991 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2y4 80.9 33.4 
682.2596 861.2831 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2y5 80.9 33.4 
682.2596 998.342 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2y6 80.9 33.4 
682.2596 1135.401 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+2y7 80.9 33.4 
455.1755 366.1772 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+3b3 64.3 22.4 
455.1755 503.2361 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+3b4 64.3 22.4 
455.1755 616.3202 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+3b5 64.3 22.4 
455.1755 731.3471 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+3b6 64.3 22.4 
455.1755 633.1721 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+3y3 64.3 22.4 
455.1755 748.1991 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+3y4 64.3 22.4 
455.1755 861.2831 FGFR1_653_654(loop).DIHHIDY[Pho]Y[Pho]K.+3y5 64.3 22.4 
703.3127 415.2187 FGFR2_608.DLVSC[CAM]TY[Pho]QLAR.+2b4 82.4 34.2 
703.3127 487.2987 FGFR2_608.DLVSC[CAM]TY[Pho]QLAR.+2y4 82.4 34.2 
703.3127 730.3284 FGFR2_608.DLVSC[CAM]TY[Pho]QLAR.+2y5 82.4 34.2 
703.3127 831.376 FGFR2_608.DLVSC[CAM]TY[Pho]QLAR.+2y6 82.4 34.2 
703.3127 991.4067 FGFR2_608.DLVSC[CAM]TY[Pho]QLAR.+2y7 82.4 34.2 
703.3127 1078.439 FGFR2_608.DLVSC[CAM]TY[Pho]QLAR.+2y8 82.4 34.2 
703.3127 1177.507 FGFR2_608.DLVSC[CAM]TY[Pho]QLAR.+2y9 82.4 34.2 
553.733 674.2255 FGFR2_616.GMEY[Pho]LASQK.+2b5 71.5 28.8 
553.733 362.2034 FGFR2_616.GMEY[Pho]LASQK.+2y3 71.5 28.8 
553.733 433.2405 FGFR2_616.GMEY[Pho]LASQK.+2y4 71.5 28.8 
553.733 546.3246 FGFR2_616.GMEY[Pho]LASQK.+2y5 71.5 28.8 
553.733 789.3542 FGFR2_616.GMEY[Pho]LASQK.+2y6 71.5 28.8 
553.733 918.3968 FGFR2_616.GMEY[Pho]LASQK.+2y7 71.5 28.8 
659.2436 457.2041 FGFR2_656_657(loop).DINNIDY[Pho]Y[Pho]K.+2b4 79.2 32.6 
659.2436 570.2882 FGFR2_656_657(loop).DINNIDY[Pho]Y[Pho]K.+2b5 79.2 32.6 
659.2436 748.1991 FGFR2_656_657(loop).DINNIDY[Pho]Y[Pho]K.+2y4 79.2 32.6 
659.2436 861.2831 FGFR2_656_657(loop).DINNIDY[Pho]Y[Pho]K.+2y5 79.2 32.6 
659.2436 975.3261 FGFR2_656_657(loop).DINNIDY[Pho]Y[Pho]K.+2y6 79.2 32.6 
663.7438 466.2045 FGFR3_647_648(loop).DVHNLDY[Pho]Y[Pho]K.+2b4 79.5 32.8 
663.7438 579.2885 FGFR3_647_648(loop).DVHNLDY[Pho]Y[Pho]K.+2b5 79.5 32.8 
663.7438 694.3155 FGFR3_647_648(loop).DVHNLDY[Pho]Y[Pho]K.+2b6 79.5 32.8 
663.7438 937.3451 FGFR3_647_648(loop).DVHNLDY[Pho]Y[Pho]K.+2b7 79.5 32.8 
663.7438 748.1991 FGFR3_647_648(loop).DVHNLDY[Pho]Y[Pho]K.+2y4 79.5 32.8 
663.7438 861.2831 FGFR3_647_648(loop).DVHNLDY[Pho]Y[Pho]K.+2y5 79.5 32.8 
663.7438 975.3261 FGFR3_647_648(loop).DVHNLDY[Pho]Y[Pho]K.+2y6 79.5 32.8 
800.4051 397.2809 FGFR4_754.VLLAVSEEY[Pho]LDLR.+2b4 89.5 37.7 
800.4051 496.3493 FGFR4_754.VLLAVSEEY[Pho]LDLR.+2b5 89.5 37.7 
800.4051 583.3814 FGFR4_754.VLLAVSEEY[Pho]LDLR.+2b6 89.5 37.7 
800.4051 759.3437 FGFR4_754.VLLAVSEEY[Pho]LDLR.+2y5 89.5 37.7 
800.4051 888.3863 FGFR4_754.VLLAVSEEY[Pho]LDLR.+2y6 89.5 37.7 
800.4051 1104.461 FGFR4_754.VLLAVSEEY[Pho]LDLR.+2y8 89.5 37.7 
800.4051 1203.529 FGFR4_754.VLLAVSEEY[Pho]LDLR.+2y9 89.5 37.7 
473.7233 372.0955 FGR_180_FYN_185_YES_194.GAY[Pho]SLSIR.+2b3 65.7 25.9 
473.7233 459.1275 FGR_180_FYN_185_YES_194.GAY[Pho]SLSIR.+2b4 65.7 25.9 
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473.7233 572.2116 FGR_180_FYN_185_YES_194.GAY[Pho]SLSIR.+2b5 65.7 25.9 
473.7233 375.235 FGR_180_FYN_185_YES_194.GAY[Pho]SLSIR.+2y3 65.7 25.9 
473.7233 488.3191 FGR_180_FYN_185_YES_194.GAY[Pho]SLSIR.+2y4 65.7 25.9 
473.7233 575.3511 FGR_180_FYN_185_YES_194.GAY[Pho]SLSIR.+2y5 65.7 25.9 
473.7233 818.3808 FGR_180_FYN_185_YES_194.GAY[Pho]SLSIR.+2y6 65.7 25.9 
725.2797 490.2984 FGR_208.LDMGGY[Pho]Y[Pho]ITTR.+2y4 84 35 
725.2797 733.328 FGR_208.LDMGGY[Pho]Y[Pho]ITTR.+2y5 84 35 
725.2797 976.3577 FGR_208.LDMGGY[Pho]Y[Pho]ITTR.+2y6 84 35 
725.2797 1033.379 FGR_208.LDMGGY[Pho]Y[Pho]ITTR.+2y7 84 35 
725.2797 1090.401 FGR_208.LDMGGY[Pho]Y[Pho]ITTR.+2y8 84 35 
725.2797 1221.441 FGR_208.LDMGGY[Pho]Y[Pho]ITTR.+2y9 84 35 
696.7423 814.2291 FGR_412(loop).DDEY[Pho]NPC[CAM]QGSK.+2b6 81.9 33.9 
696.7423 291.1663 FGR_412(loop).DDEY[Pho]NPC[CAM]QGSK.+2y3 81.9 33.9 
696.7423 419.2249 FGR_412(loop).DDEY[Pho]NPC[CAM]QGSK.+2y4 81.9 33.9 
696.7423 579.2555 FGR_412(loop).DDEY[Pho]NPC[CAM]QGSK.+2y5 81.9 33.9 
696.7423 676.3083 FGR_412(loop).DDEY[Pho]NPC[CAM]QGSK.+2y6 81.9 33.9 
696.7423 790.3512 FGR_412(loop).DDEY[Pho]NPC[CAM]QGSK.+2y7 81.9 33.9 
520.2046 665.1855 FLT3_597.EY[Pho]EYDLK.+2b4 69 27.6 
520.2046 780.2124 FLT3_597.EY[Pho]EYDLK.+2b5 69 27.6 
520.2046 538.2871 FLT3_597.EY[Pho]EYDLK.+2y4 69 27.6 
520.2046 667.3297 FLT3_597.EY[Pho]EYDLK.+2y5 69 27.6 
520.2046 665.1855 FLT3_599.EYEY[Pho]DLK.+2b4 69 27.6 
520.2046 780.2124 FLT3_599.EYEY[Pho]DLK.+2b5 69 27.6 
520.2046 618.2535 FLT3_599.EYEY[Pho]DLK.+2y4 69 27.6 
520.2046 747.2961 FLT3_599.EYEY[Pho]DLK.+2y5 69 27.6 
689.7891 447.1908 FLT3_842(loop).DIMSDSNY[Pho]VVR.+2b4 81.4 33.7 
689.7891 616.2854 FLT3_842(loop).DIMSDSNY[Pho]VVR.+2y4 81.4 33.7 
689.7891 730.3284 FLT3_842(loop).DIMSDSNY[Pho]VVR.+2y5 81.4 33.7 
689.7891 817.3604 FLT3_842(loop).DIMSDSNY[Pho]VVR.+2y6 81.4 33.7 
689.7891 932.3873 FLT3_842(loop).DIMSDSNY[Pho]VVR.+2y7 81.4 33.7 
689.7891 1019.419 FLT3_842(loop).DIMSDSNY[Pho]VVR.+2y8 81.4 33.7 
689.7891 1150.46 FLT3_842(loop).DIMSDSNY[Pho]VVR.+2y9 81.4 33.7 
660.2612 458.1882 FRK_387(loop).VDNEDIY[Pho]ESR.+2b4 79.3 32.6 
660.2612 573.2151 FRK_387(loop).VDNEDIY[Pho]ESR.+2b5 79.3 32.6 
660.2612 634.2232 FRK_387(loop).VDNEDIY[Pho]ESR.+2y4 79.3 32.6 
660.2612 747.3073 FRK_387(loop).VDNEDIY[Pho]ESR.+2y5 79.3 32.6 
660.2612 862.3342 FRK_387(loop).VDNEDIY[Pho]ESR.+2y6 79.3 32.6 
660.2612 991.3768 FRK_387(loop).VDNEDIY[Pho]ESR.+2y7 79.3 32.6 
660.2612 1105.42 FRK_387(loop).VDNEDIY[Pho]ESR.+2y8 79.3 32.6 
716.7809 1056.348 FYN_213_214_YES_222_223.LDNGGY[Pho]Y[Pho]ITTR.+2b8 83.4 34.7 
716.7809 1157.395 FYN_213_214_YES_222_223.LDNGGY[Pho]Y[Pho]ITTR.+2b9 83.4 34.7 
716.7809 733.328 FYN_213_214_YES_222_223.LDNGGY[Pho]Y[Pho]ITTR.+2y5 83.4 34.7 
716.7809 976.3577 FYN_213_214_YES_222_223.LDNGGY[Pho]Y[Pho]ITTR.+2y6 83.4 34.7 
716.7809 1033.379 FYN_213_214_YES_222_223.LDNGGY[Pho]Y[Pho]ITTR.+2y7 83.4 34.7 
716.7809 1090.401 FYN_213_214_YES_222_223.LDNGGY[Pho]Y[Pho]ITTR.+2y8 83.4 34.7 
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716.7809 1204.444 FYN_213_214_YES_222_223.LDNGGY[Pho]Y[Pho]ITTR.+2y9 83.4 34.7 
657.7976 656.3039 FYN_440_SRC_439_YES_446.WTAPEAALY[Pho]GR.+2b6 79.1 32.5 
657.7976 588.2541 FYN_440_SRC_439_YES_446.WTAPEAALY[Pho]GR.+2y4 79.1 32.5 
657.7976 659.2913 FYN_440_SRC_439_YES_446.WTAPEAALY[Pho]GR.+2y5 79.1 32.5 
657.7976 730.3284 FYN_440_SRC_439_YES_446.WTAPEAALY[Pho]GR.+2y6 79.1 32.5 
657.7976 859.371 FYN_440_SRC_439_YES_446.WTAPEAALY[Pho]GR.+2y7 79.1 32.5 
657.7976 956.4237 FYN_440_SRC_439_YES_446.WTAPEAALY[Pho]GR.+2y8 79.1 32.5 
657.7976 1027.461 FYN_440_SRC_439_YES_446.WTAPEAALY[Pho]GR.+2y9 79.1 32.5 
710.3188 444.2089 HCK_209.TLDNGGFY[Pho]ISPR.+2b4 82.9 34.4 
710.3188 1205.499 HCK_209.TLDNGGFY[Pho]ISPR.+2y10 82.9 34.4 
710.3188 472.2878 HCK_209.TLDNGGFY[Pho]ISPR.+2y4 82.9 34.4 
710.3188 715.3175 HCK_209.TLDNGGFY[Pho]ISPR.+2y5 82.9 34.4 
710.3188 862.3859 HCK_209.TLDNGGFY[Pho]ISPR.+2y6 82.9 34.4 
710.3188 919.4073 HCK_209.TLDNGGFY[Pho]ISPR.+2y7 82.9 34.4 
710.3188 976.4288 HCK_209.TLDNGGFY[Pho]ISPR.+2y8 82.9 34.4 
645.2741 457.2293 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2b4 78.2 32.1 
645.2741 571.2722 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2b5 78.2 32.1 
645.2741 347.2037 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2y3 78.2 32.1 
645.2741 590.2334 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2y4 78.2 32.1 
645.2741 719.276 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2y5 78.2 32.1 
645.2741 833.3189 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2y6 78.2 32.1 
645.2741 948.3459 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2y7 78.2 32.1 
645.2741 1077.388 HCK_LYN_411_397(loop).VIEDNEY[Pho]TAR.+2y8 78.2 32.1 
876.3891 428.214 IGF1R_1014.ELGQGSFGMVY[Pho]EGVAK.+2b4 95 40.4 
876.3891 1180.511 IGF1R_1014.ELGQGSFGMVY[Pho]EGVAK.+2y10 95 40.4 
876.3891 503.2824 IGF1R_1014.ELGQGSFGMVY[Pho]EGVAK.+2y5 95 40.4 
876.3891 746.312 IGF1R_1014.ELGQGSFGMVY[Pho]EGVAK.+2y6 95 40.4 
876.3891 845.3805 IGF1R_1014.ELGQGSFGMVY[Pho]EGVAK.+2y7 95 40.4 
876.3891 976.4209 IGF1R_1014.ELGQGSFGMVY[Pho]EGVAK.+2y8 95 40.4 
876.3891 1033.442 IGF1R_1014.ELGQGSFGMVY[Pho]EGVAK.+2y9 95 40.4 
659.2554 601.1905 IGF1R_1161_INSR_1185.DIY[Pho]ETDYYR.+2b4 79.2 32.6 
659.2554 702.2382 IGF1R_1161_INSR_1185.DIY[Pho]ETDYYR.+2b5 79.2 32.6 
659.2554 817.2652 IGF1R_1161_INSR_1185.DIY[Pho]ETDYYR.+2b6 79.2 32.6 
659.2554 616.2726 IGF1R_1161_INSR_1185.DIY[Pho]ETDYYR.+2y4 79.2 32.6 
659.2554 846.3628 IGF1R_1161_INSR_1185.DIY[Pho]ETDYYR.+2y6 79.2 32.6 
659.2554 1089.392 IGF1R_1161_INSR_1185.DIY[Pho]ETDYYR.+2y7 79.2 32.6 
614.9221 726.2131 INSR_1355.SY[Pho]EEHIPYTHMNGGK.+3b5 75.9 31 
614.9221 839.2971 INSR_1355.SY[Pho]EEHIPYTHMNGGK.+3b6 75.9 31 
614.9221 643.2981 INSR_1355.SY[Pho]EEHIPYTHMNGGK.+3y6 75.9 31 
614.9221 744.3457 INSR_1355.SY[Pho]EEHIPYTHMNGGK.+3y7 75.9 31 
614.9221 907.4091 INSR_1355.SY[Pho]EEHIPYTHMNGGK.+3y8 75.9 31 
614.9221 1004.462 INSR_1355.SY[Pho]EEHIPYTHMNGGK.+3y9 75.9 31 
614.9221 509.1878 INSR_1361.SYEEHIPY[Pho]THMNGGK.+3b4 75.9 31 
614.9221 759.3308 INSR_1361.SYEEHIPY[Pho]THMNGGK.+3b6 75.9 31 
614.9221 375.1987 INSR_1361.SYEEHIPY[Pho]THMNGGK.+3y4 75.9 31 
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614.9221 506.2391 INSR_1361.SYEEHIPY[Pho]THMNGGK.+3y5 75.9 31 
614.9221 643.2981 INSR_1361.SYEEHIPY[Pho]THMNGGK.+3y6 75.9 31 
614.9221 744.3457 INSR_1361.SYEEHIPY[Pho]THMNGGK.+3y7 75.9 31 
614.9221 1084.428 INSR_1361.SYEEHIPY[Pho]THMNGGK.+3y9 75.9 31 
652.2476 688.2226 INSRR_1141.DVY[Pho]ETDYYR.+2b5 78.7 32.3 
652.2476 803.2495 INSRR_1141.DVY[Pho]ETDYYR.+2b6 78.7 32.3 
652.2476 966.3128 INSRR_1141.DVY[Pho]ETDYYR.+2b7 78.7 32.3 
652.2476 616.2726 INSRR_1141.DVY[Pho]ETDYYR.+2y4 78.7 32.3 
652.2476 717.3202 INSRR_1141.DVY[Pho]ETDYYR.+2y5 78.7 32.3 
652.2476 846.3628 INSRR_1141.DVY[Pho]ETDYYR.+2y6 78.7 32.3 
652.2476 1089.392 INSRR_1141.DVY[Pho]ETDYYR.+2y7 78.7 32.3 
821.3558 590.2821 ITK_512(loop).FVLDDQY[Pho]TSSTGTK.+2b5 91 38.4 
821.3558 1167.457 ITK_512(loop).FVLDDQY[Pho]TSSTGTK.+2y10 91 38.4 
821.3558 493.2617 ITK_512(loop).FVLDDQY[Pho]TSSTGTK.+2y5 91 38.4 
821.3558 580.2937 ITK_512(loop).FVLDDQY[Pho]TSSTGTK.+2y6 91 38.4 
821.3558 681.3414 ITK_512(loop).FVLDDQY[Pho]TSSTGTK.+2y7 91 38.4 
821.3558 924.371 ITK_512(loop).FVLDDQY[Pho]TSSTGTK.+2y8 91 38.4 
821.3558 1052.43 ITK_512(loop).FVLDDQY[Pho]TSSTGTK.+2y9 91 38.4 
529.2519 583.2164 JAK1_220.Y[Pho]IPETLNK.+2b4 69.7 27.9 
529.2519 684.264 JAK1_220.Y[Pho]IPETLNK.+2b5 69.7 27.9 
529.2519 797.3481 JAK1_220.Y[Pho]IPETLNK.+2b6 69.7 27.9 
529.2519 475.2875 JAK1_220.Y[Pho]IPETLNK.+2y4 69.7 27.9 
529.2519 604.3301 JAK1_220.Y[Pho]IPETLNK.+2y5 69.7 27.9 
529.2519 701.3828 JAK1_220.Y[Pho]IPETLNK.+2y6 69.7 27.9 
489.6912 547.1258 JAK1_993.GMDY[Pho]LGSR.+2b4 66.8 26.5 
489.6912 717.2314 JAK1_993.GMDY[Pho]LGSR.+2b6 66.8 26.5 
489.6912 675.2862 JAK1_993.GMDY[Pho]LGSR.+2y5 66.8 26.5 
489.6912 790.3131 JAK1_993.GMDY[Pho]LGSR.+2y6 66.8 26.5 
968.4404 685.2788 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2b6 101.7 43.7 
968.4404 798.3628 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2b7 101.7 43.7 
968.4404 869.3999 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2b8 101.7 43.7 
968.4404 982.484 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2b9 101.7 43.7 
968.4404 711.3672 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2y6 101.7 43.7 
968.4404 954.3968 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2y7 101.7 43.7 
968.4404 1067.481 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2y8 101.7 43.7 
968.4404 1138.518 JAK2_201.ENDQTPLAIY[Pho]NSISYK.+2y9 101.7 43.7 
968.4404 869.3999 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2b8 101.7 43.7 
968.4404 982.484 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2b9 101.7 43.7 
968.4404 477.1745 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2y3 101.7 43.7 
968.4404 677.2906 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2y5 101.7 43.7 
968.4404 791.3335 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2y6 101.7 43.7 
968.4404 954.3968 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2y7 101.7 43.7 
968.4404 1067.481 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2y8 101.7 43.7 
968.4404 1138.518 JAK2_206.ENDQTPLAIYNSISY[Pho]K.+2y9 101.7 43.7 
619.8001 737.2654 JAK2_221.IQDY[Pho]HILTR.+2b5 76.3 31.2 
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619.8001 850.3495 JAK2_221.IQDY[Pho]HILTR.+2b6 76.3 31.2 
619.8001 963.4336 JAK2_221.IQDY[Pho]HILTR.+2b7 76.3 31.2 
619.8001 502.3348 JAK2_221.IQDY[Pho]HILTR.+2y4 76.3 31.2 
619.8001 639.3937 JAK2_221.IQDY[Pho]HILTR.+2y5 76.3 31.2 
619.8001 882.4233 JAK2_221.IQDY[Pho]HILTR.+2y6 76.3 31.2 
619.8001 997.4503 JAK2_221.IQDY[Pho]HILTR.+2y7 76.3 31.2 
637.303 401.1667 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3b4 77.6 32.3 
637.303 644.1963 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3b5 77.6 32.3 
637.303 1209.684 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3y10 77.6 32.3 
637.303 601.3919 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3y5 77.6 32.3 
637.303 702.4396 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3y6 77.6 32.3 
637.303 831.4822 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3y7 77.6 32.3 
637.303 968.5411 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3y8 77.6 32.3 
637.303 1081.625 JAK2_570.EVGDY[Pho]GQLHETEVLLK.+3y9 77.6 32.3 
767.8724 730.2881 JAK2_931.LIMEY[Pho]LPYGSLR.+2b5 87.1 36.5 
767.8724 843.3722 JAK2_931.LIMEY[Pho]LPYGSLR.+2b6 87.1 36.5 
767.8724 595.3198 JAK2_931.LIMEY[Pho]LPYGSLR.+2y5 87.1 36.5 
767.8724 692.3726 JAK2_931.LIMEY[Pho]LPYGSLR.+2y6 87.1 36.5 
767.8724 805.4567 JAK2_931.LIMEY[Pho]LPYGSLR.+2y7 87.1 36.5 
767.8724 1048.486 JAK2_931.LIMEY[Pho]LPYGSLR.+2y8 87.1 36.5 
767.8724 1177.529 JAK2_931.LIMEY[Pho]LPYGSLR.+2y9 87.1 36.5 
807.8556 730.2881 JAK2_931_934.LIMEY[Pho]LPY[Pho]GSLR.+2b5 90 37.9 
807.8556 843.3722 JAK2_931_934.LIMEY[Pho]LPY[Pho]GSLR.+2b6 90 37.9 
807.8556 432.2565 JAK2_931_934.LIMEY[Pho]LPY[Pho]GSLR.+2y4 90 37.9 
807.8556 675.2862 JAK2_931_934.LIMEY[Pho]LPY[Pho]GSLR.+2y5 90 37.9 
807.8556 772.3389 JAK2_931_934.LIMEY[Pho]LPY[Pho]GSLR.+2y6 90 37.9 
807.8556 885.423 JAK2_931_934.LIMEY[Pho]LPY[Pho]GSLR.+2y7 90 37.9 
807.8556 1128.453 JAK2_931_934.LIMEY[Pho]LPY[Pho]GSLR.+2y8 90 37.9 
767.8724 650.3218 JAK2_934.LIMEYLPY[Pho]GSLR.+2b5 87.1 36.5 
767.8724 763.4059 JAK2_934.LIMEYLPY[Pho]GSLR.+2b6 87.1 36.5 
767.8724 1103.488 JAK2_934.LIMEYLPY[Pho]GSLR.+2b8 87.1 36.5 
767.8724 1160.51 JAK2_934.LIMEYLPY[Pho]GSLR.+2b9 87.1 36.5 
767.8724 675.2862 JAK2_934.LIMEYLPY[Pho]GSLR.+2y5 87.1 36.5 
767.8724 772.3389 JAK2_934.LIMEYLPY[Pho]GSLR.+2y6 87.1 36.5 
767.8724 1048.486 JAK2_934.LIMEYLPY[Pho]GSLR.+2y8 87.1 36.5 
767.8724 1177.529 JAK2_934.LIMEYLPY[Pho]GSLR.+2y9 87.1 36.5 
759.3482 716.2725 JAK3_904.LVMEY[Pho]LPSGC[CAM]LR.+2b5 86.5 36.2 
759.3482 829.3566 JAK3_904.LVMEY[Pho]LPSGC[CAM]LR.+2b6 86.5 36.2 
759.3482 592.2872 JAK3_904.LVMEY[Pho]LPSGC[CAM]LR.+2y5 86.5 36.2 
759.3482 689.3399 JAK3_904.LVMEY[Pho]LPSGC[CAM]LR.+2y6 86.5 36.2 
759.3482 802.424 JAK3_904.LVMEY[Pho]LPSGC[CAM]LR.+2y7 86.5 36.2 
759.3482 1045.454 JAK3_904.LVMEY[Pho]LPSGC[CAM]LR.+2y8 86.5 36.2 
759.3482 1174.496 JAK3_904.LVMEY[Pho]LPSGC[CAM]LR.+2y9 86.5 36.2 
652.8196 583.2891 JAK3_929.LLLY[Pho]SSQIC[CAM]K.+2b4 78.7 32.4 
652.8196 670.3212 JAK3_929.LLLY[Pho]SSQIC[CAM]K.+2b5 78.7 32.4 
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652.8196 757.3532 JAK3_929.LLLY[Pho]SSQIC[CAM]K.+2b6 78.7 32.4 
652.8196 885.4118 JAK3_929.LLLY[Pho]SSQIC[CAM]K.+2b7 78.7 32.4 
652.8196 998.4958 JAK3_929.LLLY[Pho]SSQIC[CAM]K.+2b8 78.7 32.4 
652.8196 635.3181 JAK3_929.LLLY[Pho]SSQIC[CAM]K.+2y5 78.7 32.4 
652.8196 1078.464 JAK3_929.LLLY[Pho]SSQIC[CAM]K.+2y8 78.7 32.4 
487.6747 602.0935 JAK3_980_981(loop).DY[Pho]Y[Pho]VVR.+2b3 66.7 26.4 
487.6747 701.162 JAK3_980_981(loop).DY[Pho]Y[Pho]VVR.+2b4 66.7 26.4 
487.6747 373.2558 JAK3_980_981(loop).DY[Pho]Y[Pho]VVR.+2y3 66.7 26.4 
487.6747 616.2854 JAK3_980_981(loop).DY[Pho]Y[Pho]VVR.+2y4 66.7 26.4 
564.9334 485.1796 KIT_547.Y[Pho]LQKPMYEVQWK.+3b3 72.3 28.3 
564.9334 613.2745 KIT_547.Y[Pho]LQKPMYEVQWK.+3b4 72.3 28.3 
564.9334 841.3678 KIT_547.Y[Pho]LQKPMYEVQWK.+3b6 72.3 28.3 
564.9334 560.3191 KIT_547.Y[Pho]LQKPMYEVQWK.+3y4 72.3 28.3 
564.9334 689.3617 KIT_547.Y[Pho]LQKPMYEVQWK.+3y5 72.3 28.3 
564.9334 852.425 KIT_547.Y[Pho]LQKPMYEVQWK.+3y6 72.3 28.3 
564.9334 1080.518 KIT_547.Y[Pho]LQKPMYEVQWK.+3y8 72.3 28.3 
591.5888 613.2745 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3b4 74.2 29.8 
591.5888 841.3678 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3b6 74.2 29.8 
591.5888 1084.397 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3b7 74.2 29.8 
591.5888 461.2507 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3y3 74.2 29.8 
591.5888 560.3191 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3y4 74.2 29.8 
591.5888 689.3617 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3y5 74.2 29.8 
591.5888 932.3914 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3y6 74.2 29.8 
591.5888 1160.485 KIT_547_553.Y[Pho]LQKPMY[Pho]EVQWK.+3y8 74.2 29.8 
564.9334 405.2132 KIT_553.YLQKPMY[Pho]EVQWK.+3b3 72.3 28.3 
564.9334 533.3082 KIT_553.YLQKPMY[Pho]EVQWK.+3b4 72.3 28.3 
564.9334 761.4015 KIT_553.YLQKPMY[Pho]EVQWK.+3b6 72.3 28.3 
564.9334 560.3191 KIT_553.YLQKPMY[Pho]EVQWK.+3y4 72.3 28.3 
564.9334 689.3617 KIT_553.YLQKPMY[Pho]EVQWK.+3y5 72.3 28.3 
564.9334 932.3914 KIT_553.YLQKPMY[Pho]EVQWK.+3y6 72.3 28.3 
564.9334 1063.432 KIT_553.YLQKPMY[Pho]EVQWK.+3y7 72.3 28.3 
622.3203 399.2238 KIT_609.VVEATAY[Pho]GLIK.+2b4 76.5 31.3 
622.3203 500.2715 KIT_609.VVEATAY[Pho]GLIK.+2b5 76.5 31.3 
622.3203 430.3024 KIT_609.VVEATAY[Pho]GLIK.+2y4 76.5 31.3 
622.3203 673.3321 KIT_609.VVEATAY[Pho]GLIK.+2y5 76.5 31.3 
622.3203 744.3692 KIT_609.VVEATAY[Pho]GLIK.+2y6 76.5 31.3 
622.3203 845.4168 KIT_609.VVEATAY[Pho]GLIK.+2y7 76.5 31.3 
622.3203 916.454 KIT_609.VVEATAY[Pho]GLIK.+2y8 76.5 31.3 
622.3203 1045.497 KIT_609.VVEATAY[Pho]GLIK.+2y9 76.5 31.3 
509.7157 431.1521 KIT_823(loop).NDSNY[Pho]VVK.+2b4 68.3 27.2 
509.7157 674.1818 KIT_823(loop).NDSNY[Pho]VVK.+2b5 68.3 27.2 
509.7157 773.2502 KIT_823(loop).NDSNY[Pho]VVK.+2b6 68.3 27.2 
509.7157 588.2793 KIT_823(loop).NDSNY[Pho]VVK.+2y4 68.3 27.2 
509.7157 702.3222 KIT_823(loop).NDSNY[Pho]VVK.+2y5 68.3 27.2 
509.7157 789.3542 KIT_823(loop).NDSNY[Pho]VVK.+2y6 68.3 27.2 
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531.6645 430.1569 KSYK_525_526(loop).ADENY[Pho]Y[Pho]K.+2b4 69.9 28 
531.6645 673.1865 KSYK_525_526(loop).ADENY[Pho]Y[Pho]K.+2b5 69.9 28 
531.6645 633.1721 KSYK_525_526(loop).ADENY[Pho]Y[Pho]K.+2y3 69.9 28 
531.6645 747.2151 KSYK_525_526(loop).ADENY[Pho]Y[Pho]K.+2y4 69.9 28 
531.6645 876.2576 KSYK_525_526(loop).ADENY[Pho]Y[Pho]K.+2y5 69.9 28 
651.2979 1059.462 KSYK_74.ELNGTY[Pho]AIAGGR.+2y10 78.6 32.3 
651.2979 360.199 KSYK_74.ELNGTY[Pho]AIAGGR.+2y4 78.6 32.3 
651.2979 473.2831 KSYK_74.ELNGTY[Pho]AIAGGR.+2y5 78.6 32.3 
651.2979 544.3202 KSYK_74.ELNGTY[Pho]AIAGGR.+2y6 78.6 32.3 
651.2979 787.3498 KSYK_74.ELNGTY[Pho]AIAGGR.+2y7 78.6 32.3 
651.2979 888.3975 KSYK_74.ELNGTY[Pho]AIAGGR.+2y8 78.6 32.3 
651.2979 945.419 KSYK_74.ELNGTY[Pho]AIAGGR.+2y9 78.6 32.3 
732.3187 427.23 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3b5 84.5 37.4 
732.3187 760.3624 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3b8 84.5 37.4 
732.3187 859.4308 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3b9 84.5 37.4 
732.3187 442.2409 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3y4 84.5 37.4 
732.3187 556.2838 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3y5 84.5 37.4 
732.3187 719.3471 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3y6 84.5 37.4 
732.3187 962.3768 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3y7 84.5 37.4 
732.3187 1019.398 LCK_263.LGAGQFGEVWMGY[Pho]YNGHTK.+3y8 84.5 37.4 
732.3187 427.23 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3b5 84.5 37.4 
732.3187 760.3624 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3b8 84.5 37.4 
732.3187 859.4308 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3b9 84.5 37.4 
732.3187 442.2409 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3y4 84.5 37.4 
732.3187 556.2838 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3y5 84.5 37.4 
732.3187 799.3134 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3y6 84.5 37.4 
732.3187 962.3768 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3y7 84.5 37.4 
732.3187 1019.398 LCK_264.LGAGQFGEVWMGYY[Pho]NGHTK.+3y8 84.5 37.4 
896.4213 585.2667 LCK_414.WTAPEAINY[Pho]GTFTIK.+2b5 96.5 41.1 
896.4213 656.3039 LCK_414.WTAPEAINY[Pho]GTFTIK.+2b6 96.5 41.1 
896.4213 1207.576 LCK_414.WTAPEAINY[Pho]GTFTIK.+2y10 96.5 41.1 
896.4213 508.313 LCK_414.WTAPEAINY[Pho]GTFTIK.+2y4 96.5 41.1 
896.4213 666.3821 LCK_414.WTAPEAINY[Pho]GTFTIK.+2y6 96.5 41.1 
896.4213 909.4118 LCK_414.WTAPEAINY[Pho]GTFTIK.+2y7 96.5 41.1 
896.4213 1023.455 LCK_414.WTAPEAINY[Pho]GTFTIK.+2y8 96.5 41.1 
896.4213 1136.539 LCK_414.WTAPEAINY[Pho]GTFTIK.+2y9 96.5 41.1 
710.9772 599.297 LCK_470.MVRPDNC[CAM]PEELY[Pho]QLMR.+3b5 82.9 36.3 
710.9772 713.3399 LCK_470.MVRPDNC[CAM]PEELY[Pho]QLMR.+3b6 82.9 36.3 
710.9772 873.3706 LCK_470.MVRPDNC[CAM]PEELY[Pho]QLMR.+3b7 82.9 36.3 
710.9772 1099.466 LCK_470.MVRPDNC[CAM]PEELY[Pho]QLMR.+3b9 82.9 36.3 
710.9772 547.3021 LCK_470.MVRPDNC[CAM]PEELY[Pho]QLMR.+3y4 82.9 36.3 
710.9772 790.3317 LCK_470.MVRPDNC[CAM]PEELY[Pho]QLMR.+3y5 82.9 36.3 
710.9772 903.4158 LCK_470.MVRPDNC[CAM]PEELY[Pho]QLMR.+3y6 82.9 36.3 
966.4506 635.1749 LMTK1_283(loop).EDY[Pho]FVTADQLWVPLR.+2b4 101.6 43.6 
966.4506 734.2433 LMTK1_283(loop).EDY[Pho]FVTADQLWVPLR.+2b5 101.6 43.6 
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966.4506 1198.658 LMTK1_283(loop).EDY[Pho]FVTADQLWVPLR.+2y10 101.6 43.6 
966.4506 484.3242 LMTK1_283(loop).EDY[Pho]FVTADQLWVPLR.+2y4 101.6 43.6 
966.4506 670.4035 LMTK1_283(loop).EDY[Pho]FVTADQLWVPLR.+2y5 101.6 43.6 
966.4506 1026.573 LMTK1_283(loop).EDY[Pho]FVTADQLWVPLR.+2y8 101.6 43.6 
966.4506 1097.61 LMTK1_283(loop).EDY[Pho]FVTADQLWVPLR.+2y9 101.6 43.6 
475.7046 432.2241 LMTK1_479.GLNFEY[Pho]K.+2b4 65.8 26 
475.7046 561.2667 LMTK1_479.GLNFEY[Pho]K.+2b5 65.8 26 
475.7046 519.1851 LMTK1_479.GLNFEY[Pho]K.+2y3 65.8 26 
475.7046 666.2535 LMTK1_479.GLNFEY[Pho]K.+2y4 65.8 26 
475.7046 780.2964 LMTK1_479.GLNFEY[Pho]K.+2y5 65.8 26 
556.2523 478.1374 LMTK2_1448.Y[Pho]FSPPPPAR.+2b3 71.7 28.9 
556.2523 575.1901 LMTK2_1448.Y[Pho]FSPPPPAR.+2b4 71.7 28.9 
556.2523 672.2429 LMTK2_1448.Y[Pho]FSPPPPAR.+2b5 71.7 28.9 
556.2523 440.2616 LMTK2_1448.Y[Pho]FSPPPPAR.+2y4 71.7 28.9 
556.2523 537.3144 LMTK2_1448.Y[Pho]FSPPPPAR.+2y5 71.7 28.9 
556.2523 634.3671 LMTK2_1448.Y[Pho]FSPPPPAR.+2y6 71.7 28.9 
556.2523 721.3991 LMTK2_1448.Y[Pho]FSPPPPAR.+2y7 71.7 28.9 
571.5737 505.1806 LMTK2_1468.STEQSWPHSAPY[Pho]SR.+3y3 72.8 28.7 
571.5737 602.2334 LMTK2_1468.STEQSWPHSAPY[Pho]SR.+3y4 72.8 28.7 
571.5737 673.2705 LMTK2_1468.STEQSWPHSAPY[Pho]SR.+3y5 72.8 28.7 
571.5737 760.3025 LMTK2_1468.STEQSWPHSAPY[Pho]SR.+3y6 72.8 28.7 
571.5737 897.3615 LMTK2_1468.STEQSWPHSAPY[Pho]SR.+3y7 72.8 28.7 
571.5737 994.4142 LMTK2_1468.STEQSWPHSAPY[Pho]SR.+3y8 72.8 28.7 
604.2237 488.1065 LMTK2_295(loop).EDY[Pho]IETDDK.+2b3 75.2 30.6 
604.2237 601.1905 LMTK2_295(loop).EDY[Pho]IETDDK.+2b4 75.2 30.6 
604.2237 730.2331 LMTK2_295(loop).EDY[Pho]IETDDK.+2b5 75.2 30.6 
604.2237 478.2144 LMTK2_295(loop).EDY[Pho]IETDDK.+2y4 75.2 30.6 
604.2237 607.257 LMTK2_295(loop).EDY[Pho]IETDDK.+2y5 75.2 30.6 
604.2237 720.341 LMTK2_295(loop).EDY[Pho]IETDDK.+2y6 75.2 30.6 
604.2237 963.3707 LMTK2_295(loop).EDY[Pho]IETDDK.+2y7 75.2 30.6 
673.2411 844.2202 LMTK3_296_297(loop).EDY[Pho]Y[Pho]LTPER.+2b5 80.2 33.1 
673.2411 502.262 LMTK3_296_297(loop).EDY[Pho]Y[Pho]LTPER.+2y4 80.2 33.1 
673.2411 615.3461 LMTK3_296_297(loop).EDY[Pho]Y[Pho]LTPER.+2y5 80.2 33.1 
673.2411 858.3757 LMTK3_296_297(loop).EDY[Pho]Y[Pho]LTPER.+2y6 80.2 33.1 
673.2411 1101.405 LMTK3_296_297(loop).EDY[Pho]Y[Pho]LTPER.+2y7 80.2 33.1 
833.8905 751.4097 LTK_862.GLQPQNLWNPTY[Pho]R.+2b7 91.9 38.9 
833.8905 937.489 LTK_862.GLQPQNLWNPTY[Pho]R.+2b8 91.9 38.9 
833.8905 1051.532 LTK_862.GLQPQNLWNPTY[Pho]R.+2b9 91.9 38.9 
833.8905 616.2491 LTK_862.GLQPQNLWNPTY[Pho]R.+2y4 91.9 38.9 
833.8905 730.292 LTK_862.GLQPQNLWNPTY[Pho]R.+2y5 91.9 38.9 
833.8905 916.3713 LTK_862.GLQPQNLWNPTY[Pho]R.+2y6 91.9 38.9 
833.8905 1029.455 LTK_862.GLQPQNLWNPTY[Pho]R.+2y7 91.9 38.9 
833.8905 1143.498 LTK_862.GLQPQNLWNPTY[Pho]R.+2y8 91.9 38.9 
711.3085 430.1932 LYN_193.SLDNGGY[Pho]YISPR.+2b4 83 34.5 
711.3085 950.3292 LYN_193.SLDNGGY[Pho]YISPR.+2b8 83 34.5 
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711.3085 1221.494 LYN_193.SLDNGGY[Pho]YISPR.+2y10 83 34.5 
711.3085 472.2878 LYN_193.SLDNGGY[Pho]YISPR.+2y4 83 34.5 
711.3085 635.3511 LYN_193.SLDNGGY[Pho]YISPR.+2y5 83 34.5 
711.3085 878.3808 LYN_193.SLDNGGY[Pho]YISPR.+2y6 83 34.5 
711.3085 935.4023 LYN_193.SLDNGGY[Pho]YISPR.+2y7 83 34.5 
711.3085 992.4237 LYN_193.SLDNGGY[Pho]YISPR.+2y8 83 34.5 
711.3085 1106.467 LYN_193.SLDNGGY[Pho]YISPR.+2y9 83 34.5 
751.2916 430.1932 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2b4 85.9 35.9 
751.2916 487.2147 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2b5 85.9 35.9 
751.2916 1143.38 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2b9 85.9 35.9 
751.2916 715.3175 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2y5 85.9 35.9 
751.2916 958.3471 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2y6 85.9 35.9 
751.2916 1015.369 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2y7 85.9 35.9 
751.2916 1072.39 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2y8 85.9 35.9 
751.2916 1186.433 LYN_193_194.SLDNGGY[Pho]Y[Pho]ISPR.+2y9 85.9 35.9 
711.3085 430.1932 LYN_194.SLDNGGYY[Pho]ISPR.+2b4 83 34.5 
711.3085 1221.494 LYN_194.SLDNGGYY[Pho]ISPR.+2y10 83 34.5 
711.3085 472.2878 LYN_194.SLDNGGYY[Pho]ISPR.+2y4 83 34.5 
711.3085 715.3175 LYN_194.SLDNGGYY[Pho]ISPR.+2y5 83 34.5 
711.3085 878.3808 LYN_194.SLDNGGYY[Pho]ISPR.+2y6 83 34.5 
711.3085 935.4023 LYN_194.SLDNGGYY[Pho]ISPR.+2y7 83 34.5 
711.3085 992.4237 LYN_194.SLDNGGYY[Pho]ISPR.+2y8 83 34.5 
711.3085 1106.467 LYN_194.SLDNGGYY[Pho]ISPR.+2y9 83 34.5 
853.3461 503.1919 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2b4 93.3 39.6 
853.3461 844.3142 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2b7 93.3 39.6 
853.3461 957.3982 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2b8 93.3 39.6 
853.3461 506.2643 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2y4 93.3 39.6 
853.3461 749.294 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2y5 93.3 39.6 
853.3461 862.378 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2y6 93.3 39.6 
853.3461 1106.448 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2y8 93.3 39.6 
853.3461 1203.5 LYN_473.VENC[CAM]PDELY[Pho]DIMK.+2y9 93.3 39.6 
768.6505 1045.433 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3b10 87.2 39.4 
768.6505 635.2784 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3b6 87.2 39.4 
768.6505 887.3642 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3b8 87.2 39.4 
768.6505 347.2037 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3y3 87.2 39.4 
768.6505 446.2722 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3y4 87.2 39.4 
768.6505 689.3018 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3y5 87.2 39.4 
768.6505 818.3444 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3y6 87.2 39.4 
768.6505 999.3584 MAPK1(loop).VADPDHDHTGFLT[Pho]EY[Pho]VATR.+3y7 87.2 39.4 
777.9943 663.3097 MAPK3(loop).IADPEHDHTGFLT[Pho]EY[Pho]VATR.+3b6 87.8 39.9 
777.9943 915.3955 MAPK3(loop).IADPEHDHTGFLT[Pho]EY[Pho]VATR.+3b8 87.8 39.9 
777.9943 1016.443 MAPK3(loop).IADPEHDHTGFLT[Pho]EY[Pho]VATR.+3b9 87.8 39.9 
777.9943 446.2722 MAPK3(loop).IADPEHDHTGFLT[Pho]EY[Pho]VATR.+3y4 87.8 39.9 
777.9943 689.3018 MAPK3(loop).IADPEHDHTGFLT[Pho]EY[Pho]VATR.+3y5 87.8 39.9 
777.9943 818.3444 MAPK3(loop).IADPEHDHTGFLT[Pho]EY[Pho]VATR.+3y6 87.8 39.9 
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777.9943 999.3584 MAPK3(loop).IADPEHDHTGFLT[Pho]EY[Pho]VATR.+3y7 87.8 39.9 
638.6899 616.2014 MERTK_749_753_754_TYRO3_681_685_686.IY[Pho]SGDY[Pho]Y[Pho]R.+2b5 77.7 31.8 
638.6899 859.2311 MERTK_749_753_754_TYRO3_681_685_686.IY[Pho]SGDY[Pho]Y[Pho]R.+2b6 77.7 31.8 
638.6899 661.1783 MERTK_749_753_754_TYRO3_681_685_686.IY[Pho]SGDY[Pho]Y[Pho]R.+2y3 77.7 31.8 
638.6899 776.2052 MERTK_749_753_754_TYRO3_681_685_686.IY[Pho]SGDY[Pho]Y[Pho]R.+2y4 77.7 31.8 
638.6899 833.2267 MERTK_749_753_754_TYRO3_681_685_686.IY[Pho]SGDY[Pho]Y[Pho]R.+2y5 77.7 31.8 
638.6899 920.2587 MERTK_749_753_754_TYRO3_681_685_686.IY[Pho]SGDY[Pho]Y[Pho]R.+2y6 77.7 31.8 
598.7067 364.1867 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2b3 74.8 30.4 
598.7067 421.2082 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2b4 74.8 30.4 
598.7067 536.2351 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2b5 74.8 30.4 
598.7067 779.2648 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2b6 74.8 30.4 
598.7067 661.1783 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2y3 74.8 30.4 
598.7067 776.2052 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2y4 74.8 30.4 
598.7067 833.2267 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2y5 74.8 30.4 
598.7067 920.2587 MERTK_TYRO3_753_754 685_686(loop).IYSGDY[Pho]Y[Pho]R.+2y6 74.8 30.4 
657.2803 658.2766 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3b6 79 33.3 
657.2803 901.3063 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3b7 79 33.3 
657.2803 433.2041 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3y4 79 33.3 
657.2803 548.2311 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3y5 79 33.3 
657.2803 661.3151 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3y6 79 33.3 
657.2803 774.3992 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3y7 79 33.3 
657.2803 875.4469 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3y8 79 33.3 
657.2803 932.4684 MET_1093.GHFGC[CAM]VY[Pho]HGTLLDNDGK.+3y9 79 33.3 
648.7329 478.2296 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2b4 78.4 32.2 
648.7329 549.2667 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2b5 78.4 32.2 
648.7329 907.3233 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2b7 78.4 32.2 
648.7329 633.1721 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2y3 78.4 32.2 
648.7329 748.1991 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2y4 78.4 32.2 
648.7329 819.2362 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2y5 78.4 32.2 
648.7329 906.2682 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2y6 78.4 32.2 
648.7329 1069.332 MUSK_755_756(loop).NIYSADY[Pho]Y[Pho]K.+2y7 78.4 32.2 
638.2501 472.1479 NTRK1_676.DIY[Pho]STDYYR.+2b3 77.6 31.8 
638.2501 559.18 NTRK1_676.DIY[Pho]STDYYR.+2b4 77.6 31.8 
638.2501 775.2546 NTRK1_676.DIY[Pho]STDYYR.+2b6 77.6 31.8 
638.2501 616.2726 NTRK1_676.DIY[Pho]STDYYR.+2y4 77.6 31.8 
638.2501 717.3202 NTRK1_676.DIY[Pho]STDYYR.+2y5 77.6 31.8 
638.2501 804.3523 NTRK1_676.DIY[Pho]STDYYR.+2y6 77.6 31.8 
638.2501 1047.382 NTRK1_676.DIY[Pho]STDYYR.+2y7 77.6 31.8 
693.8009 426.1806 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2b4 81.7 33.8 
693.8009 555.2232 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2b5 81.7 33.8 
693.8009 654.2916 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2b6 81.7 33.8 
693.8009 733.3103 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2y5 81.7 33.8 
693.8009 832.3787 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2y6 81.7 33.8 
693.8009 961.4213 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2y7 81.7 33.8 
693.8009 1058.474 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2y8 81.7 33.8 
137 
 
693.8009 1155.527 NTRK1_757.AC[CAM]PPEVY[Pho]AIMR.+2y9 81.7 33.8 
671.2254 465.198 NTRK2_3_706_707_709_710(loop).DVYSTDY[Pho]Y[Pho]R.+2b4 80 33 
671.2254 566.2457 NTRK2_3_706_707_709_710(loop).DVYSTDY[Pho]Y[Pho]R.+2b5 80 33 
671.2254 681.2726 NTRK2_3_706_707_709_710(loop).DVYSTDY[Pho]Y[Pho]R.+2b6 80 33 
671.2254 661.1783 NTRK2_3_706_707_709_710(loop).DVYSTDY[Pho]Y[Pho]R.+2y3 80 33 
671.2254 776.2052 NTRK2_3_706_707_709_710(loop).DVYSTDY[Pho]Y[Pho]R.+2y4 80 33 
671.2254 877.2529 NTRK2_3_706_707_709_710(loop).DVYSTDY[Pho]Y[Pho]R.+2y5 80 33 
671.2254 964.2849 NTRK2_3_706_707_709_710(loop).DVYSTDY[Pho]Y[Pho]R.+2y6 80 33 
983.4098 431.2653 NTRK2_558.VFLAEC[CAM]Y[Pho]NLC[CAM]PEQDK.+2b4 102.8 44.3 
983.4098 720.3385 NTRK2_558.VFLAEC[CAM]Y[Pho]NLC[CAM]PEQDK.+2b6 102.8 44.3 
983.4098 963.3682 NTRK2_558.VFLAEC[CAM]Y[Pho]NLC[CAM]PEQDK.+2b7 102.8 44.3 
983.4098 1190.495 NTRK2_558.VFLAEC[CAM]Y[Pho]NLC[CAM]PEQDK.+2b9 102.8 44.3 
983.4098 776.3243 NTRK2_558.VFLAEC[CAM]Y[Pho]NLC[CAM]PEQDK.+2y6 102.8 44.3 
983.4098 889.4084 NTRK2_558.VFLAEC[CAM]Y[Pho]NLC[CAM]PEQDK.+2y7 102.8 44.3 
983.4098 1003.451 NTRK2_558.VFLAEC[CAM]Y[Pho]NLC[CAM]PEQDK.+2y8 102.8 44.3 
631.2423 458.1323 NTRK2_702_NTRK3_705.DVY[Pho]STDYYR.+2b3 77.1 31.6 
631.2423 545.1643 NTRK2_702_NTRK3_705.DVY[Pho]STDYYR.+2b4 77.1 31.6 
631.2423 761.2389 NTRK2_702_NTRK3_705.DVY[Pho]STDYYR.+2b6 77.1 31.6 
631.2423 717.3202 NTRK2_702_NTRK3_705.DVY[Pho]STDYYR.+2y5 77.1 31.6 
631.2423 804.3523 NTRK2_702_NTRK3_705.DVY[Pho]STDYYR.+2y6 77.1 31.6 
631.2423 1047.382 NTRK2_702_NTRK3_705.DVY[Pho]STDYYR.+2y7 77.1 31.6 
728.3552 423.2966 NTRK3_516.IPVIENPQY[Pho]FR.+2b4 84.2 35.1 
728.3552 552.3392 NTRK3_516.IPVIENPQY[Pho]FR.+2b5 84.2 35.1 
728.3552 666.3821 NTRK3_516.IPVIENPQY[Pho]FR.+2b6 84.2 35.1 
728.3552 790.3284 NTRK3_516.IPVIENPQY[Pho]FR.+2y5 84.2 35.1 
728.3552 904.3713 NTRK3_516.IPVIENPQY[Pho]FR.+2y6 84.2 35.1 
728.3552 1033.414 NTRK3_516.IPVIENPQY[Pho]FR.+2y7 84.2 35.1 
728.3552 1146.498 NTRK3_516.IPVIENPQY[Pho]FR.+2y8 84.2 35.1 
728.3552 1245.566 NTRK3_516.IPVIENPQY[Pho]FR.+2y9 84.2 35.1 
811.3702 560.3079 NTRK3_558.VFLAEC[CAM]Y[Pho]NLSPTK.+2b5 90.3 38.1 
811.3702 720.3385 NTRK3_558.VFLAEC[CAM]Y[Pho]NLSPTK.+2b6 90.3 38.1 
811.3702 1190.495 NTRK3_558.VFLAEC[CAM]Y[Pho]NLSPTK.+2b9 90.3 38.1 
811.3702 659.3723 NTRK3_558.VFLAEC[CAM]Y[Pho]NLSPTK.+2y6 90.3 38.1 
811.3702 902.4019 NTRK3_558.VFLAEC[CAM]Y[Pho]NLSPTK.+2y7 90.3 38.1 
811.3702 1062.433 NTRK3_558.VFLAEC[CAM]Y[Pho]NLSPTK.+2y8 90.3 38.1 
816.3604 645.2838 PGFRA_742.QADTTQY[Pho]VPMLER.+2b6 90.6 38.2 
816.3604 987.3819 PGFRA_742.QADTTQY[Pho]VPMLER.+2b8 90.6 38.2 
816.3604 645.3389 PGFRA_742.QADTTQY[Pho]VPMLER.+2y5 90.6 38.2 
816.3604 744.4073 PGFRA_742.QADTTQY[Pho]VPMLER.+2y6 90.6 38.2 
816.3604 987.4369 PGFRA_742.QADTTQY[Pho]VPMLER.+2y7 90.6 38.2 
816.3604 1115.496 PGFRA_742.QADTTQY[Pho]VPMLER.+2y8 90.6 38.2 
816.3604 1216.543 PGFRA_742.QADTTQY[Pho]VPMLER.+2y9 90.6 38.2 
640.2896 715.2811 PGFRA_762.SLY[Pho]DRPASYK.+2b5 77.8 31.9 
640.2896 883.371 PGFRA_762.SLY[Pho]DRPASYK.+2b7 77.8 31.9 
640.2896 970.403 PGFRA_762.SLY[Pho]DRPASYK.+2b8 77.8 31.9 
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640.2896 565.298 PGFRA_762.SLY[Pho]DRPASYK.+2y5 77.8 31.9 
640.2896 721.3991 PGFRA_762.SLY[Pho]DRPASYK.+2y6 77.8 31.9 
640.2896 836.4261 PGFRA_762.SLY[Pho]DRPASYK.+2y7 77.8 31.9 
640.2896 1079.456 PGFRA_762.SLY[Pho]DRPASYK.+2y8 77.8 31.9 
453.8509 444.153 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3b3 64.2 22.3 
453.8509 559.18 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3b4 64.2 22.3 
453.8509 715.2811 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3b5 64.2 22.3 
453.8509 812.3338 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3b6 64.2 22.3 
453.8509 477.1745 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3y3 64.2 22.3 
453.8509 548.2116 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3y4 64.2 22.3 
453.8509 645.2644 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3y5 64.2 22.3 
453.8509 801.3655 PGFRA_762_768.SLY[Pho]DRPASY[Pho]K.+3y6 64.2 22.3 
640.2896 635.3148 PGFRA_768.SLYDRPASY[Pho]K.+2b5 77.8 31.9 
640.2896 732.3675 PGFRA_768.SLYDRPASY[Pho]K.+2b6 77.8 31.9 
640.2896 803.4046 PGFRA_768.SLYDRPASY[Pho]K.+2b7 77.8 31.9 
640.2896 890.4367 PGFRA_768.SLYDRPASY[Pho]K.+2b8 77.8 31.9 
640.2896 645.2644 PGFRA_768.SLYDRPASY[Pho]K.+2y5 77.8 31.9 
640.2896 801.3655 PGFRA_768.SLYDRPASY[Pho]K.+2y6 77.8 31.9 
640.2896 916.3924 PGFRA_768.SLYDRPASY[Pho]K.+2y7 77.8 31.9 
694.7812 497.2177 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2b4 81.8 33.9 
694.7812 612.2446 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2b5 81.8 33.9 
694.7812 1056.349 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2b8 81.8 33.9 
694.7812 333.2132 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2y3 81.8 33.9 
694.7812 690.2858 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2y5 81.8 33.9 
694.7812 777.3179 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2y6 81.8 33.9 
694.7812 892.3448 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2y7 81.8 33.9 
694.7812 1029.404 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+2y8 81.8 33.9 
463.5233 612.2446 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3b5 64.9 22.8 
463.5233 699.2767 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3b6 64.9 22.8 
463.5233 813.3196 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3b7 64.9 22.8 
463.5233 333.2132 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3y3 64.9 22.8 
463.5233 576.2429 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3y4 64.9 22.8 
463.5233 690.2858 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3y5 64.9 22.8 
463.5233 777.3179 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3y6 64.9 22.8 
463.5233 892.3448 PGFRA_849(loop).DIMHDSNY[Pho]VSK.+3y7 64.9 22.8 
665.795 416.0853 PGFRB_686.Y[Pho]GDLVDYLHR.+2b3 79.7 32.8 
665.795 529.1694 PGFRB_686.Y[Pho]GDLVDYLHR.+2b4 79.7 32.8 
665.795 628.2378 PGFRB_686.Y[Pho]GDLVDYLHR.+2b5 79.7 32.8 
665.795 588.3253 PGFRB_686.Y[Pho]GDLVDYLHR.+2y4 79.7 32.8 
665.795 703.3522 PGFRB_686.Y[Pho]GDLVDYLHR.+2y5 79.7 32.8 
665.795 802.4206 PGFRB_686.Y[Pho]GDLVDYLHR.+2y6 79.7 32.8 
665.795 915.5047 PGFRB_686.Y[Pho]GDLVDYLHR.+2y7 79.7 32.8 
705.7782 416.0853 PGFRB_686_692.Y[Pho]GDLVDY[Pho]LHR.+2b3 82.6 34.3 
705.7782 529.1694 PGFRB_686_692.Y[Pho]GDLVDY[Pho]LHR.+2b4 82.6 34.3 
705.7782 628.2378 PGFRB_686_692.Y[Pho]GDLVDY[Pho]LHR.+2b5 82.6 34.3 
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705.7782 668.2916 PGFRB_686_692.Y[Pho]GDLVDY[Pho]LHR.+2y4 82.6 34.3 
705.7782 783.3185 PGFRB_686_692.Y[Pho]GDLVDY[Pho]LHR.+2y5 82.6 34.3 
705.7782 882.3869 PGFRB_686_692.Y[Pho]GDLVDY[Pho]LHR.+2y6 82.6 34.3 
705.7782 995.471 PGFRB_686_692.Y[Pho]GDLVDY[Pho]LHR.+2y7 82.6 34.3 
665.795 449.2031 PGFRB_692.YGDLVDY[Pho]LHR.+2b4 79.7 32.8 
665.795 548.2715 PGFRB_692.YGDLVDY[Pho]LHR.+2b5 79.7 32.8 
665.795 668.2916 PGFRB_692.YGDLVDY[Pho]LHR.+2y4 79.7 32.8 
665.795 783.3185 PGFRB_692.YGDLVDY[Pho]LHR.+2y5 79.7 32.8 
665.795 882.3869 PGFRB_692.YGDLVDY[Pho]LHR.+2y6 79.7 32.8 
665.795 995.471 PGFRB_692.YGDLVDY[Pho]LHR.+2y7 79.7 32.8 
665.795 1110.498 PGFRB_692.YGDLVDY[Pho]LHR.+2y8 79.7 32.8 
444.1991 449.2031 PGFRB_692.YGDLVDY[Pho]LHR.+3b4 63.5 21.8 
444.1991 548.2715 PGFRB_692.YGDLVDY[Pho]LHR.+3b5 63.5 21.8 
444.1991 663.2984 PGFRB_692.YGDLVDY[Pho]LHR.+3b6 63.5 21.8 
444.1991 668.2916 PGFRB_692.YGDLVDY[Pho]LHR.+3y4 63.5 21.8 
444.1991 783.3185 PGFRB_692.YGDLVDY[Pho]LHR.+3y5 63.5 21.8 
444.1991 882.3869 PGFRB_692.YGDLVDY[Pho]LHR.+3y6 63.5 21.8 
811.3299 332.1088 PGFRB_751.DESVDY[Pho]VPMLDMK.+2b3 90.3 38.1 
811.3299 789.2339 PGFRB_751.DESVDY[Pho]VPMLDMK.+2b6 90.3 38.1 
811.3299 888.3023 PGFRB_751.DESVDY[Pho]VPMLDMK.+2b7 90.3 38.1 
811.3299 506.2643 PGFRB_751.DESVDY[Pho]VPMLDMK.+2y4 90.3 38.1 
811.3299 734.3575 PGFRB_751.DESVDY[Pho]VPMLDMK.+2y6 90.3 38.1 
811.3299 833.426 PGFRB_751.DESVDY[Pho]VPMLDMK.+2y7 90.3 38.1 
811.3299 1076.456 PGFRB_751.DESVDY[Pho]VPMLDMK.+2y8 90.3 38.1 
811.3299 1191.483 PGFRB_751.DESVDY[Pho]VPMLDMK.+2y9 90.3 38.1 
453.6839 317.1092 PGFRB_857(loop).DSNY[Pho]ISK.+2b3 64.2 25.2 
453.6839 560.1388 PGFRB_857(loop).DSNY[Pho]ISK.+2b4 64.2 25.2 
453.6839 673.2229 PGFRB_857(loop).DSNY[Pho]ISK.+2b5 64.2 25.2 
453.6839 347.2289 PGFRB_857(loop).DSNY[Pho]ISK.+2y3 64.2 25.2 
453.6839 590.2586 PGFRB_857(loop).DSNY[Pho]ISK.+2y4 64.2 25.2 
453.6839 704.3015 PGFRB_857(loop).DSNY[Pho]ISK.+2y5 64.2 25.2 
681.2968 1038.431 PGFRB_934.MAQPAHASDEIY[Pho]EIMQK.+3b10 80.8 34.7 
681.2968 636.2922 PGFRB_934.MAQPAHASDEIY[Pho]EIMQK.+3b6 80.8 34.7 
681.2968 909.3883 PGFRB_934.MAQPAHASDEIY[Pho]EIMQK.+3b9 80.8 34.7 
681.2968 519.2959 PGFRB_934.MAQPAHASDEIY[Pho]EIMQK.+3y4 80.8 34.7 
681.2968 648.3385 PGFRB_934.MAQPAHASDEIY[Pho]EIMQK.+3y5 80.8 34.7 
681.2968 891.3682 PGFRB_934.MAQPAHASDEIY[Pho]EIMQK.+3y6 80.8 34.7 
681.2968 1004.452 PGFRB_934.MAQPAHASDEIY[Pho]EIMQK.+3y7 80.8 34.7 
603.933 587.1749 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3b4 75.1 30.4 
603.933 787.291 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3b6 75.1 30.4 
603.933 520.313 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3y4 75.1 30.4 
603.933 634.3559 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3y5 75.1 30.4 
603.933 771.4148 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3y6 75.1 30.4 
603.933 886.4417 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3y7 75.1 30.4 
603.933 1023.501 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3y8 75.1 30.4 
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603.933 1110.533 PTK6_342(loop).EDVY[Pho]LSHDHNIPYK.+3y9 75.1 30.4 
826.7946 492.2089 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+2b4 91.4 38.6 
826.7946 579.2409 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+2b5 91.4 38.6 
826.7946 459.2463 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+2y3 91.4 38.6 
826.7946 702.2759 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+2y4 91.4 38.6 
826.7946 945.3056 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+2y5 91.4 38.6 
826.7946 1074.348 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+2y6 91.4 38.6 
826.7946 1161.38 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+2y7 91.4 38.6 
551.5321 492.2089 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+3b4 71.3 27.6 
551.5321 579.2409 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+3b5 71.3 27.6 
551.5321 708.2835 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+3b6 71.3 27.6 
551.5321 459.2463 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+3y3 71.3 27.6 
551.5321 702.2759 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+3y4 71.3 27.6 
551.5321 945.3056 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+3y5 71.3 27.6 
551.5321 1074.348 PTK7_960_961(loop).DVYNSEY[Pho]Y[Pho]HFR.+3y6 71.3 27.6 
593.7663 554.201 RET_826.VGPGY[Pho]LGSGGSR.+2b5 74.4 30.2 
593.7663 667.2851 RET_826.VGPGY[Pho]LGSGGSR.+2b6 74.4 30.2 
593.7663 463.2259 RET_826.VGPGY[Pho]LGSGGSR.+2y5 74.4 30.2 
593.7663 520.2474 RET_826.VGPGY[Pho]LGSGGSR.+2y6 74.4 30.2 
593.7663 633.3315 RET_826.VGPGY[Pho]LGSGGSR.+2y7 74.4 30.2 
593.7663 876.3611 RET_826.VGPGY[Pho]LGSGGSR.+2y8 74.4 30.2 
593.7663 933.3826 RET_826.VGPGY[Pho]LGSGGSR.+2y9 74.4 30.2 
663.7605 458.1323 RET_900.DVY[Pho]EEDSYVK.+2b3 79.5 32.8 
663.7605 587.1749 RET_900.DVY[Pho]EEDSYVK.+2b4 79.5 32.8 
663.7605 716.2175 RET_900.DVY[Pho]EEDSYVK.+2b5 79.5 32.8 
663.7605 496.2766 RET_900.DVY[Pho]EEDSYVK.+2y4 79.5 32.8 
663.7605 611.3035 RET_900.DVY[Pho]EEDSYVK.+2y5 79.5 32.8 
663.7605 740.3461 RET_900.DVY[Pho]EEDSYVK.+2y6 79.5 32.8 
663.7605 869.3887 RET_900.DVY[Pho]EEDSYVK.+2y7 79.5 32.8 
663.7605 1112.418 RET_900.DVY[Pho]EEDSYVK.+2y8 79.5 32.8 
663.7605 507.2086 RET_905(loop).DVYEEDSY[Pho]VK.+2b4 79.5 32.8 
663.7605 636.2511 RET_905(loop).DVYEEDSY[Pho]VK.+2b5 79.5 32.8 
663.7605 489.2109 RET_905(loop).DVYEEDSY[Pho]VK.+2y3 79.5 32.8 
663.7605 576.2429 RET_905(loop).DVYEEDSY[Pho]VK.+2y4 79.5 32.8 
663.7605 691.2698 RET_905(loop).DVYEEDSY[Pho]VK.+2y5 79.5 32.8 
663.7605 820.3124 RET_905(loop).DVYEEDSY[Pho]VK.+2y6 79.5 32.8 
663.7605 949.355 RET_905(loop).DVYEEDSY[Pho]VK.+2y7 79.5 32.8 
663.7605 1112.418 RET_905(loop).DVYEEDSY[Pho]VK.+2y8 79.5 32.8 
685.2523 616.1092 RON_1238_1239(loop).EY[Pho]Y[Pho]SVQQHR.+2b3 81.1 33.5 
685.2523 703.1412 RON_1238_1239(loop).EY[Pho]Y[Pho]SVQQHR.+2b4 81.1 33.5 
685.2523 802.2096 RON_1238_1239(loop).EY[Pho]Y[Pho]SVQQHR.+2b5 81.1 33.5 
685.2523 930.2682 RON_1238_1239(loop).EY[Pho]Y[Pho]SVQQHR.+2b6 81.1 33.5 
685.2523 568.295 RON_1238_1239(loop).EY[Pho]Y[Pho]SVQQHR.+2y4 81.1 33.5 
685.2523 997.4251 RON_1238_1239(loop).EY[Pho]Y[Pho]SVQQHR.+2y7 81.1 33.5 
670.2358 493.2293 ROR1_645_646(loop).EIYSADY[Pho]Y[Pho]R.+2b4 80 33 
141 
 
670.2358 564.2664 ROR1_645_646(loop).EIYSADY[Pho]Y[Pho]R.+2b5 80 33 
670.2358 661.1783 ROR1_645_646(loop).EIYSADY[Pho]Y[Pho]R.+2y3 80 33 
670.2358 776.2052 ROR1_645_646(loop).EIYSADY[Pho]Y[Pho]R.+2y4 80 33 
670.2358 847.2423 ROR1_645_646(loop).EIYSADY[Pho]Y[Pho]R.+2y5 80 33 
670.2358 934.2744 ROR1_645_646(loop).EIYSADY[Pho]Y[Pho]R.+2y6 80 33 
670.2358 1097.338 ROR1_645_646(loop).EIYSADY[Pho]Y[Pho]R.+2y7 80 33 
641.2275 463.2187 ROR2_645_646(loop).EVYAADY[Pho]Y[Pho]K.+2b4 77.9 31.9 
641.2275 534.2558 ROR2_645_646(loop).EVYAADY[Pho]Y[Pho]K.+2b5 77.9 31.9 
641.2275 633.1721 ROR2_645_646(loop).EVYAADY[Pho]Y[Pho]K.+2y3 77.9 31.9 
641.2275 748.1991 ROR2_645_646(loop).EVYAADY[Pho]Y[Pho]K.+2y4 77.9 31.9 
641.2275 819.2362 ROR2_645_646(loop).EVYAADY[Pho]Y[Pho]K.+2y5 77.9 31.9 
641.2275 890.2733 ROR2_645_646(loop).EVYAADY[Pho]Y[Pho]K.+2y6 77.9 31.9 
641.2275 1053.337 ROR2_645_646(loop).EVYAADY[Pho]Y[Pho]K.+2y7 77.9 31.9 
755.8525 443.1326 ROS1_135.Y[Pho]AQLLGSWTYTK.+2b3 86.2 36.1 
755.8525 556.2167 ROS1_135.Y[Pho]AQLLGSWTYTK.+2b4 86.2 36.1 
755.8525 669.3008 ROS1_135.Y[Pho]AQLLGSWTYTK.+2b5 86.2 36.1 
755.8525 785.3828 ROS1_135.Y[Pho]AQLLGSWTYTK.+2y6 86.2 36.1 
755.8525 842.4043 ROS1_135.Y[Pho]AQLLGSWTYTK.+2y7 86.2 36.1 
755.8525 955.4884 ROS1_135.Y[Pho]AQLLGSWTYTK.+2y8 86.2 36.1 
755.8525 1068.572 ROS1_135.Y[Pho]AQLLGSWTYTK.+2y9 86.2 36.1 
795.8357 556.2167 ROS1_135_144.Y[Pho]AQLLGSWTY[Pho]TK.+2b4 89.1 37.5 
795.8357 669.3008 ROS1_135_144.Y[Pho]AQLLGSWTY[Pho]TK.+2b5 89.1 37.5 
795.8357 813.3542 ROS1_135_144.Y[Pho]AQLLGSWTY[Pho]TK.+2b7 89.1 37.5 
795.8357 491.1901 ROS1_135_144.Y[Pho]AQLLGSWTY[Pho]TK.+2y3 89.1 37.5 
795.8357 922.3706 ROS1_135_144.Y[Pho]AQLLGSWTY[Pho]TK.+2y7 89.1 37.5 
795.8357 1035.455 ROS1_135_144.Y[Pho]AQLLGSWTY[Pho]TK.+2y8 89.1 37.5 
795.8357 1148.539 ROS1_135_144.Y[Pho]AQLLGSWTY[Pho]TK.+2y9 89.1 37.5 
755.8525 476.2504 ROS1_144.YAQLLGSWTY[Pho]TK.+2b4 86.2 36.1 
755.8525 589.3344 ROS1_144.YAQLLGSWTY[Pho]TK.+2b5 86.2 36.1 
755.8525 491.1901 ROS1_144.YAQLLGSWTY[Pho]TK.+2y3 86.2 36.1 
755.8525 592.2378 ROS1_144.YAQLLGSWTY[Pho]TK.+2y4 86.2 36.1 
755.8525 865.3492 ROS1_144.YAQLLGSWTY[Pho]TK.+2y6 86.2 36.1 
755.8525 922.3706 ROS1_144.YAQLLGSWTY[Pho]TK.+2y7 86.2 36.1 
755.8525 1035.455 ROS1_144.YAQLLGSWTY[Pho]TK.+2y8 86.2 36.1 
755.8525 1148.539 ROS1_144.YAQLLGSWTY[Pho]TK.+2y9 86.2 36.1 
488.7015 317.1278 ROS1_2069.GC[CAM]VY[Pho]LER.+2b3 66.7 26.5 
488.7015 560.1575 ROS1_2069.GC[CAM]VY[Pho]LER.+2b4 66.7 26.5 
488.7015 673.2415 ROS1_2069.GC[CAM]VY[Pho]LER.+2b5 66.7 26.5 
488.7015 417.2456 ROS1_2069.GC[CAM]VY[Pho]LER.+2y3 66.7 26.5 
488.7015 660.2753 ROS1_2069.GC[CAM]VY[Pho]LER.+2y4 66.7 26.5 
488.7015 759.3437 ROS1_2069.GC[CAM]VY[Pho]LER.+2y5 66.7 26.5 
703.2953 657.228 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3b5 82.4 35.8 
703.2953 788.2685 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3b6 82.4 35.8 
703.2953 887.3369 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3b7 82.4 35.8 
703.2953 462.2195 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3y4 82.4 35.8 
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703.2953 647.2995 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3y6 82.4 35.8 
703.2953 807.3301 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3y7 82.4 35.8 
703.2953 936.3727 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3y8 82.4 35.8 
703.2953 1037.42 ROS1_2274.EGLNY[Pho]MVLATEC[CAM]GQGEEK.+3y9 82.4 35.8 
810.0118 1099.395 RYK_492(loop).DLFPMDY[Pho]HC[CAM]LGDNENRPVR.+3b8 90.2 41.7 
810.0118 1169.602 RYK_492(loop).DLFPMDY[Pho]HC[CAM]LGDNENRPVR.+3y10 90.2 41.7 
810.0118 641.3842 RYK_492(loop).DLFPMDY[Pho]HC[CAM]LGDNENRPVR.+3y5 90.2 41.7 
810.0118 884.4697 RYK_492(loop).DLFPMDY[Pho]HC[CAM]LGDNENRPVR.+3y7 90.2 41.7 
810.0118 999.4966 RYK_492(loop).DLFPMDY[Pho]HC[CAM]LGDNENRPVR.+3y8 90.2 41.7 
810.0118 1056.518 RYK_492(loop).DLFPMDY[Pho]HC[CAM]LGDNENRPVR.+3y9 90.2 41.7 
813.8289 372.0955 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2b3 90.4 38.2 
813.8289 645.2102 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2b5 90.4 38.2 
813.8289 732.2423 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2b6 90.4 38.2 
813.8289 1095.532 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2y10 90.4 38.2 
813.8289 594.2882 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2y5 90.4 38.2 
813.8289 796.3472 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2y7 90.4 38.2 
813.8289 895.4156 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2y8 90.4 38.2 
813.8289 982.4476 SRC_187.GAY[Pho]C[CAM]LSVSDFDNAK.+2y9 90.4 38.2 
648.287 430.1932 SRC_216.LDSGGFY[Pho]ITSR.+2b5 78.4 32.2 
648.287 476.2827 SRC_216.LDSGGFY[Pho]ITSR.+2y4 78.4 32.2 
648.287 719.3124 SRC_216.LDSGGFY[Pho]ITSR.+2y5 78.4 32.2 
648.287 866.3808 SRC_216.LDSGGFY[Pho]ITSR.+2y6 78.4 32.2 
648.287 923.4023 SRC_216.LDSGGFY[Pho]ITSR.+2y7 78.4 32.2 
648.287 980.4237 SRC_216.LDSGGFY[Pho]ITSR.+2y8 78.4 32.2 
648.287 1067.456 SRC_216.LDSGGFY[Pho]ITSR.+2y9 78.4 32.2 
652.2819 471.2449 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2b4 78.7 32.3 
652.2819 714.3305 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2b6 78.7 32.3 
652.2819 347.2037 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2y3 78.7 32.3 
652.2819 590.2334 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2y4 78.7 32.3 
652.2819 719.276 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2y5 78.7 32.3 
652.2819 833.3189 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2y6 78.7 32.3 
652.2819 948.3459 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2y7 78.7 32.3 
652.2819 1077.388 SRC_YES_FYN_LCK_419_426_420_394(loop).LIEDNEY[Pho]TAR.+2y8 78.7 32.3 
633.2503 344.1452 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2b3 77.3 31.7 
633.2503 587.1749 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2b4 77.3 31.7 
633.2503 408.2089 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2y4 77.3 31.7 
633.2503 495.2409 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2y5 77.3 31.7 
633.2503 592.2937 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2y6 77.3 31.7 
633.2503 679.3257 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2y7 77.3 31.7 
633.2503 922.3554 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2y8 77.3 31.7 
633.2503 1035.439 SRMS_380(loop).DDIY[Pho]SPSSSSK.+2y9 77.3 31.7 
807.3402 491.25 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2b4 90 37.9 
807.3402 606.277 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2b5 90 37.9 
807.3402 1123.43 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2y10 90 37.9 
807.3402 1238.457 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2y11 90 37.9 
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807.3402 536.2675 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2y6 90 37.9 
807.3402 637.3151 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2y7 90 37.9 
807.3402 880.3448 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2y8 90 37.9 
807.3402 1008.403 TEC_519(loop).YVLDDQY[Pho]TSSSGAK.+2y9 90 37.9 
452.1966 316.1139 TIE1_1007(loop).GEEVY[Pho]VK.+2b3 64.1 25.1 
452.1966 415.1823 TIE1_1007(loop).GEEVY[Pho]VK.+2b4 64.1 25.1 
452.1966 658.212 TIE1_1007(loop).GEEVY[Pho]VK.+2b5 64.1 25.1 
452.1966 489.2109 TIE1_1007(loop).GEEVY[Pho]VK.+2y3 64.1 25.1 
452.1966 588.2793 TIE1_1007(loop).GEEVY[Pho]VK.+2y4 64.1 25.1 
452.1966 717.3219 TIE1_1007(loop).GEEVY[Pho]VK.+2y5 64.1 25.1 
451.7046 315.1299 TIE2_992(loop).GQEVY[Pho]VK.+2b3 64 25.1 
451.7046 414.1983 TIE2_992(loop).GQEVY[Pho]VK.+2b4 64 25.1 
451.7046 657.228 TIE2_992(loop).GQEVY[Pho]VK.+2b5 64 25.1 
451.7046 489.2109 TIE2_992(loop).GQEVY[Pho]VK.+2y3 64 25.1 
451.7046 588.2793 TIE2_992(loop).GQEVY[Pho]VK.+2y4 64 25.1 
451.7046 717.3219 TIE2_992(loop).GQEVY[Pho]VK.+2y5 64 25.1 
800.7058 1068.566 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3b10 89.5 41.1 
800.7058 761.3763 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3b7 89.5 41.1 
800.7058 971.5131 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3b9 89.5 41.1 
800.7058 504.2776 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3y4 89.5 41.1 
800.7058 601.3304 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3y5 89.5 41.1 
800.7058 672.3675 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3y6 89.5 41.1 
800.7058 832.3982 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3y7 89.5 41.1 
800.7058 1018.477 TNK1_277(loop).YVMGGPRPIPY[Pho]AWC[CAM]APESLR.+3y8 89.5 41.1 
836.8607 491.25 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2b4 92.1 39 
836.8607 1182.471 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2y10 92.1 39 
836.8607 422.2398 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2y4 92.1 39 
836.8607 509.2718 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2y5 92.1 39 
836.8607 596.3039 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2y6 92.1 39 
836.8607 695.3723 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2y7 92.1 39 
836.8607 938.4019 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2y8 92.1 39 
836.8607 1067.445 TXK_420(loop).YVLDDEY[Pho]VSSFGAK.+2y9 92.1 39 
690.7547 591.2885 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2b6 81.5 33.7 
690.7547 720.3311 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2b7 81.5 33.7 
690.7547 661.1783 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2y3 81.5 33.7 
690.7547 790.2209 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2y4 81.5 33.7 
690.7547 927.2798 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2y5 81.5 33.7 
690.7547 984.3012 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2y6 81.5 33.7 
690.7547 1113.344 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2y7 81.5 33.7 
690.7547 1210.397 TYK2_1054_1055(loop).AVPEGHEY[Pho]Y[Pho]R.+2y8 81.5 33.7 
508.9047 423.1987 UFO_634.HGDLHSFLLY[Pho]SR.+3b4 68.2 25.3 
508.9047 560.2576 UFO_634.HGDLHSFLLY[Pho]SR.+3b5 68.2 25.3 
508.9047 505.1806 UFO_634.HGDLHSFLLY[Pho]SR.+3y3 68.2 25.3 
508.9047 618.2647 UFO_634.HGDLHSFLLY[Pho]SR.+3y4 68.2 25.3 
508.9047 731.3488 UFO_634.HGDLHSFLLY[Pho]SR.+3y5 68.2 25.3 
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508.9047 878.4172 UFO_634.HGDLHSFLLY[Pho]SR.+3y6 68.2 25.3 
508.9047 965.4492 UFO_634.HGDLHSFLLY[Pho]SR.+3y7 68.2 25.3 
572.229 471.1639 UFO_698.IY[Pho]NGDYYR.+2b3 72.8 29.5 
572.229 528.1854 UFO_698.IY[Pho]NGDYYR.+2b4 72.8 29.5 
572.229 643.2123 UFO_698.IY[Pho]NGDYYR.+2b5 72.8 29.5 
572.229 806.2757 UFO_698.IY[Pho]NGDYYR.+2b6 72.8 29.5 
572.229 616.2726 UFO_698.IY[Pho]NGDYYR.+2y4 72.8 29.5 
572.229 673.294 UFO_698.IY[Pho]NGDYYR.+2y5 72.8 29.5 
572.229 787.3369 UFO_698.IY[Pho]NGDYYR.+2y6 72.8 29.5 
612.2121 448.2191 UFO_702_703(loop).IYNGDY[Pho]Y[Pho]R.+2b4 75.7 30.9 
612.2121 563.246 UFO_702_703(loop).IYNGDY[Pho]Y[Pho]R.+2b5 75.7 30.9 
612.2121 661.1783 UFO_702_703(loop).IYNGDY[Pho]Y[Pho]R.+2y3 75.7 30.9 
612.2121 776.2052 UFO_702_703(loop).IYNGDY[Pho]Y[Pho]R.+2y4 75.7 30.9 
612.2121 833.2267 UFO_702_703(loop).IYNGDY[Pho]Y[Pho]R.+2y5 75.7 30.9 
612.2121 947.2696 UFO_702_703(loop).IYNGDY[Pho]Y[Pho]R.+2y6 75.7 30.9 
787.3613 1024.55 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2b10 88.5 37.2 
787.3613 683.3545 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2b7 88.5 37.2 
787.3613 796.4386 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2b8 88.5 37.2 
787.3613 895.507 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2b9 88.5 37.2 
787.3613 550.1731 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2y3 88.5 37.2 
787.3613 679.2157 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2y4 88.5 37.2 
787.3613 778.2841 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2y5 88.5 37.2 
787.3613 891.3682 VGFR1_911.QGGPLMVIVEY[Pho]C[CAM]K.+2y6 88.5 37.2 
689.3054 643.1912 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3b4 81.4 35.1 
689.3054 757.2341 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3b5 81.4 35.1 
689.3054 858.2818 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3b6 81.4 35.1 
689.3054 929.3189 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3b7 81.4 35.1 
689.3054 986.3404 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3b8 81.4 35.1 
689.3054 589.3304 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3y5 81.4 35.1 
689.3054 752.3937 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3y6 81.4 35.1 
689.3054 967.4843 VGFR2_1214.FHY[Pho]DNTAGISQYLQNSK.+3y8 81.4 35.1 
422.6655 328.1139 VGFR2_3_1059_1068(loop).DPDY[Pho]VR.+2b3 61.9 24.1 
422.6655 571.1436 VGFR2_3_1059_1068(loop).DPDY[Pho]VR.+2b4 61.9 24.1 
422.6655 517.217 VGFR2_3_1059_1068(loop).DPDY[Pho]VR.+2y3 61.9 24.1 
422.6655 632.244 VGFR2_3_1059_1068(loop).DPDY[Pho]VR.+2y4 61.9 24.1 
635.31 458.1323 VGFR2_951.DY[Pho]VGAIPVDLK.+2b3 77.4 31.7 
635.31 586.1909 VGFR2_951.DY[Pho]VGAIPVDLK.+2b5 77.4 31.7 
635.31 699.2749 VGFR2_951.DY[Pho]VGAIPVDLK.+2b6 77.4 31.7 
635.31 571.345 VGFR2_951.DY[Pho]VGAIPVDLK.+2y5 77.4 31.7 
635.31 684.4291 VGFR2_951.DY[Pho]VGAIPVDLK.+2y6 77.4 31.7 
635.31 755.4662 VGFR2_951.DY[Pho]VGAIPVDLK.+2y7 77.4 31.7 
635.31 812.4876 VGFR2_951.DY[Pho]VGAIPVDLK.+2y8 77.4 31.7 
635.31 911.556 VGFR2_951.DY[Pho]VGAIPVDLK.+2y9 77.4 31.7 
896.8513 787.1888 VGFR3_1230_1231.Y[Pho]Y[Pho]NWVSFPGC[CAM]LAR.+2b4 96.5 41.1 
896.8513 973.2893 VGFR3_1230_1231.Y[Pho]Y[Pho]NWVSFPGC[CAM]LAR.+2b6 96.5 41.1 
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896.8513 1120.358 VGFR3_1230_1231.Y[Pho]Y[Pho]NWVSFPGC[CAM]LAR.+2b7 96.5 41.1 
896.8513 1217.41 VGFR3_1230_1231.Y[Pho]Y[Pho]NWVSFPGC[CAM]LAR.+2b8 96.5 41.1 
896.8513 1192.593 VGFR3_1230_1231.Y[Pho]Y[Pho]NWVSFPGC[CAM]LAR.+2y10 96.5 41.1 
896.8513 1006.514 VGFR3_1230_1231.Y[Pho]Y[Pho]NWVSFPGC[CAM]LAR.+2y9 96.5 41.1 
836.3542 1181.518 VGFR3_1265.TFEEFPMTPTTY[Pho]K.+2b10 92.1 39 
836.3542 507.2086 VGFR3_1265.TFEEFPMTPTTY[Pho]K.+2b4 92.1 39 
836.3542 1080.471 VGFR3_1265.TFEEFPMTPTTY[Pho]K.+2b9 92.1 39 
836.3542 491.1901 VGFR3_1265.TFEEFPMTPTTY[Pho]K.+2y3 92.1 39 
836.3542 592.2378 VGFR3_1265.TFEEFPMTPTTY[Pho]K.+2y4 92.1 39 
836.3542 689.2906 VGFR3_1265.TFEEFPMTPTTY[Pho]K.+2y5 92.1 39 
836.3542 1165.5 VGFR3_1265.TFEEFPMTPTTY[Pho]K.+2y9 92.1 39 
496.2361 270.1812 VGFR3_853.VLGY[Pho]GAFGK.+2b3 67.3 26.7 
496.2361 513.2109 VGFR3_853.VLGY[Pho]GAFGK.+2b4 67.3 26.7 
496.2361 641.2695 VGFR3_853.VLGY[Pho]GAFGK.+2b6 67.3 26.7 
496.2361 422.2398 VGFR3_853.VLGY[Pho]GAFGK.+2y4 67.3 26.7 
496.2361 479.2613 VGFR3_853.VLGY[Pho]GAFGK.+2y5 67.3 26.7 
496.2361 722.2909 VGFR3_853.VLGY[Pho]GAFGK.+2y6 67.3 26.7 
496.2361 779.3124 VGFR3_853.VLGY[Pho]GAFGK.+2y7 67.3 26.7 
679.2916 415.1798 ZAP70_164.MPWY[Pho]HSSLTR.+2b3 80.6 33.3 
679.2916 658.2095 ZAP70_164.MPWY[Pho]HSSLTR.+2b4 80.6 33.3 
679.2916 476.2827 ZAP70_164.MPWY[Pho]HSSLTR.+2y4 80.6 33.3 
679.2916 563.3148 ZAP70_164.MPWY[Pho]HSSLTR.+2y5 80.6 33.3 
679.2916 700.3737 ZAP70_164.MPWY[Pho]HSSLTR.+2y6 80.6 33.3 
679.2916 943.4033 ZAP70_164.MPWY[Pho]HSSLTR.+2y7 80.6 33.3 
679.2916 1129.483 ZAP70_164.MPWY[Pho]HSSLTR.+2y8 80.6 33.3 
453.1968 415.1798 ZAP70_164.MPWY[Pho]HSSLTR.+3b3 64.2 22.2 
453.1968 658.2095 ZAP70_164.MPWY[Pho]HSSLTR.+3b4 64.2 22.2 
453.1968 795.2684 ZAP70_164.MPWY[Pho]HSSLTR.+3b5 64.2 22.2 
453.1968 476.2827 ZAP70_164.MPWY[Pho]HSSLTR.+3y4 64.2 22.2 
453.1968 563.3148 ZAP70_164.MPWY[Pho]HSSLTR.+3y5 64.2 22.2 
453.1968 700.3737 ZAP70_164.MPWY[Pho]HSSLTR.+3y6 64.2 22.2 
560.2395 444.153 ZAP70_178.LY[Pho]SGAQTDGK.+2b3 72 29 
560.2395 501.1745 ZAP70_178.LY[Pho]SGAQTDGK.+2b4 72 29 
560.2395 700.2702 ZAP70_178.LY[Pho]SGAQTDGK.+2b6 72 29 
560.2395 619.3046 ZAP70_178.LY[Pho]SGAQTDGK.+2y6 72 29 
560.2395 676.326 ZAP70_178.LY[Pho]SGAQTDGK.+2y7 72 29 
560.2395 763.3581 ZAP70_178.LY[Pho]SGAQTDGK.+2y8 72 29 
731.768 313.187 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2b4 84.5 35.2 
731.768 428.214 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2b5 84.5 35.2 
731.768 630.2729 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2b7 84.5 35.2 
731.768 590.2334 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2y4 84.5 35.2 
731.768 833.2631 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2y5 84.5 35.2 
731.768 920.2951 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2y6 84.5 35.2 
731.768 1035.322 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2y7 84.5 35.2 
731.768 1150.349 ZAP70_492_493(loop).ALGADDSY[Pho]Y[Pho]TAR.+2y8 84.5 35.2 
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636.8028 514.262 ZAP70_69.QLNGTY[Pho]AIAGGK.+2b5 77.5 31.8 
636.8028 1031.456 ZAP70_69.QLNGTY[Pho]AIAGGK.+2y10 77.5 31.8 
636.8028 445.2769 ZAP70_69.QLNGTY[Pho]AIAGGK.+2y5 77.5 31.8 
636.8028 516.314 ZAP70_69.QLNGTY[Pho]AIAGGK.+2y6 77.5 31.8 
636.8028 759.3437 ZAP70_69.QLNGTY[Pho]AIAGGK.+2y7 77.5 31.8 
636.8028 860.3914 ZAP70_69.QLNGTY[Pho]AIAGGK.+2y8 77.5 31.8 







3 SH2 Superbinder Modified Yeast Two Hybrid System for 
Identifying Tyrosine Kinase Substrates 
 Abstract 
TKs provide therapeutic targets in many different cancer types, as the pTyr- mediated 
signaling network plays a critical role in a wide range of cancer-related cellular activities. 
Tyrosine phosphorylation has been identified in over half of human proteins, but substrates 
for any given TK have not been systematically investigated, largely due to the lack of a 
reliable high-throughput in vivo approach. Here, a modified yeast two hybrid (Y2H) system 
is presented that is designed for screening for direct TK substrates in a high-precision and 
high-throughput manner. This system co-expresses a superbinder SH2 bait and a 
conditional promoter regulated TK for screening tyrosine phosphorylated preys. The 
superbinder SH2 greatly promotes the sensitivity of reporter output and the conditionally 
expressed TK allows reverse-screening for eliminating false positives. In a mid-scale Src 
tyrosine kinase substrate screening of a human cDNA library, 94 positive colonies were 
isolated from approximate 170,000 mated cells, which represented 48 proteins or protein 
fragments. Even without further in vivo validation, 9 proteins of these candidates are known 





TKs are attractive therapeutic targets because aberrant TK activations are hallmarks of 
many cancer types. TKs, as well as pTyr-mediated signal transduction, play a critical role 
in a wide range of cancer-related events including proliferation, differentiation, metastasis, 
and apoptosis (Hunter, 2009; Levitzki, 2013; Lim and Pawson, 2010; Manning et al., 2002; 
Seet et al., 2006). Our current understanding of the pTyr signaling cascade is primarily 
reliant on the study of TKs that phosphorylate specific tyrosine residues and SH2 proteins 
that recognize the TK substrates to mediate signal transduction. Recent advances of pTyr-
peptide enrichment and MS approaches have revolutionized the study of the pTyr signaling 
network by allowing fast and comprehensive identification of pTyr sites. A preliminary 
study by our group reported over 10,000 pTyr sites from cultured cancer cells, of which 
approximately 3,000 sites are novel (Bian et al., 2016). In contrast to the rapidly growing 
number of pTyr sites, the kinome profile of TKs is slow to emerge mainly because of the 
promiscuous nature of TK kinase specificities, which makes conventional kinase-assay-
based approaches not necessarily reliable. In addition, functional redundancy and cross-
activation among these TKs also limit the application of MS-based in vivo approaches. For 
instance, the most well-studied Src tyrosine kinase, which is also the first described 
oncoprotein reported in 1979 (Oppermann et al., 1979; Sefton et al., 1980; Stehelin et al., 
1977), has only 67 substrates verified both in vitro and in vivo as summarized in the 
PhosphoSitePlus database (Hornbeck et al., 2015). However, only a few of these substrates 
were identified by high-throughput approaches (Kanner et al., 1989; Kanner et al., 1990; 
Reynolds et al., 2014).  
Here, a modified yeast two-hybrid (Y2H) system is reported, which is based on a 
superbinder SH2 that is engineered from the natural Src SH2 domain (Kaneko et al., 2012a; 
Kaneko et al., 2012b). This system can profile the TK-substrate pairings in a high-
throughput and high-precision manner.  Unlike mammalian cells, yeast cells do not have 
any functional TKs or SH2 domains (Castellanos and Mazon, 1985), thus providing a clean 
background for studying tyrosine phosphorylation. Previously, several groups made 
successful attempts in verifying pTyr-dependent protein-protein interactions (PPI) in yeast 
expressing different tyrosine kinases, by borrowing an identical strategy of co-expressing 
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an active tyrosine kinase with the bait (BD fusion SH2 containing proteins) and the prey 
(AD fusion TK substrates) (Fig.3.1 A), as summarized in (Grossmann et al., 2015). A 
similar Y2H system was established by introducing a bait containing the superbinder SH2 
and a conditionally expressed Src tyrosine kinase. This greatly increased the readout 
sensitivity of reporter genes and made the system applicable for the screening of novel 
tyrosine kinase substrates from a conventional cDNA library. In a mid-scale ~170,000 
colonies screening of a human cDNA library, 94 independent colonies were isolated which 
grew on the selection medium in a Src-dependent manner. 48 in-frame proteins or protein 
fragments larger than 150 amino acids were identified from these candidate positives, of 
which at least 9 proteins were known Src substrates or direct interactors. In addition, to 
further simplify the after-screening identification and expand the applicability of this Y2H 
system, a novel screening strategy was designed based on SH2-AP-MS.  From a mixture 
of 48 candidate positive colonies, the AD proteins were immunoprecipitated then their 
tyrosine phosphorylated sites were analyzed by SH2-AP-MS. In the preliminary test, three 
pTyr peptides were identified among the 48 proteins. With proper optimization, this new 
strategy will in theory allow the enrichment of positive colonies in liquid culturing and the 
simultaneous identification of AD insertion proteins and phosphorylation sites from a 
mixture of positive colonies, therefore is suitable for large-scale cDNA library screening 




 Materials and Methods 
3.3.1 Cloning and transformation 
All the backbone vectors were purchased from ClonTech along with the Matchmaker Gold 
yeast two hybrid system. The pBridge BD vector with two multiple cloning sites (MCSs) 
was used for expressing Src kinase and SH2 bait simultaneously. The Src kinase was 
integrated into the MCS2 using Not1 and Bgl2 restriction sites, the SH2 wild-type (WT) 
or triple mutant (TrM) was integrated into the MCS1 using EcoR1 and BamH1 restriction 
sites. All prey DNA fragments were synthesized in vitro and then integrated into pGADT7 
AD vector using restriction sites Nde1/Xho1 (artificial substrate), Nde1/BamH1 (RACK1-
Y228 and TNS3-Y1173 substrates), or Xho1/BamH1 (RACK1-Y246 and TNS3-Y1256 
substrates). All plasmids were amplified in DH5α E. coli strain with proper antibiotics and 
purified by miniprep following manufacturer's instructions. 
To prepare competent yeast cells, the yeast strains Y2HGold and Y187 were first streaked 
on a YPDA agar plate from a frozen stock. The plate was incubated at 30°C for 3~4 days 
until colonies appeared. A fresh single colony (diameter 2~3 mm) was picked and 
incubated in 3 ml YPDA medium at 30 °C with shaking at 250 rpm for 8~12 hours.  5 μl 
of the culture was transferred into 50 ml fresh YPDA medium and incubated overnight 
until the OD600 reached 0.15~0.3. Cells were collected by centrifugation and resuspended 
in 100 ml fresh YPDA medium, then incubated until the OD600 reached 0.4~0.5. Cells were 
collected by centrifugation again then washed by deionized water, and finally resuspended 
in 1.5 ml 1.1x TE/LiAc buffer.  
To transform, 50 μl of competent cells were gently mixed with 100 ng purified plasmid 
DNA, 5 μl yeast carrier DNA (10 μg/μl) and 500 μl PEG/LiAc buffer. The mixture was 
incubated at 30 °C for 30 min with occasional vortexing. 20 μl DMSO was added into the 
mixture which was then subjected to heat-shock in a 42 °C water bath for 15 min. 
Transformed cells were collected by centrifugation and incubated on appropriate selection 
agar at 30°C for 3~4 days until colonies appeared.  
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3.3.2 Optimization of Src kinase expression in yeast 
The yeast mating, toxicity test, and self-activation test were carried out following the 
procedures described in the ClonTech Matchmaker Gold yeast two hybrid system user 
manual. To determine the Src activity, the yeast strains were cultured in liquid -Leu 
medium supplemented with different concentrations of methionine. Cells were lysed 
directly in SDS gel loading buffer, boiling for five minutes and identical amounts of lysate 
protein was loaded on an SDS gel for electrophoresis. Tyrosine phosphorylation was 
visualized by western blot using anti-pTyr antibody 4G10, anti-mouse-HRP (horseradish 
peroxidase) and peroxidase substrate for enhanced chemiluminescence (ECL). To 
determine a proper Src expression level, the mated yeast strains pBridge-TrM-
Src/pGADT7-artificial and pBridge-WT-Src/pGADT7-artificial were cultured in -Leu/-
Trp liquid medium. The same number of cells were collected then cultured in -Leu/-Trp/-
His liquid medium supplemented with different concentrations of methionine. The relative 
yeast growth rate was determined by measuring OD600 of the liquid culture. 
3.3.3 Quantification of MEL1 reporter gene expression 
The α-Galactosidase assay was used for quantifying the MEL1 reporter gene expression. 
The procedures were modified from the ClonTech Yeast Handbook. Briefly, fresh colonies 
of different yeast strains were firstly cultured in liquid -Leu/-Trp medium. Cells were 
collected and carefully washed with 0.9% sodium chloride to completely remove medium 
residue. The same number of cells were pre-cultured overnight in -Leu/-Trp/-His liquid 
medium supplemented with 100 μM methionine. The OD600 was determined, cells were 
pelleted by centrifugation and the clear supernatant was transferred into fresh 
microcentrifuge tubes. To measure the catalytic activity of the α-galactosidase, the 
supernatant was incubated with p-nitrophenyl-α-D-galactoside (PNP-α-Gal) substrate at 
30°C for one hour, then the concentration of the hydrolysis product p-nitrophenol was 




3.3.4 Human cDNA library screening 
The Y2H Gold strain with pBridge-TrM-Src was used as bait, screening against the 
ClonTech Mate & Plate Library (Universal Human). The library was constructed from 
human cDNA derived from a few different tissues or organs.  One fresh colony containing 
the bait was cultured in 50 ml -Trp liquid medium supplemented with 5 mM methionine 
overnight until the OD600 reached 0.8. Cells were collected and re-suspended in 5 ml -Trp 
liquid medium. For yeast cell mating, the bait cells, 1 ml of the pre-made library and 45 ml 
of 2 x YPDA liquid medium (50 μg/μl kanamycin) were mixed together in a sterile 2 L 
flask and incubated at 30°C for 24 hours with slow shaking. All cells were collected by 
centrifugation and resuspended in 10 ml 0.5 x YPDA liquid medium. To count the number 
of mated cells, 100 μl of the mated culture was spread in 1/10, 1/100, 1/1000 and 1/10000 
dilutions on 100 mm -Leu/-Trp (5 mM methionine) plates and cultured at 30°C for 5 days. 
The number of colonies were recorded to estimate total mated cells and mating efficiency. 
The remainder of the mated culture was spread in 50 150 mm -Leu/-Trp/-His (100 μM 
methionine) plates and cultured at 30°C for 5 days. All separable colonies (in any sizes) 
that grew on the -His plates were picked and replicated in -Leu/-Trp/-His (100 μM 
methionine) plates three times. The Src-dependency of these colonies were further 
validated by comparing their growth in -Leu/-Trp/-His medium with either 100 μM or 5 
mM methionine. 
3.3.5 SH2-AP-MS identification of AD insertions 
48 positive colonies were cultured individually in liquid -Leu/-Trp medium containing 5 
mM methionine. Cells were collected by centrifugation and resuspended in 0.9% NaCl. 
The same number of cells from each colony were mixed together and re-incubated in liquid 
-Leu/-Trp/-His medium containing 100 mM methionine at 30°C overnight. The total cell 
lysate was extracted using the CelLytic Y Cell Lysis Reagent (Sigma, C4482).  Two 
milligrams total lysate was immuno-precipitated with 4 μg of GAL4-AD antibody (Santa 
Cruz, sc1663). The precipitated protein was digested by trypsin (Promega, V5111) 
following the procedures described in section 2.4.5, then the pTyr peptides were isolated 
by superbinder SH2 enrichment. A data-dependent acquisition scanning was carried out 
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using a Thermo QExactive MS system equipped with EasyLC1000 and the raw data was 




3.4.1 Design of the SH2 superbinder modified Y2H system 
Since the original GAL4-based Y2H system has been successfully modified to verify pTyr-
dependent protein-protein interactions, a similar GAL4-based system from ClonTech was 
further modified by introducing the superbinder SH2 as the bait. A great advantage of this 
Matchmaker Gold Y2H system is the BD-compatible vector pBridge that has two multiple 
cloning sites (MCSs). pBridge can co-express two independent proteins: a BD-fusion bait, 
and an additional protein under control of the conditional promoter MET25, which is 
regulated by the presence of the methionine in the culture medium.  
First, two baits were constructed in the pBridge vector containing the constitutively active 
Src kinase under MET25 promoter, with either superbinder SH2-TrM or its wild-type 
variant SH2-WT fused with the BD domain (BD-TrM-Src and BD-WT-Src). Also, one 
prey was constructed in the pGADT7 vector containing the four tandem repeats of an 
artificial TK substrate peptide AAYANAA fused with AD domain (AD-artificial) (Clark 
and Peterson, 2002). The DNA fragment of the artificial substrate was made by annealing 
two complementary oligonucleotides that were synthesized in vitro. Next, the baits and 
prey were transformed into yeast strain Y2HGold separately for toxicity and self-activation 
tests. Both baits were found to be toxic, but the toxicity was attenuated by adding 
methionine or Src kinase inhibitor-1 (SKI-1) into the culture medium, suggesting that Src 
expression inhibited yeast growth (Fig.3.1 B). Src kinase activity was determined by 
western blot using anti-pTyr antibody 4G10. As shown in Fig.3.1 C, strong tyrosine 
phosphorylation was observed in the total cell lysate from yeast grown without methionine. 
As well, the signal was still detectable from yeast grown with 1 mM methionine, a 
concentration normally suggested to be able to turn off MET25 promoter. This indicates 
that Src kinase is expressed and active within yeast, which is consistent with a previous 
report stating that the prey could be effectively phosphorylated by low-abundant TKs in a 
yeast two hybrid (Grossmann et al., 2015). In the toxicity and self-activation test, the AD-
artificial did not alter the yeast growth, as expected, while none of these constructs self-
activated the HIS3 reporter (Suppl.3.1). 
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Because Src was moderately toxic to yeast, its expression level was further adjusted to find 
the optimal expression that maximizes yeast growth rate in HIS3 selection medium. The 
prey plasmid pGADT7-AD-artificial was transformed into the yeast strain Y187 and mated 
with the two baits, pBridge-TrM-Src and pBridge-WT-Src, in Y2HGold strain separately. 
When cultured in the HIS3 selection medium containing different concentrations of 
methionine, 100 µM methionine was determined to be the optimal condition for both 
colonies (Fig.3.1 D). In the on-plate screening for MEL1 and HIS3 reporters, both colonies 
were confirmed to be secreting -galactosidase and resisting lack of histidine in the 
presence of 100 µM but not 5 mM methionine (Fig.3.1 E). On the same plates, the positive 
colony (pGBKT7-53/pGADT7-T), but not the negative colony (pGBKT7-Lam/pGADT7-
T), expressed MEL1 and HIS3. It was also observed that the control colonies grew much 
larger than the Src-expressing colonies with 100 µM methionine. Next, a quantification of 
MEL1 expression was carried out in these colonies by determining the activity of secreted 
-galactosidase. As shown in Fig.3.1 F, the TrM-containing colony exhibited comparable 
-galactosidase activity to the positive colony, which was two-fold of that in the WT-
containing colony. Overall, these data demonstrate that Src expression with 100 µM 
methionine effectively phosphorylated the artificial substrate (AAYANAA) 4 in vivo and 
the superbinder SH2 increased the readout sensitivity of the reporter genes. The interaction 
between SH2-TrM and phosphorylated (AAYANAA)4 could be defined, by the high yield 
of -galactosidase, as strong, but the overall growth rate of the yeast colony was much 
slower than the positive control colony due to the toxicity of Src expression. Therefore, the 
strategy and stringency of large-scale cDNA library screening might require further 




Figure 3.1 SH2 superbinder based Y2H for validating TK-substrate pairing 
A) The design of the modified Y2H system with superbinder SH2 bait. The superbinder SH2 (bait) 
interacts with the phosphorylated substrate (prey) with a tyrosine kinase co-expressed in yeast; B) 
Src kinase is toxic to yeast growth. In Y2HGold strains transformed by pBridge-WT-Src or 
pBrdige-TrM-Src, the yeast growth was greatly inhibited with the Src expression in the absence of 
methionine in the medium. Yeast growth was recovered in media supplemented with either 1 mM 
methionine or 2 μM Src kinase inhibitor SKI-1 that inhibited the Src kinase expression or activity; 
C) Src kinase was active and effectively phosphorylated proteins in yeast. The lysates of Y2HGold-
pBrdige and Y2HGold-pBridge-WT-Src cultured with different concentrations of methionine were 
analyzed by western blot using anti-pTyr monoclonal antibody 4G10. 5 mM methionine, but not 1 
mM methionine, was found to completely turn off the Src expression. D) Optimization of Src 
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expression in yeast. Two baits pBridge-WT-Src and pBridge-TrM-Src in Y2Hgold were mated 
with the artificial Src kinase substrate prey pGADT7-artificial in Y187 and then grown in liquid –
Leu/-Trp/-His medium containing different concentrations of methionine. Maximum growth of 
both mated cells was observed under 100 μM methionine condition, TrM containing cells grew 
faster than WT containing cells in all conditions; E) Both mated cells exhibited Src-dependent 
expression of MEL1 and HIS3 reporters. The positive control is pGBKT7-53 x pGADT7-T, the 
negative control is pGBKT7-Lam x pGADT7-T; F) TrM greatly increased the expression of the 




3.4.2 System evaluation with known peptide substrates of Src kinase 
The modified system was further evaluated using a few peptide preys generated from 
known Src substrate proteins. Ten known Src-Phosphorylated peptides whose binding 
affinities (dissociation constant, Kd) to SH2-TrM or SH2-WT were determined 
individually by fluorescence polarization (FP) assay were synthesized in vitro. SH2-TrM 
exhibited overall stronger binding affinities to these peptides than SH2-WT (Suppl.3.2). 
Four peptides, RACK1-Y228, RACK1-Y246, TNS3 (tensin3)-Y1173 and TNS3-Y1256 
were selected which exhibited a wide range of binding affinity to the SH2-TrM and SH2-
WT (Fig.3.2 A; Suppl.3.2). The DNA fragments with four tandem repeats of these peptides 
were synthesized by annealing two complementary oligonucleotides in vitro, which were 
then integrated into the pGADT7 vector and transformed into the Y2HGold and Y187 
strains. No toxicity or self-activation was observed in these prey-Y2HGold strains (Fig.3.2 
B). The prey-Y187 strains were then mated with the two bait colonies pBridge-Src-TrM 
and pBridge-Src-WT in Y2HGold. In HIS3 selection medium (-Leu/-Trp/-His + 100 µM 
methionine), three SH2-TrM containing colonies grew out after 5 days, including RACK1-
Y228-TrM, RACK1-Y246-TrM, and TNS3-Y1173-TrM. As expected, none of these 
colonies grew out in similar selection medium containing 5 mM methionine (Fig.3.2 C). It 
was observed that all three colonies were much smaller in diameter compared to the 
positive control pGBKT7-53/pGADT7-T. In addition, the TNS3-Y1173 colony tended to 
grow faster than the RACK1-Y228 and RACK1-Y246 colonies even though the TNS3-
Y1173 peptide had the weakest binding affinity to SH2-TrM by FP. The expression of the 
MEL1 reporter was quantified by α-galactosidase assay. As shown in Fig.3.2 D, the TNS3-
Y1173-TrM indeed exhibited the highest MEL expression in all eight colonies, even 
though its affinity to SH2-TrM (12.9 μM) was determined to be weak or moderate. This 
finding is consistent with an early Y2H study reporting that there is no linear correlation 
between reporter expression and the bait-prey binding affinity (Estojak et al., 1995). For 
individual substrate peptides, the SH2-TrM colonies always had higher MEL1 expression 
compared to the SH2-WT colonies. In conclusion, the superbinder SH2 modified Y2H 
exhibited good sensitivity in detecting tyrosine phosphorylation in these preys and have 




Figure 3.2 Evaluation of the Y2H system in recognizing Src kinase substrates 
A) Four known substrate peptides of Src kinase with different binding affinities to SH2-WT and 
SH2-TrM; B) None of the substrate preys exhibited toxicity or self-activation; C) SH2-TrM 
promoted the cell growth in HIS3 selection medium. Three of the four substrate prey strains grew 
out in HIS3 selection medium when mated with SH2-TrM bait but not SH2-WT bait; D) SH2-TrM-





3.4.3 cDNA library screening for Src kinase substrate 
A mid-scale library screening was performed using a universal human cDNA library that 
was made from a mixture of mRNA extracted from cell lines derived from different human 
tissues or organs (ClonTech). A high-stringency screening strategy was designed including 
both forward and reverse screening procedures (Tab.3.1). First, the pBridge-TrM-Src 
Y2HGold strain was mated with the cDNA library in the Y187 strain. Approximately 
170,000 mated cells were spread on the HIS3 selection plates (-Trp/-Leu/-His/100 μM 
methionine). Considering that Src expression is toxic and inhibits yeast cell growth, all 
separable colonies were picked after 5 days of incubation. Around 600 candidate colonies 
exhibited stable growth on the HIS3 selection medium after steaking three times on fresh 
medium. Next, these colonies were replicated on HIS3 selection plates with either 100 μM 
or 5mM methionine to eliminate false positives exhibiting no obvious growth differences. 
Finally, the Src-dependency was further validated by determining the colony growth rates 
in liquid culture with either 100 μM or 5 mM methionine. 94 colonies were isolated as 
candidate positives. 
The AD-insertion were PCR amplified from plasmids extracted from the positive 
candidates. Based on the size of the PCR products, there should be few duplicates in these 
AD-insertions (Suppl.3.3). Therefore, the conventional analysis by restriction enzyme 
digestion was skipped, and the AD-insertions were sent for DNA sequencing directly. 72 
different DNA fragments were identified from 94 candidate positives, including 17 full-
length proteins and 31 protein fragments larger than 150 amino acids that are in frame. It 
is intriguing that this short list contains at least nine verified Src substrates or direct 
interactors, as well as several known Src partners that are functionally related, and most 





Table 3.1 Library-scale screening for Src kinase substrates 
 
Quick facts of a mid-scale human cDNA library screening. The pBridge-TrM-Src Y2HGold strain 
was mated with the human cDNA library in the Y187 strain. Around 170,000 mated cells were 
spread on HIS3 selection plates with 100 μM methionine for 5 days incubation. About 800 grown-
out colonies were isolated for subsequent forward and reverse screenings to confirm the HIS3 
reporter expression and Src-dependency. 94 candidate positive colonies were isolated for AD-
insertion sequencing, which contains 72 different AD-insertions representing 17 in-frame full-




Table 3.2 Selected Src substrates and functional partners in candidate positives 
Entry Function  Insertion Known pTyr  Refs 
AT1B1 Substrate 340bp to end 3 (Tian et al., 2006) 
AT1B3 Substrate 682bp to end N/A (Tian et al., 2006) 
CAN3 Interactor full length N/A (Hossain et al., 2013) 
CBLB Substrate 2449bp to end 1 (Sanjay et al., 2001; Yokouchi et al., 
2001) 
DAAM1 Interactor 2593bp to end 1 (Aspenstrom et al., 2006) 
GRDN Substrate 2131bp+0.9kb 1 (Lin et al., 2011; Nakai et al., 2014; 
Omori et al., 2015) 
ROCK1 Substrate 1240bp+1.2kb 2 (Lee et al., 2010) 
SDC2 Interactor 142bp to end 3 (Afratis et al., 2017; Ott and 
Rapraeger, 1998) 
SHLB1 Substrate 505bp to end N/A (Yamaguchi et al., 2008) 
TS101 Essential for 
Src mobility 
full length 4 (Tu et al., 2010) 
 
Selected candidate positives that include known Src substrates, interactors or functional partners. 
Most of these proteins or protein fragments have known tyrosine phosphorylation sites, while a few 




3.4.4 SH2-AP-MS for after-screening prey identification   
The Y2H is the most cost-efficient high-throughput in vivo assay for identifying protein-
protein interactions. As presented above, the superbinder SH2 modified Y2H system is 
capable of screening for tyrosine kinase substrates on a library scale. The reverse screening 
largely contributes to the high genuine-positive rate, which eliminated approximately 80% 
of false positives isolated from the forward screening (Tab.3.1). However, the strategy 
seems highly time-inefficient because of the time-consuming on-plates screening and after-
screening validation even for this mid-scale screening. It could be expected that a 
conventional million-colony screening might isolate over one thousand candidate positives 
due to duplicates and the relatively broad specificity of tyrosine kinases. Therefore, a new 
AD identification strategy was tested by introducing SH2-AP-MS to analyze tyrosine 
phosphorylation on AD proteins, which in theory would allow a quick identification of AD 
insertion proteins and pTyr sites from a matrix of positive colonies. 
48 candidate positives were cultured individually in liquid -Leu/-Trp medium containing 5 
mM methionine, which inhibits Src expression to maximize cell growth. An equal number 
of cells were mixed together and re-incubated overnight in -Leu/-Trp/-His medium 
containing 100 μM methionine, which promotes Src expression to allow prey 
phosphorylation. The total cell lysate was extracted for immuno-precipitation (IP) using a 
GAL4-AD antibody. The precipitated protein was tryptic-digested, then the tyrosine 
phosphorylation peptides were enriched by superbinder SH2 and profiled by MS. However, 
only three pTyr sites were identified from 2 mg of total yeast lysate precipitated by 4 μg 
GLA4-AD antibody, including HINFP_Y333 (Histone 4 transcription factor, Q9BQA5), 
OCAD1_Y87 (OCIA domain-containing protein 1, Q9NX40) and SPZ1_Y358 
(Spermatogenic leucine zipper protein 1, Q9BXG8), of which the HINFP-Y333 
phosphorylation was identified in an acute myelogenous leukemia cell previously 





Over the last two decades, TKs have emerged as attractive therapeutic targets, and TK 
inhibitors have played an increasingly prominent role in the treatment of cancer and other 
diseases.  TKs and the pTyr-binding proteins have been globally profiled in humans. But 
our understanding of TK specificities lags when the number of identified pTyr sites 
expands rapidly along with the advance of mass spectrometry. This is largely due to the 
lack of a reliable and high-throughput in vivo assay for TK-substrate profiling. Even though 
TKs provide direct therapeutic targets in cancer, seeking more tractable therapeutic targets 
among the TK associated proteins are of great value in the clinic. For instance, there is a 
plethora of information about Src activation in preclinical models of many different cancer 
types, but the efficacy of multiple Src inhibitors are not highly promising in clinical 
applications or trials (Mayer and Krop, 2010). The reasons for failure of Src inhibitors in 
the clinic are not well understood but it is likely due to the inhibition of Src kinase family 
members in immune cells, which could inhibit host immune resistance against tumor cells 
or even render patients vulnerable to infections (Elias and Ditzel, 2015; Kreutzman et al., 
2011). Therefore, profiling TK substrates that act downstream in tumorigenesis might offer 
excellent opportunities to identify promising therapeutic targets with a more desired effect.  
The pioneer study of high-throughput screening for Src kinase substrates was carried out 
shortly after the discovery of pTyr-specific antibodies. A shotgun-based approach led to 
the cDNA cloning and functional characterization of a few substrates which are now well 
known and rigorously validated by other studies (Kanner et al., 1989; Kanner et al., 1990; 
Reynolds et al., 2014). Other than that, most reported Src substrates were identified from 
individual low-throughput studies (Lee et al., 2010; Lin et al., 2011; Nakai et al., 2014; 
Omori et al., 2015; Tian et al., 2006; Yamaguchi et al., 2008; Yokouchi et al., 2001). 
Taking advantage of the superbinder SH2 bait, our modified Y2H is capable of screening 
for substrates of Src tyrosine kinase in a high-throughput manner. As a proof of concept, 
the cDNA library screening exhibited a low duplication rate as expected for this mid-scale 
screening. Even though not fully validated, the short list of 48 candidate positives contains 
at least 9 known Src substrates or direct interactors. Here the reverse screening largely 
contributes to the high genuine positive rate because ~ 80% HIS3 expressing colonies were 
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determined to be false positives. According to the PhosphositePlus database, these AD 
insertions have 77 potential tyrosine phosphorylation sites while the entire human 
proteome contains approximately 10,000 pTyr sites from proteins encoded by 20, 000 
genes (Suppl.3.4) (Hornbeck et al., 2015).  Even though a stringent screening strategy was 
performed, and the reverse screening seemed highly effective, false positives might still 
exist among these 48 colonies. To further validate the Src substrates, more tests should be 
carried out in yeast, including the re-transformation of bait and positive AD plasmids and 
switch of vectors.  
This modified Y2H system can be immediately applied for the validation of individual TK-
substrate pairing. More adjustments on the experimental pipeline are necessary if aiming 
for a global TK substrate profiling. The cDNA library is not optimal for this purpose due 
to imperfect cDNA synthesis. The ClonTech human general cDNA library has AD 
insertions 1.3 kb size on average, and consistently we failed to identify many full-length 
proteins (Tab.2, Suppl.34). The human ORFeome library could be superior. This library 
now includes full-length ORF constructs for over 15,000 genes, and has been successfully 
used in Y2H for a mega-scale library against library screening,  representing so far the most 
comprehensive human protein-protein interaction network to date (Rolland et al., 2014; 
Rual et al., 2005). To improve the efficiency of after-screening work, the SH2-AP-MS was 
tested for fast identification of AD insertions, however, the preliminary result was not 
highly encouraging. Three pTyr sites were identified from a matrix of 48 positive colonies, 
with only one previously reported site. Increasing the amount of lysate and antibody or 
reducing the complexity of the matrix may immediately help to identify more pTyr sites. 
However, the low abundance of bait/prey expression in this GAL4 system could be another 
cause for the poor MS detection. Using a membrane-based (split-ubiquitin) Y2H system 
may result in better MS detection for higher bait/prey expression levels (Stagljar et al., 
1998). Compared to the GAL4 system, the split-ubiquitin system also allows the expression 
of receptor tyrosine kinase with a highly hydrophobic region. Additionally, the cytosol 
tyrosine phosphorylation of prey proteins could be more efficient in the split-ubiquitin 
system, which will bring less toxicity to yeast growth, and therefore, facilitating the 
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4 Summary and Perspectives 
The human genome encodes around 500 protein kinases (Manning et al., 2002). The TK 
family consists of 90 members and tyrosine phosphorylation only contributes to around 5% 
of all protein phosphorylation (Ushiro and Cohen, 1980). However, the significance of TKs 
and pTyr-mediated signaling is not reflected by the abundance, particularly regarding 
cellular activities related to tumorigenesis and cancer malignance (Lim and Pawson, 2010). 
TKs are a major type of biomarker in many cancer types (Gharwan and Groninger, 2016; 
Hunter, 2009; Wu et al., 2015), and TK deregulation can occur in multiple  ways: gene 
fusion (chromosomal translocation), gene amplification, mutation, truncation and 
overexpression. Moreover, abnormalities in other components within the pTyr-mediated 
signaling network also can alter the signaling outcome (Du and Lovly, 2018). Over the last 
two decades, more than half of all FDA approved anti-cancer targeted therapeutics are 
either small molecule TK inhibitors or RTK inhibition antibodies (Bhullar et al., 2018; 
Gharwan and Groninger, 2016; Twomey et al., 2017; Wu et al., 2015; Zhang et al., 2009). 
As introduced earlier, some TKs are well known biomarkers in specific cancer types, for 
example, ABL in leukemia, EGFR and ALK in lung cancer, and HER2 in breast cancer. It 
is intriguing that ABL, EGFR and ALK are also reported to be oncogenic in breast cancer, 
even though the corresponding frequencies are much lower, indicating these may not be 
the dominant TKs in driving tumorigenesis in breast tissue (Greuber et al., 2013; Hanna et 
al., 2015; Masuda et al., 2012; Siraj et al., 2015; Srinivasan and Plattner, 2006). Because 
many TKs stimulate cancer-related cellular activities via the same signaling pathways 
(MAPK/PI3K), it is not surprising that TK deregulation is able to transform cells in general. 
In TK inhibition therapy, functional redundancy likely contributes to intrinsic drug 
resistance and fast-developing acquired resistance in many cases reported in the clinic, as 
the inhibition of the primary TK biomarker could be compensated by the deregulation of 
non-target TKs (Lin and Shaw, 2016).  
Targeted therapy experienced two breakthroughs in oncology in recent years. Unlike all 
previous approvals which limited the application of a targeted therapeutic to one or a few 
tumor types, the Trk inhibitor larotrectinib and a few PD-1 antibodies were approved as 
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tumor-type-agnostic therapeutics. Larotrectinib is the first selective small molecule pan-
Trk (tropomyosin receptor kinases) inhibitor, which blocks the ATP-binding site of Trk 
receptors encoded by the NTRK (neurotrophic receptor tyrosine kinase) gene family 
(Drilon et al., 2018). Similar to ALK, Trks are normally expressed in human neuronal 
tissue and functions in the physiology of nervous system development, and the deregulation 
of Trks is mainly caused by gene fusions with many different fusion partners (Amatu et 
al., 2016). Trk gene fusions have been identified at high frequencies (up to or greater than 
90%) in some rare cancer types, such as ETV6-NRTK3 fusion in secretory breast 
carcinoma (Drilon et al., 2016), but at very low frequencies (commonly < 1%) in a wide 
variety of common cancer types (Amatu et al., 2016). It is estimated that 1,500 to 5,000 
patients may carry a Trk gene fusion out of the 500,000 U.S. cancer patients diagnosed 
each year (Cocco et al., 2018; Khotskaya et al., 2017). The gold standard FISH assay has 
already been developed for the examination of Trk fusion, but the cost-to-benefit ratio is 
obviously not ideal due to the low frequency. In addition, FISH will require different sets 
of probes for different fusion partners, therefore NGS seems to be a more practical assay 
for examining Trk fusion, which could easily look for the genomic alternations of all TKs 
in a single test. 
Although NGS is superior to IHC/FISH in multiplexing, the choice of examination 
methodology in clinical practice remains a matter of debate. Previously, the accuracy of 
IHC, FISH and NGS were investigated in the determination of ALK status in lung cancer. 
The conclusion was that NGS should be considered a supplementary test associated with 
IHC/FISH combined ALK testing, rather than the new gold standard method (Cabillic et 
al., 2014; Ilie et al., 2015; Niu et al., 2017; Pekar-Zlotin et al., 2015; Uguen et al., 2015). 
It is interesting that single-test-positive cases were reported in these studies (IHC+FISH-
NGS-, IHC-FISH+NGS-, or IHC-FISH-NGS+), and ALK inhibition efficacy varied in the 
same subtype. This observation may not be simply due to the differential criteria or 
reproducibility of these assays, but also related to the imperfect correlation between 
mRNA/protein abundance and kinase signaling outcome. The ALK locus is a hotspot of 
chromosomal translocation, although the reason remains unclear. Over 30 ALK kinase 
domain-containing fusion proteins with at least 22 fusion partners have been reported in 
different cancer types (Hallberg and Palmer, 2013), but the most common FISH assay is 
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designed for EML-ALK which is frequent in lung cancer (Sasaki et al., 2010; Soda et al., 
2007).  At the protein level, the on-membrane ALK protein level can be regulated by a few 
proteins, including the oncogenic adaptor protein Numb, and two Numb isoforms act 
antagonistically to promote/inhibit ALK activity (Wei et al., 2019). In addition, it is 
expected that the presence of PTPs that decrease ALK phosphorylation, the adaptor SH2 
proteins that mediate signaling transduction, and other components in MAPK/PI3K 
pathways would all be involved in the regulation of the ALK signaling outcome. 
The SH2-AP-MS assay is an orthogonal method to current approaches, designed for the 
comprehensive evaluation of TK status. Compared to gene copy number or mRNA/protein 
abundance, the phosphorylation on activity-determining tyrosine residues could be a direct 
and more reliable indicator of TK activity. The loop-panel already contains two Trk 
activation loops (TrkA and TrkB/TrkC) and the full-panel adds four other non-loop pTyr 
sites from TrkA and TrkC. This assay could detect all types of TK deregulations in theory, 
which may be more accurate in examining TK biomarkers in some cases, for instance, 
when multiple TKs cooperate in driving tumorigenesis or a TK is deregulated at the post-
translational level. To better evaluate TK status and signaling outcome, the MS detection 
panel may be further expanded, by including pTyr sites in adaptor and scaffold proteins 
(Good et al., 2011; Scott et al., 2005; Waterman et al., 2002), or pSer/pThr sites in TK 
downstream effectors (Cargnello and Roux, 2011).  
With the advance in peptide separation and MS techniques, the SH2-AP-MS assay could 
become more sensitive and robust. The LC-MS tandem system is widely used in both 
targeted and discovery proteomics studies (Gross, 2004). However, liquid chromatography 
is powerful but imperfect for peptide separation, if this assay is applied for the examination 
of TK biomarker in the clinic. Many hydrophilic and hydrophobic peptides generated from 
enzymatic fragmentation of proteins are difficult to purify or separate, because they are 
either unretained or irreversibly bound by the reversed phase C18 sorbent. In generating 
the full-TK panel (Suppl.2.5), a few activation loops were eliminated from the list due to 
exceptional hydrophobicity. Considering that the activation loops are usually among the 
most intensively phosphorylated regions in TKs (Hornbeck et al., 2015), this could result 
in miss detection or false evaluation of TK status which is unacceptable in the clinic. 
Because the thoroughly optimized SH2-AP yields an uncomplicated peptide matrix, 
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commonly containing only tens or a few hundreds of peptides enriched from a minute 
amount of tissue, some other low-capacity peptide separation techniques could be used in 
the front end. Capillary electrophoresis (CE)-MS takes advantage of the high resolving 
power, sensitivity, robustness and fast separation speed of electrophoresis (Cai and Henion, 
1995; Loo et al., 1989), which in theory will be more suitable in analyzing the SH2-AP 
enriched samples in the clinic.  
In the SH2 superbinder modified Y2H, once the SH2-AP-MS is properly integrated for the 
identification of candidate positives, this system can be more practical and efficient in 
identifying direct TK substrates systematically. The comprehensive substrate profiling will 
not only expand our understanding of the pTyr-mediated signaling network, but also 
provide great opportunity in finding novel drug targets for some TKs previously considered 
as “less-druggable”. The success of mechanism-based drug development is reliant on the 
definition of the drug target. In cancer, the drug targets are typically proteins that are 
specific in cancer cells and function more significantly in tumorigenesis and malignance 
(Santos et al., 2016). As introduced, many TKs are ideal drug targets and the development 
of kinase inhibition therapeutics is straight forward and well-established. Some TK 
inhibition therapies are exceptionally successful in the clinic. For example, CML patients 
treated by imatinib have a striking 10-year survival rate of 83.3%, while the 5-year survival 
rate was less than 30% before imatinib was approved (Hochhaus et al., 2017; Moen et al., 
2007). In contrast, the inhibitors of the Src kinase, the first described oncogene which is 
determined to be highly oncogenic in many solid tumors, only exhibit promising efficacies 
in pre-clinical models (Hunter and Sefton, 1980; Mayer and Krop, 2010; Sefton et al., 
1980). The poor clinical performance is likely related to high protein similarity within the 
Src family. The application of Src inhibitors usually also blocks Src family members which 
are active in immune cells, resulting in the inhibition of patient immune resistance against 
tumor cells or even rendering patients vulnerable to infections (Elias and Ditzel, 2015; 
Kreutzman et al., 2011). In theory, the efficacy of these less-selective therapeutics can be 
dramatically improved by targeted drug delivery. In the case of Src inhibition in solid 
tumors, one possible strategy is nanonizing the inhibitor or conjugate the inhibitor to nano-
sized carrier. Taking advantage of the enhanced permeability and retention (EPR) effect, 
the intravenously administered nano-sized drug could passively accumulate in the 
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advanced-stage solid tumors via passing the “leaky” vessels (Matsumura and Maeda, 
1986). However, the efficiency of EPR is still controversial and drug nanonization strategy 
is not well established  (Danhier, 2016; Nichols and Bae, 2014). Alternatively, since the 
development of a highly selective Src inhibitor remains challenging, it is perhaps more 
practical to look for “druggable” targets from Src direct substrates or associated proteins 
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